Page last updated: 2024-10-18

iodine and Cystic Fibrosis

iodine has been researched along with Cystic Fibrosis in 1143 studies

Iodine: A nonmetallic element of the halogen group that is represented by the atomic symbol I, atomic number 53, and atomic weight of 126.90. It is a nutritionally essential element, especially important in thyroid hormone synthesis. In solution, it has anti-infective properties and is used topically.
diiodine : Molecule comprising two covalently bonded iodine atoms with overall zero charge..

Cystic Fibrosis: An autosomal recessive genetic disease of the EXOCRINE GLANDS. It is caused by mutations in the gene encoding the CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR expressed in several organs including the LUNG, the PANCREAS, the BILIARY SYSTEM, and the SWEAT GLANDS. Cystic fibrosis is characterized by epithelial secretory dysfunction associated with ductal obstruction resulting in AIRWAY OBSTRUCTION; chronic RESPIRATORY INFECTIONS; PANCREATIC INSUFFICIENCY; maldigestion; salt depletion; and HEAT PROSTRATION.

Research Excerpts

ExcerptRelevanceReference
"We provide evidence that combination lumacaftor and ivacaftor improves FEV1 for patients with cystic fibrosis who are homozygous for phe508del CFTR, with a modest effect on sweat chloride concentration."9.19A CFTR corrector (lumacaftor) and a CFTR potentiator (ivacaftor) for treatment of patients with cystic fibrosis who have a phe508del CFTR mutation: a phase 2 randomised controlled trial. ( Bell, SC; Boyle, MP; Huang, X; Konstan, MW; McColley, SA; Patel, NR; Rietschel, E; Rodman, D; Rowe, SM; Waltz, D, 2014)
"We randomly assigned 39 adults with cystic fibrosis and at least one G551D-CFTR allele to receive oral VX-770 every 12 hours at a dose of 25, 75, or 150 mg or placebo for 14 days (in part 1 of the study) or VX-770 every 12 hours at a dose of 150 or 250 mg or placebo for 28 days (in part 2 of the study)."9.14Effect of VX-770 in persons with cystic fibrosis and the G551D-CFTR mutation. ( Accurso, FJ; Aitken, ML; Ashlock, MA; Boyle, MP; Campbell, PW; Clancy, JP; Donaldson, SH; Dong, Q; Dunitz, JM; Durie, PR; Freedman, SD; Hornick, DB; Konstan, MW; Mayer-Hamblett, N; Moss, RB; Olson, ER; Ordoñez, CL; Pilewski, JM; Ramsey, BW; Rose, LM; Rowe, SM; Rubenstein, RC; Sagel, SD; Stone, AJ; Uluer, AZ; Zha, J, 2010)
"Twenty-one children receiving topiramate and 20 healthy controls with no signs or symptoms of pulmonary or gastrointestinal disease and a negative family history for cystic fibrosis (CF) underwent bilateral pilocarpine iontophoresis and sweat collection via Macroduct® system."7.78Elevated sweat chloride concentration in children without cystic fibrosis who are receiving topiramate therapy. ( Guglani, L; Kurland, G; Lower, D; Sitwat, B; Weiner, DJ, 2012)
"To examine immunoreactive trypsinogen (IRT)-based screening for cystic fibrosis (CF) for recall rate, genotype distribution, and "borderline" sweat test results."7.73Two-tiered immunoreactive trypsinogen-based newborn screening for cystic fibrosis in Colorado: screening efficacy and diagnostic outcomes. ( Accurso, FJ; Hammond, KB; Sontag, MK; Wagener, JS; Zielenski, J, 2005)
"To quantitate the proportion of infants identified through cystic fibrosis (CF) newborn screening (NBS) by an immunoreactive trypsinogen (IRT)/DNA screening algorithm who have an unclear diagnosis as defined by the findings of an elevated IRT level and either 1) 2 CF gene (CFTR) mutations detected and sweat chloride level <60 mEq/L; or 2) 0 or 1 CFTR mutations and a "borderline" sweat chloride level >or=30 and <60 mEq/L."7.73Diagnostic dilemmas resulting from the immunoreactive trypsinogen/DNA cystic fibrosis newborn screening algorithm. ( Comeau, AM; Parad, RB, 2005)
" Chest computed tomography showed the diffuse bronchiectasis in both lungs, and their diagnosis was confirmed by the repeated analysis of a quantitative pilocarpine iontophoresis test (QPIT)."7.73Cystic fibrosis in Korean children:a case report identified by a quantitative pilocarpine iontophoresis sweat test and genetic analysis. ( Ahn, KM; Kang, IJ; Kim, JH; Lee, JH; Lee, MG; Lee, SI; Park, HY, 2005)
"To characterize the time course and physiologic significance of decline in serum immunoreactive trypsinogen (IRT) levels in infants with cystic fibrosis (CF) by mode of diagnosis and genotype, and to examine IRT heritability."7.73Genetic and physiologic correlates of longitudinal immunoreactive trypsinogen decline in infants with cystic fibrosis identified through newborn screening. ( Accurso, FJ; Corey, M; Hokanson, JE; Marshall, JA; Sommer, SS; Sontag, MK; Zerbe, GO, 2006)
"Statewide screening for cystic fibrosis based on measurements of immunoreactive trypsinogen in dried blood spots is feasible and can be implemented with acceptable rates of repeat testing and false positive and false negative results."7.68Efficacy of statewide neonatal screening for cystic fibrosis by assay of trypsinogen concentrations. ( Abman, SH; Accurso, FJ; Hammond, KB; Sokol, RJ, 1991)
"A three day loading with sodium bromide was performed in 19 healthy controls, 16 definite cystic fibrosis heterozygotes, and 14 homozygote patients with cystic fibrosis."7.67Detection of cystic fibrosis heterozygotes using a modified loading with bromide. ( Gressmann, HW; Theile, H; Winiecki, P, 1985)
"Cystic fibrosis is the most common life-limiting genetic condition in Caucasians caused by Cystic Fibrosis Transmembrane conductance Regulator (CFTR) gene mutations."5.48Effect of topiramate on sweat chloride level while screening for cystic fibrosis. ( Graff, G; Siddaiah, R; Thau, E, 2018)
" Methods An open-label, prospective pharmacokinetic study was performed."5.46Individual pharmacokinetic variation leads to underdosing of ciprofloxacin in some cystic fibrosis patients. ( Buchard, A; Dalbøge, CS; Dalhoff, K; Duno, M; Høiby, N; Johansen, HK; Nielsen, XC; Pressler, T; Schultz, AN; Wang, H, 2017)
"Cystic fibrosis is a common disease which has an associated characteristic symptom of high sweat chloride content."5.39Electrochemical detection of chloride levels in sweat using silver nanoparticles: a basis for the preliminary screening for cystic fibrosis. ( Batchelor-McAuley, C; Compton, RG; Toh, HS; Tschulik, K, 2013)
"Although ataluren did not improve lung function in the overall population of nonsense-mutation cystic fibrosis patients who received this treatment, it might be beneficial for patients not taking chronic inhaled tobramycin."5.19Ataluren for the treatment of nonsense-mutation cystic fibrosis: a randomised, double-blind, placebo-controlled phase 3 trial. ( Accurso, FJ; Ajayi, T; Barth, J; Branstrom, A; Bronsveld, I; De Boeck, K; Elborn, JS; Elfring, GL; Fajac, I; Kerem, E; Knoop, C; Konstan, MW; Malfroot, A; McColley, SA; Melotti, P; Peltz, SW; Quattrucci, S; Rietschel, E; Rosenbluth, DB; Rowe, SM; Sermet-Gaudelus, I; Spiegel, RJ; Walker, PA; Welch, EM; Wilschanski, M; Zeitlin, PL, 2014)
"We provide evidence that combination lumacaftor and ivacaftor improves FEV1 for patients with cystic fibrosis who are homozygous for phe508del CFTR, with a modest effect on sweat chloride concentration."5.19A CFTR corrector (lumacaftor) and a CFTR potentiator (ivacaftor) for treatment of patients with cystic fibrosis who have a phe508del CFTR mutation: a phase 2 randomised controlled trial. ( Bell, SC; Boyle, MP; Huang, X; Konstan, MW; McColley, SA; Patel, NR; Rietschel, E; Rodman, D; Rowe, SM; Waltz, D, 2014)
"Collection of sweat via pilocarpine iontophoresis is commonly used to diagnose cystic fibrosis (CF), with thousands of tests performed each day."5.17Skin pretreatment with microneedles prior to pilocarpine iontophoresis increases sweat production. ( Buono, MJ; Prausnitz, MR; Wing, D, 2013)
"Ivacaftor (VX-770) is a cystic fibrosis transmembrane conductance regulator (CFTR) potentiator that was approved in the United States for the treatment of cystic fibrosis (CF) in patients ≥ 6 years of age who have a G551D mutation; however, the most prevalent disease-causing CFTR mutation, F508del, causes a different functional defect."5.16Ivacaftor in subjects with cystic fibrosis who are homozygous for the F508del-CFTR mutation. ( Borowitz, DS; Flume, PA; Geller, DE; Li, H; Liou, TG; Ordoñez, CL; Yen, K, 2012)
"We randomly assigned 39 adults with cystic fibrosis and at least one G551D-CFTR allele to receive oral VX-770 every 12 hours at a dose of 25, 75, or 150 mg or placebo for 14 days (in part 1 of the study) or VX-770 every 12 hours at a dose of 150 or 250 mg or placebo for 28 days (in part 2 of the study)."5.14Effect of VX-770 in persons with cystic fibrosis and the G551D-CFTR mutation. ( Accurso, FJ; Aitken, ML; Ashlock, MA; Boyle, MP; Campbell, PW; Clancy, JP; Donaldson, SH; Dong, Q; Dunitz, JM; Durie, PR; Freedman, SD; Hornick, DB; Konstan, MW; Mayer-Hamblett, N; Moss, RB; Olson, ER; Ordoñez, CL; Pilewski, JM; Ramsey, BW; Rose, LM; Rowe, SM; Rubenstein, RC; Sagel, SD; Stone, AJ; Uluer, AZ; Zha, J, 2010)
" The sweat obtained from patients with cystic fibrosis has been compared with that from normal children: the concentrations of cyclic AMP and cyclic GMP are the same."5.05Is salt reabsorption in the human sweat duct subject to control? ( Schwarz, V; Simpson, IM, 1985)
"The administration of pharmacologic quantities of iodine such as iodides for the treatment of pulmonary disease, organic iodine present in medications and x-ray contrast dyes, and the ingestion of iodine-rich natural foods, may result in goiter, hypothyroidism, or hyperthyroidism, especially in patients with underlying thyroid disease."4.75Adverse effects of iodides on thyroid function. ( Braverman, LE; Vagenakis, AG, 1975)
"We examined the relation between the number of (TG) repeats at the (IVS8)-(TG)m(T)5 locus of the CFTR gene with neonatal serum immunoreactive trypsinogen (IRT) and sweat chloride (SC) concentrations in hypertrypsinogenemic infants with genotype ΔF508-9T/5T identified by California cystic fibrosis newborn screening."3.78Impact of IVS8-(TG)m(T)n on IRT and sweat chloride levels in newborns identified by California CF newborn screening. ( Keiles, S; Kharrazi, M; Koepke, R; Parad, R, 2012)
"Twenty-one children receiving topiramate and 20 healthy controls with no signs or symptoms of pulmonary or gastrointestinal disease and a negative family history for cystic fibrosis (CF) underwent bilateral pilocarpine iontophoresis and sweat collection via Macroduct® system."3.78Elevated sweat chloride concentration in children without cystic fibrosis who are receiving topiramate therapy. ( Guglani, L; Kurland, G; Lower, D; Sitwat, B; Weiner, DJ, 2012)
" The United States CF Foundation recently proposed the term cystic fibrosis transmembrane conductance regulator related metabolic syndrome (CRMS) to describe infants with elevated immunoreactive trypsinogen (IRT) on NBS who do not meet diagnostic criteria for CF."3.77Clinical outcomes in infants with cystic fibrosis transmembrane conductance regulator (CFTR) related metabolic syndrome. ( Desai, H; Dixon, M; Platt, M; Ren, CL, 2011)
"Newborn screening (NBS) for cystic fibrosis (CF) offers the opportunity for early diagnosis and improved outcomes in patients with CF and has been universally available in the state of Massachusetts since 1999 using an immunoreactive trypsinogen (IRT)-DNA algorithm."3.76Cystic fibrosis newborn screening: using experience to optimize the screening algorithm. ( Comeau, AM; Dorkin, HL; Gerstle, R; Hale, JE; Lapey, A; O'Sullivan, BP; Parad, RB; Spencer, T; Yee, W, 2010)
"To examine immunoreactive trypsinogen (IRT)-based screening for cystic fibrosis (CF) for recall rate, genotype distribution, and "borderline" sweat test results."3.73Two-tiered immunoreactive trypsinogen-based newborn screening for cystic fibrosis in Colorado: screening efficacy and diagnostic outcomes. ( Accurso, FJ; Hammond, KB; Sontag, MK; Wagener, JS; Zielenski, J, 2005)
"To characterize the time course and physiologic significance of decline in serum immunoreactive trypsinogen (IRT) levels in infants with cystic fibrosis (CF) by mode of diagnosis and genotype, and to examine IRT heritability."3.73Genetic and physiologic correlates of longitudinal immunoreactive trypsinogen decline in infants with cystic fibrosis identified through newborn screening. ( Accurso, FJ; Corey, M; Hokanson, JE; Marshall, JA; Sommer, SS; Sontag, MK; Zerbe, GO, 2006)
" Chest computed tomography showed the diffuse bronchiectasis in both lungs, and their diagnosis was confirmed by the repeated analysis of a quantitative pilocarpine iontophoresis test (QPIT)."3.73Cystic fibrosis in Korean children:a case report identified by a quantitative pilocarpine iontophoresis sweat test and genetic analysis. ( Ahn, KM; Kang, IJ; Kim, JH; Lee, JH; Lee, MG; Lee, SI; Park, HY, 2005)
"Describe and define limitations of early pilocarpine iontophoresis (sweat testing) for cystic fibrosis (CF) newborn screening (NBS)."3.73Sweat testing infants detected by cystic fibrosis newborn screening. ( Comeau, AM; Dorkin, HL; Dovey, M; Gerstle, R; Martin, T; O'Sullivan, BP; Parad, RB, 2005)
"To quantitate the proportion of infants identified through cystic fibrosis (CF) newborn screening (NBS) by an immunoreactive trypsinogen (IRT)/DNA screening algorithm who have an unclear diagnosis as defined by the findings of an elevated IRT level and either 1) 2 CF gene (CFTR) mutations detected and sweat chloride level <60 mEq/L; or 2) 0 or 1 CFTR mutations and a "borderline" sweat chloride level >or=30 and <60 mEq/L."3.73Diagnostic dilemmas resulting from the immunoreactive trypsinogen/DNA cystic fibrosis newborn screening algorithm. ( Comeau, AM; Parad, RB, 2005)
"We tested 39 patients with idiopathic chronic pancreatitis (mean age at diagnosis, 33 years) for common mutations of CFTR and of genes encoding a trypsin inhibitor (PSTI) and trypsinogen (PRSS1)."3.71Cystic fibrosis gene mutations and pancreatitis risk: relation to epithelial ion transport and trypsin inhibitor gene mutations. ( Cohn, JA; Jowell, PS; Knowles, MR; Noone, PG; Silverman, LM; Zhou, Z, 2001)
"To assess the performance of a two tier neonatal screening programme (IRT/DNA/IRT) for cystic fibrosis, based on immunoreactive trypsinogen (IRT) followed by direct cystic fibrosis transmembrane conductance regulator (CFTR) gene analysis (based on a panel of up to 31 mutations) in hypertrypsinaemic newborn infants and to compare it with a previous screening protocol."3.71Screening for cystic fibrosis in newborn infants: results of a pilot programme based on a two tier protocol (IRT/DNA/IRT) in the Italian population. ( Ambrosioni, A; Bassotti, A; Corbetta, C; Giunta, A; Padoan, R; Seia, M, 2002)
"Statewide screening for cystic fibrosis based on measurements of immunoreactive trypsinogen in dried blood spots is feasible and can be implemented with acceptable rates of repeat testing and false positive and false negative results."3.68Efficacy of statewide neonatal screening for cystic fibrosis by assay of trypsinogen concentrations. ( Abman, SH; Accurso, FJ; Hammond, KB; Sokol, RJ, 1991)
"Two methods for the determination of sodium in the sweat after stimulation by pilocarpine-iontophoresis were compared in 227 patients, among them 27 with a known cystic fibrosis."3.67[Diagnosis of mucoviscidosis by examination of sweat: value of conductometry]. ( Bergmann, S; Hoffmann, C; Sprössig, C; Wunderlich, P, 1989)
"Because patients with cystic fibrosis (CF) consistently lack sweating response to isoproterenol (ISO) in vivo and in vitro, we studied to what extent beta-adrenergic defect is expressed in CF heterozygotes."3.67Variable reduction in beta-adrenergic sweat secretion in cystic fibrosis heterozygotes. ( Sato, F; Sato, K, 1988)
"A four year regional screening programme to detect cystic fibrosis using measurement of immunoreactive trypsinogen is described."3.67Screening for cystic fibrosis: a four year regional experience. ( Black, A; Redmond, A; Roberts, G; Stanfield, M, 1988)
"Sweat tests were carried out on 14 patients with cystic fibrosis and 14 controls when on no antibiotics and when taking oral flucloxacillin."3.67Sweat tests and flucloxacillin. ( Green, A; Griffiths, PD; Weller, PH; Williams, J, 1988)
"A three day loading with sodium bromide was performed in 19 healthy controls, 16 definite cystic fibrosis heterozygotes, and 14 homozygote patients with cystic fibrosis."3.67Detection of cystic fibrosis heterozygotes using a modified loading with bromide. ( Gressmann, HW; Theile, H; Winiecki, P, 1985)
"In order to study the disposition which is thought to be latent in chronic pancreatitis, we investigated the sweat chloride concentration of 95 normal subjects, 43 cases of chronic pancreatitis, 12 cases of cholelithiasis, 15 cases of peptic ulcers, 16 cases of hepatic diseases and 23 cases of diabetes mellitus with the sweat test, using the method of pilocarpine iontophoresis."3.66The significance of the sweat test in chronic pancreatitis. ( Endo, K; Hanawa, M; Koizumi, M; Takahashi, S; Takebe, T, 1978)
" Observed safety results support further evaluation of GLPG2222, including in combination with other CFTR modulators."2.90CFTR activity is enhanced by the novel corrector GLPG2222, given with and without ivacaftor in two randomized trials. ( Barry, PJ; Bell, SC; Bellaire, S; Conrath, K; De Boeck, K; de Kock, H; Drevinek, P; Elborn, JS; Geller, DE; Kanters, D; Minić, P; Muller, K; Plant, BJ; Van Braeckel, E; Van de Steen, O; van der Ent, K; Verhulst, S, 2019)
"Cystic fibrosis is a severe monogenic disease that affects around 7 300 patients in France."2.82[Therapeutic advances in cystic fibrosis: from genetics to treatment personalized]. ( Durieu, I; Durupt, S; Reynaud, Q, 2022)
" Results of ivacaftor pharmacokinetics suggested that exposure was similar to that reported in adults (median Cmin were 536 ng/mL for the 50 mg dose; 580 ng/mL for the 75 mg dose; median ivacaftor AUC values were 9840 ng × h/mL and 10 200 ng × h/mL, respectively)."2.82Safety, pharmacokinetics, and pharmacodynamics of ivacaftor in patients aged 2-5 years with cystic fibrosis and a CFTR gating mutation (KIWI): an open-label, single-arm study. ( Cooke, J; Cunningham, S; Davies, JC; Green, Y; Harris, WT; Lapey, A; Regelmann, WE; Robertson, S; Rosenfeld, M; Sawicki, GS; Southern, KW, 2016)
" Efficacy was determined using nasal transepithelial potential difference and sweat chloride measurements prior to dosing and at 1, 2, and 4 hr postdose."2.70A phase I randomized, multicenter trial of CPX in adult subjects with mild cystic fibrosis. ( Ahrens, RC; Aitken, ML; Hilliard, KA; Kelley, TJ; Konstan, MW; Launspach, J; McCarty, NA; Milgram, LJ; Regelmann, WE; Standaert, TA; Teresi, M; Tuthill, C; Weatherly, MR, 2002)
"Biomarkers in cystic fibrosis are used i."2.52Biomarkers in Paediatric Cystic Fibrosis Lung Disease. ( Ramsey, KA; Schultz, A; Stick, SM, 2015)
"Cystic fibrosis is responsible for severe chronic pulmonary disorders in children."2.50Cystic fibrosis: need for mass deployable screening methods. ( Agarwal, A; Sengar, AS; Singh, MK, 2014)
"Cystic fibrosis is the most common lethal genetic disease in Caucasians, manifesting as progressive lung dysfunction, pancreatic insufficiency, and intestinal disease."2.44Cystic fibrosis: newborn screening in America. ( Kleven, DT; McCudden, CR; Willis, MS, 2008)
"Cystic fibrosis is an autosomal recessive disorder affecting the lungs, pancreas, intestines, sweat ducts and liver, due to an abnormal salt transport across the apical border of epithelial cells."2.41[From gene to disease; from defective chloride ion transport to cystic fibrosis]. ( Scheffer, H; van den Ouweland, AM; Veeze, HJ, 2001)
"Exercise-related hyponatremia is an infrequent but potentially life-threatening accompaniment of prolonged exercise."2.41Hyponatremia associated with exercise: risk factors and pathogenesis. ( Montain, SJ; Sawka, MN; Wenger, CB, 2001)
"Cystic fibrosis is a genetic recessive disorder caused by mutations in the gene that encodes the CFTR protein."2.41[Diagnosis of cystic fibrosis in adults]. ( Chinet, T; Fajac, I; Ferec, C; Garcia Carmona, T; Nguyen-Khoa, T, 2000)
"Cystic fibrosis is a genetic disease occurring more frequently in Caucasians."2.41[Diagnosis and management of cystic fibrosis in children]. ( Clement, A; Fauroux, B; Tamalet, A, 2000)
"In young adults with acute pancreatitis a wide etiologic spectrum has to be considered."2.38Relapsing pancreatitis as initial manifestation of cystic fibrosis in a young man without pulmonary disease. ( Denzel, K; Gerok, W; Gross, V; Schoelmerich, J, 1989)
"Sinusitis is almost universal, and nasal polyposis is frequently present."2.37Diagnosis and treatment of cystic fibrosis. An update. ( Davis, PB; di Sant'Agnese, PA, 1984)
"Pilocarpine was used at a concentration ∼130-times lower than that used in the classical Gibson and Cooke sweat test."1.72Needle-free iontophoresis-driven β-adrenergic sweat rate test. ( Frédérick, R; Gohy, S; Leal, T; Lebecque, P; Mottais, A; Reynaerts, A; Vanbever, R; Vermeulen, F, 2022)
"Cystic fibrosis is the most common metabolic chronic disease among European Caucasian children."1.51The Incidence of Cystic Fibrosis in the Central Region of Anatolia in Turkey Between 2015 and 2016 ( Acıcan, D; Demir, O; Ercan, Ö; Erdoğan, M; Göçlü, F; Güney, D; Hangül, M; Kendirci, M; Köse, M; Öznavruz, H; Pekcan, S; Şahlar, TE, 2019)
"Cystic fibrosis is the most common life-limiting genetic condition in Caucasians caused by Cystic Fibrosis Transmembrane conductance Regulator (CFTR) gene mutations."1.48Effect of topiramate on sweat chloride level while screening for cystic fibrosis. ( Graff, G; Siddaiah, R; Thau, E, 2018)
" Methods An open-label, prospective pharmacokinetic study was performed."1.46Individual pharmacokinetic variation leads to underdosing of ciprofloxacin in some cystic fibrosis patients. ( Buchard, A; Dalbøge, CS; Dalhoff, K; Duno, M; Høiby, N; Johansen, HK; Nielsen, XC; Pressler, T; Schultz, AN; Wang, H, 2017)
"AH1N1 virus infections caused classic influenza symptoms in the majority of cystic fibrosis patients while others experienced severe outcomes."1.46Incidental late diagnosis of cystic fibrosis following AH1N1 influenza virus pneumonia: a case report. ( Bianco, A; Calabrese, C; Carnovale, V; Ferrara, N; Iacotucci, P; Iadevaia, C; Mazzarella, G; Perrotta, F; Rea, G, 2017)
"Cases of bronchial asthma, diagnosed by GINA guideline 2008, and age matched healthy controls were included."1.42Higher sweat chloride levels in patients with asthma: a case-control study. ( Awasthi, S; Dixit, P; Maurya, N, 2015)
"Because diagnosing cystic fibrosis is a combined effort between local pediatric departments, biochemical and genetic departments and cystic fibrosis centers, a national harmonization is necessary to assure correct clinical use."1.40Lack of harmonization in sweat testing for cystic fibrosis - a national survey. ( Christiansen, AL; Nybo, M, 2014)
"To determine if oral dosing with the CFTR-potentiator ivacaftor (VX-770, Kalydeco) improves CFTR-dependent sweating in CF subjects carrying G551D or R117H-5T mutations, we optically measured sweat secretion from 32-143 individually identified glands in each of 8 CF subjects; 6 F508del/G551D, one G551D/R117H-5T, and one I507del/R117H-5T."1.40A little CFTR goes a long way: CFTR-dependent sweat secretion from G551D and R117H-5T cystic fibrosis subjects taking ivacaftor. ( Char, JE; Cho, HJ; Davies, Z; Dunn, C; Frisbee, E; Jeong, JH; Milla, C; Moss, RB; Park, IH; Thomas, EA; Wine, JJ; Wolfe, MH, 2014)
"Exercise-associated hyponatremia is known to be a complex process resulting from the interplay of hydration, arginine vasopressin, and sodium balance."1.40The need for salt: does a relationship exist between cystic fibrosis and exercise-associated hyponatremia? ( Hew-Butler, TD; Hoffman, MD; Lewis, DP; Owen, BE; Rogers, IR; Stuempfle, KJ; Verbalis, JG, 2014)
"Sensitivity and specificity were calculated as well as the means and coefficient of variation by test and by extremity."1.40A new method of sweat testing: the CF Quantum®sweat test. ( Eickhoff, J; Makholm, L; Rock, MJ, 2014)
" A clinical trial performed to support ivacaftor dose selection demonstrated a dose-response relationship between improvement in FEV(1) and decrease in sweat chloride, a measure of CFTR function."1.39Change in sweat chloride as a clinical end point in cystic fibrosis clinical trials: the ivacaftor experience. ( Chowdhury, BA; Durmowicz, AG; Rosebraugh, CJ; Witzmann, KA, 2013)
"Aquagenic palmoplantar keratoderma (APK) is a cutaneous phenomenon marked by the formation of edematous, translucent papules and plaques on the palms after water immersion."1.39[Aquagenic palmoplantar keratoderma in children with cystic fibrosis]. ( Chaillou, E; Chevalier, MC; Chiffoleau, M; Darviot, E; Giniès, JL; Martin, L; Pelatan, C; Troussier, F; Weil, B, 2013)
"Cystic fibrosis is a common disease which has an associated characteristic symptom of high sweat chloride content."1.39Electrochemical detection of chloride levels in sweat using silver nanoparticles: a basis for the preliminary screening for cystic fibrosis. ( Batchelor-McAuley, C; Compton, RG; Toh, HS; Tschulik, K, 2013)
"Cystic fibrosis is a chronic progressive autosomal recessive disorder caused by the CFTR gene mutations."1.35[Standardized sweat chloride analysis for the diagnosis of cystic fibrosis in Korea]. ( Ahn, KM; Cha, SI; Ki, CS; Kim, JH; Kim, SJ; Lee, M; Park, HY, 2008)
"Cystic fibrosis is a lethal autosomal recessive disorder usually associated with lung disease, pancreatic insufficiency and high sweat chloride levels."1.35Clinical and molecular characterization of S1118F-CFTR. ( Conoley, VG; Frederick, CA; Kappes, J; Li, C; Naren, AP; Nekkalapu, S; Penmatsa, H; Stokes, DC; Zhang, W, 2009)
"Cystic fibrosis is the most common, multiorgan inherited autosomal recessive disorder."1.35[Ascites and extreme lipid abnormalities as initial symptoms of cystic fibrosis in a 5-years-old girl--case report]. ( Iwańczak, B; Iwańczak, F; Pytrus, T; Ryzko, J; Smigiel, R; Socha, P, 2009)
"In sweat of 11 patients with G6PD deficiency we did not find any abnormality."1.35Sweat test in patients with glucose-6-phosphate-1-dehydrogenase deficiency. ( Barben, J; Casaulta, C; Schoeni, MH; Stirnimann, A, 2008)
"Cystic fibrosis is usually diagnosed during the first years of life."1.35[The diagnosis of cystic fibrosis in adults: lessons from a family story]. ( Bienvenu, T; Burgel, PR; Coman, T; Desmazes-Dufeu, N; Dusser, D; Fajac, I; Hubert, D; Kanaan, R, 2009)
" From a panel of short chain fatty acid derivatives, we showed that 2,2-dimethyl-butyrate (ST20) and alpha-methylhydrocinnamic acid (ST7), exhibiting high oral bioavailability and sustained plasma levels, correct the DeltaF508-CFTR defect."1.33Novel short chain fatty acids restore chloride secretion in cystic fibrosis. ( Kim, US; Nguyen, TD; Perrine, SP, 2006)
"Cystic fibrosis is the most common autosomal recessive genetic defect of one gene CFTR, where a variety of mutations were revealed."1.33[Genotype and phenotype of gastrointestinal symptoms analysis in children with cystic fibrosis]. ( Iwańczak, F; Mowszet, K; Pawłowicz, J; Sasiadek, M; Smigiel, R; Stawarski, A; Stembalska, A, 2005)
"Failure to thrive was was defined by either a weight below the 5th precentile or crossing of 2 major precentiles in 1 year."1.32Diagnosing cystic fibrosis--asthma and failure to thrive as indications for a sweat test. ( Bar-Zohar, D; Belson, A; Reif, S; Segal-Algranati, D, 2004)
"Primary sclerosing cholangitis (PSC) and cystic fibrosis (CF) are both slowly progressive cholestatic liver diseases characterized by fibro-obliterative inflammation of the biliary tract."1.32Increased prevalence of CFTR mutations and variants and decreased chloride secretion in primary sclerosing cholangitis. ( Bishop, MD; Chopra, S; Durie, PR; Freedman, SD; Malmberg, E; Regan, MM; Ricci, R; Shea, JC; Sheth, S; Tsui, LC; Walker, C; Zielenski, J, 2003)
"This study was to ascertain the reliability of sweat-testing by the Macroduct collection method combined with conductivity analysis (MCS) compared with the Gibson and Cooke technique (GCT)."1.31Reliability of sweat-testing by the Macroduct collection method combined with conductivity analysis in comparison with the classic Gibson and Cooke technique. ( Borruso, A; Di Cesare, G; Mastella, G; Menin, L; Zanolla, L, 2000)
"Chronic rhinosinusitis is a consistent feature of the autosomal recessive disorder cystic fibrosis (CF)."1.31Mutation in the gene responsible for cystic fibrosis and predisposition to chronic rhinosinusitis in the general population. ( Cutting, GR; Kim, J; Leopold, DA; Moylan, B; Proud, D; Rubenstein, RC; Togias, A; Wang, X; Zeitlin, PL, 2000)
"Cystic fibrosis is caused by mutations in the cystic fibrosis transmembrane regulator (CFTR) gene."1.31Lung disease associated with the IVS8 5T allele of the CFTR gene. ( Friedman, KJ; Ganeshananthan, M; Knowles, MR; Noone, PG; Pue, CA; Silverman, LM; Simon, RH; Wakeling, EL; Zhou, Z, 2000)
"Nonclassic forms of cystic fibrosis have been associated with mutations that reduce but do not eliminate the function of the CFTR protein."1.31Variant cystic fibrosis phenotypes in the absence of CFTR mutations. ( Cutting, GR; Groman, JD; Meyer, ME; Wilmott, RW; Zeitlin, PL, 2002)
"We found no patients with severe acute pancreatitis who had CFTR gene mutations, suggesting that these alterations are not a risk factor for the disease in our population."1.31CFTR gene mutations in patients suffering from acute pancreatitis. ( Kostuch, M; Kulczycki, L; Rudzki, S; Semczuk, A, 2002)
" Age-corrected values for sweat electrolytes, rate of progression of lung disease as assessed by Brasfield chest x-ray scores, and severity of pancreatic insufficiency as assessed by daily supplemented enzyme dosage were obtained for 55, 59, and 59 patients, respectively."1.28Correlation of phenotypic and genetic heterogeneity in cystic fibrosis: variability in sweat electrolyte levels contributes to heterogeneity and is increased with the XV-2c/KM19 B haplotype. ( Erickson, RP; Farber, R; Howatt, WF; Ober, C; Witt, M, 1991)
"Adults with cystic fibrosis have significantly increased sweat electrolyte concentrations (90-120 mmol/l)."1.28[Reference values of Na(+) and Cl(-) concentrations in adult sweat]. ( Ferner, S; Heilmann, W; Koszmagk, R; Lehmann, A, 1990)
"These findings suggested Bartter's syndrome."1.27Cystic fibrosis mimicking Bartter's syndrome. ( Davison, AG; Snodgrass, GJ, 1983)
"A higher incidence of premature labor is noted and all patients are best managed in tertiary referral centers."1.27Diagnosis of maternal cystic fibrosis during pregnancy. ( Hanson, R; Johnson, SR; Varner, MW; Yates, SJ, 1983)
"Pancreatitis is a known complication of cystic fibrosis and may occur at any time in the course of the disease; in rare instances, pancreatitis is the first presenting manifestation."1.27Pancreatitis as initial presentation of cystic fibrosis in young adults. A report of two cases. ( Achkar, E; Masaryk, TJ, 1983)
"This case of Munchausen syndrome by proxy highlights the extent to which the diagnosis of cystic fibrosis rests on reliable history and laboratory data and emphasizes the extremes to which perpetrators of this form of child abuse may go to make their case."1.27Munchausen syndrome by proxy simulating cystic fibrosis. ( Orenstein, DM; Wasserman, AL, 1986)
"Sweat electrolytes were initially elevated in a child who was diagnosed as having celiac disease and also in one with psychosocial failure to thrive."1.27Abnormal sweat electrolytes in a case of celiac disease and a case of psychosocial failure to thrive. Review of other reported causes. ( Ruddy, RM; Scanlin, TF, 1987)
"Patients with cystic fibrosis have characteristic disturbances in the electrolyte composition of their sweat, saliva, and pancreatic secretions."1.27Higher bioelectric potentials due to decreased chloride absorption in the sweat glands of patients with cystic fibrosis. ( Bijman, J; Quinton, PM, 1983)
"The diagnosis of cystic fibrosis is straight forward if the clinical findings and sweat sodium are considered together."1.27Is the sweat test infallible in cystic fibrosis? ( Collins, JE; Rolles, CJ, 1985)
"No known cases of cystic fibrosis have been missed."1.26Cystic fibrosis screening in the newborn. ( Elliot, RB; Robinson, PG, 1976)
"Cystic fibrosis has been diagnosed during life in three South Indian infants on the basis of characteristic clinical features and a positive sweat test."1.26Cystic fibrosis in South India. ( Hill, PG; Jadhav, M; Maya, PP; Sudarsanam, D, 1980)

Research

Studies (1,143)

TimeframeStudies, this research(%)All Research%
pre-1990582 (50.92)18.7374
1990's113 (9.89)18.2507
2000's172 (15.05)29.6817
2010's212 (18.55)24.3611
2020's64 (5.60)2.80

Authors

AuthorsStudies
Ramsey, B1
Bush, A7
Naehrlich, L4
Dörr, HG1
Bagheri-Behrouzi, A2
Rauh, M1
SILVERMAN, FN1
SHIRKEY, HC1
REEMTSMA, K2
DI SANT'AGNESE, PA11
MALM, JR1
BARKER, HG2
MACDOUGALL, LG1
Nguyen, TD1
Kim, US1
Perrine, SP1
Santos, GF1
Reenstra, WW1
Chao, AC1
Zifferblatt, JB1
Wagner, JA1
Dong, YJ1
Gruenert, DC1
Gardner, P2
Matson, RS1
Rampal, JB1
Coassin, PJ1
Gabriel, SE1
Makhlina, M1
Martsen, E1
Thomas, EJ1
Lethem, MI1
Boucher, RC5
Vagenakis, AG1
Braverman, LE1
Mason, DK1
Harden, RM1
Alexander, WD1
Reynaerts, A2
Vermeulen, F5
Mottais, A1
Gohy, S2
Lebecque, P7
Frédérick, R1
Vanbever, R1
Leal, T8
Terlizzi, V4
Claut, L2
Colombo, C4
Tosco, A4
Castaldo, A2
Fabrizzi, B1
Lucarelli, M1
Cimino, G2
Carducci, C1
Dolce, D2
Biffi, A1
Bonomi, P1
Timpano, S1
Padoan, R9
Maguire, B1
Blake, O1
Boran, G1
Borovickova, I1
Abdelfadil, S1
Murray, C1
Elnazir, B1
Linnane, B2
Pallenberg, ST1
Junge, S1
Ringshausen, FC1
Sauer-Heilborn, A1
Hansen, G1
Dittrich, AM1
Tümmler, B10
Nietert, M1
Gonska, T12
Keenan, K3
Au, J1
Dupuis, A5
Chilvers, MA1
Burgess, C1
Bjornson, C1
Fairservice, L1
Brusky, J1
Kherani, T1
Jober, A1
Kosteniuk, L1
Price, A1
Itterman, J1
Morgan, L1
Mateos-Corral, D1
Hughes, D1
Donnelly, C1
Smith, MJ2
Iqbal, S1
Arpin, J1
Reisman, J1
Hammel, J1
van Wylick, R1
Derynck, M1
Henderson, N1
Solomon, M6
Ratjen, F2
Woodley, FW1
Gecili, E1
Szczesniak, RD1
Shrestha, CL1
Nemastil, CJ1
Kopp, BT1
Hayes, D3
Cirilli, N6
Southern, KW8
Barben, J10
Munck, A15
Wilschanski, M11
Nguyen-Khoa, T8
Aralica, M3
Simmonds, NJ5
De Wachter, E3
Leniček Krleža, J1
Tješić-Drinković, D1
Crneković, K1
Culej, J1
Fressl Juroš, G1
Horvat, V1
Metzner, D1
Pamuković Jaram, D1
Pipić Kitter, A1
Smaić, F1
Šimić Vojak, S1
Šimičević, L1
Verić, V1
Gallagher, A1
Hooley, K1
Costello, S1
Felsenstein, S1
Mullane, D1
Dempsey, E1
Ní Chróinín, M1
DeRose, L1
Kim, J2
Farahmand, M1
Shinbashi, MY1
Joo, NS2
Wine, JJ4
Mathiaparanam, S1
de Macedo, AN1
Gill, B1
Pedder, L1
Hill, S1
Britz-McKibbin, P1
Hatton, A3
Drummond, D1
Aoust, L1
Schlatter, J1
Martin, C1
Ramel, S1
Kiefer, S1
Gachelin, E1
Stremler, N2
Cosson, L1
Gabsi, A1
Remus, N3
Benhamida, M1
Hadchouel, A1
Fajac, I12
Girodon, E10
Sermet-Gaudelus, I15
Mayer-Hamblett, N7
Zemanick, ET4
Odem-Davis, K2
VanDevanter, D1
Warden, M1
Rowe, SM19
Young, J1
Konstan, MW11
Birket, SE1
Burat, B1
Baiwir, D1
Fléron, M1
Eppe, G1
Mazzucchelli, G1
Sahoo, N1
Dhochak, N1
Jat, KR1
Sankar, J1
Lodha, R3
Sethuraman, G2
Kabra, M3
Kabra, SK4
Solomon, GM1
Melotti, P6
Graeber, SY2
Bronsveld, I7
Cutting, GR10
Reynaud, Q2
Durupt, S3
Durieu, I5
Salinas, DB1
Ginsburg, DK1
Wee, CP1
Saeed, MM1
Brewington, JJ1
Bedran, RM2
Alvim, CG3
Sader, OG1
Alves Júnior, JV1
Pereira, FH1
Nolasco, DM1
Zhang, L2
Camargos, P3
Ha, JH1
Jeong, Y1
Ahn, J1
Hwang, S1
Jeon, S1
Kim, D1
Ko, J1
Kang, B1
Jung, Y1
Choi, J2
Han, H1
Gu, J1
Cho, S1
Kim, H1
Bok, M1
Park, SA1
Jeong, JH2
Park, I1
Alexopoulos, A1
Chouliaras, G1
Kakourou, T1
Dakoutrou, M1
Petrocheilou, A1
Nasi, L1
Thanopoulou, I1
Siahanidou, S1
Kanaka-Gantenbein, C1
Kontara, L1
Michos, A1
Loukou, I1
Nomiyama, S1
Ribeiro, JD6
Rock, MJ10
Baker, M2
Farrell, PM22
Omosule, CL1
Dietzen, DJ2
Roper, SM1
Taghizadeh-Behbahani, M1
Hemmateenejad, B1
Shamsipur, M1
Tavassoli, A1
van Koningsbruggen-Rietschel, S2
Conrath, K3
Fischer, R1
Sutharsan, S2
Kempa, A1
Gleiber, W1
Schwarz, C1
Hector, A1
Van Osselaer, N1
Pano, A1
Corveleyn, S1
Bwirire, D1
Santermans, E1
Muller, K2
Bellaire, S2
Van de Steen, O3
Harris, JK1
Wagner, BD1
Robertson, CE1
Stevens, MJ1
Heltshe, SL7
Sagel, SD4
Heijerman, HGM2
McKone, EF8
Downey, DG1
Van Braeckel, E3
Tullis, E12
Mall, MA7
Welter, JJ1
Ramsey, BW8
McKee, CM4
Marigowda, G3
Moskowitz, SM5
Waltz, D6
Sosnay, PR4
Simard, C4
Ahluwalia, N3
Xuan, F5
Zhang, Y2
Taylor-Cousar, JL7
McCoy, KS3
Middleton, PG4
Dřevínek, P3
Lands, LC3
Polineni, D2
Nair, N1
Savage, J2
Tian, S3
Jain, R1
Zhou, Z5
Alvarez, D1
Milla, C5
Zare, RN1
Brown, A1
Jenkins, L1
Reid, A1
Leavy, A1
McDowell, G1
McIlroy, C1
Thompson, A1
McNaughten, B1
Secunda, KE1
Guimbellot, JS1
Jovanovic, B1
Jain, M2
Bensliman, S1
Lefevre, N1
Duchateau, J1
Hanssens, L1
Bourmaud, A1
Bellon, G5
Picq, P1
Semple, A1
Clark, T1
Allen, NM1
Krishnananthan, T2
Nwokoro, C1
Porzio, M1
Herzig, M1
Bienvenu, T9
Pagin, A1
Burgel, PR4
Audrézet, MP6
Salvatore, M2
Amato, A2
Floridia, G2
Censi, F2
Ferrari, G2
Tosto, F2
Raia, V6
Castaldo, G3
Capoluongo, E2
Caruso, U2
Corbetta, C5
Taruscio, D2
Aalbers, BL2
Hofland, RW1
de Winter-de Groot, KM2
Arets, HGM1
de Kiviet, AC1
van Oirschot-van de Ven, MMM1
Kruijswijk, MA1
Schotman, S1
Michel, S1
van der Ent, CK2
Declercq, D1
Marchand, S2
Van Daele, S1
Van Biervliet, S1
van Mourik, P1
Vonk, AM1
Kruisselbrink, E1
Hirtz, S1
Beekman, JM1
Marvelli, A1
Campi, B1
Mergni, G2
Di Cicco, ME1
Turini, P1
Scardina, P1
Zucchi, R1
Pifferi, M1
Taccetti, G2
Paolicchi, A1
la Marca, G1
Saba, A1
McColley, SA9
Elbert, A1
Wu, R1
Ren, CL5
Sontag, MK6
LeGrys, VA18
Doull, I3
Course, CW2
Hanks, RE1
Forton, JT1
Thia, LP1
Moat, SJ1
Abdul Rahim, FH1
Thambiah, CS1
Samsudin, IN1
Mohamed Mokhtar, N1
Hauke, A1
Oertel, S1
Knoke, L1
Fein, V1
Maier, C1
Brinkmann, F1
Jank, MPM1
Bauer, SE1
Wesson, M1
Oles, SK1
VanDevanter, DR2
Clancy, JP5
Skalland, M1
Sehgal, IS1
Dhooria, S1
Bal, A1
Aggarwal, AN1
Prasad, KT1
Muthu, V1
Sharda, S1
Agarwal, R1
Ray, TR1
Ivanovic, M1
Curtis, PM1
Franklin, D1
Guventurk, K1
Jeang, WJ1
Chafetz, J1
Gaertner, H1
Young, G1
Rebollo, S1
Model, JB1
Lee, SP1
Ciraldo, J1
Reeder, JT1
Hourlier-Fargette, A1
Bandodkar, AJ1
Aranyosi, AJ1
Ghaffari, R1
Haymond, S1
Rogers, JA1
Treggiari, D2
Kleinfelder, K1
Bertini, M1
Tridello, G4
Fedrigo, A1
Pintani, E3
Iansa, P2
Casiraghi, A1
Minghetti, P1
Cipolli, M3
Sorio, C1
Zagefka, H1
Huynh, HP1
Senger, AR1
Derington, CG1
Colantonio, LD1
Herrick, JS1
Cook, J1
King, JB1
Rosenson, RS1
Poudel, B1
Monda, KL1
Navar, AM1
Mues, KE1
Stevens, VW1
Nelson, RE1
Vanneman, ME1
Muntner, P1
Bress, AP1
Ma, B1
Ren, G1
Xu, J1
Yin, C1
Shi, Y1
Rahsepar, AA1
Bluemke, DA1
Habibi, M1
Liu, K1
Kawel-Boehm, N1
Ambale-Venkatesh, B1
Fernandes, VRS1
Rosen, BD1
Lima, JAC1
Carr, JC1
Freitag, TM1
Chen-Sankey, JC1
Duarte, DA1
Ramsey, MW1
Choi, K1
Winkler-Heil, R1
Hussain, M1
Hofmann, W1
Nicotera, AG1
Dicanio, D1
Pironti, E1
Bonsignore, M1
Cafeo, A1
Efthymiou, S1
Mondello, P1
Salpietro, V1
Houlden, H1
Di Rosa, G1
Hayes-Ryan, D1
O'Donoghue, K1
McCarthy, C2
Totorika, A1
Meaney, S1
Pang, RD1
Dormanesh, A1
Hoang, Y1
Chu, M1
Allem, JP1
Girón-Ortega, JA1
Márquez-Coello, M1
Gutiérrez-Saborido, D1
Arizcorreta, A1
Cuesta-Sancho, S1
Girón-González, JA1
Dovrat, G1
Pevzner, S1
Berthon, C1
Lerner, A2
Maimon, E1
Vainer, R1
Karpasas, M1
Ben-Elyiahu, Y1
Moisy, P1
Bettelheim, A1
Zilbermann, I1
Vanden Broeck, SMP1
Nelson, DJ1
Collado, A1
Falivene, L1
Cavallo, L1
Cordes, DB1
Slawin, AMZ1
Van Hecke, K1
Nahra, F1
Cazin, CSJ1
Nolan, SP1
Kranidiotis-Hisatomi, N1
Yi, H1
Oestreich, M1
Kwiezinski, C1
Weller, C1
van Pinxteren, D1
Brüggemann, M1
Mertes, S1
Stratmann, F1
Herrmann, H1
Menin, L3
Borruso, A2
Ren, L1
Liu, L3
Shu, X1
Lin, W1
Yang, P1
Chen, J2
Teo, KL1
Xiao, F1
Wang, H2
Yao, T1
Zhao, X1
Yang, X1
Yu, DYW1
Rogach, AL1
Bordet, A1
Leitner, W1
Gao, S1
Xia, F1
Li, B2
Abdul Razak, IB1
Liu, Y2
Lu, K1
Brown, DE1
Wang, R1
Cheng, Y1
Ni, S1
Qu, H1
Xing, H1
Xu, Z1
Zhu, X1
Yuan, M1
Wang, L3
Yu, J1
Li, Y1
Yang, L1
Liu, H1
Cao, L1
Zhang, S1
Zhao, D1
Yan, T1
Yang, G1
Lin, Z1
Luo, M1
Ye, N1
Lee, SW1
Carnicelli, J1
Getya, D1
Gitsov, I1
Phillips, KS1
Ren, D1
Grützmacher, PG1
Suarez, S1
Tolosa, A1
Gachot, C1
Song, G1
Wang, B1
Presser, V1
Mücklich, F1
Anasori, B1
Rosenkranz, A1
Demireva, M1
Armentrout, PB1
Feng, D1
Cao, K1
He, ZZ1
Knibbs, LD1
Jalaludin, B1
Leskinen, A1
Roponen, M1
Komppula, M1
Jalava, P1
Guo, PY1
Xu, SL1
Yang, BY1
Hu, L1
Zeng, XW1
Chen, G1
Yu, HY1
Lin, L1
Dong, G1
Machulkin, AE1
Shafikov, RR1
Uspenskaya, AA1
Petrov, SA1
Ber, AP1
Skvortsov, DA1
Nimenko, EA1
Zyk, NU1
Smirnova, GB1
Pokrovsky, VS1
Abakumov, MA1
Saltykova, IV1
Akhmirov, RT1
Garanina, AS1
Polshakov, VI1
Saveliev, OY1
Ivanenkov, YA1
Aladinskaya, AV1
Finko, AV1
Yamansarov, EU1
Krasnovskaya, OO1
Erofeev, AS1
Gorelkin, PV1
Dontsova, OA1
Beloglazkina, EK1
Zyk, NV1
Khazanova, ES1
Majouga, AG1
Zheng, YK1
Su, BJ1
Wang, YQ1
Wang, HS1
Liao, HB1
Liang, D1
Shataer, D1
Li, J1
Duan, XM1
Xin, XL1
Aisa, HA1
Allu, SR1
Ravotto, L1
Troxler, T1
Vinogradov, SA1
Cheruku, RR1
Tracy, EC1
Tabaczynski, W1
Missert, JR1
Baumann, H1
Pandey, RK1
Rohde, JM1
Karavadhi, S1
Pragani, R1
Fang, Y1
Zhang, W2
McIver, A1
Zheng, H1
Liu, Q1
Davis, MI1
Urban, DJ1
Lee, TD1
Cheff, DM1
Hollingshead, M1
Henderson, MJ2
Martinez, NJ1
Brimacombe, KR1
Yasgar, A1
Zhao, W1
Klumpp-Thomas, C1
Michael, S1
Covey, J1
Moore, WJ1
Stott, GM1
Li, Z3
Simeonov, A1
Jadhav, A1
Frye, S1
Hall, MD1
Shen, M1
Wang, X2
Patnaik, S1
Boxer, MB1
Zhang, H2
Cheng, C1
Huang, B1
Chen, R1
Huang, Y1
Chen, H1
Pei, W1
Katahara, S1
Sugiyama, Y1
Yamane, M1
Komiya, Y1
Sato, T1
Chida, N1
Kumar, M1
Varkki, SD1
Prenzel, F1
Ceglarek, U1
Adams, I1
Hammermann, J1
Issa, U1
Lohse, G1
Mainz, JG2
Meister, J1
Spittel, D1
Thoss, K1
Vogel, M1
Duckstein, F1
Henn, C1
Hentschel, J1
Fernandez Elviro, C1
Blanchon, S1
Hoehnel, S1
Schumacher, U1
Sauty, A1
Brandenberg, N1
Regamey, N1
Cimbalo, C1
Sepe, A1
Salvadori, L2
Sadou Yayé, H1
Caudron, E1
Nicolis, I1
Prognon, P1
Pradeau, D1
Paul, GR1
Bai, S1
Jackson, K1
Kondratyeva, E1
Bukharova, T1
Efremova, A1
Melyanovskaya, Y1
Bulatenko, N1
Davydenko, K1
Filatova, A1
Skoblov, M1
Krasovsky, S1
Petrova, N1
Polyakov, A1
Adyan, T1
Amelina, E1
Shadrina, V1
Zhekaite, E1
Zodbinova, A1
Chernyak, A1
Zinchenko, R1
Kutsev, S1
Goldshtein, D1
Javanbakht, A1
Kelliher, MT1
Poore, BA1
Harris, VS1
Cervinski, MA1
Barry, PJ3
Álvarez, A1
McBennett, KA1
Jun, LS1
Prieto-Centurion, V1
Krleza, JL1
Emaminejad, S1
Gao, W1
Wu, E1
Davies, ZA1
Yin Yin Nyein, H1
Challa, S1
Ryan, SP1
Fahad, HM1
Chen, K1
Shahpar, Z1
Talebi, S1
Javey, A1
Davis, RW1
Kuehni, CE4
Schindler, M1
Mazur, A1
Malzacher, A1
Hornung, R1
Guerra, L1
D'Oria, S1
Favia, M1
Castellani, S1
Santostasi, T1
Polizzi, AM2
Mariggiò, MA1
Gallo, C1
Casavola, V1
Montemurro, P1
Leonetti, G2
Manca, A2
Conese, M1
Delmas, D1
Lemonnier, L2
Cheillan, D2
Roussey, M8
Caudri, D1
Zitter, D1
Tiddens, H2
Zhang, C1
Kim, JP1
Creer, M1
Yang, J1
Liu, Z1
Collie, JTB1
Massie, J11
Jones, OAH1
Morrison, PD2
Greaves, RF5
Moon, TC2
Laux, J2
Accurso, F3
Dagan, A1
Cohen-Cymberknoh, M1
Shteinberg, M2
Levine, H1
Vilozni, D1
Bezalel, Y1
Bar Aluma, BE1
Sarouk, I1
Ashkenazi, M1
Lavie, M1
Tsabari, R1
Blau, H8
Kerem, E9
Bentur, L4
Efrati, O2
Livnat, G2
Quigley, SJ1
Connellan, S1
Ward, A1
Ryan, P1
Iadevaia, C1
Iacotucci, P2
Carnovale, V2
Calabrese, C1
Rea, G1
Ferrara, N2
Perrotta, F1
Mazzarella, G1
Bianco, A1
Jolly, L2
Scott, S2
Wiley, VC1
Metz, MP1
Mackay, RJ2
Ibarra-González, I1
Campos-Garcia, FJ1
Herrera-Pérez, LDA1
Martínez-Cruz, P1
Moreno-Graciano, CM1
Contreras-Capetillo, SN1
León-Burgos, V1
Maldonado-Solis, FA1
Alcántara-Ortigoza, MA1
González Del Angel, A1
Vela-Amieva, M1
Durmowicz, AG3
Lim, R1
Rogers, H1
Rosebraugh, CJ3
Chowdhury, BA3
Edmondson, C1
Grime, C1
Prasad, A1
Cowlard, J1
Nwokoro, CEC1
Ruiz, G1
Wallis, C3
Balfour-Lynn, IM3
Başaran, AE1
Karataş-Torun, N1
Maslak, İC1
Bingöl, A1
Alper, ÖM1
Espel, JC1
Palac, HL1
Bharat, A1
Cullina, J1
Prickett, M1
Sala, M1
Ruf, K1
Demerath, A1
Hebestreit, H1
Kunzmann, S1
Braggion, C2
Sirianni, S1
Seia, M4
Pisi, G1
Spaggiari, C1
Quattromano, E1
Bignamini, E1
Brandino, D1
Bella, S1
Argentini, R1
Bolia, R1
Hardikar, W1
Robinson, P4
Wiencek, JR1
Lo, SF1
Lewis, D1
Blow, A1
Tye, J1
Hew-Butler, T1
Choi, DH2
Thaxton, A1
Jeong, IC1
Kim, K1
Searson, PC2
Rocco, I1
De Gregorio, F1
Sepe, AO1
Buzzetti, R1
Minicuci, N1
Abou Alaiwa, MH1
Launspach, JL1
Grogan, B1
Carter, S1
Zabner, J3
Stoltz, DA1
Singh, PK1
Welsh, MJ2
Siddaiah, R1
Thau, E1
Graff, G1
Gomez, CCS1
Marson, FAL2
Servidoni, MF3
Ribeiro, AF5
Ribeiro, MÂGO1
Gama, VAL1
Costa, ET2
Vieira Junior, FU1
Nagy, B1
Bene, Z1
Fejes, Z1
Reid, D1
Ronan, NJ1
McCarthy, Y1
Smith, D1
Nagy, A1
Joseloff, E2
Balla, G1
Kappelmayer, J1
Macek, M5
Bell, SC3
Plant, BJ5
Amaral, MD2
Balogh, I1
Keating, D1
Burr, L1
Daines, C1
Sass, LA1
Robertson, S3
Van Goor, F5
Young, T2
Davies, JC9
Brown, C1
Horsley, A1
Prais, D1
Uluer, A1
Shilling, RA1
Bratcher, PE1
Hunt, KC1
Pickard, K1
Bend, J1
Martiniano, SA1
Hangül, M1
Pekcan, S1
Köse, M1
Acıcan, D1
Şahlar, TE1
Erdoğan, M1
Kendirci, M1
Güney, D1
Öznavruz, H1
Demir, O1
Ercan, Ö1
Göçlü, F1
Masson, A1
Schneider-Futschik, EK1
Baatallah, N1
Flament, T1
Le Bourgeois, M3
Chedevergne, F1
Bailly, C1
Kyrilli, S1
Achimastos, D1
Hinzpeter, A1
Edelman, A4
Rueegg, CS3
Gallati, S4
Jurca, M2
Jung, A1
Casaulta, C3
Brewington, J1
Kmit, A1
Pereira, SV1
Vinagre, AM2
Leite, GS1
Bertuzzo, CS3
Singh, A1
Shastri, S2
Sreedevi, KN2
Hanks, R1
Gartner, S1
Castellani, C14
Mayell, SJ2
Winters, V1
Murphy, J1
Salinas, D1
Rosenfeld, M3
Cunningham, S2
Harris, WT2
Lapey, A4
Regelmann, WE4
Sawicki, GS2
Chilvers, M2
Higgins, M1
Cooke, J2
De Boeck, K8
Elborn, JS6
Minić, P1
Verhulst, S1
Kanters, D2
de Kock, H2
Geller, DE2
van der Ent, K1
Derichs, N5
Allamassey, L1
Namour, F1
Pao, C1
Antrum, JHG1
Allison, K1
Salvatore, D1
Colangelo, C1
Francalanci, M1
Lucidi, V2
Vitullo, P1
Walker, S1
Flume, P1
McNamara, J2
Chmiel, J1
Harris, RS1
Haseltine, E1
Stiles, D1
Li, C2
Zhou, H1
Owen, CA1
Sawicki, G1
Yaakov, Y2
Santra, G1
Banerjee, S1
Pullan, NJ1
Thurston, V1
Barber, S1
Seliger, VI1
Rodman, D2
Schmelz, A1
Mueller, P1
Wing, D1
Prausnitz, MR1
Buono, MJ1
Torresani, T1
Fingerhut, R1
Baumgartner, MR1
Toh, HS1
Batchelor-McAuley, C1
Tschulik, K1
Compton, RG1
Lewis, DP1
Hoffman, MD1
Stuempfle, KJ1
Owen, BE1
Rogers, IR1
Verbalis, JG1
Hew-Butler, TD1
Traeger, N1
Shi, Q1
Dozor, AJ1
Dalbeck, M1
Valiulis, A1
Skurvydienė, I1
Misevičienė, V1
Kasnauskienė, J1
Vaidelienė, L1
Utkus, A1
Michl, RK1
Mentzel, HJ1
Gerber, A1
Beck, JF1
Harrison, MJ1
Murphy, DM1
McGarry, ME2
Nielson, DW2
Witzmann, KA2
Ooi, CY3
Ellis, L6
Jarvi, K3
Martin, S4
Ray, PN1
Steele, L2
Kortan, P2
Dorfman, R3
Zielenski, J9
Corey, M14
Durie, P9
Char, JE2
Cho, HJ2
Dunn, C2
Frisbee, E2
Modlin, SE1
Park, IH2
Thomas, EA2
Tran, KV1
Verma, R1
Wolfe, MH2
Weil, B1
Chaillou, E1
Troussier, F1
Pelatan, C1
Chiffoleau, M1
Darviot, E1
Chevalier, MC1
Martin, L1
Giniès, JL2
Collie, JT2
Massie, RJ4
Jones, OA2
Jones, AM1
Webb, AK1
Horsley, AR1
Grasemann, H1
Mena-Bravo, A1
Luque de Castro, MD1
Welsh, SK1
Gross, JE1
Larson, NS1
Berg, JM1
Roy, D1
Pinsker, JE1
Chinazzo, C1
De Alessandri, A1
Menoni, S1
Romanisio, G1
Rebora, A1
Rongioletti, F1
Mattar, AC1
Leone, C1
Rodrigues, JC1
Adde, FV1
Davies, Z1
Moss, RB2
Williams, SN1
Nussbaum, E3
Chin, TW1
Do, PC1
Singh, KE1
Randhawa, I1
Aqil, B1
West, A1
Dowlin, M1
Tam, E1
Nordstrom, C1
Buffone, G1
Devaraj, S1
Bonadia, LC1
de Lima Marson, FA1
Paschoal, IA2
Pereira, MC2
Accurso, FJ8
Zha, J2
Stone, AJ2
Dong, Q2
Ordonez, CL3
Hoch, HE1
Campbell, PW4
Ashlock, MA2
Ni, A1
Ray, P1
Awasthi, S1
Dixit, P1
Maurya, N1
Malfroot, A2
Rosenbluth, DB1
Walker, PA1
Knoop, C1
Quattrucci, S1
Rietschel, E2
Zeitlin, PL7
Barth, J1
Elfring, GL1
Welch, EM1
Branstrom, A1
Spiegel, RJ1
Peltz, SW1
Ajayi, T1
Quinton, PM6
Makholm, L2
Eickhoff, J1
Sengar, AS1
Agarwal, A1
Singh, MK1
Donaldson, SH2
Borowitz, D1
Gelfond, D1
Khan, U1
Van Dalfsen, JM1
Boyle, MP2
Huang, X1
Patel, NR1
Kubáň, P1
Greguš, M1
Pokojová, E1
Skřičková, J1
Foret, F1
Doorn, J1
Storteboom, TT1
Mulder, AM1
de Jong, WH1
Rottier, BL1
Kema, IP1
El-Chammas, KI1
Rumman, N1
Goh, VL1
Quintero, D1
Goday, PS1
Christiansen, AL1
Nybo, M1
Ferril, GR1
Nick, JA1
Getz, AE1
Barham, HP1
Saavedra, MT1
Nichols, DP1
Curran-Everett, D1
Kingdom, TT1
Ramakrishnan, VR1
Bagheri-Hanson, A1
Nedwed, S1
Rueckes-Nilges, C1
Gomez, CC2
Servidoni, Mde F1
Marson, FA2
Canavezi, PJ1
Ribeiro, MA2
Toro, AA2
Pavan, CR1
Rondon, MV1
Lorena, SL1
Vieria, FU1
DeMarco, ML1
Brown, SM2
Mandal, A1
Tian, X2
Xu, KF2
Xu, W1
Li, X3
Yue, C1
Zhang, P1
Xiao, Y1
Zhang, X1
Gomes, DL1
Gomes, FS1
Cajazeiro, JM1
Mazumdar, M1
Christiani, DC1
Biswas, SK1
Ibne-Hasan, OS1
Kapur, K1
Hug, C1
Velentgas, P1
Swenson, AJ1
Goss, CH1
Vernooij-van Langen, A1
Dompeling, E1
Yntema, JB1
Arets, B1
Loeber, G1
Dankert-Roelse, J2
Essawi, O1
Farraj, M1
De Leeneer, K1
Steyaert, W1
De Pauw, K1
De Paepe, A1
Claes, K1
Essawi, T1
Coucke, PJ1
Steiß, JO1
Zimmer, KP1
Nährlich, L1
Rodriguez, S1
Ahrens, R1
Johnson, C1
Mu, X1
Xin, X1
Fan, C1
Zheng, Z1
Groves, T2
Wiley, V1
Fitzgerald, DA2
Guglani, L2
Abdulhamid, I1
Najafi, M1
Alimadadi, H1
Rouhani, P1
Kiani, MA1
Khodadad, A1
Motamed, F1
Moraveji, A1
Hooshmand, M1
Haghi Ashtıani, MT1
Rezaei, N1
Levy, H4
Ramsey, KA1
Schultz, A1
Stick, SM1
Grimaldi, C1
Brémont, F2
Berlioz-Baudoin, M1
Brouard, J2
Corvol, H3
Couderc, L1
Lezmi, G1
Pin, I2
Petit, I1
Reix, P3
Schweitzer, C1
Thumerelle, C1
Dubus, JC1
De Schutter, I1
Meulemans, A1
Buyl, R1
Schulz, A1
Selimovic, A1
Mujicic, E1
Milisic, S1
Mesihovic-Dinarevic, S1
Dzinovic, A1
Cengic, S1
Bakalovic, G1
Moro, M1
Djozic, M1
Lukic-Bilela, L1
Nugent, M1
Schneck, K2
Stachiw-Hietpas, D1
Laxova, A4
Lakser, O1
Rock, M1
Dahmer, MK1
Biller, J1
Nasr, SZ2
Simpson, P1
Tamanini, A3
Assael, BM2
Green, Y1
Shen, Y1
Liu, J1
Zhong, L1
Mogayzel, PJ3
Zhao, S1
Spalinger, J1
Carta, C1
de Stefano, MC1
Lee, M2
Vecchio-Pagán, B1
Sharma, N1
Waheed, A1
Raraigh, KS3
Robbins, S1
Han, ST1
Franca, AL1
Pellicore, MJ1
Evans, TA1
Arcara, KM1
Nguyen, H1
Luan, S1
Belchis, D1
Hertecant, J1
Sly, WS1
Le Camus, C1
Bilton, D2
Milenković, D1
Bergougnoux, A1
Boureau-Wirth, A1
Rouzier, C1
Altieri, JP1
Verneau, F1
Larrieu, L1
Koenig, M1
Claustres, M3
Raynal, C2
Souza Dos Santos Simon, MI1
Forte, GC1
da Silva Pereira, J1
da Fonseca Andrade Procianoy, E1
Drehmer, M1
Collaco, JM2
Blackman, SM1
Rommens, JM1
Pace, RG1
Boelle, PY1
McGready, J1
Strug, LJ1
Knowles, MR10
Bergamini, G1
Toltzis, P1
Kharrazi, M2
Wine, J1
Mesbahi, M1
Friedman, H1
Cohen, M1
Escabasse, V1
Bassinet, L2
Fidler, MC1
Beusmans, J1
Panorchan, P1
Faria, AG1
Morais, LB1
Sakano, E1
Goto, M1
Hessel, G1
Levy, CE1
Peixoto, AO1
Simões, MC1
Lomazi, EA1
Nogueira, RJ1
Yoshida, R1
Ruge, B1
Emiralioğlu, N1
Özçelik, U1
Yalçın, E1
Doğru, D1
Kiper, N2
Illek, B1
Ly, NP1
Zlock, L1
Olshansky, S1
Moreno, C1
Finkbeiner, WE1
de Monestrol, I1
Gulmans, V2
Wanyama, S1
Thomas, M2
Kim, JS1
Ratkiewicz, M1
Pastore, M1
Thompson, R2
Sheikh, SI1
Schultz, AN1
Høiby, N1
Nielsen, XC1
Pressler, T1
Dalhoff, K1
Duno, M1
Buchard, A1
Johansen, HK1
Dalbøge, CS1
Bosch, B1
Sosnay, P1
Mak, DYF1
Ishiguro, H2
Cuppens, H4
Amaral, M1
Couderc Kohen, L1
Weiss, L1
Wizla, N1
Vrielynck, S1
LLerena, K1
Deneuville, E5
Leonard, A2
Godding, V2
Villanueva, P1
Wallemacq, P2
Mishra, A2
Greaves, R2
Smith, K1
Carlin, JB1
Wootton, A1
Stirling, R1
Buchdahl, R1
Rosenstein, BJ9
White, TB2
Durie, PR8
Parad, RB5
Kleven, DT1
McCudden, CR1
Willis, MS1
Kim, SJ1
Cha, SI1
Park, HY2
Ahn, KM2
Ki, CS1
Kim, JH2
Sharp, JK1
Gonzalo-Ruiz, J1
Mas, R1
de Haro, C1
Cabruja, E1
Camero, R1
Alonso-Lomillo, MA1
Muñoz, FJ1
Florkowski, CM1
George, PM1
Sies, CW1
Woods, S1
Craig, JV1
Sermet, I2
Brownlee, KG1
Schwarz, MJ1
O'Sullivan, BP4
Zwerdling, RG1
Soultan, ZN1
Foster, MM1
Newman, NB1
Anbar, RD2
Stanke, F2
Veeze, H2
Ballmann, M4
Coman, T1
Desmazes-Dufeu, N2
Hubert, D7
Kanaan, R1
Dusser, D6
Khemiri, M1
Ben Rhouma, A1
Bouzid, S1
Messaoud, T1
Guesmi, M1
Hamzaoui, M1
Fattoum, S1
Khaldi, F1
Barsaoui, S1
Costantino, L1
Paracchini, V1
Porcaro, L2
Capasso, P1
Coviello, D1
Torresani, E1
Magazzù, D1
Consalvo, V1
Monti, A1
Costantini, D2
Goubau, C1
Skalická, V3
Hjelte, L1
Vasar, M1
Rose, JB1
John, B1
Adeli, K1
Dwyer, TJ1
Alison, JA1
McKeough, ZJ1
Elkins, MR1
Bye, PT1
Coakley, J1
Mackay, R2
Bransden, A1
Doery, JC1
Chiriano, A1
Robins, H2
Montgomery, GS1
Howenstine, M1
Abdul-Wahab, A2
Janahi, IA2
Abdel-Rahman, MO2
Ip, W2
Turner, D1
Han, WS1
Rose, J1
Quinton, P2
Penmatsa, H1
Frederick, CA1
Nekkalapu, S1
Conoley, VG1
Kappes, J1
Stokes, DC1
Naren, AP1
Grenet, D1
Siret, D1
Languepin, J1
Mely, L1
Fanton, A1
Labbé, A3
Domblides, P1
Vic, P2
Dagorne, M1
Reynaud-Gaubert, M1
Counil, F1
Varaigne, F1
Bellis, G2
Abu-Alshiekh, NK1
Kofahi, SM1
Nusair, ZM1
Keating, CL1
Liu, X1
Dimango, EA1
Goldberg, S1
Schwartz, S1
Mimouni, F1
Francis, M1
Stankiewicz, H1
Izbicki, G1
Picard, E1
Pytrus, T1
Iwańczak, B1
Smigiel, R2
Ryzko, J1
Socha, P1
Iwańczak, F2
Svensson, AM1
Chou, LS1
Miller, CE1
Robles, JA1
Swensen, JJ1
Voelkerding, KV1
Mao, R1
Lyon, E1
Panny, SR1
Hamosh, A1
Crestani, B1
Beucher, J1
Leray, E1
Roblin, M1
Turck, D2
Foucaud, P1
Rault, G2
Derelle, J1
David, V1
Journel, H1
Veillard, D1
Al-Mendalawi, MD2
Hall, E1
Lapworth, R1
Hale, JE1
Dorkin, HL2
Gerstle, R2
Spencer, T1
Yee, W1
Comeau, AM4
Roussel, D3
Bui, S3
Huet, F4
Guillot, M1
Aboutaam, R1
Renouil, M1
des Georges, M1
Iron, A4
Thauvin-Robinet, C2
Lenoir, G4
Sands, D3
Stremmler, N1
Vavrova, V9
Lebourgeois, M1
Sarles, J1
Sanz, J1
Von Kanel, T1
Stolpe, C1
Zapf, A1
Sommerburg, O1
Lindner, M1
Muckenthaler, M1
Kohlmueller, D1
Leible, S1
Feneberg, R1
Kulozik, AE1
Hoffmann, GF1
Rota, M1
Feldmann, D5
Chawla, A1
Turcotte, FG1
Usmani, K1
Kanu, AC1
D'Souza, L1
Roughton, M1
Alton, EW3
Hodson, ME4
Brunswick, P1
Calvet, JH1
Freedman, SD4
Berthiaume, Y1
Schibli, S1
Ołtarzewski, M1
Nowakowska, A3
Zybert, K1
Dunitz, JM1
Hornick, DB1
Pilewski, JM1
Rubenstein, RC4
Uluer, AZ1
Aitken, ML3
Rose, LM1
Olson, ER1
Dillard, JP3
Shen, L1
Robinson, JD1
Lang, CW1
Lester, LA1
Ross, LF1
Brown, MB2
Haack, KK1
Pollack, BP1
Millard-Stafford, M2
McCarty, NA4
Desai, H1
Platt, M1
Dixon, M1
Hooman, N1
Jafari, D1
Jalali-Farahani, S1
Lahouti Harahdashti, A1
Hulstein, JJ1
van 't Sant, P1
Nelson, MR1
Adamski, CR1
Tluczek, A4
Sebro, R1
Dimmock, D1
Raby, BA1
Cannon, CL1
Broeckel, U1
Risch, NJ1
Kirk, JM6
Sitwat, B1
Lower, D1
Kurland, G1
Weiner, DJ1
Zaleski, C2
Sanders, DB1
Lai, HJ1
Keiles, S1
Koepke, R1
Parad, R1
Curnow, L1
Glazner, J2
Armstrong, DS1
Francis, I2
Cornel, MC2
Gille, JJ1
Loeber, JG1
Vernooij-van Langen, AM1
Bolhuis, PA1
Flume, PA2
Liou, TG1
Borowitz, DS1
Li, H1
Yen, K1
Wagener, JS2
Nakakuki, M1
Fujiki, K1
Yamamoto, A1
Ko, SB1
Yi, L1
Ishiguro, M1
Yamaguchi, M1
Kondo, S1
Maruyama, S1
Yanagimoto, K1
Naruse, S1
Krulišová, V1
Balaščaková, M1
Piskáčková, T1
Holubová, A1
Paděrová, J1
Křenková, P1
Dvořáková, L1
Zemková, D1
Kračmar, P1
Chovancová, B1
Stambergová, A1
Votava, F1
Laguna, TA2
Lin, N1
Wang, Q1
Holme, B1
Molyneux, L1
Avolio, J1
Conrad, D1
Shamsuddin, AK1
Padman, R1
Flathers, K1
Passi, V1
La Pean, A1
Farrell, MH1
Eskra, KL1
de Becdelièvre, A1
Jimenez, C1
Lalau, G2
Gautier, E1
Rollet, J3
Flori, J1
Nové-Josserand, R1
Soufir, JC1
Haloun, A1
Houssin, E1
David, A1
Janny, L1
Chiron, R1
Rives, N1
Hairion, D1
Collignon, P1
Valeri, A1
Karsenty, G1
Rossi, A1
Férec, C4
Leclerc, J1
Georges, Md1
Gérard, B1
Boisseau, P1
Cabet-Bey, F1
Clavel, C2
Bieth, E2
Simon-Bouy, B1
Izard, V1
Steffann, J1
Viville, S1
Costa, C1
Drouineaud, V1
Fauque, P1
Binquet, C1
Bonithon-Kopp, C1
Morris, MA1
Faivre, L1
Goossens, M3
Bassotti, A2
Ambrosioni, A1
Giunta, A1
Groman, JD1
Meyer, ME1
Wilmott, RW2
Korpela, K1
Kostuch, M1
Rudzki, S1
Semczuk, A1
Kulczycki, L1
Molina, G1
González, FJ1
Cave, R1
Cornejo de, M1
Navarro, S1
Deglin, M1
Milinarsky, A1
Carvallo de, P1
Leite, MF1
Nathanson, MH1
Gera, S1
Chacko, S1
Mathew, J1
Ghosh, M1
Lebacq, J1
Cumps, J1
Chinet, T2
Blouquit, S1
Ashavaid, TF1
Dherai, AJ1
Kondkar, AA1
Raghavan, R1
Udani, SV1
Udwadia, ZF1
Desai, D1
Sheth, S1
Shea, JC1
Bishop, MD1
Chopra, S1
Regan, MM1
Malmberg, E1
Walker, C1
Ricci, R1
Tsui, LC6
van den Bergh, FA1
Martens, A1
Lee, DS1
Rosenberg, MA1
Peterson, A1
Hoffman, G3
Laessig, RH2
Locham, KK1
Sodhi, M1
Kamath, BM1
Bhargava, S1
Markowitz, JE1
Ruchelli, E1
Scanlin, TF2
Mascarenhas, M1
Viel, M1
Leroy, C1
Van Esch, H1
Couderc, R1
Desgeorges, M1
Mittre, H1
Blayau, M1
Bozon, D1
Malinge, MC1
Monnier, N1
Bonnefont, JP2
Dumur, V3
Cazeneuve, C1
Yiğit, H1
Selimoğlu, MA1
Altinkaynak, S1
DARLING, RC4
DISANT'AGNESE, PA1
PERERA, GA2
ANDERSEN, DH1
DI SANT'AGNESE, P2
PERARA, GA1
SHEA, E2
LICHT, TS1
STERN, M2
SHWACHMAN, H23
WEBB, BW1
FLUTE, PT1
VINK, CL2
STOPPELMAN, MR1
MACFARLANE, JC1
NORMAN, AP1
STROUD, CE1
FINCH, E1
FIGUEIRA, F1
MATTAR, G1
DA MARQUES, JC1
WEEKS, MM1
BROWN, GA1
MISCH, KA1
HOLDEN, HM1
ANDERSON, CM7
FREEMAN, M4
CATZEL, P1
HENNEQUET, A3
DEBRIS, P1
MARIE, J1
JADRNICEK, M1
PODIVINSKY, R1
GROSSMAN, H1
DENNING, CR3
FISCHL, J1
SEGAL, S1
GIBBS, GE3
LUTIER, F1
GIBSON, LE10
COOKE, RE1
GLUCK, L1
WOOD, JA1
FISHMAN, AP1
ARISZ, L1
MALKIEWICZ, ML1
REINKING, JW1
de VRIES, W1
CLARKE, JT1
ELIAN, E1
FANCONI, A1
HUTCHINGS, RH1
GRONBEAK, P1
HUHNSTOCK, K2
SCHWARZ, G2
DEBRIS, MM3
ISRAEL, L3
SCHULTZE-JENA, BS2
KRYSTIK, F1
KOCH, F1
TOLCKMITT, W1
ZELLMER, R2
MEIMBERG, A1
KOCH, E1
BLOXSOM, A1
BRODKEY, JS1
GHADIMI, H1
ALLAN, J1
HUBBARD, L1
ANDREWS, BF1
BRUTON, OC1
KNOBLOCK, EC1
BATSON, R1
YOUNG, WC1
SHEPARD, FM1
BORGHERESI, S1
SILENZI, M1
BOUCHER, H1
SOUQUET, R1
ROUMAGOUX, J1
FROMANTIN, M1
ROQUES, C1
SATTA, S1
ROYER, G1
PARADO, C1
BRETON, A1
PONTE, C1
GAUDIER, B1
TRAISNEL, M1
COLTMAN, CA2
ATWELL, RJ2
DUBOWSKI, KM1
ETHERIDGE, JE1
BIRDSONG, M1
EYERMAN, EL1
HURLEY, RJ1
IRWIN, RL1
FORTINA, A1
SJAASTAD, O1
STUR, O5
ZIMPRICH, H1
TOMASOVA, H4
VOKAC, Z1
van TONGEREN, J1
LOBECK, CC4
MCSHERRY, NR3
PERRINI, M1
DALFINO, G3
PESOLA, EL1
VISAKORPI, JK1
PHILLIPS, WR2
DISANT AGNESE, PA1
SIEGENTHALER, P7
HAMPAI, A2
SPAHR, A1
VULLIET, V1
FAVRE, R1
DUNHAM, R1
WEIGEL, HW1
PARSONS, J1
ELRICK, H1
HLAD, CJ1
MILLER, E1
CATTA, J1
BELLIARD, P1
COATES, EO2
BRINKMAN, GL1
DEL ZOTTI, G2
PROTO, R2
SLEGERS, JF3
ROMANO, C1
BERTOLOTTI, E1
DEPRA, M1
GUP, AM1
BRIGGS, GW1
SINGER, Z2
KOWALSKI, S2
MACHALSKI, M2
DEHALLER, R1
DUBACH, UC1
GOLDBLOOM, RB1
SEKELJ, P2
PERRY, DJ1
MOUNT, GE1
WRIGHT, ET1
SIBINGA, MS2
BARBERO, GJ3
LIEBERMAN, J2
KELLOGG, F1
PRUITT, A1
KARLISH, AJ1
TARNOKY, AL3
FRANCOIS, R1
ZSOLDOS, G1
BAN, I1
ALBERT, B1
DE HALLER, R3
RICHTERICH, R3
FRIOLET, B3
CAVALIERI, S2
MASTELLA, G14
BERNARD, R1
COIGNET, J1
CASAMATA, G1
GERIN, E1
WISER, WC1
BEIER, FR1
TYRAKOWSKA, J2
GWOZDZIEWICZ, T1
SCHAEPPI, R1
VANCURA, P1
BERNARD, E1
ISRAUEL, L1
TIPARESCU, E1
VASILIU, A1
DUMITRESCU, M1
BARTA, L1
SZABO, J1
SZOEKE, L1
JIRKA, M4
SPOCK, A4
WILSON, WP1
HALLER, J1
HALLER, R1
MULLER, AF2
BARRERAHERNANDEZ, EU1
KOPITO, L6
CANCIULLO, D1
CARCO, P1
CASTELLINI, G1
OSINSKA, B1
SADOWNIK, J1
TERRENI, F1
TADDEUCCI, E1
TROUTMAN, EG2
GHARIB, R1
JOOS, HA1
HILTY, LB1
STANDLEY, ET1
KULCZYCKI, LL3
GUIN, GH1
MANN, N1
MAHMOODIAN, A6
TOWNLEY, RR1
KHAW, KT5
SEGAR, WE1
HANCOCK, CJ1
SAWYER, T1
BULLARD, RW1
CHWALIBOGOWSKI, A1
SOBANSKI, T1
ZAREBA, J5
MYERS, MF1
HIRAYAMA, T1
UNO, K1
SHIROTA, H1
WARWICK, WJ12
HANSEN, L4
HEUSDEN, A2
BAUCHE, P1
DODINVAL, P1
THAMDRUP, E1
GRONAEK, P1
LARSEN, JV1
LARON, Z1
PETERSON, EM2
SIMANKOVA, N3
BELSKA, M1
RASKA, B1
HUEBNER, R1
KLOTZ, HP1
CHIMENES, H1
HUEBNER, D1
OKNINSKA, A1
OLIVER, WJ1
WATSON, DF1
ROTHENBERGER, D1
RUIZ LOPEZ, A1
GORDON DE CAMIN, D1
ALEJANDRO AMPUERO, P1
DE LA ROSA DE AMPUERO, SI1
Augarten, A6
Berman, H1
Aviram, M4
Diver-Habber, A1
Akons, H3
Ben Tur, L2
Rivlin, J2
Katznelson, D2
Szeinberg, A5
Kerem, BS4
Theodor, L1
Paret, G2
Yahav, Y6
Modi, AC1
Quittner, AL1
Baumer, JH1
Leigh, MW1
de Sousa, JS1
Ferrer González, P1
Pereda Pérez, A1
Ferrer Calvete, J2
Carson, CL1
Bernard, CJ1
Levy, EM1
Granados, P1
Rawe, V1
Olmedo, SB1
Luna, MC1
Cafferata, E1
Pivetta, OH1
Davis, PB6
Schluchter, MD1
Festini, F1
Braccini, G1
Campana, S1
de Martino, M1
Dawson, KP1
Frossard, PM1
Al-Awar, B1
Dodge, JA4
Dequeker, E2
Lezana, JL1
Vargas, MH1
Karam-Bechara, J1
Aldana, RS1
Furuya, ME1
Ellaffi, M1
Dall'ava-Santucci, J1
Katherisan, N1
Gupta, A1
Mumford, S1
Cade, A1
Jones, R1
Gilljam, M1
Tullis, DE1
Lukela, M1
DeGuzman, D1
Weinberger, S1
Saint, S1
Moser, C1
Funk, MJ1
Ammann, RA2
Metlagel, A1
Schoeni, MH3
Clements, B1
Lee, JH1
Lee, MG1
Kang, IJ1
Lee, SI1
Davé, S1
Honney, S1
Raymond, J1
Beauchamp, M2
Eng, W1
Schechter, MS1
Laughon, MM1
Barker, PM1
Miller, S1
Sorscher, EJ1
Koscik, RL2
Highsmith, WE3
Friedman, KJ5
Burch, LH3
Silverman, LM6
Grey, V1
Gilbert, CJ1
Griffiths, MJ1
Holland, MR1
Gama, R1
Dovey, M1
Martin, T1
Kopish, GJ1
Litsheim, TJ1
Hammond, KB3
Epaud, R1
Niel, F1
Guigonis, V1
Clement, A3
Bensman, A1
Ulinski, T1
Taylor, C1
Dodge, J2
Sinaasappel, M1
George, P1
Kirk, J2
Mainz, J1
Hammer, U1
Rokahr, C1
Hubler, A1
Zintl, F1
Bradley, JM1
Naguib, ML1
Schrijver, I1
Pique, LM1
Doss, SS1
Abu Zekry, MA1
Aziz, M1
Modaff, P1
Pfeil, D1
Lifchez, C1
Freeman, ME1
Gershan, W1
Sullivan, B1
Losty, HC1
Wheatley, H1
Ziedalski, TM1
Kao, PN1
Henig, NR1
Jacobs, SS1
Ruoss, SJ1
Hokanson, JE1
Marshall, JA1
Sommer, SS1
Zerbe, GO1
Minasian, CC1
Sriskandan, S1
Ballestero, Y1
Hernandez, MI1
Rojo, P1
Manzanares, J1
Nebreda, V1
Carbajosa, H1
Infante, E1
Baro, M1
Van Hoorenbeeck, K1
Storm, K1
van den Ende, J1
Biervliet, M1
Desager, KN1
Green, A8
Wilfond, BS2
Russo, MC1
Nobili, R1
Valle, EP1
Burgos, RI1
Valle, JR1
Egas Béjar, D1
Ruiz-Cabezas, JC1
Desax, MC1
Hammer, J1
Spinas, R1
Schöni, MH3
Yankaskas, JR1
Quittell, LM1
Marshall, BC1
Doull, IJ1
Hall, SJ1
Bradley, DM1
Stawarski, A1
Pawłowicz, J1
Stembalska, A1
Mowszet, K1
Sasiadek, M1
Baral, V1
Connett, G1
Bar-Zohar, D1
Segal-Algranati, D1
Belson, A1
Reif, S1
Dörk, T1
Laabs, U1
Ritzka, M1
Posselt, HG1
Harms, HK1
Griese, M1
Bijman, J7
Seitz, CS1
Gaigl, Z1
Bröcker, EB1
Trautmann, A1
Ben Tov, A1
Madgar, I1
Barak, A1
Laufer, J2
Dalcin, Pde T1
Abreu E Silva, FA1
Segal, I1
Adler, SN1
Broide, E1
Santo, M1
Klar, A2
Ellis, I1
Mountford, R1
Shteyer, E1
Koerbin, G1
Farquhar, J1
Hickman, PE1
Stirnimann, A1
Paranjape, SM1
Hsia, DY1
O'Flynn, M1
Rowley, WF1
Dobrilla, G1
Grand, RJ1
Talamo, RC2
Pallavicini, JC1
Magid, SL1
Smith, CC1
Dolowitz, DA1
Cabanel, G3
Voog, R3
Rambaud, P4
Ploss, RS1
Emrich, HM8
Stoll, E3
Colombo, JP2
Rossi, E5
Mangos, JA2
Buechele, M2
Koroshec, J2
Szczepański, Z12
Hager-Malecka, B8
Sliwa, F3
Musialowicz, J5
Pyda, E3
Houstĕk, J4
Stern, RC5
Boat, TF5
Doershuk, CF6
David, TJ3
Phillips, BM1
Bonforte, RJ2
Mo-Suwan, L1
Chungpanich, S1
Kamal, MF1
Nazer, H1
Warren, RH1
Jones, B1
Heffington, R1
Sato, K3
Sato, F3
Roomans, GM1
Von Euler, AM1
Ceder, O2
Webster, HL4
Orenstein, DM3
Henke, KG2
Costill, DL1
Lemon, PJ1
Coury, AJ1
Fogt, EJ1
Norenberg, MS1
Untereker, DF1
Davison, AG1
Snodgrass, GJ1
Heeley, AF3
Watson, D1
Green, CG1
Blythe, SA1
Johnson, SR1
Varner, MW1
Yates, SJ1
Hanson, R1
Beldon, I1
Power, R1
Duncan, FR1
Bamber, M1
Batten, JC2
Lynch, G2
Littlewood, JM5
Kusoffsky, E1
Strandvik, B1
Troell, S1
Penneys, NS1
Haft, J1
Rubin, R1
Yeung, WH1
Palmer, J2
Schidlow, D1
Bye, MR1
Huang, NN4
Carter, EP1
Barrett, AD1
Kuzemko, JA1
Hjelm, M2
Davey, J1
Dinwiddie, R1
Jackson, D1
Quartey-Papafio, P1
Gaskin, K5
Levison, H6
Forstner, G3
Eichenhorn, MS1
Franckx, J1
Shmerling, DH1
Lüthi, M1
Zurbrügg, RP1
Masaryk, TJ1
Achkar, E1
Adams, A1
Westwood, A2
McCrae, WM1
Kraemer, R2
Bähler, P1
Rosario, NA1
Neto, RS1
Nitta, A1
Marinoni, LP1
Zöllner, H5
Klinke, D2
Del Rio, S1
Muntz, JA1
Dieckman, L1
Corkey, CW2
Langbaum, TS6
Metz, SJ1
Randolph, VS1
Izant, RJ1
Wood, RE5
Matthews, LW3
Gelfand, EW1
Wieseman, HG1
Volbrandt, M1
Stephan, U2
Sagoll, RJ1
Bowling, SA1
Gurwitz, D1
Benson, RG1
Isherwood, DM1
McEvoy, FA2
Wood, A1
Forsyth, JS1
Gillies, DR1
Wilson, SG1
Neff, RK1
Evensen, SA1
Senger, H1
Theile, H3
Boehm, G2
Gottschalk, B3
Selditz, P1
Zimmermann, K1
Mattes, S1
Wende, W1
Nielsen, OH1
Flensborg, EW2
Spigelblatt, L2
Rosenfeld, R2
Rochefort, F1
Beer, SI1
Laver, J1
Fried, K1
Benson, L1
Heyman, E1
Rosenberg, T1
Rigillo, N1
Zaccaro, A1
Pisano, R1
Trisolini, S1
Maya, PP1
Hill, PG1
Sudarsanam, D1
Jadhav, M1
Lewandowski, J1
Obuchowicz, A1
Swietochowska, I1
Rudzki, K1
Hubbard, VS1
Cuasay, LR1
Tocci, P1
Forrest, DC1
Wilcken, B6
Turner, G1
Barlow, WK1
Markiewicz, D3
Rusakow, LS1
Guarín, M1
Osborne, LR1
Lynch, M1
Geddes, DM1
Pryor, JP1
Santis, GK1
Ravnik-Glavac, M1
Glavac, D1
Chernick, M1
Dean, M1
Olsen, JC2
Boat, TE1
Gorvoy, JD1
Quittel, L1
Stewart, B1
Shuber, AP1
McCray, PB1
Northall, H1
York, GA1
Doughty, IM1
Ward, I1
Schwarz, M4
Pignatti, PF4
Luisetti, M1
Veeze, HJ2
Fitzgerald, D1
Van Asperen, P2
Henry, R1
Waters, D1
Freelander, M1
Wilson, M1
Gregg, RG1
Hassemer, D1
Mischler, EH1
Corrado, G1
Canuzzi, P1
Capuano, M1
Antonelli, M1
Gervais, R2
Rigot, JM1
Delomel-Vinner, E1
Lafitte, JJ2
Roussel, P2
Bey-Omar, F3
Calemard, L1
Boggio, D2
Lejeune, H1
Gilly, R1
Morel, Y2
Durand, DV2
Vormann, J1
Magdorf, K1
Günther, T1
Wahn, U1
Larsen, J1
Campbell, S1
Faragher, EB1
Götz, M3
Eichler, I2
Waldherr, S1
Dobianer, K1
Spona, J1
Hanukoglu, A1
Bistritzer, T1
Rakover, Y1
Mandelberg, A1
Burnett, RW1
Noiman, S1
Rivlin, Y1
Tal, A1
Ben-Tur, L1
Kesteloot, M1
Houdret, N1
MacLusky, I1
Costes, B1
Ghanem, N1
Fanen, P1
Verlingue, C1
Morin, JF1
Mercier, B1
Geetha, H2
Jayakeerthy, CM1
Haeckel, R1
Hänecke, P1
Turcios, NL1
Hansen, LG3
Brown, I1
English, MC1
Hendricks, ML1
Gilbert, F1
Arzimanoglou, II1
Bialer, M1
Denning, C1
Gorvoy, J1
Honorof, J1
Ores, C1
Quittell, L1
Arzimanoglou, I1
Koscik, RE1
Hacham, S1
Sheva Kerem, B1
Doolman, R2
Altshuler, R1
Pogorzelski, A1
Zebrak, J1
Tomalak, W1
Bal, J1
Obersztyn, E1
Maciejko, D1
Mazurczak, T1
Colin, AA1
Sawyer, SM1
Mickle, JE2
Oates, RD1
Milunsky, A2
Amos, JA2
Lucero, MA1
Murphy, T1
Faro, A1
Kocoshis, SA1
Blatt, J1
Launay, V1
Debray, P1
Keevil, BG2
Wong, WK1
Brand, PL1
Gerritsen, J1
van Aalderen, WM1
Nichols, SP1
Tierney, DP1
Taylor, RP1
James, TJ1
Raeburn, JA1
Bates, CM1
Baum, M1
Quigley, R1
Vital Durand, D1
Strong, TV2
Smith, T1
Collins, FS1
Delmarco, A2
Pradal, U3
Cabrini, G1
Bonizzato, A3
Luk'ianova, EG1
Nissim-Rafinia, M1
Argaman, Z1
Hiba, O1
Branski, D1
Kerem, B1
Retsch-Bogart, GZ1
De Braekeleer, M2
Allard, C2
Leblanc, JP2
Simard, F2
Aubin, G2
Wenzel, FG1
Horn, TD1
Hall, SK2
Keffler, SM1
Weller, P2
Skorupa, W1
Wierzbicka, M1
Kuś, J1
Fulmer-Smentek, SB1
Egan, MM1
Schwiebert, E1
Guggino, W1
Moss, R1
Gilfillan, A1
Warner, JP1
Marshall, T1
Greening, A1
Ho, LP1
Hargreave, T1
Stack, B1
McIntyre, D1
Davidson, R1
Dean, JC1
Middleton, W1
Brock, DJ1
Rabbi-Bortolini, E1
Bernardino, AL1
Lopes, AL1
Ferri, AS1
Passos-Bueno, MR1
Zatz, M1
Wilson, DC1
Ip, WF1
Chernick, CV1
Sharer, N1
Malone, G1
Howarth, A1
Painter, J1
Super, M2
Braganza, J1
Cohn, JA2
Noone, PG3
Jowell, PS2
Wellesley, D1
Wellesey, D1
Benetazzo, MG2
Chmiel, JF1
Drumm, ML1
Ferkol, TW1
Kercsmar, CM1
Johnson, DW1
Parnham, A1
Herzig, K1
Wittmann, J1
Josserand, RN1
Filicori, M1
Foresta, C1
La Sala, GB1
Pérez-Aguilar, F1
Cesur, Y1
Bereket, A1
Anadol, D1
Gocmen, A1
Yordam, N1
Girón Moreno, RM1
Ancochea Bermúdez, J1
McWilliams, TJ1
Wilsher, ML1
Kolbe, J1
Heeley, ME1
Woolf, DA1
Quirante, CG1
Ngugen Khoa, AT1
Olsen, M1
Robertson, CF1
Sawka, MN2
Montain, SJ2
McCloskey, M1
Redmond, AO1
Hill, A1
Di Cesare, G1
Zanolla, L1
Shmilovich, H1
Sela, BA1
Moylan, B1
Leopold, DA1
Togias, A1
Proud, D1
Pue, CA1
Wakeling, EL1
Ganeshananthan, M1
Simon, RH1
Tamalet, A1
Fauroux, B2
Garcia Carmona, T1
Estivill, X1
Scheffer, H2
Schwartz, M1
Cassiman, JJ2
Callen, A1
Diener-West, M1
Desmarquest, P1
Tamalat, A1
Boule, M1
Tournier, G1
Lynch, A1
Diamond, D1
Leader, M1
Saglani, S1
Begnini, A1
Ciske, DJ1
Haavisto, A1
Rock, LZ1
Wenger, CB1
Brown, IV1
Laine, WC1
Hansen, KL1
van den Ouweland, AM1
Standaert, TA2
Teresi, M1
Tuthill, C1
Launspach, J2
Kelley, TJ2
Milgram, LJ2
Hilliard, KA2
Weatherly, MR2
Ahrens, RC2
Han, SH1
Teresi, ME1
Crowley, S1
van der Merwe, DE1
Ubbink, JB1
Delport, R1
Becker, P1
Dhatt, GS1
Vermaak, WJ1
De Boeck, C1
Jaspers, M1
Hukelmann, M1
Oster, O1
Eisenhut, M1
Nikolajek, WP1
Dukarskiĭ, FG1
Antonova, MV1
Shchebletsov, VL1
Bray, PT4
Clark, GC3
Moody, GJ3
Thomas, JD3
Schröder, CP1
Chandra, RK1
Madhavankutty, K1
Way, RC1
Bochkova, DN1
Nemerskaia, LA1
Antonowicz, I1
Ishida, S1
Heitz, J1
Katz, S1
Thom, R1
Bowman, BH2
Barnett, DR1
Gyurkovits, K4
Markus, V1
Bittera, I1
Pavlov, GV1
Shilko, VI1
Aver'ianova, NI1
Smalley, CA2
Addy, DP2
Kibel, MA1
Jensen, O1
Changus, JE1
Pitot, HC1
Hamdi, I1
Bloom, AL1
Goodchild, MC4
Helwich, E2
Ellam, SV1
Chase, HP1
Cotton, EK1
Elliott, RB3
Davidson, AG1
Applegarth, DA1
Wong, LT1
Hicks, JM1
Lloyd-Still, JD3
Simon, SH1
Wessel, HU1
Priest, JB1
Beckerman, RC1
Szibor, R4
Gedschold, J1
Thal, W3
Schwarz, V4
Simpson, NI1
Ahuja, AS1
Chakravarty, SC1
Bhattacharya, SN1
Sarkar, DK1
Holsclaw, DS2
Keith, HH1
Velösy, G1
Berky, G1
Gunn, T1
Belmonte, MM1
Colle, E1
Dupont, C1
Pozderka, B1
Osváth, P1
Fornai, K1
Kiss, A1
Veres, B1
Endre, L1
Abramowsky, CR1
László, A3
Finley, PR1
Dye, JA1
Lichti, DA1
Byers, JM1
Williams, RJ1
Hanawa, M1
Takebe, T1
Takahashi, S1
Koizumi, M1
Endo, K1
Thomas, G1
Barnes, GL2
McNaught, S1
Gordes, E1
Brusilow, SW3
Griffiths, AD3
Bull, FE3
Mohmoodian, A1
Huff, DS1
Arey, JB1
Chicoine, R1
Mitchell-Heggs, P1
Mearns, M1
Bruns, WT1
Connell, TR1
Lacey, JA1
Whisler, KE1
Rosenlund, ML3
Selekman, JA1
Kim, HK1
Kritchevsky, D1
Dahlheim, H1
Kowalski, M1
Eigel-Hanus, G1
Oberländer, U1
Dierschke, R1
Várová, V1
Herrod, HG1
Romagnoli, C1
Siccardi, M1
Zuppa, AA1
Segni, G1
Webster, L1
Lochlin, H1
Lenik, J1
Nikolaejek, WP1
Berggren, L1
Hellsing, K2
Kollberg, H3
Bayliss, VM1
Bowen, HJ1
Burnow, RN1
Sherington, J1
Cohen, LF1
Lundgren, DW1
Beveridge, J1
Tocci, PM1
McKey, RM1
Banaś, D2
Nowakowska, H1
Rutkowski, J2
Faero, O1
Ovlisen, B1
Shapiro, BL1
Pence, TV1
Smith, QT1
Sarsfield, JK1
Davies, JM1
Green, M1
Mascia, AV1
Behrendt, H1
Crozier, DN1
Sturgess, JM1
Feigelson, J1
Audebaud, G1
Toty, L1
Robinson, PG2
Hartley, CB1
Kjellman, B1
Tengström, B1
Elliot, RB1
Ryley, HC2
Zucollo, A1
Martiarena, J1
Luna, C1
Pivetta, O1
Villagra, A1
Catanzaro, O1
van Biezen, P1
Overbeek, SE1
Hilvering, C1
Turkel, SB1
Cafaro, DR1
Vajde, E1
Tarján, E1
Böcs, K1
Lantos, A1
Keston, M1
McIntosh, I1
al Essa, S1
Héraud, MC1
Arbre, P1
Goddon, G1
Alton, E1
Riedler, J1
Arrer, E1
Brisson, GR1
Boisvert, P1
Péronnet, F1
Perrault, H1
Boisvert, D1
Lafond, JS1
Abman, SH1
Sokol, RJ1
Smit, LS1
Turpin, SV1
Cole, JL1
Hon, CT1
Petty, TL1
Craig, MW1
Rosenow, EC2
Kobayashi, K1
O'Brien, WE2
Beaudet, AL2
Gleeson, M1
Henry, RL1
Gowen, CW2
Gowen, MA1
Witt, M1
Erickson, RP1
Ober, C1
Howatt, WF1
Farber, R1
Gasparini, P1
Borgo, G1
Wiersbitzky, H1
Wiersbitzky, S1
Ballke, EH1
Kirsch, G1
Roberts, CM1
Butland, RJ1
Saunders, C1
Greenland, JH1
Ferrer-Calvete, J2
Ribes, C2
Montero, C2
Custance, JM1
Laing, SC1
Vaughan, M1
Ribes Koninckx, C1
Montero Brens, C1
Rommens, J1
Ferner, S1
Koszmagk, R1
Lehmann, A1
Heilmann, W1
Schwartzman, MN1
Janes, SR1
Erbe, RW1
Pelteret, RM1
Spragg, J1
Strieder, DJ1
Shaw, LF1
Kelly, DH1
Shannon, DC1
Stableforth, DE1
Werness, ME1
Feldman, GL1
Lewiston, N1
Fernbach, SD1
Williamson, R1
Wainwright, BJ1
Thomásová, H1
Hein, J1
Sprössig, C2
Wunderlich, P1
Bergmann, S1
Hoffmann, C1
Simmonds, E1
Alfaham, M1
Prosser, R1
Penney, MD1
Gross, V1
Schoelmerich, J1
Denzel, K1
Gerok, W1
Devlin, J1
Beckett, NS1
Su, CT1
Beanblossom, B1
Chalmers, G1
Dankert-Roelse, JE1
Meerman, GJ1
Knol, K1
ten Kate, LP1
Patton, MA1
Harris, A1
Quinlan, C1
Newton, R1
Hall, K1
Griffiths, P2
O'Halloran, M1
Brown, J2
Darnedde, T1
Schlesinger, E1
von der Hardt, H1
Walsh, DB1
Symon, DN1
Stewart, L1
Russell, G1
Shetty, KT1
Simpson, IM1
Shepherd, R1
Skeoch, CH1
Coutts, NA1
Goel, KM1
Follett, EA1
Baxter, PS1
Taylor, CJ1
Worthy, E1
Canciani, M1
Forno, S1
Orr, HT1
Parker, T1
Wielinski, CL1
Clawson, CC1
Roberts, G1
Stanfield, M1
Black, A1
Redmond, A3
Robertson, MT1
Coyne, RV1
Walton, DF1
Stanghelle, JK1
Maehlum, S1
Skyberg, D1
Landaas, S1
Oftebro, H1
Bardón, A1
McDowell, J1
Macfarlane, T1
Koshobu, T1
Hirai, H1
Hikita, T1
Kawasaki, Y1
Burioka, N1
Sasaki, T1
Williams, J2
Griffiths, PD1
Weller, PH1
Vaelioja, L1
McShane, S1
Beaudry, PH1
Levine, MI1
Green, RL1
Rodnan, J1
Zarkovic, J1
Roscher, A1
Pillion, DJ2
Meezan, E2
Kovach, L1
Leshkova, L1
Falush, F1
Lukach, I1
Mikhalichkova, I1
Wang, JY1
Hsieh, KH1
Chang, MH1
Chen, SH1
Lue, HC1
Cole, DE1
Landry, DA1
Boucher, MJ1
Gillespie, CT1
Beck, R1
Hill, JG1
Brown, P1
Briddon, A1
Wasserman, AL1
Miller, M1
Ruddy, RM1
Vázquez, C1
Azcárate, MJ1
Sojo, A1
Vitoria, JC1
Tagle, S1
Guiraldes, E1
Jarpa, S1
Estay, R1
Fica, A1
Rider, JP1
Castillo, A1
Silverman, BL1
Hazinski, TA1
Hunt, CE1
Fitzpatrick, SB1
Savilahti, E1
Ståhlberg, MR1
Borowitz, SM1
Ghishan, FK1
Lawson, EE1
Gingras-Leatherman, J1
Gatzy, JT1
Türler, K1
Käser, H1
Gressmann, HW1
Winiecki, P1
Itano, M1
Symons, JL1
Collins, JE1
Rolles, CJ1
Dodds, P1
Pennock, C1
Christoffel, KS1
Brown, G1
Urbano Ispizua, A1
Estruch Riba, R1
Grau Junyent, JM1
Mont Girbau, L1
Pedro-Botet Montoya, JC1
Urbano-Márquez, A1
Miller, ME1
Cosgriff, JM1
Schwartz, RH1
Schanker, HM1
Rajfer, J1
Saxon, A1
Fellmann, N1
Gachon, AM1
Coudert, J1
Doggett, RG1
Harrison, GM1
Carter, RE1
Carey, JP1
Turino, GM1
Brimblecombe, FS1
Chamberlain, J1
Moynahan, EJ1
Neale, L1
Brogan, TD1
Gordon, RS1
Cage, GW1
Madoff, L1
Kaiser, D4
Drack, E3
Mengoli, C1
McWhirter, WR1
Steinrud, J1
Winkel, S1
Udovicki, J1
Basicević, V1
Fabricius, EM1
Pätzug, U1
Nelson, R1
Burnell, RH1
Robertson, EF1
McCombs, ML1
Lorin, MI1
Mandel, ID1
Bender, SW2
Palombini, BC1
Souza, PR1
Fontaine, G1
Farriaux, JP1
Sobień-Kopczyńska, S1
Polakowska, H1
Cybulska-Mazur, J1
Wasilewska, J1
Tecklin, JS1
Taussig, LM2
Braunstein, GD1
Arvanitakis, SN1
Hardy, JD1
Davison, SH1
Higgins, MU1
Polycarpou, PN1
Gürson, CT1
Sertel, H1
Gürkan, M1
Pala, S1
Szabo, LV1
Kenny, MA1
Lee, W1
Paunier, L1
Girardin, E1
Sizonenko, PG1
Wyss, M1
Megevand, A1
Sokol, G1
Taylor, B2
Otto-Buczkowska, E1
Sońta-Jakimczyk, D1
Rózycka, U1
Caplin, I1
Haynes, JT1
Belmonte, M1
Rasmussen, K1
McDougall, D1
Baggs, J1
Beratis, NG1
Conover, JH1
Conod, EJ1
Hirschhorn, K1
Coleman, RL1
Lichtenstein, S1
Gebala, A2
Gurdziel, Z1
MacLean, WC1
Tripp, RW1
Költzsch, V1
Müller, H1
Koziar, H1
Hänggeli, CA1
Glotova, AV2
Fadeeva, MA1
Zaslavskaia, KA1
Amendt, P2
Mayr, K1
Schindl, R1
Del Porto, G1
Di Tonto, B1
Vlachos, P1
Liakakos, D1
Tataev, ZB1
Fedeeva, MA1
Avanesova, EG1
Landström, O1
Cogswell, JJ1
Risdon, RA1
Beck, JD1
Zöllner, J1
Zahn, RK1
Matsumoto, K1
Jacyk, W1
Ikai, K1
Sugie, I1
Sugino, I1
Nitta, H1
Iida, T1
Ogawa, J1
Suchi, T1
Blanicky, P1
Colombo, ML1
De Candussio, G1
Baravalle, A1
Stock, HJ1
Stock, W1
Giese, U1
McLean, DC1
Gottlieb, R1
Mayo, J1
Carlson, DM1
Jehanne, M1
Guivarch, J1
Mace, JW1
Schanberger, JE1
Romańska, K1
Smigla, K1
Prasad, LS1
Sinha, KP1
Rahman, A1
Kattwinkel, J1
Gottlieb, RP1
Jutzi, E1
Conrad, HC1
Biener, G1
Vulović, D1
Mikuska, M1
Filipović, D1
Subotić, Z1
Sićević, S1
Komi, N2
Miyanaga, T1
Murakami, K1
Seki, Y1
Becroft, DM1
Fleisher, TL1
González Lebrón, A1
Gudel, J1
Hinkel, GK1
Korth, G1
Fedeczko, D1
Stapińska, J1
Garapich, M1
Reuter, W1
Devi, CS1
Rao, NR1
Ramaiah, Y1
Herold, W1
Mantovanelli, S1
Buffatti, GA1
Kamarýt, J1
Brunecký, Z1
Laxová, R1
Kapranov, NI2
Darnault, F1
Marchal, A1
Beaudoing, A1
Roget, J1
Lhoste, C1
Vedovini, F1
Puglisi, P1
Pindinelli, C1
Johnson, GF1
Thompson, MF1
Fetteroff, S1
Fasano, AN1
Samánek, M1
Ruth, C1
Snobl, O1
Gul'iants, VS1
Böhme, B1
Pereira, C1
Orson, J1
Krupińska-Sanecka, I1
Leśkiewicz, W1
Zórawska, H1
Boniver, R1
Geubelle, F1
Hesse, E1
Sutcliffe, CH2
Style, PP2
Knauff, RE1
Green, MN1
Krawczyńska, H1
Rondio, H1
Domanasiewicz, M1
Koziorowski, C1
Lewandowska, J1
Matheisel, K1
Nowakowski, TK1
Grandchamp, A1
Hany, A1
Mérier, L1
Press, P1
Schutt, WH1
Isles, TE1
Lee, RA1
Berger, H1
Buffatti, G1
Garofalo, E1
Gaffuri, E1
Brugnone, F1
Reggiani, A1
Saia, B1
Mussa, GC1
Zytkiewicz, A1
Friedlmander, S1
Gasber, RE1
Lieb, L1
Krauze, M1
Matuszewski, W1
Nowotny, J1
Stejfa, M1
Hladký, M1
Cerbák, R1
Huvar, A1
Schulz, IJ1
Brehm, G1
Jenkins, ME1
Rivarola, MA1
Migeon, CJ1
Hide, DW1
Burman, D1
Gregg, RH1
Boucher, RE1
De Haller, J1
Hallett, WY1
Knudson, AG1
Massey, FJ1
Otheguy, OP1
Bodino, JA1
Morales, A1
De Toma, M1
Sawyer, CJ1
Scott, AV1
Summer, GK1
Jaggi, OP1
Sproul, A1
Huang, N1
Varpela, E1
Silvola, H1
Hakola, N1
Mei, V2
Comellini, L2
Secciani, L2
Paolucci, G2
Novák, J1

Clinical Trials (43)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
A Phase IIa, Randomized, Double-blind, Placebo-controlled Study to Evaluate GLPG2737 in Orkambi-treated Subjects With Cystic Fibrosis Homozygous for the F508del Mutation[NCT03474042]Phase 222 participants (Actual)Interventional2017-11-29Completed
Functional and Phenotypic Characteristics of Blood Neutrophils in Cystic Fibrosis[NCT04970225]130 participants (Anticipated)Interventional2021-07-08Recruiting
A Phase 3, Randomized, Double-blind, Controlled Study Evaluating the Efficacy and Safety of VX-445 Combination Therapy in Subjects With Cystic Fibrosis Who Are Homozygous for the F508del Mutation (F/F)[NCT03525548]Phase 3113 participants (Actual)Interventional2018-08-03Completed
TAAI Erasmus Research Initiative to Fight CF: Monitoring Inflammation in CF Lung Disease Into a New Era[NCT05752019]100 participants (Anticipated)Observational2022-03-21Active, not recruiting
Symptom Based Performance of Airway Clearance Therapy After Starting Highly Effective CFTR Modulator Therapy for Cystic Fibrosis[NCT05392855]30 participants (Anticipated)Interventional2023-09-05Recruiting
A Phase 3, Randomized, Double-blind, Controlled Study Evaluating the Efficacy and Safety of VX-445 Combination Therapy in Subjects With Cystic Fibrosis Who Are Heterozygous for the F508del Mutation and a Minimal Function Mutation (F/MF)[NCT03525444]Phase 3405 participants (Actual)Interventional2018-06-15Completed
Prospective Study of the Phenotypic Expression of Cystic Fibrosis (CF) Screened Positive Newborns With an Atypical Form of CF (DPAM)[NCT02869932]130 participants (Actual)Interventional2012-03-31Completed
A Phase 3, Randomized, Double-blind, Controlled Study Evaluating the Efficacy and Safety of VX-445 Combination Therapy in Subjects With Cystic Fibrosis Who Are Heterozygous for the F508del Mutation and a Gating or Residual Function Mutation (F/G and F/RF [NCT04058353]Phase 3271 participants (Actual)Interventional2019-08-28Completed
A New Optical Sweat Test Method Based on a Citric Acid-derived Multi-halide Sensor[NCT03367494]25 participants (Actual)Interventional2018-03-01Terminated (stopped due to Investigator Decision)
Effect of the CFTR-modulating Triple Therapy Elexacaftor - Tezacaftor - Ivacaftor on Numerical Distribution in Peripheral Mononuclear Immune Cells Derived From Patients With Cystic Fibrosis[NCT05576324]130 participants (Anticipated)Observational2020-12-30Recruiting
A Phase 1/2 Study of VX-445 in Healthy Subjects and Subjects With Cystic Fibrosis[NCT03227471]Phase 1/Phase 2225 participants (Actual)Interventional2017-01-23Completed
A Phase 1, Randomized, Double Blind, Placebo Controlled, Dose Escalation, and Bioavailability Study Evaluating the Safety and Pharmacokinetics of VX-659 in Healthy Subjects and in Subjects With Cystic Fibrosis[NCT03029455]Phase 1163 participants (Actual)Interventional2016-11-30Completed
A Phase 2, Randomized, Double-blind, Controlled Study to Evaluate the Safety and Efficacy of VX-659 Combination Therapy in Subjects Aged 18 Years and Older With Cystic Fibrosis[NCT03224351]Phase 2124 participants (Actual)Interventional2017-08-08Completed
Baby Observational and Nutritional Study (BONUS)[NCT01424696]231 participants (Actual)Observational2011-12-31Completed
A Phase 3, 2-Arm, Roll-Over Study to Evaluate the Long-term Safety and Pharmacodynamics of Ivacaftor Treatment in Pediatric Subjects With Cystic Fibrosis and a CFTR Gating Mutation[NCT01946412]Phase 333 participants (Actual)Interventional2013-12-31Completed
A Phase IIa, Randomized, Double-blind, Placebo-controlled Study to Evaluate Multiple Doses of GLPG2222 in Subjects With Cystic Fibrosis Who Are Homozygous for the F508del Mutation[NCT03119649]Phase 259 participants (Actual)Interventional2017-03-18Completed
A Phase IIa, Randomized, Double-blind, Placebo-controlled Study to Evaluate GLPG2222 in Ivacaftor-treated Subjects With Cystic Fibrosis Harbouring One F508del CFTR Mutation and a Second Gating (Class III) Mutation[NCT03045523]Phase 237 participants (Actual)Interventional2017-01-31Completed
A Phase IIa, Open-label Study of Multiple Doses of GLPG1837 in Subjects With Cystic Fibrosis and the G551D Mutation[NCT02707562]Phase 226 participants (Actual)Interventional2016-02-29Completed
A Phase 3, Open Label Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of VX-661 in Combination With Ivacaftor in Subjects 6 Through 11 Years of Age With Cystic Fibrosis, Homozygous or Heterozygous for the F508del CFTR Mutation[NCT02953314]Phase 383 participants (Actual)Interventional2016-11-30Completed
A Phase 2a, Randomized, Double-Blind, Placebo-Controlled Study of VX-770 to Evaluate Safety, Pharmacokinetics, and Biomarkers of CFTR Activity in Cystic Fibrosis (CF) Subjects With Genotype G551D[NCT00457821]Phase 239 participants (Actual)Interventional2007-05-31Completed
A Phase 3 Efficacy and Safety Study of PTC124 as an Oral Treatment for Nonsense-Mutation-Mediated Cystic Fibrosis[NCT00803205]Phase 3238 participants (Actual)Interventional2009-09-08Completed
Personalized Therapy of Cystic Fibrosis: Set-up of Response Markers[NCT02965326]75 participants (Anticipated)Interventional2016-05-31Recruiting
A Phase 2, Multicenter, Double-Blinded, Placebo-Controlled, Multiple-Dose Study to Evaluate Safety, Tolerability, Efficacy, Pharmacokinetics, and Pharmacodynamics of Lumacaftor Monotherapy, and Lumacaftor and Ivacaftor Combination Therapy in Subjects With[NCT01225211]Phase 2312 participants (Actual)Interventional2010-10-31Completed
Registry Study on Primary Ciliary Dyskinesia in Chinese children-a Multicenter, Prospective Cohort Study[NCT02704455]100 participants (Anticipated)Observational2016-05-31Not yet recruiting
A Phase 3, 2-Part, Open-Label Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of Ivacaftor in Subjects With Cystic Fibrosis Who Are 2 Through 5 Years of Age and Have a CFTR Gating Mutation[NCT01705145]Phase 335 participants (Actual)Interventional2013-01-31Completed
Gene Modifiers of Cystic Fibrosis Lung Disease[NCT00037765]600 participants (Anticipated)Observational2001-09-30Active, not recruiting
Short Term Effects of Ivacaftor in Non-G551D Cystic Fibrosis Patients[NCT01784419]10 participants (Actual)Interventional2013-10-31Completed
COVID-19 Antibody Responses In Cystic Fibrosis[NCT04904445]40 participants (Anticipated)Observational2021-05-21Active, not recruiting
A Phase II Study to Establish the Efficacy of Synthetic Human SecretiN in Human Acute Pancreatitis (SNAP) Study[NCT03686618]Phase 240 participants (Anticipated)Interventional2018-10-01Recruiting
Nutritional Impact of Ivacaftor Treatment in 4 Month to 2 Year Old Children With CF Gating Mutations[NCT03783286]15 participants (Actual)Observational2019-02-06Completed
Cystic Fibrosis Related Bone Disease: the Role of CFTR[NCT01549314]79 participants (Actual)Observational2012-04-30Completed
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Safety and Efficacy of VX-770 in Subjects Aged 12 Years and Older With Cystic Fibrosis Who Are Homozygous for the F508del-CFTR Mutation[NCT00953706]Phase 2140 participants (Actual)Interventional2009-09-30Terminated (stopped due to Following review of results obtained from a pre-specified 6-month analysis of Part B data the study was terminated on the basis of futility.)
Nutritional Impact of Orkambi Treatment in 2 to 5 Year Old Children Homozygous for F508del Mutations[NCT03795363]28 participants (Actual)Observational2019-04-10Completed
Phase II Study: LYM-X-SORB™, an Organized Lipid Matrix: Fatty Acids and Choline in CF[NCT00406536]Phase 2110 participants (Actual)Interventional2007-01-31Completed
Sustained Impact of Hypertonic Saline on Mucociliary Clearance in Young Children With Cystic Fibrosis[NCT01031706]23 participants (Actual)Interventional2009-09-30Completed
Pragmatic Implementation Trial of a CF Primary Palliative Care Intervention[NCT04923880]643 participants (Actual)Interventional2021-06-25Active, not recruiting
Characterization of β-cell Function and Insulin Sensitivity in Pre-transplant Patients With Cystic Fibrosis[NCT04379726]150 participants (Anticipated)Observational2020-07-01Not yet recruiting
Randomized Cross Over Study of Inhaled Hypertonic Xylitol Versus Hypertonic Saline in Stable Subjects With Cystic Fibrosis[NCT01355796]Phase 1/Phase 230 participants (Actual)Interventional2011-05-31Completed
Randomized Cross-over Physiologic Study of High Flow Nasal Oxygen Cannula Versus Non-invasive Ventilation in Cystic Fibrosis. The HIFEN Study[NCT02262871]15 participants (Actual)Interventional2014-12-31Completed
A Randomized, Double-Blind, Placebo-Controlled, Multi-Center, Crossover Study to Evaluate the Effectiveness and Safety of PANCRECARB® MS-16 (Pancrelipase) in Reducing Steatorrhea in Children and Adults With Cystic Fibrosis[NCT00432861]Phase 329 participants (Actual)Interventional2007-01-31Completed
A Single Arm 48-Week Follow-on Safety Study to the Core Study (A Multicentre, Multinational, Open-Label, Randomised, Parallel Group Clinical Trial of Tobrineb®/Actitob®/Bramitob® (Tobramycin Solution for Nebulisation, 300mg Twice Daily in 4mL Unit Dose Vi[NCT01111383]Phase 3209 participants (Actual)Interventional2009-09-30Completed
Fluid Balance During Exercise in the Heat With Water, Flavored Placebo, or a Carbohydrate-electrolyte Beverage Intake (The APEX Study)[NCT01893853]24 participants (Actual)Interventional2012-10-31Completed
Development a Core Set for Adults With Cystic Fibrosis Based on the International Classification of Functioning, Disability, and Health (ICF)[NCT06128499]30 participants (Anticipated)Observational2023-12-20Not yet recruiting
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Absolute Change in Cystic Fibrosis Questionnaire-Revised (CFQ-R) Respiratory Domain Score

The CFQ-R is a validated participant-reported outcome measuring health-related quality of life for participants with cystic fibrosis. Respiratory domain assessed respiratory symptoms, score range: 0-100; higher scores indicate fewer symptoms and better health-related quality of life. (NCT03525548)
Timeframe: From Baseline at Week 4

Interventionunits on a scale (Least Squares Mean)
TEZ/IVA-1.4
VX-445/TEZ/IVA TC16.0

Absolute Change in Percent Predicted Forced Expiratory Volume in 1 Second (ppFEV1)

FEV1 is the volume of air that can forcibly be blown out in one second, after full inspiration. (NCT03525548)
Timeframe: From Baseline at Week 4

Interventionpercentage points (Least Squares Mean)
TEZ/IVA0.4
VX-445/TEZ/IVA TC10.4

Absolute Change in Sweat Chloride (SwCl)

Sweat samples were collected using an approved collection device. (NCT03525548)
Timeframe: From Baseline at Week 4

Interventionmillimole per liter (mmol/L) (Least Squares Mean)
TEZ/IVA1.7
VX-445/TEZ/IVA TC-43.4

Observed Pre-Dose Concentration (Ctrough) of VX-445, TEZ, TEZ Metabolite (M1-TEZ), and IVA

(NCT03525548)
Timeframe: Day 1 and Week 4

Interventionmicrogram per milliliter (mcg/mL) (Mean)
TEZ: Day 1TEZ: Week 4M1-TEZ: Day 1M1-TEZ: Week 4IVA: Day 1IVA: Week 4
TEZ/IVA1.711.484.844.860.6520.530

Observed Pre-Dose Concentration (Ctrough) of VX-445, TEZ, TEZ Metabolite (M1-TEZ), and IVA

(NCT03525548)
Timeframe: Day 1 and Week 4

Interventionmicrogram per milliliter (mcg/mL) (Mean)
VX-445: Day 1VX-445: Week 4TEZ: Day 1TEZ: Week 4M1-TEZ: Day 1M1-TEZ: Week 4IVA: Day 1IVA: Week 4
VX-445/TEZ/IVA TCNA4.841.601.894.765.280.5980.652

Safety and Tolerability as Assessed by Number of Participants With Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)

(NCT03525548)
Timeframe: From first dose of study drug in TC treatment period up to 28 days after last dose of study drug or to the completion of study participation date, whichever occurs first (up to Week 8)

,
Interventionparticipants (Number)
Participants with AEsParticipants with SAEs
TEZ/IVA331
VX-445/TEZ/IVA TC322

Absolute Change in BMI Z-score for Participants <=20 Years of Age at Baseline

BMI was defined as weight in kg divided by height in m^2. Z-score is a statistical measure to describe whether a mean was above or below the standard. BMI, adjusted for age and sex, was analyzed as BMI-for-age z-score. A z-score of 0 is equal to the mean and is considered normal. Lower numbers indicate values lower than the mean and higher numbers indicate values higher than the mean. Higher values are indicative of higher BMI. (NCT03525444)
Timeframe: From Baseline at Week 24

Interventionz-score (Least Squares Mean)
Placebo0.04
VX-445/TEZ/IVA TC0.34

Absolute Change in Body Mass Index (BMI)

BMI was defined as weight in kilogram (kg) divided by height in square meter (m^2). (NCT03525444)
Timeframe: From Baseline at Week 24

Interventionkilogram per meter square (kg/m^2) (Least Squares Mean)
Placebo0.09
VX-445/TEZ/IVA TC1.13

Absolute Change in Body Weight

(NCT03525444)
Timeframe: From Baseline at Week 24

Interventionkg (Least Squares Mean)
Placebo0.5
VX-445/TEZ/IVA TC3.4

Absolute Change in Cystic Fibrosis Questionnaire Revised (CFQ-R) Respiratory Domain Score

The CFQ-R is a validated participant-reported outcome measuring health-related quality of life for participants with cystic fibrosis. Respiratory domain assessed respiratory symptoms, score range: 0-100; higher scores indicating fewer symptoms and better health-related quality of life. (NCT03525444)
Timeframe: From Baseline at Week 4

Interventionunits on a scale (Least Squares Mean)
Placebo-1.9
VX-445/TEZ/IVA TC18.1

Absolute Change in Cystic Fibrosis Questionnaire Revised (CFQ-R) Respiratory Domain Score

The CFQ-R is a validated participant-reported outcome measuring health-related quality of life for participants with cystic fibrosis. Respiratory domain assessed respiratory symptoms, score range: 0-100; higher scores indicating fewer symptoms and better health-related quality of life. (NCT03525444)
Timeframe: From Baseline through Week 24

Interventionunits on a scale (Least Squares Mean)
Placebo-2.7
VX-445/TEZ/IVA TC17.5

Absolute Change in Percent Predicted Forced Expiratory Volume in 1 Second (ppFEV1)

FEV1 is the volume of air that can forcibly be blown out in one second, after full inspiration. (NCT03525444)
Timeframe: From Baseline at Week 4

Interventionpercentage points (Least Squares Mean)
Placebo-0.2
VX-445/TEZ/IVA TC13.6

Absolute Change in Percent Predicted Forced Expiratory Volume in 1 Second (ppFEV1)

FEV1 is the volume of air that can forcibly be blown out in one second, after full inspiration. (NCT03525444)
Timeframe: From Baseline through Week 24

Interventionpercentage points (Least Squares Mean)
Placebo-0.4
VX-445/TEZ/IVA TC13.9

Absolute Change in Sweat Chloride

Sweat samples were collected using an approved collection device. (NCT03525444)
Timeframe: From Baseline at Week 4

Interventionmmol/L (Least Squares Mean)
Placebo0.1
VX-445/TEZ/IVA TC-41.2

Absolute Change in Sweat Chloride (SwCl)

Sweat samples were collected using an approved collection device. (NCT03525444)
Timeframe: From Baseline through Week 24

Interventionmillimole per liter (mmol/L) (Least Squares Mean)
Placebo-0.4
VX-445/TEZ/IVA TC-42.2

Number of Pulmonary Exacerbations (PEx)

Pulmonary exacerbation was defined as the treatment with new or changed antibiotic therapy (intravenous, inhaled, or oral) for greater than or equal to 4 sinopulmonary signs/symptoms. (NCT03525444)
Timeframe: From Baseline through Week 24

Interventionpulmonary exacerbation events (Number)
Placebo113
VX-445/TEZ/IVA TC41

Time-to-first Pulmonary Exacerbation (PEx)

Pulmonary exacerbation was defined as the treatment with new or changed antibiotic therapy (intravenous, inhaled, or oral) for greater than or equal to 4 sinopulmonary signs/symptoms. (NCT03525444)
Timeframe: From Baseline through Week 24

Interventiondays (Median)
PlaceboNA
VX-445/TEZ/IVA TCNA

Observed Pre-dose Concentration (Ctrough) of VX-445, TEZ, M1-TEZ, and IVA

(NCT03525444)
Timeframe: Pre-dose on Week 4, 8, 12, and 16

Interventionmicrogram per milliliter (mcg/mL) (Mean)
VX-445 (Week 4)VX-445 (Week 8)VX-445 (Week 12)VX-445 (Week 16)TEZ (Week 4)TEZ (Week 8)TEZ (Week 12)TEZ (Week 16)M1-TEZ (Week 4)M1-TEZ (Week 8)M1-TEZ (Week 12)M1-TEZ (Week 16)IVA (Week 4)IVA (Week 8)IVA (Week 12)IVA (Week 16)
VX-445/TEZ/IVA TC5.024.904.994.752.162.142.222.325.185.095.065.290.7480.7380.7580.778

Safety and Tolerability as Assessed by Number of Participants With Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)

(NCT03525444)
Timeframe: From first dose of study drug in TC treatment period up to 28 days after last dose of study drug or to the completion of study participation date, whichever occurs first (up to 28 weeks)

,
InterventionParticipants (Count of Participants)
Participants with TEAEsParticipants with Serious TEAEs
Placebo19342
VX-445/TEZ/IVA TC18828

Absolute Change in CFQ-R Respiratory Domain Score for ELX/TEZ/IVA Group Compared to the Control Group

The CFQ-R is a validated participant-reported outcome measuring health-related quality of life for participants with cystic fibrosis. Respiratory domain assessed respiratory symptoms, score range: 0-100; higher scores indicating fewer symptoms and better health-related quality of life. (NCT04058353)
Timeframe: From Baseline Through Week 8

Interventionunits on a scale (Least Squares Mean)
Control: IVA or TEZ/IVA1.6
TC: ELX/TEZ/IVA10.3

Absolute Change in Cystic Fibrosis Questionnaire-Revised (CFQ-R) Respiratory Domain Score for ELX/TEZ/IVA Group

The CFQ-R is a validated participant-reported outcome measuring health-related quality of life for participants with cystic fibrosis. Respiratory domain assessed respiratory symptoms, score range: 0-100; higher scores indicating fewer symptoms and better health-related quality of life. (NCT04058353)
Timeframe: From Baseline Through Week 8

Interventionunits on a scale (Least Squares Mean)
TC: ELX/TEZ/IVA10.3

Absolute Change in Percent Predicted Forced Expiratory Volume in 1 Second (ppFEV1) for ELX/TEZ/IVA Group

FEV1 is the volume of air that can forcibly be blown out in one second, after full inspiration. (NCT04058353)
Timeframe: From Baseline Through Week 8

Interventionpercentage points (Least Squares Mean)
TC: ELX/TEZ/IVA3.7

Absolute Change in ppFEV1 for the ELX/TEZ/IVA Group Compared to the Control Group

FEV1 is the volume of air that can forcibly be blown out in one second, after full inspiration. (NCT04058353)
Timeframe: From Baseline Through Week 8

Interventionpercentage points (Least Squares Mean)
Control: IVA or TEZ/IVA0.2
TC: ELX/TEZ/IVA3.7

Absolute Change in SwCl for ELX/TEZ/IVA Group Compared to the Control Group

Sweat samples were collected using an approved collection device. (NCT04058353)
Timeframe: From Baseline Through Week 8

Interventionmmol/L (Least Squares Mean)
Control: IVA or TEZ/IVA0.7
TC: ELX/TEZ/IVA-22.3

Absolute Change in Sweat Chloride (SwCl) for ELX/TEZ/IVA Group

Sweat samples were collected using an approved collection device. (NCT04058353)
Timeframe: From Baseline Through Week 8

Interventionmillimole per Liter (mmol/L) (Least Squares Mean)
TC: ELX/TEZ/IVA-22.3

Safety and Tolerability as Assessed by Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)

(NCT04058353)
Timeframe: Day 1 up to Week 12

,
Interventionparticipants (Number)
Participants With TEAEsParticipants With SAEs
Control: IVA or TEZ/IVA8311
TC: ELX/TEZ/IVA885

Part A: Area Under Plasma Concentration Time Curve From Time of Dosing to Last Measurable Concentration (AUC0-tlast) of VX-445

(NCT03227471)
Timeframe: Cohort A1-5: Pre-dose to 96 hours post-dose; Cohort A7: Pre-dose to 120 hours post-dose

Interventionmicrogram*hour per milliliter (Geometric Mean)
Part A: VX-445 (Cohort A1)11.4
Part A: VX-445 (Cohort A2)30.8
Part A: VX-445 (Cohort A3)87.1
Part A: VX-445 (Cohort A4)125
Part A: VX-445 (Cohort A5)286
Part A: VX-445 (Cohort A7-Fasted)21.8
Part A: VX-445 (Cohort A7-Fed)55.1
Part A: VX-445 (Cohort A7-IV)13.6

Part A: Maximum Observed Concentration (Cmax) of VX-445

(NCT03227471)
Timeframe: Cohort A1-A5: Pre-dose to 96 hours post-dose; Cohort A7: Pre-dose to 120 hours post-dose

Interventionmicrogram per milliliter (Geometric Mean)
Part A: VX-445 (Cohort A1)0.398
Part A: VX-445 (Cohort A2)0.989
Part A: VX-445 (Cohort A3)2.52
Part A: VX-445 (Cohort A4)4.56
Part A: VX-445 (Cohort A5)7.07
Part A: VX-445 (Cohort A7-Fasted)0.486
Part A: VX-445 (Cohort A7-Fed)1.76
Part A: VX-445 (Cohort A7-IV)0.740

Part B: Observed Pre-dose Plasma Concentration (Ctrough) of VX-445

(NCT03227471)
Timeframe: Pre-dose on Day 10

Interventionmicrogram per milliliter (Geometric Mean)
Part B: VX-445 (Cohort B1)1.05
Part B: VX-445 (Cohort B2)2.81
Part B: VX-445 (Cohort B3)7.10
Part B: VX-445 (Cohort B4)11.5

Part D: Absolute Change in Cystic Fibrosis Questionnaire-Revised (CFQ-R) Respiratory Domain Score

The CFQ-R is a validated participant-reported outcome measuring health-related quality of life for participants with cystic fibrosis. Respiratory domain assessed respiratory symptoms, score range: 0-100; higher scores indicating fewer symptoms and better health-related quality of life. (NCT03227471)
Timeframe: From Baseline through Day 29

Interventionunits on a scale (Least Squares Mean)
Part D: Placebo4.2
Part D: VX-445/TEZ/IVA TC - Low Dose20.8
Part D: VX-445/TEZ/IVA TC - Medium Dose15.4
Part D: VX-445/TEZ/IVA TC - High Dose25.7

Part D: Absolute Change in Percent Predicted Forced Expiratory Volume in 1 Second (ppFEV1)

FEV1 is the volume of air that can forcibly be blown out in one second, after full inspiration. (NCT03227471)
Timeframe: From Baseline through Day 29

Interventionpercentage points (Least Squares Mean)
Part D: Placebo0.0
Part D: VX-445/TEZ/IVA TC - Low Dose11.1
Part D: VX-445/TEZ/IVA TC - Medium Dose7.9
Part D: VX-445/TEZ/IVA TC - High Dose13.8

Part D: Absolute Change in Sweat Chloride Concentration

Sweat samples were collected using an approved collection device. (NCT03227471)
Timeframe: From Baseline through Day 29

Interventionmillimole per liter (mmol/L) (Least Squares Mean)
Part D: Placebo-2.2
Part D: VX-445/TEZ/IVA TC - Low Dose-38.2
Part D: VX-445/TEZ/IVA TC - Medium Dose-33.2
Part D: VX-445/TEZ/IVA TC - High Dose-39.1

Part D: Relative Change in Percent Predicted Forced Expiratory Volume in 1 Second (ppFEV1)

FEV1 is the volume of air that can forcibly be blown out in one second, after full inspiration. (NCT03227471)
Timeframe: From Baseline through Day 29

Interventionpercent change (Least Squares Mean)
Part D: Placebo0.3
Part D: VX-445/TEZ/IVA TC - Low Dose19.3
Part D: VX-445/TEZ/IVA TC - Medium Dose13.8
Part D: VX-445/TEZ/IVA TC - High Dose26.2

Part E: Absolute Change in Cystic Fibrosis Questionnaire-Revised (CFQ-R) Respiratory Domain Score

The CFQ-R is a validated participant-reported outcome measuring health-related quality of life for participants with cystic fibrosis. Respiratory domain assessed respiratory symptoms, score range: 0-100; higher scores indicating fewer symptoms and better health-related quality of life. (NCT03227471)
Timeframe: From Baseline through Day 29

Interventionunits on a scale (Least Squares Mean)
Part E: TEZ/IVA5.2
Part E: VX-445/TEZ/IVA TC20.7

Part E: Absolute Change in Percent Predicted Forced Expiratory Volume in 1 Second (ppFEV1)

FEV1 is the volume of air that can forcibly be blown out in one second, after full inspiration. (NCT03227471)
Timeframe: From Baseline through Day 29

Interventionpercentage points (Least Squares Mean)
Part E: TEZ/IVA0.4
Part E: VX-445/TEZ/IVA TC11.0

Part E: Absolute Change in Sweat Chloride Concentration

Sweat samples were collected using an approved collection device. (NCT03227471)
Timeframe: From Baseline through Day 29

Interventionmmol/L (Least Squares Mean)
Part E: TEZ/IVA0.8
Part E: VX-445/TEZ/IVA TC-39.6

Part E: Relative Change in Percent Predicted Forced Expiratory Volume in 1 Second (ppFEV1)

FEV1 is the volume of air that can forcibly be blown out in one second, after full inspiration. (NCT03227471)
Timeframe: From Baseline through Day 29

Interventionpercent change (Least Squares Mean)
Part E: TEZ/IVA1.4
Part E: VX-445/TEZ/IVA TC19.2

Part F: Absolute Change in Cystic Fibrosis Questionnaire-Revised (CFQ-R) Respiratory Domain Score

The CFQ-R is a validated participant-reported outcome measuring health-related quality of life for participants with cystic fibrosis. Respiratory domain assessed respiratory symptoms, score range: 0-100; higher scores indicating fewer symptoms and better health-related quality of life. (NCT03227471)
Timeframe: From Baseline through Day 29

Interventionunits on a scale (Least Squares Mean)
Part F: Placebo20.2
Part F: VX-445/TEZ/VX-561 TC20.2

Part F: Absolute Change in Percent Predicted Forced Expiratory Volume in 1 Second (ppFEV1)

FEV1 is the volume of air that can forcibly be blown out in one second, after full inspiration. (NCT03227471)
Timeframe: From Baseline through Day 29

Interventionpercentage points (Least Squares Mean)
Part F: Placebo1.2
Part F: VX-445/TEZ/VX-561 TC11.7

Part F: Absolute Change in Sweat Chloride Concentration

Sweat samples were collected using an approved collection device. (NCT03227471)
Timeframe: From Baseline through Day 29

Interventionmmol/L (Least Squares Mean)
Part F: Placebo1.0
Part F: VX-445/TEZ/VX-561 TC-33.6

Part F: Relative Change in Percent Predicted Forced Expiratory Volume in 1 Second (ppFEV1)

FEV1 is the volume of air that can forcibly be blown out in one second, after full inspiration. (NCT03227471)
Timeframe: From Baseline through Day 29

Interventionpercent change (Least Squares Mean)
Part F: Placebo1.6
Part F: VX-445/TEZ/VX-561 TC19.9

Part B: Area Under Plasma Concentration Time Curve From Time of Dosing to Last Measurable Concentration (AUC0-tlast) of VX-445

(NCT03227471)
Timeframe: Pre-dose to 96 hours post-dose on Day 1 and Day 10

,,,
Interventionmicrogram*hour per milliliter (Geometric Mean)
Day 1Day 10
Part B: VX-445 (Cohort B1)17.961.4
Part B: VX-445 (Cohort B2)42.2183
Part B: VX-445 (Cohort B3)57.9452
Part B: VX-445 (Cohort B4)119692

Part B: Maximum Observed Concentration (Cmax) of VX-445

(NCT03227471)
Timeframe: Pre-dose to 96 hours post-dose on Day 1 and Day 10

,,,
Interventionmicrogram per milliliter (Geometric Mean)
Day 1Day 10
Part B: VX-445 (Cohort B1)1.182.13
Part B: VX-445 (Cohort B2)2.825.83
Part B: VX-445 (Cohort B3)3.4711.4
Part B: VX-445 (Cohort B4)9.5618.2

Part C: Area Under Plasma Concentration Time Curve From Time of Dosing to Last Measurable Concentration (AUC0-tlast) of IVA and Its Metabolites (M1-IVA and M6-IVA)

(NCT03227471)
Timeframe: Pre-dose to 96 hours post-dose on Day 1, Day 7 and Day 14

,,
Interventionnanogram*hour per milliliter (Geometric Mean)
IVA: Day 1IVA: Day 7IVA: Day 14M1-IVA: Day 1M1-IVA: Day 7M1-IVA: Day 14M6-IVA: Day 1M6-IVA: Day 7M6-IVA: Day 14
Part C: VX-445/TEZ/IVA TC (Cohort C1)63502160027900169004750075300111003970066300
Part C: VX-445/TEZ/IVA TC (Cohort C2)621018800350001480046300970001410051400123000
Part C: VX-445/TEZ/IVA TC (Cohort C3)5480169003260013300364008610090502910067100

Part C: Area Under Plasma Concentration Time Curve From Time of Dosing to Last Measurable Concentration (AUC0-tlast) of VX-445, TEZ and Its Metabolites (M1-TEZ and M2-TEZ)

(NCT03227471)
Timeframe: Pre-dose to 96 hours post-dose on Day 1, Day 7 and Day 14

,,
Interventionmicrogram*hour per milliliter (Geometric Mean)
VX-445: Day 1VX-445: Day 7VX-445: Day 14TEZ: Day 1TEZ: Day 7TEZ: Day 14M1-TEZ: Day 1M1-TEZ: Day 7M1-TEZ: Day 14M2-TEZ: Day 1M2-TEZ: Day 7M2-TEZ: Day 14
Part C: VX-445/TEZ/IVA TC (Cohort C1)48.615634541.410325217.790.93806.65108617
Part C: VX-445/TEZ/IVA TC (Cohort C2)72.517750643.810528820.11104778.19143831
Part C: VX-445/TEZ/IVA TC (Cohort C3)26.465.418342.796.927525.51255129.00123652

Part C: Maximum Observed Concentration (Cmax) of IVA and Its Metabolites (M1-IVA and M6-IVA)

(NCT03227471)
Timeframe: Pre-dose to 96 hours post-dose on Day 1, Day 7 and Day 14

,,
Interventionnanogram per milliliter (Geometric Mean)
IVA: Day 1IVA: Day 7IVA: Day 14M1-IVA: Day 1M1-IVA: Day 7M1-IVA: Day 14M6-IVA: Day 1M6-IVA: Day 7M6-IVA: Day 14
Part C: VX-445/TEZ/IVA TC (Cohort C1)4251290136012502460268090119602060
Part C: VX-445/TEZ/IVA TC (Cohort C2)46111901920119025903900118025903350
Part C: VX-445/TEZ/IVA TC (Cohort C3)4371070141010702070299063114001980

Part C: Maximum Observed Concentration (Cmax) of VX-445, TEZ and Its Metabolites (M1-TEZ and M2-TEZ)

(NCT03227471)
Timeframe: Pre-dose to 96 hours post-dose on Day 1, Day 7 and Day 14

,,
Interventionmicrogram per milliliter (Geometric Mean)
VX-445: Day 1VX-445: Day 7VX-445: Day 14TEZ: Day 1TEZ: Day 7TEZ: Day 14M1-TEZ: Day 1M1-TEZ: Day 7M1-TEZ: Day 14M2-TEZ: Day 1M2-TEZ: Day 7M2-TEZ: Day 14
Part C: VX-445/TEZ/IVA TC (Cohort C1)3.048.298.713.817.098.110.9294.345.770.5534.727.69
Part C: VX-445/TEZ/IVA TC (Cohort C2)4.8610.314.05.678.299.070.9885.196.790.6676.4110.1
Part C: VX-445/TEZ/IVA TC (Cohort C3)1.723.584.735.387.018.601.305.867.540.7165.467.93

Part C: Observed Pre-dose Concentration (Ctrough) of IVA and Its Metabolites (M1-IVA and M6-IVA)

(NCT03227471)
Timeframe: Pre-dose on Day 7 and Day 14

,,
Interventionnanogram per milliliter (Geometric Mean)
IVA: Day 7IVA: Day 14M1-IVA: Day 7M1-IVA: Day 14M6-IVA: Day 7M6-IVA: Day 14
Part C: VX-445/TEZ/IVA TC (Cohort C1)7536101790160015301360
Part C: VX-445/TEZ/IVA TC (Cohort C2)7599901960221022602600
Part C: VX-445/TEZ/IVA TC (Cohort C3)6048811400193012701640

Part C: Observed Pre-dose Concentration (Ctrough) of VX-445, TEZ and Its Metabolites (M1-TEZ and M2-TEZ)

(NCT03227471)
Timeframe: Pre-dose on Day 7 and Day 14

,,
Interventionmicrogram per milliliter (Geometric Mean)
VX-445: Day 7VX-445: Day 14TEZ: Day 7TEZ: Day 14M1-TEZ: Day 7M1-TEZ: Day 14M2-TEZ: Day 7M2-TEZ: Day 14
Part C: VX-445/TEZ/IVA TC (Cohort C1)4.634.452.733.103.364.384.066.46
Part C: VX-445/TEZ/IVA TC (Cohort C2)5.917.602.773.703.985.425.638.85
Part C: VX-445/TEZ/IVA TC (Cohort C3)2.092.922.523.624.715.524.927.38

Part D: Observed Pre-dose Plasma Concentration (Ctrough) of VX-445, TEZ and Its Metabolite (M1-TEZ), IVA and Its Metabolite (M1-IVA)

(NCT03227471)
Timeframe: Pre-dose on Day 15 and Day 29

,,
Interventionmicrogram per milliliter (Mean)
VX-445: Day 15VX-445: Day 29TEZ: Day 15TEZ: Day 29M1-TEZ: Day 15M1-TEZ: Day 29IVA: Day 15IVA: Day 29M1-IVA: Day 15M1-IVA: Day 29
Part D: VX-445/TEZ/IVA TC - High Dose5.775.571.762.224.434.740.7010.6581.451.29
Part D: VX-445/TEZ/IVA TC - Low Dose1.041.271.852.164.464.770.7200.7531.291.57
Part D: VX-445/TEZ/IVA TC - Medium Dose2.152.181.681.774.114.300.6650.7041.211.20

Part E: Observed Pre-dose Concentration (Ctrough) of VX-445, TEZ and Its Metabolite (M1-TEZ) and IVA and Its Metabolite (M1-IVA)

(NCT03227471)
Timeframe: Pre-dose on Day 15 and Day 29

Interventionmicrogram per milliliter (Mean)
VX-445: Day 15VX-445: Day 29TEZ: Day 15TEZ: Day 29M1-TEZ: Day 15M1-TEZ: Day 29IVA: Day 15IVA: Day 29M1-IVA: Day 15M1-IVA: Day 29
Part E: VX-445/TEZ/IVA TC5.075.351.861.994.574.710.6590.7981.091.43

Part E: Observed Pre-dose Concentration (Ctrough) of VX-445, TEZ and Its Metabolite (M1-TEZ) and IVA and Its Metabolite (M1-IVA)

(NCT03227471)
Timeframe: Pre-dose on Day 15 and Day 29

Interventionmicrogram per milliliter (Mean)
TEZ: Day 15TEZ: Day 29M1-TEZ: Day 15M1-TEZ: Day 29IVA: Day 15IVA: Day 29M1-IVA: Day 15M1-IVA: Day 29
Part E: TEZ/IVA1.851.843.963.730.7660.5951.220.943

Part F: Observed Pre-dose Concentration (Ctrough) of VX-445, TEZ and Its Metabolite (M1-TEZ) and VX-561

(NCT03227471)
Timeframe: Pre-dose on Day 15 and Day 29

Interventionmicrogram per milliliter (Mean)
VX-445: Day 15VX-445: Day 29TEZ: Day 15TEZ: Day 29M1-TEZ: Day 15M1-TEZ: Day 29VX-561: Day 15VX-561: Day 29
Part F: VX-445/TEZ/VX-561 TC4.405.251.802.224.995.090.4410.597

Parts A, B and C: Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)

(NCT03227471)
Timeframe: From first dose of study drug in treatment period up to safety follow-up (up to 28 days)

,,,,,,
InterventionParticipants (Count of Participants)
Participants with AEsParticipants with SAEs
Part A: Pooled Placebo (Except Cohort A7)00
Part A: VX-445 (Cohort A7)10
Part A: VX-445 (Except Cohort A7)30
Part B: Pooled Placebo (Cohort B1 to B4)20
Part B: VX-445 (Cohort B1 to B4)20
Part C: Pooled Placebo (Cohort C1 to C3)20
Part C: VX-445/TEZ/IVA TC (Cohort C1 to C3)50

Parts D, E and F: Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)

(NCT03227471)
Timeframe: From first dose of study drug in TC treatment period up to 28 days after last dose of study drug (up to 5 weeks)

,,,,,
InterventionParticipants (Count of Participants)
Participants with AEsParticipants with SAEs
Part D: Placebo122
Part D: VX-445/TEZ/IVA TC493
Part E: TEZ/IVA51
Part E: VX-445/TEZ/IVA TC190
Part F: Placebo71
Part F: VX-445/TEZ/VX-561 TC190

Absolute Change in Cystic Fibrosis Questionnaire-Revised (CFQ-R) Respiratory Domain Score

The CFQ-R is a validated participant-reported outcome measuring health-related quality of life for participants with cystic fibrosis. Respiratory domain assessed respiratory symptoms, score range: 0-100; higher scores indicating fewer symptoms and better health-related quality of life. (NCT03224351)
Timeframe: From Baseline at Day 29

Interventionunits on a scale (Least Squares Mean)
Part 1: Placebo4.7
Part 1: VX-659/TEZ/IVA TC - Low Dose24.6
Part 1: VX-659/TEZ/IVA TC - Medium Dose19.8
Part 1: VX-659/TEZ/IVA TC - High Dose21.8
Part 2: TEZ/IVA2.9
Part 2: VX-659/TEZ/IVA TC19.5
Part 3: Placebo-4.1
Part 3: VX-659/TEZ/VX-561 TC14.7

Absolute Change in Percent Predicted Forced Expiratory Volume in 1 Second (ppFEV1)

FEV1 is the volume of air that can forcibly be blown out in one second, after full inspiration. (NCT03224351)
Timeframe: From Baseline Through Day 29

Interventionpercentage points (Least Squares Mean)
Part 1: Placebo0.4
Part 1: VX-659/TEZ/IVA TC - Low Dose10.2
Part 1: VX-659/TEZ/IVA TC - Medium Dose12.0
Part 1: VX-659/TEZ/IVA TC - High Dose13.3
Part 2: TEZ/IVA0.0
Part 2: VX-659/TEZ/IVA TC9.7
Part 3: Placebo-5.0
Part 3: VX-659/TEZ/VX-561 TC12.2

Absolute Change in Sweat Chloride Concentrations

Sweat samples were collected using an approved collection device. (NCT03224351)
Timeframe: From Baseline Through Day 29

Interventionmillimole per liter (mmol/L) (Least Squares Mean)
Part 1: Placebo2.9
Part 1: VX-659/TEZ/IVA TC - Low Dose-45.7
Part 1: VX-659/TEZ/IVA TC - Medium Dose-43.8
Part 1: VX-659/TEZ/IVA TC - High Dose-51.4
Part 2: TEZ/IVA3.0
Part 2: VX-659/TEZ/IVA TC-42.2
Part 3: Placebo-1.3
Part 3: VX-659/TEZ/VX-561 TC-38.1

Relative Change in ppFEV1

FEV1 is the volume of air that can forcibly be blown out in one second, after full inspiration. (NCT03224351)
Timeframe: From Baseline Through Day 29

Interventionpercent change (Least Squares Mean)
Part 1: Placebo0.0
Part 1: VX-659/TEZ/IVA TC - Low Dose18.8
Part 1: VX-659/TEZ/IVA TC - Medium Dose21.1
Part 1: VX-659/TEZ/IVA TC - High Dose24.6
Part 2: TEZ/IVA0.1
Part 2: VX-659/TEZ/IVA TC17.3
Part 3: Placebo-11.3
Part 3: VX-659/TEZ/VX-561 TC21.5

Observed Pre-dose Concentration (Ctrough) of VX-659, TEZ, M1-TEZ, IVA, M1-IVA, and VX-561

(NCT03224351)
Timeframe: Pre-dose at Day 15 and Day 29

,,,
Interventionnanogram per milliliter (ng/mL) (Mean)
VX-659: Day 15VX-659: Day 29TEZ: Day 15TEZ: Day 29M1-TEZ: Day 15M1-TEZ: Day 29IVA: Day 15IVA: Day 29M1-IVA: Day 15M1-IVA Day 29
Part 1: VX-659/TEZ/IVA TC - High Dose11001080111010104280387042337111701030
Part 1: VX-659/TEZ/IVA TC - Low Dose393566191019104390430082471912001130
Part 1: VX-659/TEZ/IVA TC - Medium Dose622699125010503710365052244310501140
Part 2: VX-659/TEZ/IVA TC8351070135095540103810313296844866

Observed Pre-dose Concentration (Ctrough) of VX-659, TEZ, M1-TEZ, IVA, M1-IVA, and VX-561

(NCT03224351)
Timeframe: Pre-dose at Day 15 and Day 29

Interventionnanogram per milliliter (ng/mL) (Mean)
TEZ: Day 15TEZ: Day 29M1-TEZ: Day 15M1-TEZ: Day 29IVA: Day 15IVA: Day 29M1-IVA: Day 15M1-IVA Day 29
Part 2: TEZ/IVA105011504160379045849013101240

Observed Pre-dose Concentration (Ctrough) of VX-659, TEZ, M1-TEZ, IVA, M1-IVA, and VX-561

(NCT03224351)
Timeframe: Pre-dose at Day 15 and Day 29

Interventionnanogram per milliliter (ng/mL) (Mean)
VX-659: Day 15VX-659: Day 29TEZ: Day 15TEZ: Day 29M1-TEZ: Day 15M1-TEZ: Day 29VX-561: Day 15VX-561: Day 29
Part 3: VX-659/TEZ/VX-561 TC1140923100077640603660380288

Safety and Tolerability as Assessed by Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)

(NCT03224351)
Timeframe: Day 1 Through Safety Follow-up (up to Day 61 for Part 1, Day 85 for Part 2 and Day 57 for Part 3)

,,,,,,,
Interventionparticipants (Number)
Participants with TEAEsParticipants with SAEs
Part 1: Placebo93
Part 1: VX-659/TEZ/IVA TC - High Dose171
Part 1: VX-659/TEZ/IVA TC - Low Dose101
Part 1: VX-659/TEZ/IVA TC - Medium Dose154
Part 2: TEZ/IVA92
Part 2: VX-659/TEZ/IVA TC151
Part 3: Placebo63
Part 3: VX-659/TEZ/VX-561 TC182

Absolute Change From Baseline of Parent Study in Body Mass Index (BMI) at Week 12, 24, 36, 48, 60, 72 and 84

BMI = (Weight [in kg]) divided by (Stature [in meters]) ^2. Baseline was defined as the most recent measurement prior to intake of the first dose of study drug in study 108 Part B (NCT01705145). (NCT01946412)
Timeframe: Baseline (study 108), Week 12, 24, 36, 48, 60, 72 and 84 (study 109)

,
InterventionKilogram per square meter (kg/m^2) (Mean)
Baseline (n=9, 24)Absolute Change at Week 12 (n=9, 23)Absolute Change at Week 24 (n=9, 23)Absolute Change at Week 36 (n=9, 23)Absolute Change at Week 48 (n=9, 22)Absolute Change at Week 60 (n=9, 22)Absolute Change at Week 72 (n=9, 20)Absolute Change at Week 84 (n=9, 19)
Ivacaftor 50 mg15.740.030.310.15-0.31-0.12-0.38-0.16
Ivacaftor 75 mg16.060.09-0.120.09-0.13-0.060.090.28

Absolute Change From Baseline of Parent Study in Stature at Week 12, 24, 36, 48, 60, 72 and 84

Stature was measured as height if children could stand unassisted and follow directions; otherwise, stature was measured as length. Baseline was defined as the most recent measurement prior to intake of the first dose of study drug in study 108 Part B (NCT01705145). (NCT01946412)
Timeframe: Baseline (study 108), Week 12, 24, 36, 48, 60, 72 and 84 (study 109)

,
InterventionCentimeters (cm) (Mean)
Baseline (n=9, 24)Absolute Change in Week 12 (n=9, 23)Absolute Change in Week 24 (n=9, 23)Absolute Change in Week 36 (n=9, 23)Absolute Change in Week 48 (n=9, 21)Absolute Change in Week 60 (n=9, 22)Absolute Change in Week 72 (n=9, 20)Absolute Change in Week 84 (n=9, 19)
Ivacaftor 50 mg89.14.66.07.89.711.012.513.6
Ivacaftor 75 mg102.35.47.78.810.411.613.415.0

Absolute Change From Baseline of Parent Study in Sweat Chloride at Week 24, 48, 72 and 84

Sweat samples were collected using an approved Macroduct (Wescor, Logan, Utah) collection device. A volume of greater than or equal to (>=) 15 microliter was required for determination of sweat chloride. Baseline was defined as the most recent measurement prior to intake of the first dose of study drug in study 108 Part B (NCT01705145). (NCT01946412)
Timeframe: Baseline (study 108), Week 24, 48, 72 and 84 (study 109)

,
Interventionmillimole per liter (mmol/L) (Mean)
Baseline (n=7,22)Absolute Change at Week 24 (n=6,18)Absolute Change at Week 48 (n=6,15)Absolute Change at Week 72 (n=7,14)Absolute Change at Week 84 (n=6,14)
Ivacaftor 50 mg93.1-62.1-29.3-46.4-46.5
Ivacaftor 75 mg99.6-48.5-51.8-52.9-58.1

Absolute Change From Baseline of Parent Study in Weight at Week 12, 24, 36, 48, 60, 72 and 84

Baseline was defined as the most recent measurement prior to intake of the first dose of study drug in study 108 Part B (NCT01705145) (NCT01946412)
Timeframe: Baseline (study 108), Week 12, 24, 36, 48, 60, 72 and 84 (study 109)

,
Interventionkilogram (kg) (Mean)
Baseline (n=9, 24)Absolute Change at Week 12 (n= 9, 23)Absolute Change at Week 24 (n=9, 23)Absolute Change at Week 36 (n=9, 23)Absolute Change at Week 48 (n=9, 22)Absolute Change at Week 60 (n=9, 22)Absolute Change at Week 72 (n=9, 20)Absolute Change at Week 84 (n=9, 19)
Ivacaftor 50 mg12.51.32.02.42.63.23.44.0
Ivacaftor 75 mg16.81.92.53.13.44.04.85.7

Absolute Change From Baseline of Study 109 in Body Mass Index (BMI) at Week 12, 24, 36, 48, 60, 72 and 84

BMI = (Weight [in kg]) divided by (Stature [in meters]) ^2. Baseline is defined as the most recent measurement prior to intake of the first dose of study drug in study 109 (NCT01946412). (NCT01946412)
Timeframe: Baseline (study 109), Week 12, 24, 36, 48, 60, 72 and 84 (study 109)

,
Interventionkg/m^2 (Mean)
Baseline (n= 9, 24)Absolute Change at Week 12 (n= 9, 23)Absolute Change at Week 24 (n= 9, 23)Absolute Change at Week 36 (n= 9, 23)Absolute Change at Week 48 (n= 9, 22)Absolute Change at Week 60 (n= 9, 22)Absolute Change at Week 72 (n= 9, 20)Absolute Change at Week 84 (n= 9, 19)
Ivacaftor 50 mg16.07-0.30-0.02-0.18-0.64-0.45-0.71-0.49
Ivacaftor 75 mg16.33-0.16-0.36-0.16-0.35-0.29-0.21-0.01

Absolute Change From Baseline of Study 109 in Stature at Week 12, 24, 36, 48, 60, 72 and 84

Stature was measured as height if children could stand unassisted and follow directions; otherwise, stature was measured as length. Baseline is defined as the most recent measurement prior to intake of the first dose of study drug in study 109 (NCT01946412). (NCT01946412)
Timeframe: Baseline (study 109), Week 12, 24, 36, 48, 60, 72 and 84 (study 109)

,
Interventioncm (Mean)
Baseline (n=9, 24)Absolute Change at Week 12 (n=9, 23)Absolute Change at Week 24 (n=9, 23)Absolute Change at Week 36 (n=9, 23)Absolute Change at Week 48 (n=9, 21)Absolute Change at Week 60 (n=9, 22)Absolute Change at Week 72 (n=9, 20)Absolute Change at Week 84 (n=9, 19)
Ivacaftor 50 mg91.72.03.45.27.28.410.011.1
Ivacaftor 75 mg105.81.84.15.26.88.09.811.4

Absolute Change From Baseline of Study 109 in Sweat Chloride at Week 24, 48, 72 and 84

Sweat samples were collected using an approved Macroduct (Wescor, Logan, Utah) collection device. A volume of >=15 microliter was required for determination of sweat chloride. Baseline is defined as the most recent measurement prior to intake of the first dose of study drug in study 109 (NCT01946412). (NCT01946412)
Timeframe: Baseline (study 109), Week 24, 48, 72 and 84 (study 109)

,
Interventionmmol/L (Mean)
Baseline (n= 8,23)Absolute Change at Week 24 (n=7,18)Absolute Change at Week 48 (n=7,17)Absolute Change at Week 72 (n=8,15)Absolute Change at Week 84 (n=7,16)
Ivacaftor 50 mg47.8-4.318.1-1.5-2.4
Ivacaftor 75 mg52.93.4-4.5-6.0-11.2

Absolute Change From Baseline of Study 109 in Weight at Week 12, 24, 36, 48, 60, 72 and 84

Baseline is defined as the most recent measurement prior to intake of the first dose of study drug in study 109 (NCT01946412). (NCT01946412)
Timeframe: Baseline (study 109), Week 12, 24, 36, 48, 60, 72 and 84 (study 109)

,
InterventionKg (Mean)
Baseline (n= 9, 24)Absolute Change at Week 12 (n=9, 23)Absolute Change at Week 24 (n=9, 23)Absolute Change at Week 36 (n=9, 23)Absolute Change at Week 48 (n=9, 22)Absolute Change at Week 60 (n=9, 22)Absolute Change at Week 72 (n=9, 20)Absolute Change at Week 84 (n=9, 19)
Ivacaftor 50 mg13.50.31.01.41.62.22.43.0
Ivacaftor 75 mg18.30.41.01.61.92.53.34.2

Number of Participants With Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)

AE: any untoward medical occurrence in a participant during the study; the event does not necessarily have a causal relationship with the treatment. This includes any newly occurring event or previous condition that has increased in severity or frequency after the informed consent form is signed. AE includes serious as well as Non-serious AEs. SAE (subset of AE): medical event or condition, which falls into any of the following categories, regardless of its relationship to the study drug: death, life threatening adverse experience, Inpatient hospitalization/prolongation of hospitalization, persistent/significant disability or incapacity, congenital anomaly/birth defect, important medical event. AEs with start date or increased severity on or after the first dose of study drug through the end of study participation was considered treatment-emergent. (NCT01946412)
Timeframe: Day 1 up to Week 97 (for participants who completed study drug dosing); Day 1 up to 24 weeks after the last dose (up to Week 108, for participants who prematurely discontinued study drug dosing)

,
Interventionparticipants (Number)
AEsSAEs
Ivacaftor 50 mg96
Ivacaftor 75 mg245

Mean Area Under the Concentration-Time Curve From Time 0 up to 24 Hours Following Multiple Dosing (AUC[0-t]; ng.h/mL) of GLPG2222

Area under the concentration-time curve from time 0 up to 24 hours following multiple dosing (ng.h/mL), calculated by linear up/log down trapezoidal summation. All PK parameters were determined from Day 15; Day 29 data were determined if the participant was not available for full PK profiling on Day 15. (NCT03119649)
Timeframe: Day 15 (predose and 0.5, 1, 2, 3, 4, 6, and 8 hours postdose) and prior to dosing on Day 29

Interventionng.h/mL (Mean)
Cohort A: GLPG2222 50 mg QD3850
Cohort A: GLPG2222 100 mg QD9670
Cohort B: GLPG2222 200 mg QD22900
Cohort B: GLPG2222 400 mg QD46400

Mean Change From Baseline in Percent (%) Predicted FEV1 (%FEV1) at Day 29

Percent predicted FEV1 for age, gender, and height was determined from standardized spirometry assessments and estimated using the 2012 Global Lungs Initiative equation. Baseline was defined as the last non-missing predose assessment on Day 1. (NCT03119649)
Timeframe: Predose and between 1 and 2 hours postdose on Days 1 and 29, or at early discontinuation

Intervention% predicted FEV1 (Least Squares Mean)
Pooled Placebo-1.0
Cohort A: GLPG2222 50 mg QD0.1
Cohort A: GLPG2222 100 mg QD-0.3
Cohort B: GLPG2222 200 mg QD0.0
Cohort B: GLPG2222 400 mg QD1.3

Mean Change From Baseline in Sweat Chloride Concentration at Day 29

Two sweat collections, one from each arm, were obtained. Mean sweat chloride concentration was determined from both arms and measured as millimoles per liter (mmol/L). Baseline was defined as the predose value on Day 1 (or the last non-missing predose measurement). (NCT03119649)
Timeframe: Prior to dosing on Days 1 and 29, or at early discontinuation

Interventionmmol/L (Least Squares Mean)
Pooled Placebo-2.5
Cohort A: GLPG2222 50 mg QD-5.8
Cohort A: GLPG2222 100 mg QD-6.6
Cohort B: GLPG2222 200 mg QD-18.3
Cohort B: GLPG2222 400 mg QD-8.8

Mean Change From Baseline in the Respiratory Domain of the Cystic Fibrosis Questionnaire-Revised (CFQ-R) at Day 29

The CFQ-R is a validated participant-reported outcome measuring health-related quality of life for participants with cystic fibrosis. The respiratory domain assessed respiratory symptoms (for example, coughing, congestion, wheezing), derived from Questions 40, 41, 42, 45, and 46 if at least 50% of the questions had non-missing data. The scale score ranged from 0-100; higher scores indicated fewer symptoms and better health-related quality of life with a negative change indicating a worsening of symptoms. A change of 4 is considered clinically relevant. (NCT03119649)
Timeframe: Prior to dosing on Days 1 and 29, or at early discontinuation

Interventionunits on a scale (Least Squares Mean)
Pooled Placebo-2.4
Cohort A: GLPG2222 50 mg QD0.4
Cohort A: GLPG2222 100 mg QD-0.7
Cohort B: GLPG2222 200 mg QD4.5
Cohort B: GLPG2222 400 mg QD-0.8

Mean GLPG2222 Plasma Concentration Observed at Predose (Ctrough; ng/mL)

Plasma concentration of GLPG2222 observed at pre-dose (ng/mL), obtained directly from the observed concentration versus time data. Ctrough was calculated using both Day 15 and Day 29 PK data. (NCT03119649)
Timeframe: Days 15 and 29 (predose)

Interventionng/mL (Mean)
Cohort A: GLPG2222 50 mg QD48.1
Cohort A: GLPG2222 100 mg QD132
Cohort B: GLPG2222 200 mg QD343
Cohort B: GLPG2222 400 mg QD677

Mean Maximum Observed Plasma Concentration (Cmax; Nanograms Per Milliliter [mg/mL]) of GLPG2222

Maximum concentration of GLPG2222 after multiple dosing (ng/ML), obtained directly from the observed concentration versus time data. All pharmacokinetic (PK) parameters were determined from Day 15; Day 29 data were determined if the participant was not available for full PK profiling on Day 15. (NCT03119649)
Timeframe: Day 15 (predose and 0.5, 1, 2, 3, 4, 6, and 8 hours postdose) and prior to dosing on Day 29

Interventionng/mL (Mean)
Cohort A: GLPG2222 50 mg QD478
Cohort A: GLPG2222 100 mg QD1170
Cohort B: GLPG2222 200 mg QD2490
Cohort B: GLPG2222 400 mg QD5330

Median Time to Occurrence of GLPG2222 Cmax (Tmax; Hours [h])

Time of occurrence of maximum concentration of GLPG2222 after multiple dosing (h), obtained directly from the observed concentration versus time data. All PK parameters were determined from Day 15; Day 29 data were determined if the participant was not available for full PK profiling on Day 15. (NCT03119649)
Timeframe: Day 15 (predose and 0.5, 1, 2, 3, 4, 6, and 8 hours postdose) and prior to dosing on Day 29

Interventionhours (Median)
Cohort A: GLPG2222 50 mg QD2.0
Cohort A: GLPG2222 100 mg QD2.0
Cohort B: GLPG2222 200 mg QD3.0
Cohort B: GLPG2222 400 mg QD2.0

Number of Participants With Treatment-Emergent Adverse Events

Number of participants with any treatment-emergent adverse events (TEAEs) and serious or treatment-related TEAEs, as well as number of patients with TEAEs by worst intensity reported (mild, moderate, or severe). (NCT03119649)
Timeframe: First administration (Day 1) through Follow-up (Day 43)

,,,,
InterventionParticipants (Count of Participants)
Any TEAEAny Serious TEAEWorst TEAE Intensity=MildWorst TEAE Intensity=ModerateWorst TEAE Intensity=SevereAny Treatment-related TEAE
Cohort A: GLPG2222 100 mg QD1017216
Cohort A: GLPG2222 50 mg QD804402
Cohort B: GLPG2222 200 mg QD1108215
Cohort B: GLPG2222 400 mg QD909001
Pooled Placebo926212

Part B: Absolute Change in BMI-for-age z-Score

BMI was defined as weight in kg divided by height in m^2. z-score is a statistical measure to describe whether a mean was above or below the standard. BMI, adjusted for age and sex, was analyzed as BMI-for-age z-score. A z-score of 0 is equal to the mean and is considered normal. Lower numbers indicate values lower than the mean and higher numbers indicate values higher than the mean. Higher values are indicative of higher BMI. (NCT02953314)
Timeframe: From Baseline at Week 24

Interventionz-score (Least Squares Mean)
Part B-0.03

Part B: Absolute Change in Body Mass Index (BMI)

BMI was defined as weight in kg divided by height in square meter (m^2). (NCT02953314)
Timeframe: From Baseline at Week 24

Interventionkg/m^2 (Least Squares Mean)
Part B0.23

Part B: Absolute Change in Cystic Fibrosis Questionnaire-Revised (CFQ-R) Respiratory Domain Score

The CFQ-R is a validated participant-reported outcome measuring health-related quality of life for participants with cystic fibrosis. Respiratory domain assessed respiratory symptoms, score range: 0-100; higher scores indicating fewer symptoms and better health-related quality of life. (NCT02953314)
Timeframe: From Baseline through Week 24

Interventionunits on a scale (Least Squares Mean)
Part B3.4

Part B: Absolute Change in Height

(NCT02953314)
Timeframe: From Baseline at Week 24

Interventioncentimeter (cm) (Least Squares Mean)
Part B2.7

Part B: Absolute Change in Height-for-age z-Score

z-score is a statistical measure to describe whether a mean was above or below the standard. Height, adjusted for age and sex, was analyzed as height-for-age z-score. A z-score of 0 is equal to the mean and is considered normal. Lower numbers indicate values lower than the mean and higher numbers indicate values higher than the mean. Higher values are indicative of higher height. (NCT02953314)
Timeframe: From Baseline at Week 24

Interventionz-score (Least Squares Mean)
Part B0.00

Part B: Absolute Change in Percent Predicted Forced Expiratory Volume in 1 Second (ppFEV1)

FEV1 is the volume of air that can forcibly be blown out in one second, after full inspiration. (NCT02953314)
Timeframe: From Baseline through Week 24

Interventionpercentage points (Least Squares Mean)
Part B0.9

Part B: Absolute Change in Sweat Chloride

Sweat samples were collected using an approved collection device. (NCT02953314)
Timeframe: From Baseline through Week 24

Interventionmmol/L (Least Squares Mean)
Part B-14.5

Part B: Absolute Change in Sweat Chloride

Sweat samples were collected using an approved collection device. (NCT02953314)
Timeframe: From Baseline through Week 4

Interventionmillimole per liter (mmol/L) (Least Squares Mean)
Part B-13.0

Part B: Absolute Change in Weight

(NCT02953314)
Timeframe: From Baseline at Week 24

Interventionkg (Least Squares Mean)
Part B1.7

Part B: Absolute Change in Weight-for-age Z-Score

z-score is a statistical measure to describe whether a mean was above or below the standard. Weight, adjusted for age and sex, was analyzed as weight-for-age z-score. A z-score of 0 is equal to the mean and is considered normal. Lower numbers indicate values lower than the mean and higher numbers indicate values higher than the mean. Higher values are indicative of higher weight. (NCT02953314)
Timeframe: From Baseline at Week 24

Interventionz-score (Least Squares Mean)
Part B0.00

Part B: Relative Change in ppFEV1

FEV1 is the volume of air that can forcibly be blown out in one second, after full inspiration. (NCT02953314)
Timeframe: From Baseline through Week 24

Interventionpercent change (Least Squares Mean)
Part B1.4

Part A: Area Under the Concentration Versus Time Curve During Dosing Interval (AUCtau) of TEZ and IVA

(NCT02953314)
Timeframe: Day 1 and Day 14

Interventionhour*nanogram per milliliter (hr*ng/mL) (Geometric Mean)
Day 1: TEZ (<25 Kg)Day 1: TEZ (≥25 Kg)Day 14: TEZ (<25 Kg)Day 14: TEZ (≥25 Kg)Day 14: IVA (<25 Kg)Day 14: IVA (≥25 Kg)
Part A54300416006650071600505012400

Part A: AUCtau of TEZ Metabolites (M1-TEZ, M2-TEZ) and IVA Metabolites (M1-IVA, M6-IVA)

(NCT02953314)
Timeframe: Day 1 and Day 14

Interventionhr*ng/mL (Geometric Mean)
Day 1: M1-TEZ (<25 kg)Day 1: M1-TEZ (≥25 kg)Day 14: M1-TEZ (<25 kg)Day 14: M1-TEZ (≥25 kg)Day 1: M2-TEZ (<25 kg)Day 1: M2-TEZ (≥25 kg)Day 14: M2-TEZ (<25 kg)Day 14: M2-TEZ (≥25 kg)Day 14: M1-IVA (<25 kg)Day 14: M1-IVA (≥25 kg)Day 14: M6-IVA (<25 kg)Day 14: M6-IVA (≥25 kg)
Part A3650027400160000121000142001110013700011900013700303001020026000

Part A: Cmax of TEZ Metabolites (M1-TEZ, M2-TEZ) and IVA Metabolites (M1-IVA, M6-IVA)

(NCT02953314)
Timeframe: Day 1 and Day 14

Interventionng/mL (Geometric Mean)
Day 1: M1-TEZ (<25 kg)Day 1: M1-TEZ (≥25 kg)Day 14: M1-TEZ (<25 kg)Day 14: M1-TEZ (≥25 kg)Day 1: M2-TEZ (<25 kg)Day 1: M2-TEZ (≥25 kg)Day 14: M2-TEZ (<25 kg)Day 14: M2-TEZ (≥25 kg)Day 1: M1-IVA (<25 kg)Day 1: M1-IVA (≥25 kg)Day 14: M1-IVA (<25 kg)Day 14: M1-IVA (≥25 kg)Day 1: M6-IVA (<25 kg)Day 1: M6-IVA (≥25 kg)Day 14: M6-IVA (<25 kg)Day 14: M6-IVA (≥25 kg)
Part A17201530836059301130922618053502320243014603420849107010902720

Part A: Maximum Observed Concentration (Cmax) of TEZ and IVA

(NCT02953314)
Timeframe: Day 1 and Day 14

Interventionnanogram per milliliter (ng/mL) (Geometric Mean)
Day 1: TEZ (<25 Kg)Day 1: TEZ (≥25 Kg)Day 14: TEZ (<25 Kg)Day 14: TEZ (≥25 Kg)Day 1: IVA (<25 Kg)Day 1: IVA (≥25 Kg)Day 14: IVA (<25 Kg)Day 14: IVA (≥25 Kg)
Part A663043106300534065610105781490

Part A: Number of Participants With AEs and SAEs

(NCT02953314)
Timeframe: Day 1 up to Day 28

Interventionparticipants (Number)
Participants with AEsParticipants with SAEs
Part A120

Part B: AUCtau of TEZ, TEZ Metabolites (M1-TEZ, M2-TEZ), IVA, and IVA Metabolites (M1-IVA, M6-IVA )

(NCT02953314)
Timeframe: Week 16

Interventionhr*ng/mL (Geometric Mean)
TEZ (<40 kg)TEZ (≥40 kg)M1-TEZ (<40 kg)M1-TEZ (≥40 kg)M2-TEZ (<40 kg)M2-TEZ (≥40 kg)IVA (<40 kg)IVA (≥40 kg)M1-IVA (<40 kg)M1-IVA (≥40 kg)M6-IVA (<40 kg)M6-IVA (≥40 kg)
Part B50300609001040001000008840093600533074101270017200814011100

Part B: Cmax of TEZ, TEZ Metabolites (M1-TEZ, M2-TEZ), IVA, and IVA Metabolites (M1-IVA, M6-IVA)

(NCT02953314)
Timeframe: Week 16

Interventionng/mL (Geometric Mean)
TEZ (<40 kg)TEZ (≥40 kg)M1-TEZ (<40 kg)M1-TEZ (≥40 kg)M2-TEZ (<40 kg)M2-TEZ (≥40 kg)IVA (<40 kg)IVA (≥40 kg)M1-IVA (<40 kg)M1-IVA (≥40 kg)M6-IVA (<40 kg)M6-IVA (≥40 kg)
Part B480058705310544041705210725886156018708701120

Part B: Number of Participants With Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)

(NCT02953314)
Timeframe: Day 1 up to Week 28

Interventionparticipants (Number)
Participants with AEsParticipants with SAEs
Part B656

Change From Baseline in Maximum Sweat Chloride Concentration (Combined Part 1 and Part 2)

The sweat chloride (quantitative pilocarpine iontophoresis) test is a standard diagnostic tool for cystic fibrosis (CF), serving as an indicator of cystic fibrosis transmembrane conductance regulator (CFTR) activity. (NCT00457821)
Timeframe: 14 days and 28 days

,,,,
Interventionmillimoles per liter (Least Squares Mean)
Change from Baseline in Sweat Chloride, Day 14Change from Baseline in Sweat Chloride, Day ≥14
150 mg Ivacaftor q12h-46.0-44.2
25 mg Ivacaftor q12h-33.8-32.9
250 mg Ivacaftor q12h-27.1-28.2
75 mg Ivacaftor q12h-42.0-40.8
Placebo2.04.9

Change From Baseline in Nasal Potential Difference (Combined Part 1 and Part 2)

The transepithelial nasal potential difference (NPD) is a direct measure of transepithelial ion transport. NPD under conditions of zero chloride concentration perfusion solution in the presence of isoproterenol was of primary interest. (NCT00457821)
Timeframe: 14 days and 28 days

,,,,
Interventionmillivolts (Least Squares Mean)
Zero Chloride + Isoproterenol, Day 14Zero Chloride + Isoproterenol, Day ≥ 14Amiloride, Day 14Amiloride, Day ≥ 14
150 mg Ivacaftor q12h-4.6-5.3-9.9-8.8
25 mg Ivacaftor q12h-1.4-1.3-0.1-0.3
250 mg Ivacaftor q12h-7.6-8.4-5.5-4.0
75 mg Ivacaftor q12h-4.4-4.5-4.2-3.7
Placebo-0.3-0.50.3-0.7

Change From Baseline in Percent Predicted Forced Expiratory Volume in 1 Second [FEV1] (Combined Part 1 and Part 2)

"Spirometry is a standardized assessment to evaluate lung function that is the most widely used endpoint in cystic fibrosis studies.~Relative change reflects the percent change from the baseline values [100% * (X-Y)/Y], where X and Y are post-baseline and baseline values, respectively." (NCT00457821)
Timeframe: 14 days and 28 days

,,,,
Interventionpercent predicted (%) (Least Squares Mean)
Absolute Change from Baseline, Day 14Absolute Change from Baseline, Day ≥ 14Relative Change from Baseline, Day 14Relative Change from Baseline, Day ≥ 14
150 mg Ivacaftor q12h6.96.910.810.6
25 mg Ivacaftor q12h2.72.54.74.1
250 mg Ivacaftor q12h8.46.712.09.4
75 mg Ivacaftor q12h5.15.39.59.3
Placebo0.52.12.03.3

Change From Baseline in the Cystic Fibrosis Questionnaire-Revised (CFQ-R) Score (Part 2 Only)(Respiratory Domain Score)

The CFQ-R is a health-related quality of life measure for subjects with cystic fibrosis. Each domain is scored from 0 (worst) to 100 (best). A difference of at least 4 points in the respiratory domain score of the CFQ-R is considered a minimal clinically important difference (MCID). (NCT00457821)
Timeframe: 14 days and 28 days

,,
Interventionscore on a scale (Mean)
Baseline Respiratory Domain ScoreChange from Baseline in Respiratory Score, Day 14Change from Baseline in Respiratory Score, Day 28
150 mg Ivacaftor q12h68.86.36.9
250 mg Ivacaftor q12h73.05.611.9
Placebo70.82.82.8

Number of Adverse Events (Combined Part 1 and Part 2)

Adverse event data were collected up to the follow-up visit (5 to 9 days after last dose of study drug). Serious adverse events that were ongoing at the follow-up visit were followed until the event resolved, returned to baseline, or was determined to be a stable or chronic condition. (NCT00457821)
Timeframe: Baseline to Follow-up

,
Interventionevents (Number)
Number of Adverse Events (AEs)Number of Related or Possibly Related AEsNumber of Serious Adverse Events (SAEs)Number of Related or Possibly Related SAEs
Ivacaftor1794020
Placebo321100

Number of Subjects With Adverse Events (Combined Part 1 and Part 2)

Adverse event data were collected up to the follow-up visit (5 to 9 days after last dose of study drug). Serious adverse events that were ongoing at the follow-up visit were followed until the event resolved, returned to baseline, or was determined to be a stable or chronic condition. (NCT00457821)
Timeframe: Baseline to Follow-up

,
Interventionparticipants (Number)
Subjects with AEsSubjects with Related or Possibly Related AEsSubjects with SAEsSubjects with Related or Possibly Related SAEs
Ivacaftor261310
Placebo7300

Percent-Predicted of Forced Vital Capacity (FVC) at Baseline

Spirometry was used to assess pulmonary function by measuring the percentage of predicted function, which was determined on the basis of the height value obtained at the same study visit, for FVC (the amount of air that can be exhaled after taking a deep breath). Spirometry was assessed by using current guidelines of the ATS and ERS. Baseline was the average of percent-predicted FVC at screening and randomization. (NCT00803205)
Timeframe: Baseline (Week 1)

Interventionpercentage of predicted FVC (Mean)
Ataluren78.332
Placebo76.609

Percentage Change From Baseline in Percent-Predicted of FEV1 at Week 48

Spirometry was used to assess pulmonary function by measuring the percentage of predicted function, which was determined on the basis of the height value obtained at the same study visit, for FEV1 (the amount of air that can be exhaled in 1 second). Spirometry was assessed by using current guidelines of the American Thoracic Society (ATS) and European Respiratory Society (ERS). The percentage of change in percent-predicted of FEV1 was calculated as follows: ([percent-predicted FEV1-Baseline percent-predicted FEV1]/Baseline percent-predicted FEV1)*100. Baseline was the average of percent-predicted FEV1 at screening and randomization. A negative change from Baseline indicates that percent-predicted of FEV1 decreased. (NCT00803205)
Timeframe: End of Treatment (EOT) (Week 48)

Interventionpercent change (Mean)
Ataluren-2.534
Placebo-5.500

Percentage Change From Baseline in Percent-Predicted of FVC at Week 48

Spirometry was used to assess pulmonary function by measuring the percentage of predicted function, which was determined on the basis of the height value obtained at the same study visit, for FVC (the amount of air that can be exhaled after taking a deep breath). Spirometry was assessed by using current guidelines of the ATS and ERS. The percentage of change in percent-predicted of FVC was calculated as follows: ((percent-predicted FVC-Baseline percent-predicted FVC)/Baseline percent-predicted FVC)*100. Baseline was the average of percent-predicted FVC at screening and randomization. A negative change from Baseline indicates that percent-predicted of FVC decreased. (NCT00803205)
Timeframe: EOT (Week 48)

Interventionpercent change (Mean)
Ataluren-2.139
Placebo-3.484

Percentage of Predicted Function (Percent-Predicted) of Forced Expiratory Volume in One Second (FEV1) at Baseline

Spirometry was used to assess pulmonary function by measuring the percentage of predicted function, which was determined on the basis of the height value obtained at the same study visit, for FEV1 (the amount of air that can be exhaled in 1 second). Spirometry was assessed by using current guidelines of the American Thoracic Society (ATS) and European Respiratory Society (ERS). Baseline was the average of percent-predicted FEV1 at screening and randomization. (NCT00803205)
Timeframe: Baseline (Week 1)

Interventionpercentage of predicted FEV1 (Mean)
Ataluren62.092
Placebo60.232

Rate of Disruptions in Activities of Daily Living Because of Pulmonary Symptoms

During treatment, any disruption in the activities of daily living, such as missed school or work, was documented if it was due to an exacerbation-like episode. Participants and caregivers recorded all disruptions in an electronic diary. The rate of disruptions was defined as the total days with disruptions to daily living divided by the total study duration. (NCT00803205)
Timeframe: Baseline up to EOT (Week 48)

Interventiondays with disruptions per study (Mean)
Ataluren0.037
Placebo0.047

Rate of Pulmonary Exacerbations as Defined by Modified Fuch's Criteria Over 48 Weeks

A Respiratory Event Form, which collected data on various signs, symptoms, and effects for each event, was completed by the Investigator when informed by the participant of a respiratory event. Pulmonary exacerbations were assessed by using the modified Fuchs' criteria, which defines an exacerbation as a respiratory event requiring treatment with parenteral antibiotics for any 4 of the following 12 symptoms, with or without intravenous antibiotics: change in sputum; new or increased hemoptysis; increased cough; increased dyspnea; fatigue; temperature >38°C; anorexia; sinus pain; change in sinus discharge; change in physical examination of the chest; decrease in pulmonary function by 10% or more from a previously recorded value; or radiographic changes indicative of pulmonary function. The 48-week exacerbation rate was determined by adding the weekly rates for each arm and dividing the sum by 48. (NCT00803205)
Timeframe: Baseline to EOT (Week 48)

Interventionexacerbations (Mean)
Ataluren1.42
Placebo1.78

Rate of Study Drug Compliance by Patient-Reported Data

"Patient-reported data were obtained from the participant's electronic daily diary, which was completed by the participant or the caregiver. During study treatment, the electronic daily diary was to be completed by the participant or caregiver each day for each dose. For each participant, compliance is described in terms of the percentage of study drug actually taken. All calculations were based on the records of the first dose date to the last dose date. To differentiate dose strengths while maintaining the blind, each kit had a unique kit number and had prominent lettering A and B. Each kit contained 65 packets of 1 of the dose strengths (125, 250, or 1000 mg or matching placebo). Labeling for active drug and placebo was identical." (NCT00803205)
Timeframe: Baseline up to EOT (Week 48)

Interventionpercent of doses taken (Median)
Ataluren71.48
Placebo69.27

Change From Baseline in Awake Cough Hourly Rate at Week 48

The frequency of awake cough was measured using the LifeShirt, which incorporates motion-sensing transducers, electrodes, a microphone, and a 3-axis accelerometer into a lightweight vest. The rate was determined by dividing the total number of coughs by 24 (the number of hours of the observation period). Baseline was the latest, valid assessment prior to the treatment. A negative change from Baseline indicates that coughing decreased. (NCT00803205)
Timeframe: Baseline, EOT (Week 48)

,
Interventioncoughs/hour (Mean)
BaselineChange From Baseline
Ataluren28.218-0.595
Placebo24.4720.882

Change From Baseline in Body Weight at Week 48

Participants were weighed, and the weight was recorded at Baseline and then every 8 weeks during the treatment period. Baseline was the latest valid assessment prior to the treatment. A positive change from Baseline indicates that weight increased. (NCT00803205)
Timeframe: Baseline, EOT (Week 48)

,
Interventionkg (Mean)
BaselineChange From Baseline
Ataluren53.460.87
Placebo56.010.83

Change From Baseline in Sweat Chloride Concentration at Week 48

Sweat was collected, from each arm, by using pilocarpine iontophoresis. The chloride concentration in the sweat was quantified for each arm by using standard laboratory methods. Tests were also considered valid if the sweat collection time was ≤35 minutes; tests with longer collection times were also considered valid if extra time was needed to obtain sufficient volume (≥15uL) for analysis. For analysis purposes, the average of the values from each arm were computed. If the assessment was valid and/or available in only 1 arm, this value was used as if it were the average of both arms. The method used was consistent with the CFFT-TDN guidelines. Baseline was the latest, valid assessment prior to the treatment. A negative change from Baseline indicates that sweat chloride concentration decreased. (NCT00803205)
Timeframe: Baseline, EOT (Week 48)

,
Interventionmillimoles/L (Mean)
BaselineChange From Baseline
Ataluren100.140-1.325
Placebo96.586-0.619

Change From Baseline in the Concentration of C-Reactive Protein (CRP) in Serum at Week 48

Expression of CRP was measured in serum. Baseline was the latest valid assessment prior to the treatment. A positive change from Baseline indicates that CRP concentration increased. (NCT00803205)
Timeframe: Baseline, EOT (Week 48)

,
Interventionmg/liter (L) (Mean)
BaselineChange From Baseline
Ataluren6.8992.420
Placebo7.0372.031

Change From Baseline in the Concentration of Interleukin-8 (IL-8) in Serum and Sputum at Week 48

Expression of IL-8 was measured in serum and in sputum. Sputum was spontaneously produced and tested by using standardized procedures developed by the Cystic Fibrosis Foundation Therapeutics, Inc. Therapeutics Development Network (CFFT-TDN). Baseline was the latest valid assessment prior to the treatment. A negative change from Baseline indicates that the concentration of IL-8 decreased. (NCT00803205)
Timeframe: Baseline, EOT (Week 48)

,
Interventionpicograms/mL (Mean)
Serum, BaselineSerum, Change From BaselineSputum, BaselineSputum, Change From Baseline
Ataluren39.537-2.334267629.9328882.79
Placebo55.845-16.197250170.959957.24

Change From Baseline in the Concentration of Neutrophil Elastase in Sputum at Week 48

Expression of neutrophil elastase was measured in sputum. Sputum was spontaneously produced and tested by using standardized procedures developed by the CFFT-TDN. Baseline was the latest valid assessment prior to the treatment. A positive change from Baseline indicates that the concentration of neutrophil elastase increased. (NCT00803205)
Timeframe: Baseline, EOT (Week 48)

,
Interventionug/mL (Mean)
BaselineChange From Baseline
Ataluren183.645.45
Placebo227.35-8.67

Change From Baseline in the Respiratory Domain Score of the Revised Cystic Fibrosis Questionnaire (CFQ-R) at Week 48

The CFQ-R consists of 44 items, including generic scales of physical functioning, role functioning, vitality, health perceptions, emotional functioning, and social functioning, and CF-specific scales of respiratory and digestive symptoms, body image, eating disturbances, and treatment burden. Each domain score ranges from 1 to 4. Scores were linearly transformed to a 0 to 100 scale, with higher scores indicating better health. Domain scores were calculated by using the following formula: 100 * (sum of responses - minimum possible sum)/ (maximum possible sum - minimum possible sum). The minimum possible sum = number of questions * 1; the maximum possible = the number of questions * 4. Baseline was the latest, valid assessment prior to the treatment. A negative change from Baseline indicates that health has worsened. Participants may have switched age groups during the study. (NCT00803205)
Timeframe: Baseline, EOT (Week 48)

,
Interventionunits on a scale (Mean)
Aged 6-13 years, BaselineAged 6-13 years, Change From BaselineAge ≥14 years , BaselineAge ≥14 years, Change From Baseline
Ataluren77.78-0.6970.06-2.81
Placebo79.49-3.5765.95-3.32

Change From Baseline in the Total Lung Score as Assessed by Computed Tomography (CT) at Week 48

Lungs were imaged by using non-contrast, spiral CT. The total lung score for each CT scan was established by the sum of 5 characteristics from the Brody scoring system, with scores ranging from 0 to 40.5, with lower scores indicating better lung function. The characteristics scored were bronchiectasis (score range 0 - 12), mucus plugging (score range 0- 6), peribronchial thickening (score range 0 - 9), parenchyma (score range 0 - 9), and hyperinflation (score range 0 - 4.5). Baseline was the latest valid assessment prior to the treatment. A positive change from Baseline indicates that lung function worsened. (NCT00803205)
Timeframe: Baseline, EOT (Week 48)

,
Interventionunits on a scale (Mean)
BaselineChange From Baseline
Ataluren9.5310.282
Placebo9.6190.560

Change From Baseline in Total Nasal Chloride Transport as Assessed by Transepithelial Potential Difference (TEPD) at Week 48

TEPD was assessed in each nostril using standardized equipment, techniques, and solutions. Assessments were made on the nasal epithelium cells lining the inferior turbinate. Warmed solutions of Ringer's solution, amiloride, chloride-free gluconate, isoproterenol, and adenosine triphosphate (ATP) were perfused for ≥3-minute sequentially through a nasal catheter while a voltage tracing was recorded. Total chloride transport was computed for each nostril. The total chloride transport values were calculated by subtracting the voltages at the end of a perfusion from the voltage at the end of an earlier perfusion (isoproterenol - amiloride). The average of the values for each nostril was computed. If the assessment was available in only 1 nostril, this value was used as if it were the average of both nostrils. Baseline was the latest, valid assessment prior to the treatment. A positive change from Baseline indicates that nasal chloride transport increased. (NCT00803205)
Timeframe: Baseline, EOT (Week 48)

,
Interventionmillivolts (Mean)
BaselineChange From Baseline
Ataluren1.5780.312
Placebo1.9500.139

Concentration of Ataluren

Blood samples were drawn immediately before administration of the first daily dose (dose taken with breakfast) of study drug and 2 hours after the first daily dose. Whenever possible, the pre-dose sample was to be obtained within 15 minutes of drug administration. Participants in the Placebo arm did not receive Ataluren and are not included in this Outcome Measure. (NCT00803205)
Timeframe: Predose and 2 Hours Postdose at Week 1, Week 16, Week 32, EOT (Week 48)

Interventionmicrograms/milliliter (ug/mL) (Median)
Week 1 PredoseWeek 1 PostdoseWeek 16 PredoseWeek 16 PostdoseWeek 32 PredoseWeek 32 PostdoseWeek 48 PredoseWeek 48 Postdose
Ataluren014.1004.35011.9004.63013.4003.97010.500

Percentage of Participants With Treatment-Emergent Adverse Events (TEAE)

A TEAE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship that occurred or worsened in the period extending from first dose of study drug to 4 weeks after the last dose of study drug. A serious adverse event (SAE) was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. AEs included both SAEs and non-serious AEs. AE severity was graded as follows: Grade 1: mild; Grade 2: moderate; Grade 3: severe; Grade 4: life-threatening; Grade 5: fatal. A TEAE was considered related if in the opinion of the Investigator it was possibly or probably caused by the study drug. A summary of other non-serious AEs and all SAEs, regardless of causality is located in the Adverse Events module. (NCT00803205)
Timeframe: Baseline up to 4 Weeks Post-Treatment (Week 52) or Premature Discontinuation (PD)

,
Interventionpercent of participants (Number)
At least 1 TEAEGrade 1 TEAEGrade 2 TEAEGrade 3 TEAEGrade 4 TEAEGrade 5 TEAEUnrelated TEAEUnlikely related TEAEPossibly related TEAEProbably related TEAEDiscontinuation due to TEAESerious TEAE
Ataluren98.315.067.515.80025.032.528.312.56.737.5
Placebo97.516.955.125.40035.626.329.75.92.540.7

Rate of Interventions for Respiratory Symptoms

During treatment, any intervention including hospitalization or use of oral, inhaled, or intravenous antibiotics was documented if it was due to an exacerbation-like episode. Participants and caregivers recorded interventions in an electronic diary. The rate of interventions was defined as the total days with interventions divided by the total study duration. (NCT00803205)
Timeframe: Baseline up to EOT (Week 48)

,
Interventiondays with interventions per study (Mean)
HospitalizationUse of Antibiotics
Ataluren0.0100.220
Placebo0.0210.245

Rate of Study Drug Compliance by Drug Accountability

"Study drug compliance was assessed by using a Pharmacy Subject Study Drug Accountability Log (completed by the investigational site personnel). The rate of compliance was defined as 100 * (number of sachets taken/number of planned sachets) during the study. All calculations were based on the records of the first dose date to the last dose date. To differentiate dose strengths while maintaining the blind, each kit had a unique kit number and had prominent lettering A and B. Each kit contained 65 packets of 1 of the dose strengths (125, 250, or 1000 mg or matching placebo). Labeling for active drug and placebo was identical." (NCT00803205)
Timeframe: Baseline up to EOT (Week 48)

,
Interventionpercent of doses taken (Median)
Drug Kit ADrug Kit B
Ataluren90.14990.830
Placebo85.11986.614

Cohort 1: Absolute Change From Baseline in Sweat Chloride at Day 14

(NCT01225211)
Timeframe: Cohort 1: Baseline, Day 14

Interventionmmol/L (Least Squares Mean)
Cohort 1: LUM 200 mg qd - Period 1-4.442
Cohort 1: Placebo - Period 1-1.668

Cohort 1: Absolute Change From Day 14 in FEV1 at Day 21

FEV1 is the volume of air that can forcibly be blown out in one second, after full inspiration. (NCT01225211)
Timeframe: Cohort 1: Day 14, Day 21

Interventionliters (Least Squares Mean)
Cohort 1: LUM 200 mg qd+IVA 150 mg q12h - Period 20.128
Cohort 1: LUM 200 mg qd+IVA 250 mg q12h - Period 20.015
Cohort 1: Placebo - Period 2-0.046

Cohort 1: Absolute Change From Day 14 in ppFEV1 at Day 21

FEV1 and ppFEV1 are defined in Outcome Measure 6. (NCT01225211)
Timeframe: Cohort 1: Day 14, Day 21

Interventionpercent predicted of FEV1 (Least Squares Mean)
Cohort 1: LUM 200 mg qd+IVA 150 mg q12h - Period 23.46
Cohort 1: LUM 200 mg qd+IVA 250 mg q12h - Period 20.63
Cohort 1: Placebo - Period 2-1.44

Cohort 1: Absolute Change From Day 14 in Sweat Chloride at Day 21

(NCT01225211)
Timeframe: Cohort 1: Day 14, Day 21

Interventionmillimole per liter (mmol/L) (Least Squares Mean)
Cohort 1: LUM 200 mg qd+IVA 150 mg q12h - Period 2-2.131
Cohort 1: LUM 200 mg qd+IVA 250 mg q12h - Period 2-9.128
Cohort 1: Placebo - Period 20.548

Cohort 2 And 3: Absolute Change From Baseline in Sweat Chloride at Day 14

(NCT01225211)
Timeframe: Cohort 2: Baseline, Day 14

Interventionmmol/L (Least Squares Mean)
Cohort 2: LUM 200 mg qd - Period 1-6.490
Cohort 2: LUM 400 mg qd - Period 1-5.901
Cohort 2: LUM 600 mg qd (HO) - Period 1-9.442
Cohort 2: LUM 600 mg qd (HE) - Period 1-3.137
Cohort 3: LUM 400 mg q12h - Period 1-9.179
Cohort 2 and 3: Placebo (HO and HE) - Period 10.048

Cohort 2 and 3: Absolute Change From Day 28 in Cystic Fibrosis Questionnaire-Revised (CFQ-R) Respiratory Domain Score at Day 56

The CFQ-R is a validated participant-reported outcome measuring health-related quality of life for subjects with cystic fibrosis. Respiratory domain assessed respiratory symptoms (for example, coughing, congestion, wheezing), score range: 0-100; higher scores indicating fewer symptoms and better health-related quality of life. (NCT01225211)
Timeframe: Cohort 2 and 3: Day 28, Day 56

Interventionunits on a scale (Least Squares Mean)
Cohort 2: LUM 200 mg qd+IVA 250 mg q12h (HO) - Period 23.3
Cohort 2: LUM 400 mg qd+IVA 250 mg q12h (HO) - Period 27.9
Cohort 2: LUM 600 mg qd+IVA 250 mg q12h (HO) - Period 28.9
Cohort 2: LUM 600 mg qd+IVA 250 mg q12h (HE) - Period 25.5
Cohort 3: LUM 400 mg q12h+IVA 250 mg q12h (HO) - Period 211.2
Cohort 2 and 3: Placebo (HO and HE) - Period 2-8.6

Cohort 2 and 3: Absolute Change From Day 28 in ppFEV1 at Day 56

FEV1 and ppFEV1 are defined in Outcome Measure 6. (NCT01225211)
Timeframe: Cohort 2 and 3: Day 28, Day 56

Interventionpercent predicted of FEV1 (Least Squares Mean)
Cohort 2: LUM 200 mg qd+IVA 250 mg q12h (HO) - Period 21.96
Cohort 2: LUM 400 mg qd+IVA 250 mg q12h (HO) - Period 21.99
Cohort 2: LUM 600 mg qd+IVA 250 mg q12h (HO) - Period 26.15
Cohort 2: LUM 600 mg qd+IVA 250 mg q12h (HE) - Period 22.29
Cohort 3: LUM 400 mg q12h+IVA 250 mg q12h (HO) - Period 26.09
Cohort 2 and 3: Placebo (HO and HE) - Period 2-1.57

Cohort 2 And 3: Absolute Change From Day 28 in Sweat Chloride at Day 56

(NCT01225211)
Timeframe: Cohort 2 and 3: Day 28, Day 56

Interventionmmol/L (Least Squares Mean)
Cohort 2: LUM 200 mg qd+IVA 250 mg q12h (HO) - Period 20.321
Cohort 2: LUM 400 mg qd+IVA 250 mg q12h (HO) - Period 2-1.043
Cohort 2: LUM 600 mg qd+IVA 250 mg q12h (HO) - Period 2-2.900
Cohort 2: LUM 600 mg qd+IVA 250 mg q12h (HE) - Period 2-1.240
Cohort 3: LUM 400 mg q12h+IVA 250 mg q12h (HO) - Period 2-2.154
Cohort 2 and 3: Placebo (HO and HE) - Period 21.627

Cohort 2 and 3: Relative Change From Day 28 in ppFEV1 at Day 56

FEV1 and ppFEV1 are defined in Outcome Measure 6. (NCT01225211)
Timeframe: Cohort 2 and 3: Day 28, Day 56

Interventionpercent change (Least Squares Mean)
Cohort 2: LUM 200 mg qd+IVA 250 mg q12h (HO) - Period 23.13
Cohort 2: LUM 400 mg qd+IVA 250 mg q12h (HO) - Period 22.98
Cohort 2: LUM 600 mg qd+IVA 250 mg q12h (HO) - Period 29.70
Cohort 2: LUM 600 mg qd+IVA 250 mg q12h (HE) - Period 24.30
Cohort 3: LUM 400 mg q12h+IVA 250 mg q12h (HO) - Period 28.24
Cohort 2 and 3: Placebo (HO and HE) - Period 2-2.05

Cohort 4: Absolute Change From Baseline in Body Mass Index (BMI) at Day 56

BMI was defined as weight in kilogram (kg) divided by height*height in square meter (m^2). (NCT01225211)
Timeframe: Cohort 4: Baseline, Day 56

Interventionkg/m^2 (Least Squares Mean)
Cohort 4: Placebo0.08
Cohort 4: LUM 400 mg q12h+IVA 250 mg q12h-0.04

Cohort 4: Absolute Change From Baseline in CFQ-R Respiratory Domain Score at Day 56

CFQ-R respiratory domain is defined in Outcome Measure 17. (NCT01225211)
Timeframe: Cohort 4: Baseline, Day 56

Interventionunits on a scale (Least Squares Mean)
Cohort 4: Placebo-0.82
Cohort 4: LUM 400 mg q12h+IVA 250 mg q12h5.66

Cohort 4: Absolute Change From Baseline in Percent Predicted Forced Expiratory Volume in 1 Second (ppFEV1) at Day 56

FEV1 is the volume of air that can forcibly be blown out in one second, after full inspiration. ppFEV1 (predicted for age, gender, and height) was calculated using the Hankinson method. (NCT01225211)
Timeframe: Cohort 4: Baseline, Day 56

Interventionpercent predicted of FEV1 (Least Squares Mean)
Cohort 4: Placebo-1.23
Cohort 4: LUM 400 mg q12h+IVA 250 mg q12h-0.62

Cohort 4: Absolute Change From Baseline in Sweat Chloride at Day 56

(NCT01225211)
Timeframe: Cohort 4: Baseline, Day 56

Interventionmmol/L (Least Squares Mean)
Cohort 4: Placebo-0.78
Cohort 4: LUM 400 mg q12h+IVA 250 mg q12h-11.82

Cohort 4: Absolute Change From Baseline in Weight at Day 56

(NCT01225211)
Timeframe: Cohort 4: Baseline, Day 56

Interventionkg (Least Squares Mean)
Cohort 4: Placebo0.16
Cohort 4: LUM 400 mg q12h+IVA 250 mg q12h-0.11

Cohort 4: Relative Change From Baseline in Percent Predicted FEV1 at Day 56

FEV1 and ppFEV1 are defined in Outcome Measure 6. (NCT01225211)
Timeframe: Cohort 4: Baseline, Day 56

Interventionpercent change (Least Squares Mean)
Cohort 4: Placebo-2.20
Cohort 4: LUM 400 mg q12h+IVA 250 mg q12h-0.69

Cohort 1: Safety and Tolerability Based on Adverse Events (AEs)

AE: any untoward medical occurrence in a participant during study; irrespective of relationship with treatment. This includes any newly occurring event or previous condition that has increased in severity or frequency after informed consent. AE includes serious AEs (SAEs) as well as Non-SAEs. SAE (subset of AE): medical event or condition, which falls into any of the following categories, regardless of its relationship to study drug: death, life threatening adverse experience, in-patient hospitalization/prolongation of hospitalization, persistent/significant disability or incapacity, congenital anomaly/birth defect, important medical event. Number of participants with AEs and SAEs are reported. AE that started at/after initial dosing of study drug, or increased in severity after initial dosing of study drug is considered treatment-emergent. Results are reported separately for monotherapy period (Period 1: Day 1 to Day 14) and combination therapy period (Period 2: Day 15 to Day 21). (NCT01225211)
Timeframe: Cohort 1: Day 1 up to 28 days after last dose (Last dose = Day 21)

,,,,
Interventionparticipants (Number)
Participants with any AEsParticipants with SAEs
Cohort 1: LUM 200 mg qd - Period 1290
Cohort 1: LUM 200 mg qd+IVA 150 mg q12h - Period 2140
Cohort 1: LUM 200 mg qd+IVA 250 mg q12h - Period 2120
Cohort 1: Placebo - Period 1120
Cohort 1: Placebo - Period 2150

Cohort 2 and 3: Absolute Change From Baseline in ppFEV1 at Day 28 and 56

FEV1 and ppFEV1 are defined in Outcome Measure 6. (NCT01225211)
Timeframe: Cohort 2 and 3: Baseline, Day 28 and 56

,,,,,
Interventionpercent predicted of FEV1 (Least Squares Mean)
Day 28: (n= 21, 20, 20, 18, 11, 27)Day 56: (n= 21, 20, 20, 17, 10, 24)
Cohort 2 and 3: Placebo (HO and HE)-0.03-2.02
Cohort 2: LUM 200 mg qd/LUM 200 mg qd+IVA 250 mg q12h (HO)0.211.82
Cohort 2: LUM 400 mg qd/LUM 400 mg qd+IVA 250 mg q12h (HO)-1.350.64
Cohort 2: LUM 600 mg qd/LUM 600 mg qd+IVA 250 mg q12h (HE)-3.82-1.68
Cohort 2: LUM 600 mg qd/LUM 600 mg qd+IVA 250 mg q12h (HO)-2.623.59
Cohort 3: LUM 400 mg q12h/LUM 400 mg q12h+IVA 250 mg q12h (HO)-4.522.16

Cohort 2 and 3: Relative Change From Baseline in FEV1 at Day 28 and 56

FEV1 and ppFEV1 are defined in Outcome Measure 6. (NCT01225211)
Timeframe: Cohort 2 and 3: Baseline, Day 28 and 56

,,,,,
Interventionpercent change (Least Squares Mean)
Day 28: (n= 21, 20, 20, 18, 11, 27)Day 56: (n= 21, 20, 20, 17, 10, 24)
Cohort 2 and 3: Placebo (HO and HE)1.89-2.42
Cohort 2: LUM 200 mg qd/LUM 200 mg qd+IVA 250 mg q12h (HO)0.242.51
Cohort 2: LUM 400 mg qd/LUM 400 mg qd+IVA 250 mg q12h (HO)-1.151.72
Cohort 2: LUM 600 mg qd/LUM 600 mg qd+IVA 250 mg q12h (HE)-5.46-2.34
Cohort 2: LUM 600 mg qd/LUM 600 mg qd+IVA 250 mg q12h (HO)-3.135.55
Cohort 3: LUM 400 mg q12h/LUM 400 mg q12h+IVA 250 mg q12h (HO)-6.392.96

Cohort 2 and 3: Safety and Tolerability Based on Adverse Events (AEs)

Detailed description is provided in Outcome Measure 1. Results are reported separately for monotherapy period (Period 1: Day 1 to Day 28) and combination therapy period (Period 2: Day 29 to Day 56). (NCT01225211)
Timeframe: Cohort 2 and 3: Day 1 up to 28 days after last dose (Last dose = Day 56)

,,,,,,,,,
Interventionparticipants (Number)
Participants with any AEsParticipants with SAEs
Cohort 2 and 3: Placebo (HO and HE) - Period 1231
Cohort 2 and 3: Placebo (HO and HE) - Period 2204
Cohort 2: LUM 200 mg qd - Period 1182
Cohort 2: LUM 200 mg qd+IVA 250 mg q12h (HO) - Period 2120
Cohort 2: LUM 400 mg qd - Period 1180
Cohort 2: LUM 400 mg qd+IVA 250 mg q12h (HO) - Period 2151
Cohort 2: LUM 600 mg qd - Period 1373
Cohort 2: LUM 600 mg qd+IVA 250 mg q12h (HO&HE) - Period 2264
Cohort 3: LUM 400 mg q12h - Period 172
Cohort 3: LUM 400 mg q12h+IVA 250 mg q12h (HO) - Period 2101

Cohort 4: Safety and Tolerability Assessed by Number of Participants With AEs and SAEs

AEs and SAEs are defined in Outcome Measure 1. (NCT01225211)
Timeframe: Cohort 4: Day 1 up to 28 days after last dose (Last dose = Day 56)

,
Interventionparticipants (Number)
Participants with any AEsParticipants with SAEs
Cohort 4: Active Study Drug529
Cohort 4: Placebo535

Part B: Absolute Change From Baseline in Body Mass Index (BMI) at Week 24

BMI = (Weight [in kg]) divided by (Stature [in meters])^2. Data was reported as per the dose received and for overall participants. (NCT01705145)
Timeframe: Baseline, Week 24

Interventionkilogram per square meter (kg/m^2) (Mean)
Part B: Ivacaftor 50 mg0.332
Part B: Ivacaftor 75 mg0.314
Part B: Overall Ivacaftor0.319

Part B: Absolute Change From Baseline in Stature at Week 24

Stature was measured as height if children could stand unassisted and follow directions; otherwise, stature was measured as length. Data was reported as per the dose received and for overall participants. (NCT01705145)
Timeframe: Part B: Baseline, Week 24

Interventioncentimeters (cm) (Mean)
Part B: Ivacaftor 50 mg2.5
Part B: Ivacaftor 75 mg3.5
Part B: Overall Ivacaftor3.3

Part B: Absolute Change From Baseline in Sweat Chloride at Week 24

Sweat samples were collected using an approved Macroduct (Wescor, Logan, Utah) collection device. A volume of greater than or equal to (>=) 15 microliter was required for determination of sweat chloride. Data was reported as per the dose received and for overall participants. (NCT01705145)
Timeframe: Part B: Baseline, Week 24

Interventionmillimole per liter (mmol/L) (Mean)
Part B: Ivacaftor 50 mg-47.07
Part B: Ivacaftor 75 mg-46.78
Part B: Overall Ivacaftor-46.86

Part B: Absolute Change From Baseline in Weight at Week 24

Data was reported as per the dose received and for overall participants. (NCT01705145)
Timeframe: Part B: Baseline, Week 24

Interventionkilograms (kg) (Mean)
Part B: Ivacaftor 50 mg1.00
Part B: Ivacaftor 75 mg1.50
Part B: Overall Ivacaftor1.36

Part A: Number of Participants With Adverse Events (AEs), Serious Adverse Events (SAEs) and Related AEs

"AE: any adverse change from participant's baseline (pre-treatment) condition, including any adverse experience, abnormal recording/clinical laboratory assessment which occurs during course of study, whether it is considered related to study drug or not. SAE: medical event or condition, which falls into any of following categories, regardless of its relationship to the study drug: death, life threatening adverse experience, in-patient hospitalization/prolonged hospitalization, persistent/significant disability/incapacity, congenital anomaly/birth defect, important medical event.~Related AEs includes all AEs for which the causality was either related to study drug or possibly related to study drug. Data was reported as per the dose received and for overall participants." (NCT01705145)
Timeframe: Part A: Up to 93 Days

,,
Interventionparticipants (Number)
AEsSAEsRelated AEs
Part A: Ivacaftor 50 mg301
Part A: Ivacaftor 75 mg503
Part A: Overall Ivacaftor804

Part A: Plasma Concentration of Ivacaftor and Its Metabolites

Plasma concentration was reported for ivacaftor and its metabolites (hydroxymethyl ivacaftor [M1] and ivacaftor carboxylate [M6]) up to 24 hours post-dose on Day 4 (Hour 0 [pre-dose] on Day 1 and Day 4; 2, 3, 6, 24 hours post-dose on Day 4). Data was planned to be reported for overall participants in the period. (NCT01705145)
Timeframe: Part A: up to 24 hours post-dose on Day 4

Interventionnanogram per milliliter (ng/mL) (Mean)
Ivacaftor: Hour 0 on Day 1Ivacaftor: Hour 0 on Day 4Ivacaftor: 2 Hours Post-Dose on Day 4Ivacaftor: 3 Hours Post-Dose on Day 4Ivacaftor: 6 Hours Post-Dose on Day 4Ivacaftor: 24 Hours Post-Dose on Day 4M1: Hour 0 on Day 1M1: Hour 0 on Day 4M1: 2 Hours Post-Dose on Day 4M1: 3 Hours Post-Dose on Day 4M1: 6 Hours Post-Dose on Day 4M1: 24 Hours Post-Dose on Day 4M6: Hour 0 on Day 1M6: Hour 0 on Day 4M6: 2 Hours Post-Dose on Day 4M6: 3 Hours Post-Dose on Day 4M6: 6 Hours Post-Dose on Day 4M6: 24 Hours Post-Dose on Day 4
Part A: Overall Ivacaftor0.003967269575421240.0012401540231015803890.001150105013001390439

Part B: Number of Participants With Adverse Events (AEs), Serious Adverse Events (SAEs) and Related AEs

"AE: any adverse change from participant's baseline (pre-treatment) condition, including any adverse experience, abnormal recording/clinical laboratory assessment which occurs during course of study, whether it is considered related to study drug or not. AE includes both serious and non-serious AE. SAE: medical event or condition, which falls into any of following categories, regardless of its relationship to the study drug: death, life threatening adverse experience, in-patient hospitalization/prolonged hospitalization, persistent/significant disability/incapacity, congenital anomaly/birth defect, important medical event.~Related AEs includes all AEs for which the causality was either related to study drug or possibly related to study drug. Data was reported as per the dose received." (NCT01705145)
Timeframe: Part B: Up to 28 Weeks

,,
Interventionparticipants (Number)
AEsSAEsRelated AEs
Part B: Ivacaftor 50 mg1033
Part B: Ivacaftor 75 mg2338
Part B: Overall Ivacaftor33611

Part B: Plasma Concentration of Ivacaftor and Its Metabolites

Plasma concentration was reported for ivacaftor and its metabolites (M1 and M6) up to 24 hours post-dose on Day 168 (Hour 0 [predose] on Day 1, 14, 56, 112, and 168; 2, 3, 6 hours post-dose on Day 14; 1 hour post-dose on Day 56; 4, 6 hours post-dose on Day 112; 24 hours post-dose on Day 168). Data was planned to be reported for overall participants in the period. (NCT01705145)
Timeframe: Part B: up to 24 hours post-dose on Day 168

Interventionng/mL (Mean)
Ivacaftor: Hour 0 on Day 1Ivacaftor: Hour 0 on Day 14Ivacaftor: 2 Hours Post-Dose on Day 14Ivacaftor: 3 Hours Post-Dose on Day 14Ivacaftor: 6 Hours Post-Dose on Day 14Ivacaftor: Hour 0 on Day 56Ivacaftor: 1 Hour Post-Dose on Day 56Ivacaftor: Hour 0 on Day 112Ivacaftor: 4 Hours Post-Dose on Day 112Ivacaftor: 6 Hours Post-Dose on Day 112Ivacaftor: Hour 0 on Day 168Ivacaftor: 24 Hours Post-Dose on Day 168M1: Hour 0 on Day 1M1: Hour 0 on Day 14M1: 2 Hours Post-Dose on Day 14M1: 3 Hours Post-Dose on Day 14M1: 6 Hours Post-Dose on Day 14M1: Hour 0 on Day 56M1: 1 Hour Post-Dose on Day 56M1: Hour 0 on Day 112M1: 4 Hours Post-Dose on Day 112M1: 6 Hours Post-Dose on Day 112M1: Hour 0 on Day 168M1: 24 Hours Post-Dose on Day 168M6: Hour 0 on Day 1M6: Hour 0 on Day 14M6: 2 Hours Post-Dose on Day 14M6: 3 Hours Post-Dose on Day 14M6: 6 Hours Post-Dose on Day 14M6: Hour 0 on Day 56M6: 1 Hour Post-Dose on Day 56M6: Hour 0 on Day 112M6: 4 Hours Post-Dose on Day 112M6: 6 Hours Post-Dose on Day 112M6: Hour 0 on Day 168M6: 24 Hours Post-Dose on Day 168
Part B: Overall Ivacaftor0.0061493210801140448514596108010105002070.0015801870228026701340117016802450250014606020.001520143016302090151013101660181021301520632

Multibreath Washout Testing

Subjects will perform multibreath washout testing using standard techniques to measure functional residual capacity and lung clearance index at the beginning and end of each study period. (NCT01784419)
Timeframe: 14 +/- 2 days

InterventionParticipants (Count of Participants)
All Study ParticipantsNA

Spirometry

Standard spirometry will be performed at the start and end of each 2 week study period. Subjects will take study drug (ivacaftor or placebo) during each study period. (NCT01784419)
Timeframe: 14 +/- 2 days

InterventionParticipants (Count of Participants)
All Study ParticipantsNA

Sweat Chloride Concentration

Sweat chloride concentration measured by pilocarpine iontophoresis, a standard clinical laboratory technique. Sweat collection accomplished with the Wescor Macroduct system. Sweat chloride is measured at the start and end of each study period. There are two study periods during which subjects take either ivacaftor or placebo. (NCT01784419)
Timeframe: 14 +/- 2 days

Interventionmmol/L (Mean)
All Study ParticipantsNA

Areal Bone Mineral Density as Measured by DXA

Change in PA spine bone mineral density (NCT01549314)
Timeframe: Baseline and 24 months

Interventiong/cm2 (Mean)
Subjects With CF Taking Ivacaftor0.032
Subjects With CF Not Taking Ivacaftor0.024
Healthy Subjects0.029

Bone Microarchitecture and Strength Measures of the Radius and Tibia

Change in cortical volumetric bone mineral density at the radius (NCT01549314)
Timeframe: Baseline and 24 months

InterventionmgHA/cm3 (Mean)
Subjects With CF Taking Ivacaftor44.6
Subjects With CF Not Taking Ivacaftor40.1
Healthy Subjects43.7

Bone Turnover Markers

Change in osteocalcin (NCT01549314)
Timeframe: Baseline and 24 months

Interventionng/ml (Mean)
Subjects With CF Taking Ivacaftor-5.36
Subjects With CF Not Taking Ivacaftor-4.51
Healthy Subjects-4.5

Part A : Absolute Change From Part A Baseline in Cystic Fibrosis Questionnaire-Revised (CFQ-R) Respiratory Domain Score Through Week 16

The CFQ-R is a validated patient-reported outcome measuring health-related quality of life for participants with cystic fibrosis. Respiratory domain assessed respiratory symptoms (for example, coughing, congestion, wheezing), score range: 0-100; Higher scores indicating fewer symptoms and better health-related quality of life. (NCT00953706)
Timeframe: Part A baseline through Week 16

Interventionunits on a scale (Least Squares Mean)
Placebo - Part A-1.4
Ivacaftor - Part A-0.1

Part A : Absolute Change From Part A Baseline in Percent Predicted Forced Expiratory Volume in 1 Second (ppFEV1) Through Week 16

Spirometry (as measured by ppFEV1) is a standardized assessment to evaluate lung function that is the most widely used endpoint in cystic fibrosis studies. FEV1 is the volume of air that can forcibly be blown out in one second, after full inspiration. ppFEV1 (predicted for age, gender, and height) was calculated using the Knudson method. (NCT00953706)
Timeframe: Part A baseline through Week 16

Interventionpercent predicted of FEV1 (Least Squares Mean)
Placebo - Part A-0.2
Ivacaftor - Part A1.5

Part A : Absolute Change From Part A Baseline in Sweat Chloride Concentration Through Week 16

The sweat chloride (quantitative pilocarpine iontophoresis) test is a standard diagnostic tool for cystic fibrosis (CF), serving as an indicator of cystic fibrosis transmembrane conductance regulator (CFTR) activity. (NCT00953706)
Timeframe: Part A baseline through Week 16

Interventionmillimole per liter (mmol/L) (Least Squares Mean)
Placebo - Part A0.1
Ivacaftor - Part A-2.7

Part A : Rate of Change From Baseline in Weight Through Week 16

As malnutrition is common in participants with cystic fibrosis (CF) because of increased energy expenditures due to lung disease and fat malabsorption, body weight is an important clinical measure of nutritional status. (NCT00953706)
Timeframe: Part A baseline through Week 16

Interventionkilograms per 112 days (Least Squares Mean)
Placebo - Part A0.9
Ivacaftor - Part A0.8

Part B : Number of Participants With Pulmonary Exacerbations

Pulmonary exacerbation was defined as new, or changed, antibiotic therapy (intravenous, inhaled, or oral) for any 4 or more of the following signs/symptoms: change in sputum; new or increased hemoptysis; increased cough; increased dyspnea; malaise, fatigue, or lethargy; temperature above 38 degrees Celsius; anorexia or weight loss; sinus pain or tenderness; change in sinus discharge; change in physical examination of the chest; decrease in pulmonary function by 10 percent (%); and radiographic changes indicative of pulmonary infection. (NCT00953706)
Timeframe: Part B baseline through Week 64

Interventionparticipants (Number)
Placebo/Ivacaftor - Part B4
Ivacaftor/Ivacaftor - Part B16

Part B : Number of Pulmonary Exacerbation Events

Pulmonary exacerbation was defined as new, or changed, antibiotic therapy (intravenous, inhaled, or oral) for any 4 or more of the following signs/symptoms: change in sputum; new or increased hemoptysis; increased cough; increased dyspnea; malaise, fatigue, or lethargy; temperature above 38 degrees Celsius; anorexia or weight loss; sinus pain or tenderness; change in sinus discharge; change in physical examination of the chest; decrease in pulmonary function by 10 percent (%); and radiographic changes indicative of pulmonary infection. (NCT00953706)
Timeframe: Part B baseline through Week 64

Interventionevents (Number)
Placebo/Ivacaftor - Part B6
Ivacaftor/Ivacaftor - Part B26

Part B : Number of Pulmonary Exacerbation Events Per Participant Per Year

Pulmonary exacerbation was defined as new, or changed, antibiotic therapy (intravenous, inhaled, or oral) for any 4 or more of the following signs/symptoms: change in sputum; new or increased hemoptysis; increased cough; increased dyspnea; malaise, fatigue, or lethargy; temperature above 38 degrees Celsius; anorexia or weight loss; sinus pain or tenderness; change in sinus discharge; change in physical examination of the chest; decrease in pulmonary function by 10 percent (%); and radiographic changes indicative of pulmonary infection. (NCT00953706)
Timeframe: Part B baseline through Week 64

Interventionevents per participant per year (Number)
Placebo/Ivacaftor - Part B1.10
Ivacaftor/Ivacaftor - Part B0.82

Part B : Rate of Change From Part A Baseline in ppFEV1 Through Week 64

ppFEV1 is defined in Outcome Measure 1. (NCT00953706)
Timeframe: Part A baseline through Week 64

Interventionpercent predicted of FEV1 per 448 days (Least Squares Mean)
Placebo/Ivacaftor - Part B5.7445
Ivacaftor/Ivacaftor - Part B-1.0738

Part B : Rate of Change From Part B Baseline in ppFEV1 Through Week 64

ppFEV1 is defined in Outcome Measure 1. (NCT00953706)
Timeframe: Part B baseline through Week 64

Interventionpercent predicted of FEV1 per 336 days (Least Squares Mean)
Placebo/Ivacaftor - Part B5.3409
Ivacaftor/Ivacaftor - Part B-5.2994

Part B : Absolute Change From Part A and Part B Baseline in CFQ-R Respiratory Domain Score Through Week 64

The CFQ-R is a validated patient-reported outcome measuring health-related quality of life for participants with cystic fibrosis. Respiratory domain assessed respiratory symptoms (for example, coughing, congestion, wheezing), score range: 0-100; Higher scores indicating fewer symptoms and better health-related quality of life. (NCT00953706)
Timeframe: Change from Part A baseline: Part A Baseline, Week 64; Change from Part B baseline: Part B Baseline (Week 16), Week 64

,
Interventionunits on a scale (Mean)
Change From Part A Baseline at Week 64Change From Part B Baseline at Week 64
Ivacaftor/Ivacaftor - Part B1.502.62
Placebo/Ivacaftor - Part B2.102.08

Part B : Absolute Change From Part A and Part B Baseline in ppFEV1 Through Week 64

ppFEV1 is defined in Outcome Measure 1. (NCT00953706)
Timeframe: Change from Part A baseline: Part A Baseline, Week 64; Change from Part B baseline: Part B Baseline (Week 16), Week 64

,
Interventionpercent predicted of FEV1 (Mean)
Change From Part A Baseline at Week 64Change From Part B Baseline at Week 64
Ivacaftor/Ivacaftor - Part B2.7233-5.0565
Placebo/Ivacaftor - Part B8.93983.5593

Part B : Absolute Change From Part A and Part B Baseline in Sweat Chloride Concentration Through Week 64

The sweat chloride (quantitative pilocarpine iontophoresis) test is a standard diagnostic tool for cystic fibrosis (CF), serving as an indicator of cystic fibrosis transmembrane conductance regulator (CFTR) activity. (NCT00953706)
Timeframe: Change from Part A baseline: Part A Baseline, Week 64; Change from Part B baseline: Part B Baseline (Week 16), Week 64

,
Interventionmmol/L (Mean)
Change From Part A Baseline at Week 64Change From Part B Baseline at Week 64
Ivacaftor/Ivacaftor - Part B-3.65-2.44
Placebo/Ivacaftor - Part B-7.13-3.88

Part B : Absolute Change From Part A and Part B Baseline in Weight Through Week 64

As malnutrition is common in patients with cystic fibrosis (CF) because of increased energy expenditures due to lung disease and fat malabsorption, body weight is an important clinical measure of nutritional status. (NCT00953706)
Timeframe: Change from Part A baseline: Part A Baseline, Week 64; Change from Part B baseline: Part B Baseline (Week 16), Week 64

,
Interventionkilograms (kg) (Mean)
Change From Part A Baseline at Week 64Change From Part B Baseline at Week 64
Ivacaftor/Ivacaftor - Part B2.351.45
Placebo/Ivacaftor - Part B3.001.28

Change in Mucociliary Clearance Rate

"Average radio tracer clearance through 90 minutes (MCC90) is primary index of mucociliary clearance at each study.~Primary study outcome: is absolute change in MCC90 between baseline and at end of treatment (where MCC measured 8-12 hours after final dose of study drug) - reflects sustained impact on MCC" (NCT01031706)
Timeframe: Baseline versus after completion of 4 week treatment period

Interventionpercent clearance (Mean)
Hypertonic Saline2.77
Placebo-2.35

FEV1 (Spirometry) Change

Absolute change in % predicted FEV1 between baseline and after 4 weeks of treatment calculated (NCT01031706)
Timeframe: Baseline and after 4 weeks of treatment

InterventionPercentage of predicted FEV1 (Mean)
Hypertonic Saline3.38
Placebo1.09

Change in FEV1 % Predicted From Baseline

Change from baseline in FEV1(maximal amount of air you can forcefully exhale in one second) % predicted (NCT01355796)
Timeframe: Baseline and 14 days

Interventionpercentage of predicted (Mean)
Xylitol-0.1
Saline1.4

Sputum Density

Difference from baseline in density of Pseudomonas aeruginosa colonization per gram of sputum, (NCT01355796)
Timeframe: baseline and 14 days

InterventionLog colony forming units (Mean)
Xylitol-1.98
Saline0.93

Reviews

90 reviews available for iodine and Cystic Fibrosis

ArticleYear
Adverse effects of iodides on thyroid function.
    The Medical clinics of North America, 1975, Volume: 59, Issue:5

    Topics: Cystic Fibrosis; Drug Synergism; Female; Goiter; Graves Disease; Humans; Hyperthyroidism; Hypothyroi

1975
National Guidelines for the Performance of the Sweat Test in Diagnosis of Cystic Fibrosis on behalf of the Croatian Society of Medical Biochemistry and Laboratory Medicine and the Cystic Fibrosis Centre - Paediatrics and adults, University Hospital Centre
    Biochemia medica, 2022, Feb-15, Volume: 32, Issue:1

    Topics: Child; Cystic Fibrosis; Hospitals, University; Humans; Infant, Newborn; Laboratories; Pediatrics; Sw

2022
[Therapeutic advances in cystic fibrosis: from genetics to treatment personalized].
    La Revue du praticien, 2022, Volume: 72, Issue:8

    Topics: Aminophenols; Anti-Bacterial Agents; Chloride Channel Agonists; Chlorides; Cystic Fibrosis; Cystic F

2022
[Therapeutic advances in cystic fibrosis: from genetics to treatment personalized].
    La Revue du praticien, 2022, Volume: 72, Issue:8

    Topics: Aminophenols; Anti-Bacterial Agents; Chloride Channel Agonists; Chlorides; Cystic Fibrosis; Cystic F

2022
[Therapeutic advances in cystic fibrosis: from genetics to treatment personalized].
    La Revue du praticien, 2022, Volume: 72, Issue:8

    Topics: Aminophenols; Anti-Bacterial Agents; Chloride Channel Agonists; Chlorides; Cystic Fibrosis; Cystic F

2022
[Therapeutic advances in cystic fibrosis: from genetics to treatment personalized].
    La Revue du praticien, 2022, Volume: 72, Issue:8

    Topics: Aminophenols; Anti-Bacterial Agents; Chloride Channel Agonists; Chlorides; Cystic Fibrosis; Cystic F

2022
Sweat conductivity diagnostic accuracy for cystic fibrosis: a systematic review and meta-analysis.
    Archives of disease in childhood, 2023, Volume: 108, Issue:11

    Topics: Cystic Fibrosis; Humans; Prospective Studies; Retrospective Studies; Sensitivity and Specificity; Sw

2023
Current and future diagnosis of cystic fibrosis: Performance and limitations.
    Archives de pediatrie : organe officiel de la Societe francaise de pediatrie, 2020, Volume: 27 Suppl 1

    Topics: Computational Biology; Cystic Fibrosis; Cystic Fibrosis Transmembrane Conductance Regulator; Databas

2020
Genetic diagnosis in practice: From cystic fibrosis to CFTR-related disorders.
    Archives de pediatrie : organe officiel de la Societe francaise de pediatrie, 2020, Volume: 27 Suppl 1

    Topics: Algorithms; Bronchiectasis; Cystic Fibrosis; Cystic Fibrosis Transmembrane Conductance Regulator; Ex

2020
Sodium Status and Replacement in Children and Adults Living with Cystic Fibrosis: A Narrative Review.
    Journal of the Academy of Nutrition and Dietetics, 2020, Volume: 120, Issue:9

    Topics: Adult; Child; Child, Preschool; Cystic Fibrosis; Cystic Fibrosis Transmembrane Conductance Regulator

2020
Diagnostic tools and CFTR functional assays in cystic fibrosis: utility and availability in Switzerland.
    Swiss medical weekly, 2021, 04-12, Volume: 151

    Topics: Chlorides; Cystic Fibrosis; Cystic Fibrosis Transmembrane Conductance Regulator; Humans; Mutation; S

2021
Advances in the Diagnosis and Management of Cystic Fibrosis in the Genomic Era.
    Clinical chemistry, 2018, Volume: 64, Issue:6

    Topics: Chlorides; Cystic Fibrosis; Cystic Fibrosis Transmembrane Conductance Regulator; Databases, Genetic;

2018
Newborn screening for cystic fibrosis: Is there benefit for everyone?
    Paediatric respiratory reviews, 2019, Volume: 31

    Topics: Aminophenols; Chloride Channel Agonists; Chlorides; Cystic Fibrosis; Cystic Fibrosis Transmembrane C

2019
Is it cystic fibrosis? The challenges of diagnosing cystic fibrosis.
    Paediatric respiratory reviews, 2019, Volume: 31

    Topics: Algorithms; Chlorides; Cystic Fibrosis; Cystic Fibrosis Transmembrane Conductance Regulator; Forced

2019
The implications and management of cystic fibrosis screen positive, inconclusive diagnosis patients.
    Paediatric respiratory reviews, 2019, Volume: 31

    Topics: Chlorides; Cost of Illness; Cystic Fibrosis; Cystic Fibrosis Transmembrane Conductance Regulator; Di

2019
Ivacaftor treatment in patients with cystic fibrosis and the G551D-CFTR mutation.
    European respiratory review : an official journal of the European Respiratory Society, 2013, Mar-01, Volume: 22, Issue:127

    Topics: Adolescent; Adult; Aminophenols; Child; Chlorides; Cystic Fibrosis; Cystic Fibrosis Transmembrane Co

2013
Sixty-five years since the New York heat wave: advances in sweat testing for cystic fibrosis.
    Pediatric pulmonology, 2014, Volume: 49, Issue:2

    Topics: Biomarkers; Chlorides; Clinical Chemistry Tests; Cystic Fibrosis; Cystic Fibrosis Transmembrane Cond

2014
Sweat: a sample with limited present applications and promising future in metabolomics.
    Journal of pharmaceutical and biomedical analysis, 2014, Volume: 90

    Topics: Biomarkers; Cystic Fibrosis; Doping in Sports; Humans; Metabolomics; Substance Abuse Detection; Swea

2014
Cystic fibrosis: need for mass deployable screening methods.
    Applied biochemistry and biotechnology, 2014, Volume: 174, Issue:3

    Topics: Adenosine Triphosphate; Chlorides; Cystic Fibrosis; Cystic Fibrosis Transmembrane Conductance Regula

2014
Biomarkers in Paediatric Cystic Fibrosis Lung Disease.
    Paediatric respiratory reviews, 2015, Volume: 16, Issue:4

    Topics: Antibodies, Bacterial; Biomarkers; Breath Tests; Bronchoalveolar Lavage Fluid; Child; Cystic Fibrosi

2015
Question 7: For an infant with an equivocal sweat chloride following newborn screening, how likely is a diagnosis of cystic fibrosis?
    Paediatric respiratory reviews, 2016, Volume: 20

    Topics: Chlorides; Cystic Fibrosis; Humans; Infant, Newborn; Neonatal Screening; Sweat

2016
Cystic fibrosis: newborn screening in America.
    MLO: medical laboratory observer, 2008, Volume: 40, Issue:7

    Topics: Cystic Fibrosis; Cystic Fibrosis Transmembrane Conductance Regulator; DNA Mutational Analysis; Exocr

2008
Newborn screening for cystic fibrosis.
    Clinical reviews in allergy & immunology, 2008, Volume: 35, Issue:3

    Topics: Algorithms; Cystic Fibrosis; Cystic Fibrosis Transmembrane Conductance Regulator; DNA Mutational Ana

2008
Emerging issues in cystic fibrosis newborn screening.
    Current opinion in pulmonary medicine, 2010, Volume: 16, Issue:6

    Topics: Algorithms; Cystic Fibrosis; Cystic Fibrosis Transmembrane Conductance Regulator; Genetic Testing; H

2010
Newborn screening for cystic fibrosis.
    Current opinion in pediatrics, 2012, Volume: 24, Issue:3

    Topics: Biomarkers; Cystic Fibrosis; False Positive Reactions; Genetic Carrier Screening; Humans; Infant, Ne

2012
[Mucoviscidosis: CFTR mutation-specific therapy: a ray of sunshine in a cloudy sky].
    Archives de pediatrie : organe officiel de la Societe francaise de pediatrie, 2013, Volume: 20, Issue:1

    Topics: Chlorides; Cystic Fibrosis; Cystic Fibrosis Transmembrane Conductance Regulator; Epithelial Cells; E

2013
Of sweat and bile.
    Journal of hepatology, 2002, Volume: 37, Issue:5

    Topics: Antiporters; Bile; Cystic Fibrosis; Saccharomyces cerevisiae Proteins; Sweat

2002
[Genetics and cellular biology of cystic fibrosis].
    La Revue du praticien, 2003, Jan-15, Volume: 53, Issue:2

    Topics: Blood Proteins; Chlorides; Cystic Fibrosis; Cystic Fibrosis Transmembrane Conductance Regulator; Hum

2003
[Diagnosis of cystic fibrosis; simple genotyping to rule out the disease preferable to starting with the sweat test].
    Nederlands tijdschrift voor geneeskunde, 2003, May-24, Volume: 147, Issue:21

    Topics: Cystic Fibrosis; DNA; Genotype; Humans; Iontophoresis; Mutation; Pancreatic Function Tests; Pilocarp

2003
[MUCOVISCIDOSIS IN ADULTS].
    Lekarska veda v zahranici, 1964, Jan-17, Volume: 38

    Topics: Adult; Bronchitis; Cystic Fibrosis; Electroencephalography; Humans; Pancreas; Pathology; Respiratory

1964
Laboratory tests for the diagnosis of cystic fibrosis.
    American journal of clinical pathology, 2002, Volume: 117 Suppl

    Topics: Child, Preschool; Cystic Fibrosis; Cystic Fibrosis Transmembrane Conductance Regulator; Diagnosis, D

2002
Evidence based guidelines for the performance of the sweat test for the investigation of cystic fibrosis in the UK.
    Archives of disease in childhood, 2003, Volume: 88, Issue:12

    Topics: Chlorides; Cystic Fibrosis; Evidence-Based Medicine; Humans; Infant, Newborn; Neonatal Screening; Pr

2003
Diagnosis of CF despite normal or borderline sweat chloride.
    Paediatric respiratory reviews, 2004, Volume: 5 Suppl A

    Topics: Child; Chlorides; Cystic Fibrosis; DNA Mutational Analysis; Humans; Nasal Mucosa; Sweat

2004
Diagnosis of cystic fibrosis after newborn screening: the Australasian experience--twenty years and five million babies later: a consensus statement from the Australasian Paediatric Respiratory Group.
    Pediatric pulmonology, 2005, Volume: 39, Issue:5

    Topics: Australasia; Australia; Chlorides; Cystic Fibrosis; Cystic Fibrosis Transmembrane Conductance Regula

2005
An unusual presentation of cystic fibrosis in an adult.
    American journal of kidney diseases : the official journal of the National Kidney Foundation, 2005, Volume: 45, Issue:3

    Topics: Acid-Base Equilibrium; Adult; Alkalosis; Cystic Fibrosis; Cystic Fibrosis Transmembrane Conductance

2005
Sweat-testing: a review of current technical requirements.
    Pediatric pulmonology, 2005, Volume: 39, Issue:6

    Topics: Chlorides; Cystic Fibrosis; Electrolytes; False Positive Reactions; Humans; Infant, Newborn; Iontoph

2005
Information flow after a positive newborn screening for cystic fibrosis.
    The Journal of pediatrics, 2005, Volume: 147, Issue:3 Suppl

    Topics: Adult; Anxiety; Chlorides; Communication; Cystic Fibrosis; Female; Friends; Genetic Counseling; Huma

2005
Cystic fibrosis: terminology and diagnostic algorithms.
    Thorax, 2006, Volume: 61, Issue:7

    Topics: Action Potentials; Algorithms; Chlorides; Cystic Fibrosis; Cystic Fibrosis Transmembrane Conductance

2006
New tests for cystic fibrosis.
    Paediatric respiratory reviews, 2006, Volume: 7 Suppl 1

    Topics: Biomarkers; Cystic Fibrosis; Cystic Fibrosis Transmembrane Conductance Regulator; Diagnosis, Differe

2006
Guidelines for the performance of the sweat test for the diagnosis of cystic fibrosis.
    Annals of clinical biochemistry, 2007, Volume: 44, Issue:Pt 1

    Topics: Cystic Fibrosis; Humans; Infant, Newborn; Neonatal Screening; Practice Guidelines as Topic; Quality

2007
Detection of cystic fibrosis transmembrane conductance regulator activity in early-phase clinical trials.
    Proceedings of the American Thoracic Society, 2007, Aug-01, Volume: 4, Issue:4

    Topics: Biomarkers; Cystic Fibrosis; Cystic Fibrosis Transmembrane Conductance Regulator; Feasibility Studie

2007
Cystic fibrosis.
    BMJ (Clinical research ed.), 2007, Dec-15, Volume: 335, Issue:7632

    Topics: Cost of Illness; Cystic Fibrosis; Cystic Fibrosis Transmembrane Conductance Regulator; Electrolytes;

2007
Painful wrinkles in the bathtub: association with hyperhidrosis and cystic fibrosis.
    Dermatology (Basel, Switzerland), 2008, Volume: 216, Issue:3

    Topics: Adolescent; Adult; Child; Cystic Fibrosis; Cystic Fibrosis Transmembrane Conductance Regulator; DNA

2008
Cystic fibrosis in adults: diagnostic and therapeutic aspects.
    Jornal brasileiro de pneumologia : publicacao oficial da Sociedade Brasileira de Pneumologia e Tisilogia, 2008, Volume: 34, Issue:2

    Topics: Adult; Anti-Bacterial Agents; Anti-Inflammatory Agents; Cystic Fibrosis; Diagnosis, Differential; Dr

2008
Atypical cystic fibrosis and CFTR-related diseases.
    Clinical reviews in allergy & immunology, 2008, Volume: 35, Issue:3

    Topics: Adolescent; Adult; Airway Obstruction; Aspergillosis, Allergic Bronchopulmonary; Aspergillus fumigat

2008
Microprobe analysis in studies and diagnosis of cystic fibrosis.
    Annals of the New York Academy of Sciences, 1984, Volume: 428

    Topics: Animals; Blood Proteins; Calcium; Calgranulin A; Child; Cyclic AMP; Cystic Fibrosis; Disease Models,

1984
Laboratory diagnosis of cystic fibrosis.
    Critical reviews in clinical laboratory sciences, 1983, Volume: 18, Issue:4

    Topics: Adolescent; Adult; Aging; Child; Child, Preschool; Chlorides; Cystic Fibrosis; Disease; Electric Con

1983
Development of a screening system for cystic fibrosis.
    Clinical chemistry, 1983, Volume: 29, Issue:9

    Topics: Adolescent; Adult; Child; Child, Preschool; Chlorides; Clinical Trials as Topic; Cystic Fibrosis; Hu

1983
Cystic fibrosis--its biochemical detection.
    Clinical chemistry, 1983, Volume: 29, Issue:12

    Topics: Age Factors; Blood Proteins; Calgranulin A; Chemistry, Clinical; Clinical Enzyme Tests; Cystic Fibro

1983
Diagnosis and treatment of cystic fibrosis. An update.
    Chest, 1984, Volume: 85, Issue:6

    Topics: Adult; Child; Chlorides; Cystic Fibrosis; Female; Hemoptysis; Humans; Infant, Newborn; Liver Cirrhos

1984
Advances in the diagnosis and management of cystic fibrosis.
    Clinical biochemistry, 1984, Volume: 17, Issue:5

    Topics: Adolescent; Anti-Bacterial Agents; Child; Child, Preschool; Chlorides; Cystic Fibrosis; Humans; Infa

1984
Cystic fibrosis: diagnostic considerations.
    The Johns Hopkins medical journal, 1982, Volume: 150, Issue:3

    Topics: Cystic Fibrosis; Diagnosis, Differential; Electrolytes; Gastrointestinal Diseases; Humans; Liver; Re

1982
Four clinical chemistry analyses for pediatric patients: glycosylated hemoglobin, free bilirubin, sweat electrolytes, neonatal thyroxine.
    The American journal of medical technology, 1982, Volume: 48, Issue:1

    Topics: Bilirubin; Congenital Hypothyroidism; Cystic Fibrosis; Diabetes Mellitus, Type 1; Electrolytes; Glyc

1982
Diagnosis of cystic fibrosis.
    The Netherlands journal of medicine, 1995, Volume: 46, Issue:6

    Topics: Chlorine; Cystic Fibrosis; Humans; Intestines; Medical History Taking; Phenotype; Sodium; Sweat

1995
Delayed diagnosis of cystic fibrosis in children with a rare genotype (delta F508/R117H).
    Journal of paediatrics and child health, 1995, Volume: 31, Issue:3

    Topics: Child, Preschool; Chlorides; Cystic Fibrosis; Female; Gene Frequency; Genetic Carrier Screening; Gen

1995
[Cystic fibrosis of the pancreas. Historical notes, sweat test, and neonatal screening].
    La Clinica terapeutica, 1995, Volume: 146, Issue:3

    Topics: Cystic Fibrosis; History, 18th Century; History, 19th Century; History, 20th Century; Humans; Infant

1995
Cystic fibrosis for the primary care pediatrician.
    Pediatric annals, 1993, Volume: 22, Issue:9

    Topics: Adolescent; Adult; Anti-Bacterial Agents; Anti-Inflammatory Agents; Child; Cystic Fibrosis; Female;

1993
The application of saliva, sweat and tear fluid for diagnostic purposes.
    Annales de biologie clinique, 1993, Volume: 51, Issue:10-11

    Topics: Adrenal Gland Diseases; Cystic Fibrosis; Electrolytes; Humans; Lysosomal Storage Diseases; Saliva; S

1993
Primary pulmonary care of the patient with cystic fibrosis.
    Nurse practitioner forum, 1993, Volume: 4, Issue:1

    Topics: Anti-Bacterial Agents; Child; Child Nutritional Physiological Phenomena; Child, Preschool; Cystic Fi

1993
The diagnosis of cystic fibrosis.
    The New England journal of medicine, 1997, Feb-13, Volume: 336, Issue:7

    Topics: Action Potentials; Bronchoalveolar Lavage; Chlorides; Cystic Fibrosis; Diagnosis, Differential; Geno

1997
Diagnosing cystic fibrosis: blood, sweat, and tears.
    Archives of disease in childhood, 1997, Volume: 76, Issue:2

    Topics: Child; Cystic Fibrosis; Cystic Fibrosis Transmembrane Conductance Regulator; Genotype; Humans; Mutat

1997
Nonneoplastic disorders of the eccrine glands.
    Journal of the American Academy of Dermatology, 1998, Volume: 38, Issue:1

    Topics: Adult; Blister; Child; Coma; Cystic Fibrosis; Disease Susceptibility; Drug-Related Side Effects and

1998
The diagnosis of cystic fibrosis: a consensus statement. Cystic Fibrosis Foundation Consensus Panel.
    The Journal of pediatrics, 1998, Volume: 132, Issue:4

    Topics: Child; Cystic Fibrosis; Cystic Fibrosis Transmembrane Conductance Regulator; Female; Humans; Infant,

1998
[Diagnostic difficulties in cystic fibrosis].
    Revista clinica espanola, 1999, Volume: 199, Issue:12

    Topics: Cystic Fibrosis; Genotype; Humans; Sweat

1999
[The diagnosis of cystic fibrosis in the adult].
    Archivos de bronconeumologia, 2000, Volume: 36, Issue:1

    Topics: Adolescent; Adult; Biological Transport, Active; Cystic Fibrosis; Cystic Fibrosis Transmembrane Cond

2000
Fluid and electrolyte supplementation for exercise heat stress.
    The American journal of clinical nutrition, 2000, Volume: 72, Issue:2 Suppl

    Topics: Adult; Aged; Body Temperature Regulation; Calcium Chloride; Climate; Cystic Fibrosis; Dehydration; D

2000
[Diagnosis and management of cystic fibrosis in children].
    Revue des maladies respiratoires, 2000, Volume: 17, Issue:3 Pt 2

    Topics: Adult; Age Factors; Anti-Bacterial Agents; Child; Chlorides; Cystic Fibrosis; Cystic Fibrosis Transm

2000
[Diagnosis of cystic fibrosis in adults].
    Revue des maladies respiratoires, 2000, Volume: 17, Issue:3 Pt 2

    Topics: Adolescent; Adult; Age Factors; Chlorides; Chronic Disease; Cystic Fibrosis; Cystic Fibrosis Transme

2000
Hyponatremia associated with exercise: risk factors and pathogenesis.
    Exercise and sport sciences reviews, 2001, Volume: 29, Issue:3

    Topics: Cystic Fibrosis; Digestive System; Drinking; Exercise; Extracellular Space; Female; Humans; Hyponatr

2001
Cystic fibrosis.
    Pediatrics in review, 2001, Volume: 22, Issue:8

    Topics: Adolescent; Adult; Child; Child, Preschool; Chlorides; Cystic Fibrosis; Cystic Fibrosis Transmembran

2001
[From gene to disease; from defective chloride ion transport to cystic fibrosis].
    Nederlands tijdschrift voor geneeskunde, 2001, Apr-07, Volume: 145, Issue:14

    Topics: Adult; Child; Chloride Channels; Cystic Fibrosis; Cystic Fibrosis Transmembrane Conductance Regulato

2001
Recent advances in cystic fibrosis research.
    Birth defects original article series, 1976, Volume: 12, Issue:6

    Topics: Adolescent; Adult; Agglutination; Biological Transport; Child; Child, Preschool; Chlorides; Cilia; C

1976
Cystic fibrosis. A dilemma in the metabolic pathogenesis of genetic disease.
    Archives of pathology & laboratory medicine, 1976, Volume: 100, Issue:1

    Topics: Animals; Cells, Cultured; Cystic Fibrosis; Cytoplasm; Fibroblasts; Glycosaminoglycans; Humans; Immun

1976
[Methods of electrolyte determination in sweat for diagnosis of mucoviscidosis].
    Kinderarztliche Praxis, 1978, Volume: 46, Issue:12

    Topics: Child; Cystic Fibrosis; Electric Conductivity; Electrolytes; Humans; Methods; Sweat

1978
Cystic fibrosis: diagnosis, treatment, and prognosis.
    Southern medical journal, 1979, Volume: 72, Issue:2

    Topics: Aerosols; Anti-Bacterial Agents; Cough; Cystic Fibrosis; Diet; Female; Humans; Infant, Newborn; Infa

1979
Report of the committe for a study for evaluation of testing for cystic fibrosis.
    The Journal of pediatrics, 1976, Volume: 88, Issue:4 Pt 2

    Topics: Adult; Child; Cystic Fibrosis; Duodenum; Female; Financing, Government; Financing, Organized; Geneti

1976
Cystic fibrosis.
    The American review of respiratory disease, 1976, Volume: 113, Issue:6

    Topics: Biological Transport; Cystic Fibrosis; Exocrine Glands; Female; Gastrointestinal Diseases; Genital D

1976
Current biochemical approaches in cystic fibrosis research.
    Life sciences, 1976, Nov-01, Volume: 19, Issue:9

    Topics: Biological Transport; Cilia; Cystic Fibrosis; Gastrointestinal Diseases; Glycoproteins; Heterozygote

1976
Screening for cystic fibrosis.
    British medical bulletin, 1992, Volume: 48, Issue:4

    Topics: Cystic Fibrosis; Genetic Carrier Screening; Genetic Testing; Humans; Infant, Newborn; Neonatal Scree

1992
[Current methods in the diagnosis of adult-age cystic fibrosis].
    Orvosi hetilap, 1992, Jun-14, Volume: 133, Issue:24

    Topics: Adult; Age Factors; Cystic Fibrosis; Humans; Male; Sweat; Tomography, X-Ray Computed

1992
[The sweat test in cystic fibrosis].
    Padiatrie und Padologie, 1990, Volume: 25, Issue:2

    Topics: Child; Chlorides; Cystic Fibrosis; Diagnosis, Differential; Humans; Sodium; Sweat

1990
Relapsing pancreatitis as initial manifestation of cystic fibrosis in a young man without pulmonary disease.
    International journal of pancreatology : official journal of the International Association of Pancreatology, 1989, Volume: 4, Issue:2

    Topics: Adult; Chlorides; Chymotrypsin; Cystic Fibrosis; Duodenoscopy; Feces; Humans; Male; Oligospermia; Pa

1989
Transport processes in the eccrine sweat gland.
    Kidney international. Supplement, 1987, Volume: 21

    Topics: Biological Transport; Cystic Fibrosis; Eccrine Glands; Electrolytes; Humans; Osmolar Concentration;

1987
An overview of the management of cystic fibrosis.
    Journal of the Royal Society of Medicine, 1986, Volume: 79 Suppl 12

    Topics: Adolescent; Adult; Anti-Bacterial Agents; Child; Child, Preschool; Cystic Fibrosis; Diet; Humans; In

1986
Hereditary aspects of COPD.
    Postgraduate medicine, 1973, Volume: 54, Issue:3

    Topics: Adult; Alpha-Globulins; Cystic Fibrosis; Cytoplasm; Female; Heterozygote; Humans; Lung; Lung Disease

1973
Research in cystic fibrosis: a review.
    Texas reports on biology and medicine, 1973,Winter, Volume: 31, Issue:4

    Topics: Biological Transport; Calcium; Cells, Cultured; Child; Chlorides; Cough; Cystic Fibrosis; Digestive

1973
Cystic fibrosis.
    CRC critical reviews in clinical laboratory sciences, 1972, Volume: 3, Issue:3

    Topics: Adolescent; Adult; Autopsy; Child; Child, Preschool; Cystic Fibrosis; Diabetes Mellitus, Type 1; Fem

1972
[Mucoviscidosis (Cystic fibrosis)].
    Monatsschrift fur Kinderheilkunde, 1967, Volume: 115, Issue:2

    Topics: Adolescent; Child; Child, Preschool; Cystic Fibrosis; Humans; Infant; Infant, Newborn; Intestinal Ob

1967
Cystic fibrosis. Recent advances in understanding of its pathogenesis, detection of carriers and improved prognosis.
    Medical times, 1969, Volume: 97, Issue:2

    Topics: Adolescent; Calcium; Child; Cystic Fibrosis; Glycoproteins; Humans; Metabolism, Inborn Errors; Progn

1969
[Review of the progress in studies on mucoviscidosis in Poland].
    Pediatria polska, 1968, Volume: 44, Issue:1

    Topics: Adolescent; Asthma; Bronchitis; Child; Child, Preschool; Cystic Fibrosis; Diabetes Mellitus, Type 1;

1968
Cystic fibrosis in adults.
    Annual review of medicine, 1970, Volume: 21

    Topics: Cystic Fibrosis; Female; Humans; Male; Sweat

1970
[Gastric, intestinal and pancreatic diseases and pulmonary findings (including esophageal diseases)].
    Saishin igaku. Modern medicine, 1971, Volume: 26, Issue:9

    Topics: Adult; Celiac Disease; Chlorides; Cystic Fibrosis; Esophageal Neoplasms; Female; Gastrointestinal Di

1971
[Secretion of eccrine sweat].
    Polski tygodnik lekarski (Warsaw, Poland : 1960), 1971, Dec-13, Volume: 26, Issue:50

    Topics: Adenosine Triphosphate; Adrenal Glands; Cell Membrane Permeability; Cystic Fibrosis; Emotions; Glyco

1971

Trials

38 trials available for iodine and Cystic Fibrosis

ArticleYear
GLPG2737 in lumacaftor/ivacaftor-treated CF subjects homozygous for the F508del mutation: A randomized phase 2A trial (PELICAN).
    Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society, 2020, Volume: 19, Issue:2

    Topics: Adult; Aminophenols; Aminopyridines; Benzodioxoles; Chloride Channel Agonists; Cystic Fibrosis; Cyst

2020
Efficacy and safety of the elexacaftor plus tezacaftor plus ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation: a double-blind, randomised, phase 3 trial.
    Lancet (London, England), 2019, 11-23, Volume: 394, Issue:10212

    Topics: Adolescent; Aminophenols; Benzodioxoles; Child; Chloride Channel Agonists; Cystic Fibrosis; Cystic F

2019
Efficacy and safety of the elexacaftor plus tezacaftor plus ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation: a double-blind, randomised, phase 3 trial.
    Lancet (London, England), 2019, 11-23, Volume: 394, Issue:10212

    Topics: Adolescent; Aminophenols; Benzodioxoles; Child; Chloride Channel Agonists; Cystic Fibrosis; Cystic F

2019
Efficacy and safety of the elexacaftor plus tezacaftor plus ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation: a double-blind, randomised, phase 3 trial.
    Lancet (London, England), 2019, 11-23, Volume: 394, Issue:10212

    Topics: Adolescent; Aminophenols; Benzodioxoles; Child; Chloride Channel Agonists; Cystic Fibrosis; Cystic F

2019
Efficacy and safety of the elexacaftor plus tezacaftor plus ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation: a double-blind, randomised, phase 3 trial.
    Lancet (London, England), 2019, 11-23, Volume: 394, Issue:10212

    Topics: Adolescent; Aminophenols; Benzodioxoles; Child; Chloride Channel Agonists; Cystic Fibrosis; Cystic F

2019
Efficacy and safety of the elexacaftor plus tezacaftor plus ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation: a double-blind, randomised, phase 3 trial.
    Lancet (London, England), 2019, 11-23, Volume: 394, Issue:10212

    Topics: Adolescent; Aminophenols; Benzodioxoles; Child; Chloride Channel Agonists; Cystic Fibrosis; Cystic F

2019
Efficacy and safety of the elexacaftor plus tezacaftor plus ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation: a double-blind, randomised, phase 3 trial.
    Lancet (London, England), 2019, 11-23, Volume: 394, Issue:10212

    Topics: Adolescent; Aminophenols; Benzodioxoles; Child; Chloride Channel Agonists; Cystic Fibrosis; Cystic F

2019
Efficacy and safety of the elexacaftor plus tezacaftor plus ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation: a double-blind, randomised, phase 3 trial.
    Lancet (London, England), 2019, 11-23, Volume: 394, Issue:10212

    Topics: Adolescent; Aminophenols; Benzodioxoles; Child; Chloride Channel Agonists; Cystic Fibrosis; Cystic F

2019
Efficacy and safety of the elexacaftor plus tezacaftor plus ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation: a double-blind, randomised, phase 3 trial.
    Lancet (London, England), 2019, 11-23, Volume: 394, Issue:10212

    Topics: Adolescent; Aminophenols; Benzodioxoles; Child; Chloride Channel Agonists; Cystic Fibrosis; Cystic F

2019
Efficacy and safety of the elexacaftor plus tezacaftor plus ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation: a double-blind, randomised, phase 3 trial.
    Lancet (London, England), 2019, 11-23, Volume: 394, Issue:10212

    Topics: Adolescent; Aminophenols; Benzodioxoles; Child; Chloride Channel Agonists; Cystic Fibrosis; Cystic F

2019
Elexacaftor-Tezacaftor-Ivacaftor for Cystic Fibrosis with a Single Phe508del Allele.
    The New England journal of medicine, 2019, 11-07, Volume: 381, Issue:19

    Topics: Adolescent; Adult; Aminophenols; Benzodioxoles; Child; Chloride Channel Agonists; Chlorides; Cystic

2019
Elexacaftor-Tezacaftor-Ivacaftor for Cystic Fibrosis with a Single Phe508del Allele.
    The New England journal of medicine, 2019, 11-07, Volume: 381, Issue:19

    Topics: Adolescent; Adult; Aminophenols; Benzodioxoles; Child; Chloride Channel Agonists; Chlorides; Cystic

2019
Elexacaftor-Tezacaftor-Ivacaftor for Cystic Fibrosis with a Single Phe508del Allele.
    The New England journal of medicine, 2019, 11-07, Volume: 381, Issue:19

    Topics: Adolescent; Adult; Aminophenols; Benzodioxoles; Child; Chloride Channel Agonists; Chlorides; Cystic

2019
Elexacaftor-Tezacaftor-Ivacaftor for Cystic Fibrosis with a Single Phe508del Allele.
    The New England journal of medicine, 2019, 11-07, Volume: 381, Issue:19

    Topics: Adolescent; Adult; Aminophenols; Benzodioxoles; Child; Chloride Channel Agonists; Chlorides; Cystic

2019
Elexacaftor-Tezacaftor-Ivacaftor for Cystic Fibrosis with a Single Phe508del Allele.
    The New England journal of medicine, 2019, 11-07, Volume: 381, Issue:19

    Topics: Adolescent; Adult; Aminophenols; Benzodioxoles; Child; Chloride Channel Agonists; Chlorides; Cystic

2019
Elexacaftor-Tezacaftor-Ivacaftor for Cystic Fibrosis with a Single Phe508del Allele.
    The New England journal of medicine, 2019, 11-07, Volume: 381, Issue:19

    Topics: Adolescent; Adult; Aminophenols; Benzodioxoles; Child; Chloride Channel Agonists; Chlorides; Cystic

2019
Elexacaftor-Tezacaftor-Ivacaftor for Cystic Fibrosis with a Single Phe508del Allele.
    The New England journal of medicine, 2019, 11-07, Volume: 381, Issue:19

    Topics: Adolescent; Adult; Aminophenols; Benzodioxoles; Child; Chloride Channel Agonists; Chlorides; Cystic

2019
Elexacaftor-Tezacaftor-Ivacaftor for Cystic Fibrosis with a Single Phe508del Allele.
    The New England journal of medicine, 2019, 11-07, Volume: 381, Issue:19

    Topics: Adolescent; Adult; Aminophenols; Benzodioxoles; Child; Chloride Channel Agonists; Chlorides; Cystic

2019
Elexacaftor-Tezacaftor-Ivacaftor for Cystic Fibrosis with a Single Phe508del Allele.
    The New England journal of medicine, 2019, 11-07, Volume: 381, Issue:19

    Topics: Adolescent; Adult; Aminophenols; Benzodioxoles; Child; Chloride Channel Agonists; Chlorides; Cystic

2019
Triple Therapy for Cystic Fibrosis
    The New England journal of medicine, 2021, 08-26, Volume: 385, Issue:9

    Topics: Adolescent; Adult; Aminophenols; Benzodioxoles; Child; Chloride Channel Agonists; Chlorides; Cystic

2021
CFTR-dependent chloride efflux in cystic fibrosis mononuclear cells is increased by ivacaftor therapy.
    Pediatric pulmonology, 2017, Volume: 52, Issue:7

    Topics: Adolescent; Adult; Aminophenols; C-Reactive Protein; Child; Chloride Channel Agonists; Chlorides; Cy

2017
Analytical and biological variation in repeated sweat chloride concentrations in clinical trials for CFTR modulator therapy.
    Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society, 2018, Volume: 17, Issue:1

    Topics: Adult; Biological Variation, Individual; Chloride Channel Agonists; Chlorides; Cystic Fibrosis; Cyst

2018
Psychosocial Distress and Knowledge Deficiencies in Parents of Children in Ireland Who Carry an Altered Cystic Fibrosis Gene.
    Journal of genetic counseling, 2018, Volume: 27, Issue:3

    Topics: Adaptation, Psychological; Child; Cystic Fibrosis; Cystic Fibrosis Transmembrane Conductance Regulat

2018
VX-445-Tezacaftor-Ivacaftor in Patients with Cystic Fibrosis and One or Two Phe508del Alleles.
    The New England journal of medicine, 2018, 10-25, Volume: 379, Issue:17

    Topics: Adolescent; Adult; Alleles; Aminophenols; Benzodioxoles; Chloride Channel Agonists; Chlorides; Cysti

2018
VX-445-Tezacaftor-Ivacaftor in Patients with Cystic Fibrosis and One or Two Phe508del Alleles.
    The New England journal of medicine, 2018, 10-25, Volume: 379, Issue:17

    Topics: Adolescent; Adult; Alleles; Aminophenols; Benzodioxoles; Chloride Channel Agonists; Chlorides; Cysti

2018
VX-445-Tezacaftor-Ivacaftor in Patients with Cystic Fibrosis and One or Two Phe508del Alleles.
    The New England journal of medicine, 2018, 10-25, Volume: 379, Issue:17

    Topics: Adolescent; Adult; Alleles; Aminophenols; Benzodioxoles; Chloride Channel Agonists; Chlorides; Cysti

2018
VX-445-Tezacaftor-Ivacaftor in Patients with Cystic Fibrosis and One or Two Phe508del Alleles.
    The New England journal of medicine, 2018, 10-25, Volume: 379, Issue:17

    Topics: Adolescent; Adult; Alleles; Aminophenols; Benzodioxoles; Chloride Channel Agonists; Chlorides; Cysti

2018
VX-659-Tezacaftor-Ivacaftor in Patients with Cystic Fibrosis and One or Two Phe508del Alleles.
    The New England journal of medicine, 2018, 10-25, Volume: 379, Issue:17

    Topics: Adolescent; Adult; Alleles; Aminophenols; Benzodioxoles; Cells, Cultured; Chloride Channel Agonists;

2018
VX-659-Tezacaftor-Ivacaftor in Patients with Cystic Fibrosis and One or Two Phe508del Alleles.
    The New England journal of medicine, 2018, 10-25, Volume: 379, Issue:17

    Topics: Adolescent; Adult; Alleles; Aminophenols; Benzodioxoles; Cells, Cultured; Chloride Channel Agonists;

2018
VX-659-Tezacaftor-Ivacaftor in Patients with Cystic Fibrosis and One or Two Phe508del Alleles.
    The New England journal of medicine, 2018, 10-25, Volume: 379, Issue:17

    Topics: Adolescent; Adult; Alleles; Aminophenols; Benzodioxoles; Cells, Cultured; Chloride Channel Agonists;

2018
VX-659-Tezacaftor-Ivacaftor in Patients with Cystic Fibrosis and One or Two Phe508del Alleles.
    The New England journal of medicine, 2018, 10-25, Volume: 379, Issue:17

    Topics: Adolescent; Adult; Alleles; Aminophenols; Benzodioxoles; Cells, Cultured; Chloride Channel Agonists;

2018
A multicenter evaluation of sweat chloride concentration and variation in infants with cystic fibrosis.
    Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society, 2019, Volume: 18, Issue:2

    Topics: Age Factors; Analysis of Variance; Biological Variation, Population; Chlorides; Cystic Fibrosis; Cys

2019
An open-label extension study of ivacaftor in children with CF and a CFTR gating mutation initiating treatment at age 2-5 years (KLIMB).
    Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society, 2019, Volume: 18, Issue:6

    Topics: Aminophenols; Body Mass Index; Child, Preschool; Chloride Channel Agonists; Cystic Fibrosis; Cystic

2019
CFTR activity is enhanced by the novel corrector GLPG2222, given with and without ivacaftor in two randomized trials.
    Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society, 2019, Volume: 18, Issue:5

    Topics: Administration, Oral; Adult; Aminophenols; Benzoates; Benzopyrans; Biological Availability; Chloride

2019
CFTR activity is enhanced by the novel corrector GLPG2222, given with and without ivacaftor in two randomized trials.
    Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society, 2019, Volume: 18, Issue:5

    Topics: Administration, Oral; Adult; Aminophenols; Benzoates; Benzopyrans; Biological Availability; Chloride

2019
CFTR activity is enhanced by the novel corrector GLPG2222, given with and without ivacaftor in two randomized trials.
    Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society, 2019, Volume: 18, Issue:5

    Topics: Administration, Oral; Adult; Aminophenols; Benzoates; Benzopyrans; Biological Availability; Chloride

2019
CFTR activity is enhanced by the novel corrector GLPG2222, given with and without ivacaftor in two randomized trials.
    Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society, 2019, Volume: 18, Issue:5

    Topics: Administration, Oral; Adult; Aminophenols; Benzoates; Benzopyrans; Biological Availability; Chloride

2019
GLPG1837, a CFTR potentiator, in p.Gly551Asp (G551D)-CF patients: An open-label, single-arm, phase 2a study (SAPHIRA1).
    Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society, 2019, Volume: 18, Issue:5

    Topics: Adult; Aminophenols; Chloride Channel Agonists; Cystic Fibrosis; Cystic Fibrosis Transmembrane Condu

2019
A phase 3 study of tezacaftor in combination with ivacaftor in children aged 6 through 11 years with cystic fibrosis.
    Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society, 2019, Volume: 18, Issue:5

    Topics: Aminophenols; Benzodioxoles; Biological Availability; Child; Child, Preschool; Chloride Channel Agon

2019
Skin pretreatment with microneedles prior to pilocarpine iontophoresis increases sweat production.
    Clinical physiology and functional imaging, 2013, Volume: 33, Issue:6

    Topics: Administration, Cutaneous; Adult; California; Cystic Fibrosis; Electric Impedance; Equipment Design;

2013
Sweat chloride as a biomarker of CFTR activity: proof of concept and ivacaftor clinical trial data.
    Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society, 2014, Volume: 13, Issue:2

    Topics: Adult; Aminophenols; Biomarkers; Child; Chlorides; Cystic Fibrosis; Cystic Fibrosis Transmembrane Co

2014
Ataluren for the treatment of nonsense-mutation cystic fibrosis: a randomised, double-blind, placebo-controlled phase 3 trial.
    The Lancet. Respiratory medicine, 2014, Volume: 2, Issue:7

    Topics: Acute Kidney Injury; Adolescent; Adult; Anti-Bacterial Agents; Child; Chlorides; Codon, Nonsense; Cy

2014
A CFTR corrector (lumacaftor) and a CFTR potentiator (ivacaftor) for treatment of patients with cystic fibrosis who have a phe508del CFTR mutation: a phase 2 randomised controlled trial.
    The Lancet. Respiratory medicine, 2014, Volume: 2, Issue:7

    Topics: Adolescent; Adult; Aminophenols; Aminopyridines; Base Sequence; Benzodioxoles; Chlorides; Cystic Fib

2014
A CFTR corrector (lumacaftor) and a CFTR potentiator (ivacaftor) for treatment of patients with cystic fibrosis who have a phe508del CFTR mutation: a phase 2 randomised controlled trial.
    The Lancet. Respiratory medicine, 2014, Volume: 2, Issue:7

    Topics: Adolescent; Adult; Aminophenols; Aminopyridines; Base Sequence; Benzodioxoles; Chlorides; Cystic Fib

2014
A CFTR corrector (lumacaftor) and a CFTR potentiator (ivacaftor) for treatment of patients with cystic fibrosis who have a phe508del CFTR mutation: a phase 2 randomised controlled trial.
    The Lancet. Respiratory medicine, 2014, Volume: 2, Issue:7

    Topics: Adolescent; Adult; Aminophenols; Aminopyridines; Base Sequence; Benzodioxoles; Chlorides; Cystic Fib

2014
A CFTR corrector (lumacaftor) and a CFTR potentiator (ivacaftor) for treatment of patients with cystic fibrosis who have a phe508del CFTR mutation: a phase 2 randomised controlled trial.
    The Lancet. Respiratory medicine, 2014, Volume: 2, Issue:7

    Topics: Adolescent; Adult; Aminophenols; Aminopyridines; Base Sequence; Benzodioxoles; Chlorides; Cystic Fib

2014
Efficacy response in CF patients treated with ivacaftor: post-hoc analysis.
    Pediatric pulmonology, 2015, Volume: 50, Issue:5

    Topics: Adolescent; Adult; Aminophenols; Child; Chlorides; Cystic Fibrosis; Cystic Fibrosis Transmembrane Co

2015
Effect of salt supplementation on the rate of inadequate sweat collection for infants less than 3 months of age referred for the sweat test.
    Clinical laboratory, 2015, Volume: 61, Issue:3-4

    Topics: Administration, Oral; Cystic Fibrosis; Female; Humans; Infant, Newborn; Male; Neonatal Screening; Re

2015
A semi-blinded study comparing 2 methods of measuring nasal potential difference: Subcutaneous needle versus dermal abrasion.
    Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society, 2016, Volume: 15, Issue:1

    Topics: Adult; Chlorides; Cystic Fibrosis; Electrodiagnosis; Female; Humans; Male; Membrane Potentials; Nasa

2016
Safety, pharmacokinetics, and pharmacodynamics of ivacaftor in patients aged 2-5 years with cystic fibrosis and a CFTR gating mutation (KIWI): an open-label, single-arm study.
    The Lancet. Respiratory medicine, 2016, Volume: 4, Issue:2

    Topics: Aminophenols; Child, Preschool; Chloride Channel Agonists; Chlorides; Cough; Cystic Fibrosis; Cystic

2016
Variability of sweat chloride concentration in subjects with cystic fibrosis and G551D mutations.
    Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society, 2017, Volume: 16, Issue:1

    Topics: Adolescent; Adult; Aminophenols; Biological Variation, Population; Biomarkers; Child; Chloride Chann

2017
In vivo and in vitro ivacaftor response in cystic fibrosis patients with residual CFTR function: N-of-1 studies.
    Pediatric pulmonology, 2017, Volume: 52, Issue:4

    Topics: Administration, Oral; Adolescent; Adult; Aminophenols; Chloride Channel Agonists; Chlorides; Cross-O

2017
Diagnosis of cystic fibrosis by sweat testing: age-specific reference intervals.
    The Journal of pediatrics, 2008, Volume: 153, Issue:6

    Topics: Adolescent; Adult; Aged; Aging; Child; Child, Preschool; Chlorides; Cohort Studies; Cystic Fibrosis;

2008
Effect of VX-770 in persons with cystic fibrosis and the G551D-CFTR mutation.
    The New England journal of medicine, 2010, Nov-18, Volume: 363, Issue:21

    Topics: Adult; Aminophenols; Chlorides; Cross-Over Studies; Cystic Fibrosis; Cystic Fibrosis Transmembrane C

2010
Effect of VX-770 in persons with cystic fibrosis and the G551D-CFTR mutation.
    The New England journal of medicine, 2010, Nov-18, Volume: 363, Issue:21

    Topics: Adult; Aminophenols; Chlorides; Cross-Over Studies; Cystic Fibrosis; Cystic Fibrosis Transmembrane C

2010
Effect of VX-770 in persons with cystic fibrosis and the G551D-CFTR mutation.
    The New England journal of medicine, 2010, Nov-18, Volume: 363, Issue:21

    Topics: Adult; Aminophenols; Chlorides; Cross-Over Studies; Cystic Fibrosis; Cystic Fibrosis Transmembrane C

2010
Effect of VX-770 in persons with cystic fibrosis and the G551D-CFTR mutation.
    The New England journal of medicine, 2010, Nov-18, Volume: 363, Issue:21

    Topics: Adult; Aminophenols; Chlorides; Cross-Over Studies; Cystic Fibrosis; Cystic Fibrosis Transmembrane C

2010
Effect of VX-770 in persons with cystic fibrosis and the G551D-CFTR mutation.
    The New England journal of medicine, 2010, Nov-18, Volume: 363, Issue:21

    Topics: Adult; Aminophenols; Chlorides; Cross-Over Studies; Cystic Fibrosis; Cystic Fibrosis Transmembrane C

2010
Effect of VX-770 in persons with cystic fibrosis and the G551D-CFTR mutation.
    The New England journal of medicine, 2010, Nov-18, Volume: 363, Issue:21

    Topics: Adult; Aminophenols; Chlorides; Cross-Over Studies; Cystic Fibrosis; Cystic Fibrosis Transmembrane C

2010
Effect of VX-770 in persons with cystic fibrosis and the G551D-CFTR mutation.
    The New England journal of medicine, 2010, Nov-18, Volume: 363, Issue:21

    Topics: Adult; Aminophenols; Chlorides; Cross-Over Studies; Cystic Fibrosis; Cystic Fibrosis Transmembrane C

2010
Effect of VX-770 in persons with cystic fibrosis and the G551D-CFTR mutation.
    The New England journal of medicine, 2010, Nov-18, Volume: 363, Issue:21

    Topics: Adult; Aminophenols; Chlorides; Cross-Over Studies; Cystic Fibrosis; Cystic Fibrosis Transmembrane C

2010
Effect of VX-770 in persons with cystic fibrosis and the G551D-CFTR mutation.
    The New England journal of medicine, 2010, Nov-18, Volume: 363, Issue:21

    Topics: Adult; Aminophenols; Chlorides; Cross-Over Studies; Cystic Fibrosis; Cystic Fibrosis Transmembrane C

2010
Ivacaftor in subjects with cystic fibrosis who are homozygous for the F508del-CFTR mutation.
    Chest, 2012, Volume: 142, Issue:3

    Topics: Adolescent; Adult; Alleles; Aminophenols; Biomarkers; Child; Chlorides; Cystic Fibrosis; Cystic Fibr

2012
Ivacaftor in subjects with cystic fibrosis who are homozygous for the F508del-CFTR mutation.
    Chest, 2012, Volume: 142, Issue:3

    Topics: Adolescent; Adult; Alleles; Aminophenols; Biomarkers; Child; Chlorides; Cystic Fibrosis; Cystic Fibr

2012
Ivacaftor in subjects with cystic fibrosis who are homozygous for the F508del-CFTR mutation.
    Chest, 2012, Volume: 142, Issue:3

    Topics: Adolescent; Adult; Alleles; Aminophenols; Biomarkers; Child; Chlorides; Cystic Fibrosis; Cystic Fibr

2012
Ivacaftor in subjects with cystic fibrosis who are homozygous for the F508del-CFTR mutation.
    Chest, 2012, Volume: 142, Issue:3

    Topics: Adolescent; Adult; Alleles; Aminophenols; Biomarkers; Child; Chlorides; Cystic Fibrosis; Cystic Fibr

2012
Prospective and parallel assessments of cystic fibrosis newborn screening protocols in the Czech Republic: IRT/DNA/IRT versus IRT/PAP and IRT/PAP/DNA.
    European journal of pediatrics, 2012, Volume: 171, Issue:8

    Topics: Antigens, Neoplasm; Biomarkers; Biomarkers, Tumor; Clinical Protocols; Cystic Fibrosis; Cystic Fibro

2012
Conductivity determined by a new sweat analyzer compared with chloride concentrations for the diagnosis of cystic fibrosis.
    The Journal of pediatrics, 2005, Volume: 146, Issue:2

    Topics: Adult; Child; Child, Preschool; Chlorides; Cystic Fibrosis; Diagnostic Tests, Routine; Female; Human

2005
A sweat test centered protocol for the disclosure and diagnosis of cystic fibrosis in a newborn screening program.
    Pediatric pulmonology, 2007, Volume: 42, Issue:9

    Topics: Clinical Protocols; Cystic Fibrosis; Female; Humans; Infant, Newborn; Male; Neonatal Screening; Pred

2007
Development of a screening system for cystic fibrosis.
    Clinical chemistry, 1983, Volume: 29, Issue:9

    Topics: Adolescent; Adult; Child; Child, Preschool; Chlorides; Clinical Trials as Topic; Cystic Fibrosis; Hu

1983
A pilot clinical trial of oral sodium 4-phenylbutyrate (Buphenyl) in deltaF508-homozygous cystic fibrosis patients: partial restoration of nasal epithelial CFTR function.
    American journal of respiratory and critical care medicine, 1998, Volume: 157, Issue:2

    Topics: Administration, Oral; Adolescent; Adult; Chlorides; Cystic Fibrosis; Cystic Fibrosis Transmembrane C

1998
A phase I randomized, multicenter trial of CPX in adult subjects with mild cystic fibrosis.
    Pediatric pulmonology, 2002, Volume: 33, Issue:2

    Topics: Adolescent; Adult; Chlorides; Cystic Fibrosis; Cystic Fibrosis Transmembrane Conductance Regulator;

2002
Intravenous linoleic acid supplementation in children with cystic fibrosis.
    Pediatrics, 1979, Volume: 64, Issue:2

    Topics: Arachidonic Acids; Body Height; Body Weight; Child; Child, Preschool; Clinical Trials as Topic; Cyst

1979
Negative effects of oral fatty acid supplementation on sweat chloride in cystic fibrosis.
    Pediatrics, 1979, Volume: 64, Issue:1

    Topics: Adolescent; Child; Child, Preschool; Cystic Fibrosis; Female; Humans; Infant; Male; Oils; Prostaglan

1979
Paradoxical effects of essential fatty acid supplementation on lipid profiles and sweat electrolytes in cystic fibrosis.
    The British journal of nutrition, 1990, Volume: 63, Issue:2

    Topics: Adolescent; Adult; Child; Child, Preschool; Chlorides; Clinical Trials as Topic; Cystic Fibrosis; Di

1990
Does lithium carbonate affect the ion transport abnormality in cystic fibrosis?
    Pediatric pulmonology, 1990, Volume: 8, Issue:2

    Topics: Adolescent; Adult; Biological Transport; Child; Chlorides; Cystic Fibrosis; Double-Blind Method; Dru

1990
Is salt reabsorption in the human sweat duct subject to control?
    Clinical science (London, England : 1979), 1985, Volume: 68, Issue:4

    Topics: Absorption; Adolescent; Child; Cyclic AMP; Cyclic GMP; Cystic Fibrosis; Humans; Pilocarpine; Potassi

1985

Other Studies

1016 other studies available for iodine and Cystic Fibrosis

ArticleYear
Cystic Fibrosis: From Tragedy to Triumph.
    American journal of respiratory and critical care medicine, 2023, 07-01, Volume: 208, Issue:1

    Topics: Alleles; Child; Cystic Fibrosis; Humans; Iodine

2023
Iodine deficiency and subclinical hypothyroidism are common in cystic fibrosis patients.
    Journal of trace elements in medicine and biology : organ of the Society for Minerals and Trace Elements (GMS), 2013, Volume: 27, Issue:2

    Topics: Adolescent; Adult; Age Distribution; Child; Child, Preschool; Cystic Fibrosis; Female; Humans; Hypot

2013
A fat absorption test using iodized oil, with particular application as a screening test in the diagnosis of fibrocystic disease of the pancreas.
    Pediatrics, 1955, Volume: 15, Issue:2

    Topics: Cystic Fibrosis; Disease; Fats; Female; Fibrocystic Breast Disease; Humans; Iodine; Iodized Oil; Oil

1955
Cystic fibrosis of the pancreas: intestinal absorption of fat and fatty acid labeled with I 131.
    Pediatrics, 1958, Volume: 22, Issue:3

    Topics: Cystic Fibrosis; Fats; Fatty Acids; Intestinal Absorption; Intestines; Iodine

1958
ESTIMATION OF FAT ABSORPTION FROM RANDOM STOOL SPECIMENS. MEASUREMENT BY ZIRCONIUM 95 AND IODINE 131.
    American journal of diseases of children (1960), 1964, Volume: 108

    Topics: Absorption; Adolescent; Biomedical Research; Celiac Disease; Child; Cystic Fibrosis; Dogs; Feces; Io

1964
Novel short chain fatty acids restore chloride secretion in cystic fibrosis.
    Biochemical and biophysical research communications, 2006, Mar-31, Volume: 342, Issue:1

    Topics: Cell Line; Chlorides; Colforsin; Cystic Fibrosis; Fatty Acids, Volatile; Humans; Iodine; Molecular S

2006
Activation of the cystic fibrosis transmembrane regulator by cyclic AMP is not correlated with inhibition of endocytosis.
    Biochimica et biophysica acta, 1994, Oct-12, Volume: 1195, Issue:1

    Topics: Cell Line; Chloride Channels; Colforsin; Cyclic AMP; Cystic Fibrosis; Cystic Fibrosis Transmembrane

1994
Stimulation of chloride secretion by P1 purinoceptor agonists in cystic fibrosis phenotype airway epithelial cell line CFPEo-.
    British journal of pharmacology, 1994, Volume: 112, Issue:1

    Topics: Adenine Nucleotides; Adenosine; Calcium; Cell Line; Chloride Channels; Chlorides; Cystic Fibrosis; E

1994
Biopolymer synthesis on polypropylene supports. I. Oligonucleotides.
    Analytical biochemistry, 1994, Volume: 217, Issue:2

    Topics: Base Sequence; Cystic Fibrosis; DNA; DNA, Complementary; Exons; Humans; Iodine; Molecular Sequence D

1994
Permeabilization via the P2X7 purinoreceptor reveals the presence of a Ca2+-activated Cl- conductance in the apical membrane of murine tracheal epithelial cells.
    The Journal of biological chemistry, 2000, Nov-10, Volume: 275, Issue:45

    Topics: 4,4'-Diisothiocyanostilbene-2,2'-Disulfonic Acid; Animals; Bromine; Calcium; Calcium Channel Blocker

2000
The salivary and thyroid glands. A comparative study in man.
    British dental journal, 1967, Jun-06, Volume: 122, Issue:11

    Topics: Cystic Fibrosis; Humans; Iodine; Salivary Gland Diseases; Salivary Glands; Sjogren's Syndrome; Thyro

1967
Needle-free iontophoresis-driven β-adrenergic sweat rate test.
    Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society, 2022, Volume: 21, Issue:3

    Topics: Adrenergic Agents; Aminophylline; Ascorbic Acid; Child; Chlorides; Cystic Fibrosis; Cystic Fibrosis

2022
Outcomes of early repeat sweat testing in infants with cystic fibrosis transmembrane conductance regulator-related metabolic syndrome/CF screen-positive, inconclusive diagnosis.
    Pediatric pulmonology, 2021, Volume: 56, Issue:12

    Topics: Cystic Fibrosis; Cystic Fibrosis Transmembrane Conductance Regulator; Humans; Infant; Infant, Newbor

2021
Sweat testing in the modern era: A national survey of sweat testing practice in the Republic of Ireland.
    Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society, 2022, Volume: 21, Issue:3

    Topics: Chlorides; Cystic Fibrosis; Cystic Fibrosis Transmembrane Conductance Regulator; Humans; Infant, New

2022
CFTR modulation with elexacaftor-tezacaftor-ivacaftor in people with cystic fibrosis assessed by the β-adrenergic sweat rate assay.
    Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society, 2022, Volume: 21, Issue:3

    Topics: Adrenergic Agents; Aminophenols; Benzodioxoles; Chloride Channel Agonists; Chlorides; Cystic Fibrosi

2022
Outcomes of Cystic Fibrosis Screening-Positive Infants With Inconclusive Diagnosis at School Age.
    Pediatrics, 2021, 12-01, Volume: 148, Issue:6

    Topics: Age Factors; Biomarkers; Canada; Child; Chlorides; Cohort Studies; Confidence Intervals; Cystic Fibr

2021
Sweat metabolomics before and after intravenous antibiotics for pulmonary exacerbation in people with cystic fibrosis.
    Respiratory medicine, 2022, Volume: 191

    Topics: Anti-Bacterial Agents; Cystic Fibrosis; Humans; Metabolomics; Prospective Studies; Sweat

2022
Standards of care guidance for sweat testing; phase two of the ECFS quality improvement programme.
    Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society, 2022, Volume: 21, Issue:3

    Topics: Chlorides; Cystic Fibrosis; Humans; Infant, Newborn; Quality Improvement; Standard of Care; Sweat

2022
Impact of Gestational Age on Sweat Testing.
    Irish medical journal, 2022, Jan-20, Volume: 115, Issue:1

    Topics: Cystic Fibrosis; Gestational Age; Humans; Sweat

2022
Variation in CFTR-dependent 'β-sweating' among healthy adults.
    PloS one, 2022, Volume: 17, Issue:3

    Topics: Adult; Cystic Fibrosis; Cystic Fibrosis Transmembrane Conductance Regulator; Humans; Sweat; Sweat Gl

2022
Rapid chloride and bicarbonate determination by capillary electrophoresis for confirmatory testing of cystic fibrosis infants with volume-limited sweat specimens.
    Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society, 2023, Volume: 22, Issue:1

    Topics: Bicarbonates; Chlorides; Cystic Fibrosis; Electrophoresis, Capillary; Humans; Infant; Infant, Newbor

2023
The sweat chloride test has lived up to the changes in CF care.
    Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society, 2022, Volume: 21, Issue:3

    Topics: Chlorides; Cystic Fibrosis; Electric Conductivity; Humans; Sweat

2022
Reclassifying inconclusive diagnosis for cystic fibrosis with new generation sweat test.
    The European respiratory journal, 2022, Volume: 60, Issue:2

    Topics: Chlorides; Cystic Fibrosis; Cystic Fibrosis Transmembrane Conductance Regulator; Humans; Sweat

2022
Characterizing CFTR modulated sweat chloride response across the cf population: Initial results from the CHEC-SC study.
    Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society, 2023, Volume: 22, Issue:1

    Topics: Aminophenols; Benzodioxoles; Chloride Channel Agonists; Chlorides; Cystic Fibrosis; Cystic Fibrosis

2023
A step forward for an intermediate cystic fibrosis population.
    The European respiratory journal, 2022, Volume: 60, Issue:2

    Topics: Cystic Fibrosis; Humans; Sweat

2022
Sweat Proteomics in Cystic Fibrosis: Discovering Companion Biomarkers for Precision Medicine and Therapeutic Development.
    Cells, 2022, 07-31, Volume: 11, Issue:15

    Topics: Biomarkers; Chlorides; Cystic Fibrosis; Cystic Fibrosis Transmembrane Conductance Regulator; Glycosy

2022
Development of algorithm for diagnosis of cystic fibrosis in absence of sweat chloride testing in resource-limited setting.
    Pediatric pulmonology, 2022, Volume: 57, Issue:12

    Topics: Algorithms; Alkalosis; Child; Chlorides; Cystic Fibrosis; Cystic Fibrosis Transmembrane Conductance

2022
ECFS standards of care on CFTR-related disorders: Diagnostic criteria of CFTR dysfunction.
    Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society, 2022, Volume: 21, Issue:6

    Topics: Cystic Fibrosis; Cystic Fibrosis Transmembrane Conductance Regulator; Humans; Ion Transport; Mutatio

2022
Gradual increase in sweat chloride concentration is associated with a higher risk of CRMS/CFSPID to CF reclassification.
    Pediatric pulmonology, 2023, Volume: 58, Issue:4

    Topics: Child; Chlorides; Cross-Sectional Studies; Cystic Fibrosis; Cystic Fibrosis Transmembrane Conductanc

2023
Sweat conductivity for diagnosing cystic fibrosis after positive newborn screening: prospective, diagnostic test accuracy study.
    Archives of disease in childhood, 2023, Volume: 108, Issue:7

    Topics: Chlorides; Cystic Fibrosis; Cystic Fibrosis Transmembrane Conductance Regulator; Diagnostic Tests, R

2023
Variability of the sweat test in children with Cystic Fibrosis previously CRMS/CFSPID: A retrospective monocenter experience.
    Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society, 2023, Volume: 22, Issue:3

    Topics: Child; Child, Preschool; Chlorides; Cystic Fibrosis; Cystic Fibrosis Transmembrane Conductance Regul

2023
A wearable colorimetric sweat pH sensor-based smart textile for health state diagnosis.
    Materials horizons, 2023, 10-02, Volume: 10, Issue:10

    Topics: Colorimetry; Curcumin; Cystic Fibrosis; Humans; Hydrogen-Ion Concentration; Sweat; Textiles; Wearabl

2023
Aquagenic wrinkling of the palms in a cohort of Greek children diagnosed with cystic fibrosis: Associated clinical parameters.
    Journal of the European Academy of Dermatology and Venereology : JEADV, 2023, Volume: 37, Issue:11

    Topics: Child; Chlorides; Cystic Fibrosis; Edema; Greece; Humans; Hyperhidrosis; Keratosis; Pruritus; Sweat;

2023
Cystic fibrosis screen-positive neonates with one pathogenic variant still warrant sweat testing.
    Pediatric pulmonology, 2023, Volume: 58, Issue:11

    Topics: Chlorides; Cystic Fibrosis; Cystic Fibrosis Transmembrane Conductance Regulator; Humans; Infant, New

2023
Reexamining the Minimum Sweat Rate Requirement for Sweat Chloride Testing.
    The journal of applied laboratory medicine, 2023, 11-02, Volume: 8, Issue:6

    Topics: Chlorides; Cystic Fibrosis; Humans; Nonoxynol; Sweat

2023
A paper-based length of stain analytical device for naked eye (readout-free) detection of cystic fibrosis.
    Analytica chimica acta, 2019, Nov-08, Volume: 1080

    Topics: Calorimetry; Chlorides; Chromates; Cystic Fibrosis; Humans; Infant, Newborn; Limit of Detection; Pap

2019
Changes in Airway Microbiome and Inflammation with Ivacaftor Treatment in Patients with Cystic Fibrosis and the G551D Mutation.
    Annals of the American Thoracic Society, 2020, Volume: 17, Issue:2

    Topics: Adolescent; Adult; Aminophenols; Biomarkers; Cystic Fibrosis; Cystic Fibrosis Transmembrane Conducta

2020
Proof of concept for identifying cystic fibrosis from perspiration samples.
    Proceedings of the National Academy of Sciences of the United States of America, 2019, 12-03, Volume: 116, Issue:49

    Topics: Algorithms; Case-Control Studies; Chlorides; Cystic Fibrosis; Cystic Fibrosis Transmembrane Conducta

2019
How to perform and interpret the sweat test.
    Archives of disease in childhood. Education and practice edition, 2020, Volume: 105, Issue:4

    Topics: Cystic Fibrosis; Diagnostic Tests, Routine; Female; Humans; Infant, Newborn; Male; Neonatal Screenin

2020
Females with Cystic Fibrosis Demonstrate a Differential Response Profile to Ivacaftor Compared with Males.
    American journal of respiratory and critical care medicine, 2020, 04-15, Volume: 201, Issue:8

    Topics: Adolescent; Adult; Age Factors; Aminophenols; Body Mass Index; Body Weight; Child; Chloride Channel

2020
[Review of the sweat test indications in a Brussels' cystic fibrosis reference center].
    Annales de biologie clinique, 2019, 12-01, Volume: 77, Issue:6

    Topics: Adolescent; Adult; Aged; Belgium; Child; Child, Preschool; Chlorine; Cystic Fibrosis; Diagnostic Tes

2019
Phenotype of children with inconclusive cystic fibrosis diagnosis after newborn screening.
    Pediatric pulmonology, 2020, Volume: 55, Issue:4

    Topics: Child; Chlorides; Cohort Studies; Cystic Fibrosis; Cystic Fibrosis Transmembrane Conductance Regulat

2020
Identification of a novel cystic fibrosis mutation in three patients of South Asian descent.
    The clinical respiratory journal, 2020, Volume: 14, Issue:6

    Topics: Adolescent; Adult; Asian People; Cystic Fibrosis; Cystic Fibrosis Transmembrane Conductance Regulato

2020
Newborn screening for CF in France: An exemplary national experience.
    Archives de pediatrie : organe officiel de la Societe francaise de pediatrie, 2020, Volume: 27 Suppl 1

    Topics: Algorithms; Biomarkers; Cystic Fibrosis; Cystic Fibrosis Transmembrane Conductance Regulator; France

2020
The Italian External Quality Assessment Program for Cystic Fibrosis Sweat Chloride Test: Does Active Participation Improve the Quality?
    International journal of environmental research and public health, 2020, 05-04, Volume: 17, Issue:9

    Topics: Chlorides; Cystic Fibrosis; Humans; Italy; Prospective Studies; Quality Assurance, Health Care; Swea

2020
Females with cystic fibrosis have a larger decrease in sweat chloride in response to lumacaftor/ivacaftor compared to males.
    Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society, 2021, Volume: 20, Issue:1

    Topics: Adolescent; Adult; Aminophenols; Aminopyridines; Benzodioxoles; Body Mass Index; Child; Chlorides; C

2021
Have courage in using nasal potential difference for diagnostic decisions and clinical research.
    Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society, 2020, Volume: 19, Issue:4

    Topics: Courage; Cystic Fibrosis; Cystic Fibrosis Transmembrane Conductance Regulator; Humans; Nose; Sweat

2020
Comparison of Organoid Swelling and
    American journal of respiratory and critical care medicine, 2020, 12-01, Volume: 202, Issue:11

    Topics: Adolescent; Adult; Aminophenols; Aminopyridines; Benzodioxoles; Child; Chlorides; Colforsin; Cystic

2020
Sweat chloride assay by inductively coupled plasma mass spectrometry: a confirmation test for cystic fibrosis diagnosis.
    Analytical and bioanalytical chemistry, 2020, Volume: 412, Issue:25

    Topics: Adult; Case-Control Studies; Chlorides; Cystic Fibrosis; Humans; Limit of Detection; Mass Spectromet

2020
Quantity not sufficient rates and delays in sweat testing in US infants with cystic fibrosis.
    Pediatric pulmonology, 2020, Volume: 55, Issue:11

    Topics: Cystic Fibrosis; Gestational Age; Humans; Infant; Infant, Newborn; Neonatal Screening; Sweat

2020
Cystic fibrosis newborn screening: the importance of bloodspot sample quality.
    Archives of disease in childhood, 2021, Volume: 106, Issue:3

    Topics: Chlorides; Cystic Fibrosis; Cystic Fibrosis Transmembrane Conductance Regulator; Dried Blood Spot Te

2021
The role of biochemical testing in cystic fibrosis.
    The Malaysian journal of pathology, 2020, Volume: 42, Issue:2

    Topics: Child, Preschool; Cystic Fibrosis; Cystic Fibrosis Transmembrane Conductance Regulator; Diagnostic T

2020
Screen-Printed Sensor for Low-Cost Chloride Analysis in Sweat for Rapid Diagnosis and Monitoring of Cystic Fibrosis.
    Biosensors, 2020, Sep-11, Volume: 10, Issue:9

    Topics: Biosensing Techniques; Chlorides; Cystic Fibrosis; Cystic Fibrosis Transmembrane Conductance Regulat

2020
Outcomes of repeat sweat testing in cystic fibrosis newborn screen positive infants.
    Pediatric pulmonology, 2021, Volume: 56, Issue:6

    Topics: Chlorides; Cystic Fibrosis; Cystic Fibrosis Transmembrane Conductance Regulator; Humans; Infant; Inf

2021
Measuring the impact of CFTR modulation on sweat chloride in cystic fibrosis: Rationale and design of the CHEC-SC study.
    Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society, 2021, Volume: 20, Issue:6

    Topics: Adolescent; Adult; Aged; Aminophenols; Aminopyridines; Benzodioxoles; Child; Chloride Channel Agonis

2021
A Young Girl With Bronchiectasis and Elevated Sweat Chloride.
    Chest, 2021, Volume: 159, Issue:3

    Topics: Adolescent; Axonemal Dyneins; Bronchiectasis; Chronic Disease; Ciliary Motility Disorders; Cystic Fi

2021
Soft, skin-interfaced sweat stickers for cystic fibrosis diagnosis and management.
    Science translational medicine, 2021, 03-31, Volume: 13, Issue:587

    Topics: Chlorides; Cystic Fibrosis; Humans; Infant; Quality of Life; Smartphone; Sweat

2021
Optical Measurements of Sweat for in Vivo Quantification of CFTR Function in Individual Sweat Glands.
    Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society, 2021, Volume: 20, Issue:5

    Topics: Aminophenols; Aminopyridines; Benzodioxoles; Cystic Fibrosis; Cystic Fibrosis Transmembrane Conducta

2021
    Journal of applied social psychology, 2021, Volume: 51, Issue:5

    Topics: Adult; Aged; Aged, 80 and over; Air Pollutants; Air Pollution; Animals; Anti-Bacterial Agents; Anti-

2021
Pseudo-Bartter Syndrome and Intermediate Sweat Chloride Levels-It Could Still be Cystic Fibrosis!
    Indian journal of pediatrics, 2021, Volume: 88, Issue:6

    Topics: Bartter Syndrome; Chlorides; Cystic Fibrosis; Cystic Fibrosis Transmembrane Conductance Regulator; H

2021
Audit of sweat chloride testing reveals analytical errors.
    Clinical chemistry and laboratory medicine, 2021, 07-27, Volume: 59, Issue:8

    Topics: Chlorides; Cystic Fibrosis; Cystic Fibrosis Transmembrane Conductance Regulator; Diagnostic Tests, R

2021
Elevated sweat chloride test: is it always cystic fibrosis?
    Italian journal of pediatrics, 2021, May-14, Volume: 47, Issue:1

    Topics: Celiac Disease; Chlorides; Constipation; Cystic Fibrosis; Diagnosis, Differential; Female; Humans; I

2021
Towards harmonization of solutions used for cystic fibrosis diagnosis by nasal potential difference measurements: A formulation approach with CHESS® software.
    Annales pharmaceutiques francaises, 2022, Volume: 80, Issue:1

    Topics: Cystic Fibrosis; Cystic Fibrosis Transmembrane Conductance Regulator; Humans; Nasal Mucosa; Software

2022
Aquagenic wrinkling in children under two years of age: Could this be a potential clinical referral tool for cystic fibrosis among non-screened populations?
    Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society, 2021, Volume: 20, Issue:5

    Topics: Cystic Fibrosis; Female; Hand Dermatoses; Humans; Immersion; Infant; Infant, Newborn; Male; Mass Scr

2021
Health Characteristics of Patients with Cystic Fibrosis whose Genotype Includes a Variant of the Nucleotide Sequence c.3140-16T>A and Functional Analysis of this Variant.
    Genes, 2021, 05-28, Volume: 12, Issue:6

    Topics: Adolescent; Adult; Cells, Cultured; Child; Cystic Fibrosis; Cystic Fibrosis Transmembrane Conductanc

2021
An Unexpectedly Normal Sweat Chloride.
    Clinical chemistry, 2021, 07-06, Volume: 67, Issue:7

    Topics: Chlorides; Cystic Fibrosis; Cystic Fibrosis Transmembrane Conductance Regulator; Humans; Sweat

2021
Infants with cystic fibrosis transmembrane conductance regulator-related metabolic syndrome/cystic fibrosis screen positive, inconclusive diagnosis and acute recurrent pancreatitis: what definition?
    Journal of medical screening, 2022, Volume: 29, Issue:1

    Topics: Cystic Fibrosis; Cystic Fibrosis Transmembrane Conductance Regulator; Humans; Infant; Metabolic Synd

2022
Evaluating performance in sweat testing in medical biochemistry laboratories in Croatia.
    Biochemia medica, 2017, Feb-15, Volume: 27, Issue:1

    Topics: Biochemistry; Clinical Laboratory Techniques; Croatia; Cystic Fibrosis; Humans; Medical Laboratory S

2017
Autonomous sweat extraction and analysis applied to cystic fibrosis and glucose monitoring using a fully integrated wearable platform.
    Proceedings of the National Academy of Sciences of the United States of America, 2017, 05-02, Volume: 114, Issue:18

    Topics: Cystic Fibrosis; Glucose; Humans; Iontophoresis; Monitoring, Physiologic; Sweat; Wearable Electronic

2017
Feasibility and normal values of an integrated conductivity (Nanoduct™) sweat test system in healthy newborns.
    Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society, 2017, Volume: 16, Issue:4

    Topics: Cystic Fibrosis; Electric Conductivity; Female; Humans; Infant, Newborn; Male; Neonatal Screening; R

2017
Optimization of the French cystic fibrosis newborn screening programme by a centralized tracking process.
    Journal of medical screening, 2018, Volume: 25, Issue:1

    Topics: Algorithms; Cystic Fibrosis; Cystic Fibrosis Transmembrane Conductance Regulator; Female; France; Hu

2018
Is sweat chloride predictive of severity of cystic fibrosis lung disease assessed by chest computed tomography?
    Pediatric pulmonology, 2017, Volume: 52, Issue:9

    Topics: Adolescent; Bronchiectasis; Child; Child, Preschool; Chlorides; Cystic Fibrosis; Female; Humans; Inf

2017
A smartphone-based chloridometer for point-of-care diagnostics of cystic fibrosis.
    Biosensors & bioelectronics, 2017, Nov-15, Volume: 97

    Topics: Biosensing Techniques; Chlorides; Cystic Fibrosis; Equipment Design; Humans; Limit of Detection; Poi

2017
Sweat travels: the issue of sweat chloride transportation.
    Clinical chemistry and laboratory medicine, 2018, 01-26, Volume: 56, Issue:2

    Topics: Chlorides; Clinical Chemistry Tests; Cystic Fibrosis; Humans; Specimen Handling; Sweat; Transportati

2018
Ivacaftor for the p.Ser549Arg (S549R) gating mutation - The Israeli experience.
    Respiratory medicine, 2017, Volume: 131

    Topics: Adolescent; Adult; Aminophenols; Blood Glucose; Body Mass Index; Child; Chloride Channel Agonists; C

2017
Incidental late diagnosis of cystic fibrosis following AH1N1 influenza virus pneumonia: a case report.
    Journal of medical case reports, 2017, Oct-01, Volume: 11, Issue:1

    Topics: Anti-Bacterial Agents; Ceftazidime; Colistin; Cystic Fibrosis; Delayed Diagnosis; Drainage, Postural

2017
Laboratory performance of sweat conductivity for the screening of cystic fibrosis.
    Clinical chemistry and laboratory medicine, 2018, 03-28, Volume: 56, Issue:4

    Topics: Chlorides; Clinical Laboratory Techniques; Cystic Fibrosis; Electric Conductivity; Humans; Quality C

2018
Newborn cystic fibrosis screening in southeastern Mexico: Birth prevalence and novel CFTR gene variants.
    Journal of medical screening, 2018, Volume: 25, Issue:3

    Topics: Alleles; Cystic Fibrosis; Cystic Fibrosis Transmembrane Conductance Regulator; Female; Humans; Infan

2018
The U.S. Food and Drug Administration's Experience with Ivacaftor in Cystic Fibrosis. Establishing Efficacy Using In Vitro Data in Lieu of a Clinical Trial.
    Annals of the American Thoracic Society, 2018, Volume: 15, Issue:1

    Topics: Aminophenols; Chloride Channel Agonists; Clinical Trials as Topic; Cystic Fibrosis; Cystic Fibrosis

2018
Cystic fibrosis newborn screening: outcome of infants with normal sweat tests.
    Archives of disease in childhood, 2018, Volume: 103, Issue:8

    Topics: Cystic Fibrosis; Cystic Fibrosis Transmembrane Conductance Regulator; Humans; Infant, Newborn; Londo

2018
Normal sweat chloride test does not rule out cystic fibrosis.
    The Turkish journal of pediatrics, 2017, Volume: 59, Issue:1

    Topics: Chlorides; Cystic Fibrosis; Cystic Fibrosis Transmembrane Conductance Regulator; DNA Mutational Anal

2017
Another step in the journey: From CFTR mutation to sweat chloride concentration to survival.
    Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society, 2018, Volume: 17, Issue:1

    Topics: Chlorides; Cystic Fibrosis; Cystic Fibrosis Transmembrane Conductance Regulator; Genotype; Humans; M

2018
The relationship between sweat chloride levels and mortality in cystic fibrosis varies by individual genotype.
    Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society, 2018, Volume: 17, Issue:1

    Topics: Adult; Chlorides; Cystic Fibrosis; Cystic Fibrosis Transmembrane Conductance Regulator; Female; Geno

2018
Is sweat testing for cystic fibrosis feasible in patients with down syndrome?
    BMC pulmonary medicine, 2018, Jan-16, Volume: 18, Issue:1

    Topics: Adolescent; Adult; Age Factors; Case-Control Studies; Child; Child, Preschool; Chlorides; Cystic Fib

2018
May the new suggested lower borderline limit of sweat chloride impact the diagnostic process for cystic fibrosis?
    The Journal of pediatrics, 2018, Volume: 194

    Topics: Chlorides; Cystic Fibrosis; Humans; Infant; Practice Guidelines as Topic; Sweat

2018
No sweat, no genes: A diagnostic dilemma.
    Journal of paediatrics and child health, 2018, Volume: 54, Issue:5

    Topics: Biomarkers; Chlorides; Cystic Fibrosis; Cystic Fibrosis Transmembrane Conductance Regulator; Delayed

2018
Considering exercise-associated hyponatraemia as a continuum.
    BMJ case reports, 2018, Mar-09, Volume: 2018

    Topics: Adult; Aftercare; Anticonvulsants; Antidiuretic Agents; Confusion; Cystic Fibrosis; Deamino Arginine

2018
Sweat test for cystic fibrosis: Wearable sweat sensor vs. standard laboratory test.
    Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society, 2018, Volume: 17, Issue:4

    Topics: Adult; Chlorides; Cystic Fibrosis; Dimensional Measurement Accuracy; Equipment Design; Female; Human

2018
Intra-individual biological variation in sweat chloride concentrations in CF, CFTR dysfunction, and healthy pediatric subjects.
    Pediatric pulmonology, 2018, Volume: 53, Issue:6

    Topics: Adolescent; Biological Variation, Individual; Child; Chlorides; Cystic Fibrosis; Cystic Fibrosis Tra

2018
Ivacaftor-induced sweat chloride reductions correlate with increases in airway surface liquid pH in cystic fibrosis.
    JCI insight, 2018, 08-09, Volume: 3, Issue:15

    Topics: Adult; Aminophenols; Animals; Bicarbonates; Biological Transport, Active; Bronchoalveolar Lavage Flu

2018
Effect of topiramate on sweat chloride level while screening for cystic fibrosis.
    BMJ case reports, 2018, Sep-05, Volume: 2018

    Topics: Adolescent; Anticonvulsants; Asthma; Chlorides; Cystic Fibrosis; False Positive Reactions; Female; H

2018
Evaluation of continuous constant current and continuous pulsed current in sweat induction for cystic fibrosis diagnosis.
    BMC pulmonary medicine, 2018, Sep-14, Volume: 18, Issue:1

    Topics: Adolescent; Adult; Aged; Biomarkers; Child; Child, Preschool; Chlorides; Cross-Sectional Studies; Cy

2018
Human epididymis protein 4 (HE4) levels inversely correlate with lung function improvement (delta FEV
    Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society, 2019, Volume: 18, Issue:2

    Topics: Adult; Aminophenols; Biomarkers; Body Mass Index; Child; Chloride Channel Agonists; Cystic Fibrosis;

2019
Positive clinical response to ivacaftor treatment in an individual with the CFTR genotype F508del/V456A.
    Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society, 2019, Volume: 18, Issue:2

    Topics: Adult; Aminophenols; Chloride Channel Agonists; Cystic Fibrosis; Cystic Fibrosis Transmembrane Condu

2019
[Not Available].
    Kinderkrankenschwester : Organ der Sektion Kinderkrankenpflege, 2016, Volume: 35, Issue:12

    Topics: Cystic Fibrosis; Cystic Fibrosis Transmembrane Conductance Regulator; Germany; Humans; Infant; Infan

2016
Devil in the detail of newborn screening for cystic fibrosis.
    Archives of disease in childhood, 2019, Volume: 104, Issue:10

    Topics: Chlorides; Cystic Fibrosis; Cystic Fibrosis Transmembrane Conductance Regulator; Humans; Infant, New

2019
The Incidence of Cystic Fibrosis in the Central Region of Anatolia in Turkey Between 2015 and 2016
    Balkan medical journal, 2019, 05-10, Volume: 36, Issue:3

    Topics: Cross-Sectional Studies; Cystic Fibrosis; Female; Genetic Testing; Humans; Incidence; Infant; Infant

2019
Predictive factors for lumacaftor/ivacaftor clinical response.
    Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society, 2019, Volume: 18, Issue:3

    Topics: Aminophenols; Aminopyridines; Benzodioxoles; Biomarkers, Pharmacological; Child; Chloride Channel Ag

2019
Comparison of two sweat test systems for the diagnosis of cystic fibrosis in newborns.
    Pediatric pulmonology, 2019, Volume: 54, Issue:3

    Topics: Chlorides; Cystic Fibrosis; Diagnostic Tests, Routine; Electric Conductivity; Female; Humans; Infant

2019
Sweat Chloride Testing.
    JAMA, 2019, Feb-19, Volume: 321, Issue:7

    Topics: Child, Preschool; Chlorides; Cystic Fibrosis; Cystic Fibrosis Transmembrane Conductance Regulator; F

2019
Extent of rescue of F508del-CFTR function by VX-809 and VX-770 in human nasal epithelial cells correlates with SNP rs7512462 in SLC26A9 gene in F508del/F508del Cystic Fibrosis patients.
    Biochimica et biophysica acta. Molecular basis of disease, 2019, 06-01, Volume: 1865, Issue:6

    Topics: Alleles; Aminophenols; Aminopyridines; Antiporters; Base Sequence; Benzodioxoles; Body Mass Index; C

2019
Aquagenic Wrinkling of Skin: A Screening Test for Cystic Fibrosis.
    Indian pediatrics, 2019, 02-15, Volume: 56, Issue:2

    Topics: Adolescent; Case-Control Studies; Child; Child, Preschool; Cystic Fibrosis; Diagnostic Techniques an

2019
Inconclusive diagnosis after a positive newborn bloodspot screening result for cystic fibrosis; clarification of the harmonised international definition.
    Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society, 2019, Volume: 18, Issue:6

    Topics: Cystic Fibrosis; Cystic Fibrosis Transmembrane Conductance Regulator; Diagnosis, Differential; False

2019
Iontophoresis burns: a peculiar cutaneous injury from a diagnostic sweat test for cystic fibrosis.
    BMJ case reports, 2019, Jun-08, Volume: 12, Issue:6

    Topics: Burns; Conservative Treatment; Cystic Fibrosis; Female; Humans; Infant; Iontophoresis; Skin; Sweat

2019
Effectivenesss of ivacaftor in severe cystic fibrosis patients and non-G551D gating mutations.
    Pediatric pulmonology, 2019, Volume: 54, Issue:9

    Topics: Adolescent; Adult; Aminophenols; Child; Chloride Channel Agonists; Chlorides; Compassionate Use Tria

2019
Nasal potential difference in suspected cystic fibrosis patients with 5T polymorphism.
    Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society, 2020, Volume: 19, Issue:4

    Topics: Adult; Chlorides; Correlation of Data; Cystic Fibrosis; Cystic Fibrosis Transmembrane Conductance Re

2020
Adult cystic fibrosis--a rare diagnosis from India.
    The Journal of the Association of Physicians of India, 2012, Volume: 60

    Topics: Adult; Bronchiectasis; Cystic Fibrosis; Female; Humans; India; Sexual Infantilism; Sweat

2012
The impact of personalised therapies on respiratory medicine.
    European respiratory review : an official journal of the European Respiratory Society, 2013, Mar-01, Volume: 22, Issue:127

    Topics: Aminophenols; Chlorides; Cystic Fibrosis; Cystic Fibrosis Transmembrane Conductance Regulator; Genet

2013
CFTR2: How will it help care?
    Paediatric respiratory reviews, 2013, Volume: 14 Suppl 1

    Topics: Chlorides; Cystic Fibrosis; Cystic Fibrosis Transmembrane Conductance Regulator; DNA Mutational Anal

2013
Evaluation of an inductively coupled plasma mass spectrometry method for the analysis of sweat chloride and sodium for use in the diagnosis of cystic fibrosis.
    Annals of clinical biochemistry, 2013, Volume: 50, Issue:Pt 3

    Topics: Chlorides; Cystic Fibrosis; Humans; Mass Spectrometry; Sodium; Sweat

2013
The predictive potential of the sweat chloride test in cystic fibrosis patients with the G551D mutation.
    Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society, 2013, Volume: 12, Issue:6

    Topics: Administration, Oral; Adolescent; Aminophenols; Child; Chlorides; Cystic Fibrosis; Cystic Fibrosis T

2013
50 years ago in the Journal of Pediatrics: A note on studies of salt excretion in sweat: relationships between rate, conductivity, and electrolyte composition of sweat from patients with cystic fibrosis and from control subjects. Gibson, LE, di Sant’Agnes
    The Journal of pediatrics, 2013, Volume: 162, Issue:6

    Topics: Cystic Fibrosis; Cystic Fibrosis Transmembrane Conductance Regulator; History, 20th Century; Humans;

2013
Newborn screening for cystic fibrosis in Switzerland--consequences after analysis of a 4 months pilot study.
    Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society, 2013, Volume: 12, Issue:6

    Topics: Algorithms; Cystic Fibrosis; Cystic Fibrosis Transmembrane Conductance Regulator; DNA Mutational Ana

2013
Electrochemical detection of chloride levels in sweat using silver nanoparticles: a basis for the preliminary screening for cystic fibrosis.
    The Analyst, 2013, Aug-07, Volume: 138, Issue:15

    Topics: Chlorides; Cystic Fibrosis; Electrochemical Techniques; Humans; Metal Nanoparticles; Silver; Sweat

2013
The need for salt: does a relationship exist between cystic fibrosis and exercise-associated hyponatremia?
    Journal of strength and conditioning research, 2014, Volume: 28, Issue:3

    Topics: Body Weight; Case-Control Studies; Cystic Fibrosis; Cystic Fibrosis Transmembrane Conductance Regula

2014
Relationship between sweat chloride, sodium, and age in clinically obtained samples.
    Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society, 2014, Volume: 13, Issue:1

    Topics: Adolescent; Adult; Age Factors; Aged; Chemistry, Clinical; Child; Child, Preschool; Chlorides; Cysti

2014
Evaluating the predictive ability of sweat chloride.
    Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society, 2014, Volume: 13, Issue:1

    Topics: Aminophenols; Chlorides; Cystic Fibrosis; Female; Humans; Male; Quinolones; Sweat

2014
[Cystic fibrosis - a childhood illness grows up].
    Kinderkrankenschwester : Organ der Sektion Kinderkrankenpflege, 2013, Volume: 32, Issue:8

    Topics: Adolescent; Adult; Age Factors; Child; Child, Preschool; Chlorides; Combined Modality Therapy; Cysti

2013
Relevance of nasal potential difference in diagnosis of cystic fibrosis among children.
    Medicina (Kaunas, Lithuania), 2013, Volume: 49, Issue:4

    Topics: Adolescent; Child; Child, Preschool; Cystic Fibrosis; Cystic Fibrosis Transmembrane Conductance Regu

2013
A patient nicknamed 'saline': atypical course with cystic fibrosis.
    Klinische Padiatrie, 2013, Volume: 225, Issue:5

    Topics: Adolescent; Adult; Alleles; Child; Cystic Fibrosis; Cystic Fibrosis Transmembrane Conductance Regula

2013
Ivacaftor in a G551D homozygote with cystic fibrosis.
    The New England journal of medicine, 2013, Sep-26, Volume: 369, Issue:13

    Topics: Adolescent; Aminophenols; Chlorides; Cystic Fibrosis; Cystic Fibrosis Transmembrane Conductance Regu

2013
Normalization of sweat chloride concentration and clinical improvement with ivacaftor in a patient with cystic fibrosis with mutation S549N.
    Chest, 2013, Volume: 144, Issue:4

    Topics: Aminophenols; Child; Chlorides; Cystic Fibrosis; Female; Humans; Mutation; Quinolones; Sweat

2013
Response.
    Chest, 2013, Volume: 144, Issue:4

    Topics: Aminophenols; Chlorides; Cystic Fibrosis; Humans; Outcome Assessment, Health Care; Quinolones; Sweat

2013
Understanding the relationship between sweat chloride and lung function in cystic fibrosis.
    Chest, 2013, Volume: 144, Issue:4

    Topics: Aminophenols; Chlorides; Cystic Fibrosis; Humans; Outcome Assessment, Health Care; Quinolones; Sweat

2013
Does extensive genotyping and nasal potential difference testing clarify the diagnosis of cystic fibrosis among patients with single-organ manifestations of cystic fibrosis?
    Thorax, 2014, Volume: 69, Issue:3

    Topics: Adult; Alleles; Biomarkers; Cohort Studies; Cystic Fibrosis; Cystic Fibrosis Transmembrane Conductan

2014
In vivo readout of CFTR function: ratiometric measurement of CFTR-dependent secretion by individual, identifiable human sweat glands.
    PloS one, 2013, Volume: 8, Issue:10

    Topics: Adrenergic beta-Agonists; Adult; Aminophylline; Atropine; Cystic Fibrosis; Cystic Fibrosis Transmemb

2013
[Aquagenic palmoplantar keratoderma in children with cystic fibrosis].
    Archives de pediatrie : organe officiel de la Societe francaise de pediatrie, 2013, Volume: 20, Issue:12

    Topics: Adolescent; Child; Child, Preschool; Chlorides; Cystic Fibrosis; Cystic Fibrosis Transmembrane Condu

2013
Sweat chloride is not a useful marker of clinical response to Ivacaftor.
    Thorax, 2014, Volume: 69, Issue:6

    Topics: Aminophenols; Biomarkers; Body Height; Body Weight; Chlorides; Cohort Studies; Cystic Fibrosis; Forc

2014
Aquagenic wrinkling of the palms in a patient with cystic fibrosis.
    The New England journal of medicine, 2013, Dec-12, Volume: 369, Issue:24

    Topics: Aminophenols; Child; Chlorides; Cystic Fibrosis; Cystic Fibrosis Transmembrane Conductance Regulator

2013
False-negative sweat chloride testing in a child with cystic fibrosis and undiagnosed hypohidrotic ectodermal dysplasia.
    Clinical pediatrics, 2014, Volume: 53, Issue:12

    Topics: Child, Preschool; Chlorides; Cystic Fibrosis; Ectodermal Dysplasia 1, Anhidrotic; False Negative Rea

2014
Aquagenic wrinkling of the palms and cystic fibrosis: an Italian study with controls and genotype-phenotype correlations.
    Dermatology (Basel, Switzerland), 2014, Volume: 228, Issue:1

    Topics: Adolescent; Adult; Case-Control Studies; Child; Child, Preschool; Cystic Fibrosis; Cystic Fibrosis T

2014
Sweat conductivity: an accurate diagnostic test for cystic fibrosis?
    Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society, 2014, Volume: 13, Issue:5

    Topics: Child, Preschool; Chlorides; Cross-Sectional Studies; Cystic Fibrosis; Electric Conductivity; Female

2014
A little CFTR goes a long way: CFTR-dependent sweat secretion from G551D and R117H-5T cystic fibrosis subjects taking ivacaftor.
    PloS one, 2014, Volume: 9, Issue:2

    Topics: Amino Acid Substitution; Aminophenols; Case-Control Studies; Cystic Fibrosis; Cystic Fibrosis Transm

2014
Diagnosis of cystic fibrosis in the kindred of an infant with CFTR-related metabolic syndrome: importance of follow-up that includes monitoring sweat chloride concentrations over time.
    Pediatric pulmonology, 2014, Volume: 49, Issue:3

    Topics: Adolescent; Child; Child, Preschool; Chlorides; Cystic Fibrosis; Cystic Fibrosis Transmembrane Condu

2014
Implementation of a quality improvement program to improve sweat test performance in a pediatric hospital.
    Archives of pathology & laboratory medicine, 2014, Volume: 138, Issue:7

    Topics: Chlorides; Cystic Fibrosis; Hospitals, Pediatric; Humans; Infant; Infant, Newborn; Iontophoresis; Ma

2014
CFTR genotype and clinical outcomes of adult patients carried as cystic fibrosis disease.
    Gene, 2014, May-01, Volume: 540, Issue:2

    Topics: Adolescent; Adult; Chlorides; Cystic Fibrosis; Cystic Fibrosis Transmembrane Conductance Regulator;

2014
Does integration of various ion channel measurements improve diagnostic performance in cystic fibrosis?
    Annals of the American Thoracic Society, 2014, Volume: 11, Issue:4

    Topics: Adolescent; Adult; Azoospermia; Case-Control Studies; Child; Cohort Studies; Cystic Fibrosis; Cystic

2014
Higher sweat chloride levels in patients with asthma: a case-control study.
    Indian journal of pediatrics, 2015, Volume: 82, Issue:2

    Topics: Adolescent; Asthma; Case-Control Studies; Child; Child, Preschool; Chlorides; Cystic Fibrosis; Diagn

2015
A synopsis of methods of sweat tests in pathology.
    Clinical biochemistry, 2014, Volume: 47, Issue:9

    Topics: Chlorides; Clinical Chemistry Tests; Cystic Fibrosis; Humans; Sweat; Sweating

2014
A new method of sweat testing: the CF Quantum®sweat test.
    Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society, 2014, Volume: 13, Issue:5

    Topics: Chlorides; Cystic Fibrosis; Humans; Sensitivity and Specificity; Sweat

2014
Clinical mechanism of the cystic fibrosis transmembrane conductance regulator potentiator ivacaftor in G551D-mediated cystic fibrosis.
    American journal of respiratory and critical care medicine, 2014, Jul-15, Volume: 190, Issue:2

    Topics: Adolescent; Adult; Aminophenols; Biomarkers; Child; Cystic Fibrosis; Cystic Fibrosis Transmembrane C

2014
Double opposite end injection capillary electrophoresis with contactless conductometric detection for simultaneous determination of chloride, sodium and potassium in cystic fibrosis diagnosis.
    Journal of chromatography. A, 2014, Sep-05, Volume: 1358

    Topics: Case-Control Studies; Chlorides; Cystic Fibrosis; Electrophoresis, Capillary; False Positive Reactio

2014
Ion chromatography for the precise analysis of chloride and sodium in sweat for the diagnosis of cystic fibrosis.
    Annals of clinical biochemistry, 2015, Volume: 52, Issue:Pt 4

    Topics: Chlorides; Chromatography, High Pressure Liquid; Chromatography, Ion Exchange; Cystic Fibrosis; Huma

2015
Rectal prolapse and cystic fibrosis.
    Journal of pediatric gastroenterology and nutrition, 2015, Volume: 60, Issue:1

    Topics: Adolescent; Child; Child, Preschool; Chlorides; Cystic Fibrosis; Female; Humans; Incidence; Infant;

2015
Lack of harmonization in sweat testing for cystic fibrosis - a national survey.
    Scandinavian journal of clinical and laboratory investigation, 2014, Volume: 74, Issue:8

    Topics: Chlorides; Clinical Chemistry Tests; Cystic Fibrosis; Denmark; Health Care Surveys; Humans; Referenc

2014
Comparison of radiographic and clinical characteristics of low-risk and high-risk cystic fibrosis genotypes.
    International forum of allergy & rhinology, 2014, Volume: 4, Issue:11

    Topics: Adult; Case-Control Studies; Chlorides; Chronic Disease; Cystic Fibrosis; Cystic Fibrosis Transmembr

2014
Intestinal current measurement versus nasal potential difference measurements for diagnosis of cystic fibrosis: a case-control study.
    BMC pulmonary medicine, 2014, Oct-04, Volume: 14

    Topics: Adolescent; Adult; Case-Control Studies; Child; Chlorides; Cystic Fibrosis; Cystic Fibrosis Transmem

2014
Pulsed direct and constant direct currents in the pilocarpine iontophoresis sweat chloride test.
    BMC pulmonary medicine, 2014, Dec-13, Volume: 14

    Topics: Adult; Biopsy; Chlorides; Cystic Fibrosis; Electric Impedance; Electrodiagnosis; Female; Humans; Ion

2014
Sweating the small stuff: adequacy and accuracy in sweat chloride determination.
    Clinical biochemistry, 2015, Volume: 48, Issue:6

    Topics: Adolescent; Adult; Aged; Child; Child, Preschool; Chlorides; Cystic Fibrosis; Humans; Infant; Infant

2015
Sweat chloride levels in asthma.
    Indian journal of pediatrics, 2015, Volume: 82, Issue:2

    Topics: Asthma; Child; Chlorides; Cystic Fibrosis; Diagnosis, Differential; Humans; Sweat

2015
Characterization of gene mutations and phenotypes of cystic fibrosis in Chinese patients.
    Respirology (Carlton, Vic.), 2015, Volume: 20, Issue:2

    Topics: Adolescent; Adult; Age of Onset; Asian People; Azo Compounds; Child; Child, Preschool; China; Chlori

2015
From lip to lab: salty tasting skin is the main clue that raises clinical suspicion of cystic fibrosis in young infants.
    Acta paediatrica (Oslo, Norway : 1992), 2015, Volume: 104, Issue:5

    Topics: Adult; Clinical Decision-Making; Cystic Fibrosis; Epidemiologic Studies; Female; Humans; Infant; Inf

2015
Elevated sweat chloride levels due to arsenic toxicity.
    The New England journal of medicine, 2015, Feb-05, Volume: 372, Issue:6

    Topics: Adult; Aged; Arsenic; Chlorides; Cross-Sectional Studies; Cystic Fibrosis; Cystic Fibrosis Transmemb

2015
Association of sweat chloride concentration at time of diagnosis and CFTR genotype with mortality and cystic fibrosis phenotype.
    Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society, 2015, Volume: 14, Issue:5

    Topics: Adolescent; Child; Child, Preschool; Chlorides; Cystic Fibrosis; Cystic Fibrosis Transmembrane Condu

2015
Clinical evaluation of the Nanoduct sweat test system in the diagnosis of cystic fibrosis after newborn screening.
    European journal of pediatrics, 2015, Volume: 174, Issue:8

    Topics: Chlorides; Clinical Chemistry Tests; Cystic Fibrosis; Female; Humans; Infant, Newborn; Male; Nanotec

2015
Next generation sequencing to determine the cystic fibrosis mutation spectrum in Palestinian population.
    Disease markers, 2015, Volume: 2015

    Topics: Adolescent; Adult; Child; Child, Preschool; Chlorides; Cystic Fibrosis; Female; High-Throughput Nucl

2015
Misdiagnosis of cystic fibrosis based on transient pancreatic insufficiency and elevated sweat chloride.
    Klinische Padiatrie, 2015, Volume: 227, Issue:2

    Topics: Child; Child, Preschool; Chlorides; Cystic Fibrosis; Cystic Fibrosis Transmembrane Conductance Regul

2015
A paper-based skin patch for the diagnostic screening of cystic fibrosis.
    Chemical communications (Cambridge, England), 2015, Apr-14, Volume: 51, Issue:29

    Topics: Colorimetry; Cystic Fibrosis; Humans; Mass Screening; Paper; Skin; Sweat

2015
Long-term outcomes of children with intermediate sweat chloride values in infancy.
    The Journal of pediatrics, 2015, Volume: 166, Issue:6

    Topics: Child, Preschool; Chlorides; Cystic Fibrosis; Female; Humans; Infant; Infant, Newborn; Male; Neonata

2015
Genotype-phenotype relationship in Iranian patients with cystic fibrosis.
    The Turkish journal of gastroenterology : the official journal of Turkish Society of Gastroenterology, 2015, Volume: 26, Issue:3

    Topics: Age of Onset; Asian People; Chlorides; Cystic Fibrosis; Cystic Fibrosis Transmembrane Conductance Re

2015
New challenges in the diagnosis and management of cystic fibrosis.
    The Journal of pediatrics, 2015, Volume: 166, Issue:6

    Topics: Chlorides; Cystic Fibrosis; Female; Humans; Male; Neonatal Screening; Sweat

2015
Sweat test practice in pediatric pulmonology after introduction of cystic fibrosis newborn screening.
    European journal of pediatrics, 2015, Volume: 174, Issue:12

    Topics: Child; Child, Preschool; Cystic Fibrosis; Cystic Fibrosis Transmembrane Conductance Regulator; Femal

2015
A candidate reference method using ICP-MS for sweat chloride quantification.
    Clinical chemistry and laboratory medicine, 2016, Volume: 54, Issue:4

    Topics: Calibration; Chlorides; Cystic Fibrosis; Humans; Mass Spectrometry; Sweat

2016
Non-allergic asthma as a CFTR-related disorder.
    Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society, 2016, Volume: 15, Issue:5

    Topics: Adolescent; Adult; Asthma; Child; Chlorides; Cystic Fibrosis; Cystic Fibrosis Transmembrane Conducta

2016
Analysis of Cystic Fibrosis in Federation of Bosnia and Herzegovina.
    Medical archives (Sarajevo, Bosnia and Herzegovina), 2015, Volume: 69, Issue:4

    Topics: Adolescent; Bosnia and Herzegovina; Cetylpyridinium; Child; Child, Preschool; Cystic Fibrosis; Femal

2015
Refining the continuum of CFTR-associated disorders in the era of newborn screening.
    Clinical genetics, 2016, Volume: 89, Issue:5

    Topics: Adolescent; Child; Chlorides; Cohort Studies; Cross-Sectional Studies; Cystic Fibrosis; Cystic Fibro

2016
Sweat chloride and immunoreactive trypsinogen in infants carrying two
    Archives of disease in childhood, 2017, Volume: 102, Issue:7

    Topics: Child; Child, Preschool; Chlorides; Cystic Fibrosis; Cystic Fibrosis Transmembrane Conductance Regul

2017
Clinical Phenotypes and Genotypic Spectrum of Cystic Fibrosis in Chinese Children.
    The Journal of pediatrics, 2016, Volume: 171

    Topics: 3' Untranslated Regions; Adolescent; Asian People; Aspergillosis, Allergic Bronchopulmonary; Bronchi

2016
Measurement of fecal elastase improves performance of newborn screening for cystic fibrosis.
    Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society, 2016, Volume: 15, Issue:3

    Topics: Algorithms; Clinical Protocols; Cystic Fibrosis; Cystic Fibrosis Transmembrane Conductance Regulator

2016
The Italian pilot external quality assessment program for cystic fibrosis sweat test.
    Clinical biochemistry, 2016, Volume: 49, Issue:7-8

    Topics: Chlorides; Clinical Laboratory Techniques; Cystic Fibrosis; Diagnostic Tests, Routine; Follow-Up Stu

2016
Loss of carbonic anhydrase XII function in individuals with elevated sweat chloride concentration and pulmonary airway disease.
    Human molecular genetics, 2016, 05-15, Volume: 25, Issue:10

    Topics: Adolescent; Adult; Animals; Carbonic Anhydrases; Child; Child, Preschool; Chlorides; Cystic Fibrosis

2016
A false positive newborn screening result due to a complex allele carrying two frequent CF-causing variants.
    Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society, 2016, Volume: 15, Issue:3

    Topics: Alleles; Cystic Fibrosis; Cystic Fibrosis Transmembrane Conductance Regulator; Diagnosis, Differenti

2016
Validation of a Nutrition Screening Tool for Pediatric Patients with Cystic Fibrosis.
    Journal of the Academy of Nutrition and Dietetics, 2016, Volume: 116, Issue:5

    Topics: Adolescent; Body Mass Index; Body Weight; Child; Cross-Sectional Studies; Cystic Fibrosis; Energy In

2016
Sources of Variation in Sweat Chloride Measurements in Cystic Fibrosis.
    American journal of respiratory and critical care medicine, 2016, 12-01, Volume: 194, Issue:11

    Topics: Adult; Biomarkers; Chlorides; Cystic Fibrosis; Cystic Fibrosis Transmembrane Conductance Regulator;

2016
Nasal potential difference outcomes support diagnostic decisions in cystic fibrosis.
    Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society, 2016, Volume: 15, Issue:5

    Topics: Adrenergic beta-Agonists; Adult; Amiloride; Cystic Fibrosis; Cystic Fibrosis Transmembrane Conductan

2016
50 Years Ago in TheJournal ofPediatrics: The Sweat Test in Cystic Fibrosis: A Comparison of Overnight Sweat Collection versus the Pilocarpine Iontophoresis Method.
    The Journal of pediatrics, 2016, Volume: 175

    Topics: Chlorides; Cystic Fibrosis; Diagnostic Tests, Routine; History, 20th Century; Humans; Iontophoresis;

2016
Sweat chloride testing: controversies and issues.
    The Lancet. Respiratory medicine, 2016, Volume: 4, Issue:8

    Topics: Child, Preschool; Chlorides; Cystic Fibrosis; Cystic Fibrosis Transmembrane Conductance Regulator; D

2016
Changes of CFTR functional measurements and clinical improvements in cystic fibrosis patients with non p.Gly551Asp gating mutations treated with ivacaftor.
    Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society, 2017, Volume: 16, Issue:1

    Topics: Adolescent; Adult; Aminophenols; Child; Chloride Channel Agonists; Chlorides; Cystic Fibrosis; Cysti

2017
Correlation of sweat chloride and percent predicted FEV
    Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society, 2017, Volume: 16, Issue:1

    Topics: Aminophenols; Biomarkers; Chloride Channel Agonists; Chlorides; Clinical Trials as Topic; Cystic Fib

2017
Quality of sweat test (ST) based on the proportion of sweat sodium (Na) and sweat chloride (Cl) as diagnostic parameter of cystic fibrosis: are we on the right way?
    Diagnostic pathology, 2016, Oct-26, Volume: 11, Issue:1

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Child; Child, Preschool; Chlorides; Cystic Fibrosis; Fem

2016
Diagnosis of cystic fibrosis in a patient of Egyptian background.
    BMJ case reports, 2016, Oct-20, Volume: 2016

    Topics: Arabs; Asthma; Bronchiectasis; Child; Chlorides; Cystic Fibrosis; Cystic Fibrosis Transmembrane Cond

2016
Sweat Chloride: The Critical Biomarker for Cystic Fibrosis Trials.
    American journal of respiratory and critical care medicine, 2016, 12-01, Volume: 194, Issue:11

    Topics: Biomarkers; Chlorides; Cystic Fibrosis; Cystic Fibrosis Transmembrane Conductance Regulator; Humans;

2016
Diagnosis of cystic fibrosis with chloride meter (Sherwood M926S chloride analyzer®) and sweat test analysis system (CFΔ collection system®) compared to the Gibson Cooke method.
    The Turkish journal of pediatrics, 2016, Volume: 58, Issue:1

    Topics: Adolescent; Adult; Child; Child, Preschool; Chlorides; Cystic Fibrosis; Electric Conductivity; Femal

2016
Variability of sweat chloride - A never ending story.
    Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society, 2017, Volume: 16, Issue:1

    Topics: Chlorides; Cystic Fibrosis; Humans; Sweat

2017
Does newborn screening influence the young cystic fibrosis cohort included in national registries?
    The European respiratory journal, 2017, Volume: 49, Issue:1

    Topics: Age Factors; Australia; Belgium; Body Mass Index; Child; Child, Preschool; Cohort Studies; Cystic Fi

2017
Wearable Potentiometric Chloride Sweat Sensor: The Critical Role of the Salt Bridge.
    Analytical chemistry, 2016, 12-20, Volume: 88, Issue:24

    Topics: Adult; Chlorides; Cystic Fibrosis; Electrolytes; Equipment Design; Exercise; Female; Humans; Male; P

2016
Role of CFTR mutation analysis in the diagnostic algorithm for cystic fibrosis.
    World journal of pediatrics : WJP, 2017, Volume: 13, Issue:2

    Topics: Adolescent; Adult; Aged; Algorithms; Child; Chlorides; Cystic Fibrosis; Cystic Fibrosis Transmembran

2017
Individual pharmacokinetic variation leads to underdosing of ciprofloxacin in some cystic fibrosis patients.
    Pediatric pulmonology, 2017, Volume: 52, Issue:3

    Topics: Adult; Anti-Bacterial Agents; Breath Tests; Ciprofloxacin; Cystic Fibrosis; Cytochrome P-450 CYP3A;

2017
Ethnicity impacts the cystic fibrosis diagnosis: A note of caution.
    Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society, 2017, Volume: 16, Issue:4

    Topics: Adolescent; Adult; Asian People; Child, Preschool; Chlorides; Cystic Fibrosis; Cystic Fibrosis Trans

2017
[Management of infants whose diagnosis is inconclusive at neonatal screening for cystic fibrosis].
    Archives de pediatrie : organe officiel de la Societe francaise de pediatrie, 2017, Volume: 24, Issue:4

    Topics: Chlorides; Cystic Fibrosis; Cystic Fibrosis Transmembrane Conductance Regulator; Diagnosis, Differen

2017
Sweat potassium concentration may help to identify falsification of sweat test: a case report.
    Clinical biochemistry, 2008, Volume: 41, Issue:13

    Topics: Child, Preschool; Chlorides; Cystic Fibrosis; Humans; Male; Munchausen Syndrome by Proxy; Potassium;

2008
Shwachman-Diamond syndrome in a child presenting with cystic fibrosis-type symptoms and a false-positive sweat test.
    Journal of the Royal Society of Medicine, 2008, Volume: 101 Suppl 1

    Topics: Bone Marrow Diseases; Chronic Disease; Cystic Fibrosis; Diagnosis, Differential; False Positive Reac

2008
Guidelines for diagnosis of cystic fibrosis in newborns through older adults: Cystic Fibrosis Foundation consensus report.
    The Journal of pediatrics, 2008, Volume: 153, Issue:2

    Topics: Adult; Age Factors; Chlorides; Cystic Fibrosis; Cystic Fibrosis Transmembrane Conductance Regulator;

2008
[Standardized sweat chloride analysis for the diagnosis of cystic fibrosis in Korea].
    The Korean journal of laboratory medicine, 2008, Volume: 28, Issue:4

    Topics: Adolescent; Adult; Child; Child, Preschool; Chlorides; Cystic Fibrosis; Female; Humans; Infant; Iont

2008
Early determination of cystic fibrosis by electrochemical chloride quantification in sweat.
    Biosensors & bioelectronics, 2009, Feb-15, Volume: 24, Issue:6

    Topics: Adult; Biomarkers; Biosensing Techniques; Chlorides; Cystic Fibrosis; Disposable Equipment; Electroc

2009
Uncertainty of sweat chloride testing: does the right hand know what the left hand is doing?
    Annals of clinical biochemistry, 2008, Volume: 45, Issue:Pt 6

    Topics: Analysis of Variance; Child; Child, Preschool; Chlorides; Clinical Chemistry Tests; Cystic Fibrosis;

2008
A European consensus for the evaluation and management of infants with an equivocal diagnosis following newborn screening for cystic fibrosis.
    Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society, 2009, Volume: 8, Issue:1

    Topics: Cystic Fibrosis; Cystic Fibrosis Transmembrane Conductance Regulator; Genetic Testing; Humans; Infan

2009
By the sweat of our brows: how salty should a person be?
    The Journal of pediatrics, 2008, Volume: 153, Issue:6

    Topics: Aging; Chlorides; Cystic Fibrosis; Databases, Factual; Humans; Infant, Newborn; Reference Values; Sw

2008
Sweat chloride testing in infants identified as heterozygote carriers by newborn screening.
    The Journal of pediatrics, 2008, Volume: 153, Issue:6

    Topics: Carrier State; Chlorides; Cystic Fibrosis; Cystic Fibrosis Transmembrane Conductance Regulator; Gene

2008
Transient correction of the basic defect in sweat glands in an individual with cystic fibrosis carrying the complex CFTR allele F508del-R553Q.
    Thorax, 2009, Volume: 64, Issue:2

    Topics: Adult; Cystic Fibrosis; Cystic Fibrosis Transmembrane Conductance Regulator; False Negative Reaction

2009
[The diagnosis of cystic fibrosis in adults: lessons from a family story].
    Revue des maladies respiratoires, 2009, Volume: 26, Issue:1

    Topics: Adult; Age Factors; Aged; Bronchiectasis; Child; Chlorides; Cystic Fibrosis; Cystic Fibrosis Transme

2009
[Clinical characteristics and outcome of cystic fibrosis: report of 16 cases].
    La Tunisie medicale, 2008, Volume: 86, Issue:6

    Topics: Adolescent; Bronchiectasis; Child; Child, Preschool; Chronic Disease; Consanguinity; Cystic Fibrosis

2008
Borderline sweat test: Utility and limits of genetic analysis for the diagnosis of cystic fibrosis.
    Clinical biochemistry, 2009, Volume: 42, Issue:7-8

    Topics: Adolescent; Adult; Child; Child, Preschool; Cystic Fibrosis; Cystic Fibrosis Transmembrane Conductan

2009
Phenotypic characterisation of patients with intermediate sweat chloride values: towards validation of the European diagnostic algorithm for cystic fibrosis.
    Thorax, 2009, Volume: 64, Issue:8

    Topics: Adolescent; Adult; Algorithms; Child; Chlorides; Cystic Fibrosis; Cystic Fibrosis Transmembrane Cond

2009
Does the Macroduct collection system reliably define sweat chloride concentration in subjects with intermediate results?
    Clinical biochemistry, 2009, Volume: 42, Issue:12

    Topics: Adolescent; Adult; Child; Child, Preschool; Chlorides; Clinical Laboratory Techniques; Cystic Fibros

2009
Evaluation of the SenseWear activity monitor during exercise in cystic fibrosis and in health.
    Respiratory medicine, 2009, Volume: 103, Issue:10

    Topics: Adolescent; Adult; Algorithms; Analysis of Variance; Calorimetry, Indirect; Cystic Fibrosis; Energy

2009
Sweat testing for cystic fibrosis: standards of performance in Australasia.
    Annals of clinical biochemistry, 2009, Volume: 46, Issue:Pt 4

    Topics: Adolescent; Adult; Australia; Clinical Chemistry Tests; Cystic Fibrosis; Humans; Surveys and Questio

2009
Cystic fibrosis.
    Pediatrics in review, 2009, Volume: 30, Issue:8

    Topics: Anti-Bacterial Agents; Cystic Fibrosis; Cystic Fibrosis Transmembrane Conductance Regulator; Digesti

2009
Sweat chloride concentration in cystic fibrosis patients with cystic fibrosis trans-membrane conductance regulator I1234V mutation.
    Saudi medical journal, 2009, Volume: 30, Issue:8

    Topics: Adolescent; Adult; Child; Child, Preschool; Cystic Fibrosis; Cystic Fibrosis Transmembrane Conductan

2009
Sweat gland bioelectrics differ in cystic fibrosis: a new concept for potential diagnosis and assessment of CFTR function in cystic fibrosis.
    Thorax, 2009, Volume: 64, Issue:11

    Topics: Adrenergic beta-Agonists; Adult; Biomarkers; Chlorides; Cystic Fibrosis; Cystic Fibrosis Transmembra

2009
Clinical and molecular characterization of S1118F-CFTR.
    Pediatric pulmonology, 2009, Volume: 44, Issue:10

    Topics: Blotting, Western; Cells, Cultured; Chlorides; Cystic Fibrosis; Cystic Fibrosis Transmembrane Conduc

2009
Non-classic cystic fibrosis associated with D1152H CFTR mutation.
    Clinical genetics, 2010, Volume: 77, Issue:4

    Topics: Adolescent; Adult; Aged; Amino Acid Substitution; Child; Child, Preschool; Chlorides; Cohort Studies

2010
The use of sweat chloride test for screening cystic fibrosis among malnourished children suffering from frequent respiratory infections.
    Saudi medical journal, 2009, Volume: 30, Issue:12

    Topics: Child; Chlorides; Cross-Sectional Studies; Cystic Fibrosis; Humans; Malnutrition; Respiratory Tract

2009
Classic respiratory disease but atypical diagnostic testing distinguishes adult presentation of cystic fibrosis.
    Chest, 2010, Volume: 137, Issue:5

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Child; Child, Preschool; Chlorides; Cross-Sectional Stud

2010
Does sweat volume influence the sweat test result?
    Archives of disease in childhood, 2010, Volume: 95, Issue:5

    Topics: Adolescent; Adult; Aged; Child; Child, Preschool; Chlorides; Cystic Fibrosis; Electric Conductivity;

2010
[Ascites and extreme lipid abnormalities as initial symptoms of cystic fibrosis in a 5-years-old girl--case report].
    Polski merkuriusz lekarski : organ Polskiego Towarzystwa Lekarskiego, 2009, Volume: 27, Issue:161

    Topics: Ascites; Child, Preschool; Cystic Fibrosis; Cystic Fibrosis Transmembrane Conductance Regulator; Fem

2009
Detection of large rearrangements in the cystic fibrosis transmembrane conductance regulator gene by multiplex ligation-dependent probe amplification assay when sequencing fails to detect two disease-causing mutations.
    Genetic testing and molecular biomarkers, 2010, Volume: 14, Issue:2

    Topics: Chlorides; Cystic Fibrosis; Cystic Fibrosis Transmembrane Conductance Regulator; DNA Mutational Anal

2010
False negative cystic fibrosis newborn screen.
    Clinical pediatrics, 2010, Volume: 49, Issue:3

    Topics: Cystic Fibrosis; Cystic Fibrosis Transmembrane Conductance Regulator; False Negative Reactions; Huma

2010
Cystic fibrosis transmembrane conductance regulator channel dysfunction in non-cystic fibrosis bronchiectasis.
    American journal of respiratory and critical care medicine, 2010, May-15, Volume: 181, Issue:10

    Topics: Adult; Aged; Bronchiectasis; Case-Control Studies; Cystic Fibrosis; Cystic Fibrosis Transmembrane Co

2010
Psychological effects of false-positive results in cystic fibrosis newborn screening: a two-year follow-up.
    The Journal of pediatrics, 2010, Volume: 156, Issue:5

    Topics: Anxiety; Cystic Fibrosis; Cystic Fibrosis Transmembrane Conductance Regulator; False Positive Reacti

2010
Sweat chloride concentration in cystic fibrosis patients with cystic fibrosis trans-membrane conductance regulator 11234V mutation.
    Saudi medical journal, 2010, Volume: 31, Issue:3

    Topics: Adult; Chlorides; Cystic Fibrosis; Cystic Fibrosis Transmembrane Conductance Regulator; Humans; Infa

2010
Use of sweat conductivity measurements.
    Annals of clinical biochemistry, 2010, Volume: 47, Issue:Pt 4

    Topics: Cystic Fibrosis; Electric Conductivity; Humans; Sodium Chloride; Sweat

2010
Cystic fibrosis newborn screening: using experience to optimize the screening algorithm.
    Journal of inherited metabolic disease, 2010, Volume: 33, Issue:Suppl 2

    Topics: Algorithms; Biomarkers; Chlorides; Cystic Fibrosis; Cystic Fibrosis Transmembrane Conductance Regula

2010
Measurement of nasal potential difference in young children with an equivocal sweat test following newborn screening for cystic fibrosis.
    Thorax, 2010, Volume: 65, Issue:6

    Topics: Child, Preschool; Chlorides; Cystic Fibrosis; Cystic Fibrosis Transmembrane Conductance Regulator; F

2010
Clinical phenotype and genotype of children with borderline sweat test and abnormal nasal epithelial chloride transport.
    American journal of respiratory and critical care medicine, 2010, Oct-01, Volume: 182, Issue:7

    Topics: Adolescent; Biomarkers; Case-Control Studies; Child; Chlorides; Cystic Fibrosis; Cystic Fibrosis Tra

2010
Cystic fibrosis papers of the year 2009.
    Journal of the Royal Society of Medicine, 2010, Volume: 103 Suppl 1

    Topics: Amitriptyline; Antidepressive Agents, Tricyclic; Aspergillosis, Allergic Bronchopulmonary; Child; Ch

2010
Intestinal current measurement for diagnostic classification of patients with questionable cystic fibrosis: validation and reference data.
    Thorax, 2010, Volume: 65, Issue:7

    Topics: Adolescent; Adult; Child; Child, Preschool; Chlorides; Cystic Fibrosis; Cystic Fibrosis Transmembran

2010
Initial evaluation of a biochemical cystic fibrosis newborn screening by sequential analysis of immunoreactive trypsinogen and pancreatitis-associated protein (IRT/PAP) as a strategy that does not involve DNA testing in a Northern European population.
    Journal of inherited metabolic disease, 2010, Volume: 33, Issue:Suppl 2

    Topics: Antigens, Neoplasm; Biomarkers; Biomarkers, Tumor; Chlorides; Cystic Fibrosis; Cystic Fibrosis Trans

2010
[French guidelines for sweat test practice and interpretation for cystic fibrosis neonatal screening].
    Archives de pediatrie : organe officiel de la Societe francaise de pediatrie, 2010, Volume: 17, Issue:9

    Topics: Administration, Cutaneous; Chlorides; Cystic Fibrosis; Humans; Infant; Infant, Newborn; Iontophoresi

2010
When to suspect atypical cystic fibrosis.
    The Journal of family practice, 2010, Volume: 59, Issue:9

    Topics: Child; Chlorides; Cystic Fibrosis; Cystic Fibrosis Transmembrane Conductance Regulator; Deoxyribonuc

2010
The need for quality improvement in sweat testing infants after newborn screening for cystic fibrosis.
    The Journal of pediatrics, 2010, Volume: 157, Issue:6

    Topics: Cystic Fibrosis; Humans; Infant, Newborn; Neonatal Screening; Prospective Studies; Quality of Health

2010
Cystic fibrosis and survival to 40 years: a study of cystic fibrosis transmembrane conductance regulator function.
    The European respiratory journal, 2011, Volume: 37, Issue:5

    Topics: Adolescent; Adult; Cystic Fibrosis; Cystic Fibrosis Transmembrane Conductance Regulator; Female; Hum

2011
Abnormal electrochemical skin conductance in cystic fibrosis.
    Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society, 2011, Volume: 10, Issue:1

    Topics: Adult; Chloride Channels; Chlorides; Cystic Fibrosis; Cystic Fibrosis Transmembrane Conductance Regu

2011
Type of CFTR mutation determines risk of pancreatitis in patients with cystic fibrosis.
    Gastroenterology, 2011, Volume: 140, Issue:1

    Topics: Adult; Cohort Studies; Cystic Fibrosis; Cystic Fibrosis Transmembrane Conductance Regulator; Exocrin

2011
The use of sweat chloride test for screening cystic fibrosis among malnourished children suffering from frequent respiratory infections.
    Saudi medical journal, 2010, Volume: 31, Issue:10

    Topics: Child; Chlorides; Cystic Fibrosis; Humans; Malnutrition; Respiratory Tract Infections; Sweat

2010
Bilateral sweat tests with two different methods as a part of cystic fibrosis newborn screening (CF NBS) protocol and additional quality control.
    Folia histochemica et cytobiologica, 2010, Sep-30, Volume: 48, Issue:3

    Topics: Case-Control Studies; Chlorides; Cystic Fibrosis; Electric Conductivity; False Positive Reactions; H

2010
Parental information seeking following a positive newborn screening for cystic fibrosis.
    Journal of health communication, 2010, Volume: 15, Issue:8

    Topics: Adult; Cystic Fibrosis; Female; Genetic Counseling; Health Knowledge, Attitudes, Practice; Humans; I

2010
Parental understanding of newborn screening for cystic fibrosis after a negative sweat-test.
    Pediatrics, 2011, Volume: 127, Issue:2

    Topics: Adult; Comprehension; Cystic Fibrosis; Female; Genetic Carrier Screening; Genetic Counseling; Health

2011
Low abundance of sweat duct Cl- channel CFTR in both healthy and cystic fibrosis athletes with exceptionally salty sweat during exercise.
    American journal of physiology. Regulatory, integrative and comparative physiology, 2011, Volume: 300, Issue:3

    Topics: Adult; Aldosterone; Aquaporin 5; Bicycling; Biopsy; Case-Control Studies; Cystic Fibrosis; Cystic Fi

2011
Clinical outcomes in infants with cystic fibrosis transmembrane conductance regulator (CFTR) related metabolic syndrome.
    Pediatric pulmonology, 2011, Volume: 46, Issue:11

    Topics: Anti-Bacterial Agents; Child, Preschool; Chlorides; Cystic Fibrosis; Cystic Fibrosis Transmembrane C

2011
An infant with alternating metabolic acidosis and alkalosis: question.
    Pediatric nephrology (Berlin, Germany), 2012, Volume: 27, Issue:1

    Topics: Acidosis; Acute Kidney Injury; Alkalosis; Chlorides; Cystic Fibrosis; Cystic Fibrosis Transmembrane

2012
Sweat analysis using indirect ion-selective electrode on the routine chemistry analyser meets UK guidelines.
    Annals of clinical biochemistry, 2011, Volume: 48, Issue:Pt 4

    Topics: Chlorides; Cystic Fibrosis; Humans; Ion-Selective Electrodes; Reference Standards; Sodium; Sweat

2011
High-sweat Na+ in cystic fibrosis and healthy individuals does not diminish thirst during exercise in the heat.
    American journal of physiology. Regulatory, integrative and comparative physiology, 2011, Volume: 301, Issue:4

    Topics: Adult; Aldosterone; Angiotensin II; Body Weight; Case-Control Studies; Cystic Fibrosis; Dehydration;

2011
Clinical practices for intermediate sweat tests following abnormal cystic fibrosis newborn screens.
    Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society, 2011, Volume: 10, Issue:6

    Topics: Cystic Fibrosis; Diagnostic Tests, Routine; Humans; Infant, Newborn; Neonatal Screening; Practice Pa

2011
Cystic fibrosis mutations for p.F508del compound heterozygotes predict sweat chloride levels and pancreatic sufficiency.
    Clinical genetics, 2012, Volume: 82, Issue:6

    Topics: Chlorides; Cystic Fibrosis; Cystic Fibrosis Transmembrane Conductance Regulator; Genotype; Heterozyg

2012
A continuing role for sweat testing in an era of newborn screening for cystic fibrosis.
    Clinical biochemistry, 2011, Volume: 44, Issue:7

    Topics: Chlorides; Cystic Fibrosis; Cystic Fibrosis Transmembrane Conductance Regulator; Electric Conductivi

2011
Elevated sweat chloride concentration in children without cystic fibrosis who are receiving topiramate therapy.
    Pediatric pulmonology, 2012, Volume: 47, Issue:5

    Topics: Adolescent; Analgesics; Anticonvulsants; Bronchi; Cells, Cultured; Child; Chlorides; Cystic Fibrosis

2012
Factors accounting for a missed diagnosis of cystic fibrosis after newborn screening.
    Pediatric pulmonology, 2011, Volume: 46, Issue:12

    Topics: Chlorides; Cystic Fibrosis; Diagnostic Errors; Female; Humans; Infant; Infant, Newborn; Male; Neonat

2011
Comparing age of cystic fibrosis diagnosis and treatment initiation after newborn screening with two common strategies.
    Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society, 2012, Volume: 11, Issue:2

    Topics: Cystic Fibrosis; DNA Mutational Analysis; Genetic Carrier Screening; Genotyping Techniques; Humans;

2012
Impact of IVS8-(TG)m(T)n on IRT and sweat chloride levels in newborns identified by California CF newborn screening.
    Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society, 2012, Volume: 11, Issue:3

    Topics: California; Child, Preschool; Chlorides; Cystic Fibrosis; Cystic Fibrosis Transmembrane Conductance

2012
Lessons learned from 20 years of newborn screening for cystic fibrosis.
    The Medical journal of Australia, 2012, Jan-16, Volume: 196, Issue:1

    Topics: Cystic Fibrosis; Cystic Fibrosis Transmembrane Conductance Regulator; DNA; DNA Mutational Analysis;

2012
Improving test properties for neonatal cystic fibrosis screening in the Netherlands before the nationwide start by May 1st 2011.
    Journal of inherited metabolic disease, 2012, Volume: 35, Issue:4

    Topics: Cystic Fibrosis; Cystic Fibrosis Transmembrane Conductance Regulator; Genetic Testing; Humans; Infan

2012
Diagnosing cystic fibrosis: what are we sweating about?
    Thorax, 2012, Volume: 67, Issue:7

    Topics: Adolescent; Adult; Child; Cystic Fibrosis; Diagnosis, Differential; Humans; Sweat; Sweating; Young A

2012
Detection of a large heterozygous deletion and a splicing defect in the CFTR transcripts from nasal swab of a Japanese case of cystic fibrosis.
    Journal of human genetics, 2012, Volume: 57, Issue:7

    Topics: Alleles; Asian People; Base Sequence; Chlorides; Cloning, Molecular; Cystic Fibrosis; Cystic Fibrosi

2012
Comparison of quantitative sweat chloride methods after positive newborn screen for cystic fibrosis.
    Pediatric pulmonology, 2012, Volume: 47, Issue:8

    Topics: Chlorides; Cystic Fibrosis; Female; Humans; Infant; Infant, Newborn; Iontophoresis; Male; Muscarinic

2012
β-adrenergic sweat secretion as a diagnostic test for cystic fibrosis.
    American journal of respiratory and critical care medicine, 2012, Oct-15, Volume: 186, Issue:8

    Topics: Adolescent; Adrenergic beta-Agonists; Adult; Aged; Biomarkers; Case-Control Studies; Chlorides; Cyst

2012
Cystic fibrosis infant care challenges in diagnosis and management in the era of newborn screening.
    Delaware medical journal, 2012, Volume: 84, Issue:5

    Topics: Cystic Fibrosis; Cystic Fibrosis Transmembrane Conductance Regulator; Deoxyribonuclease I; Disease P

2012
To sweat or not to sweat: is that enough to diagnose cystic fibrosis?
    American journal of respiratory and critical care medicine, 2012, Oct-15, Volume: 186, Issue:8

    Topics: Adrenergic beta-Agonists; Cystic Fibrosis; Cystic Fibrosis Transmembrane Conductance Regulator; Fema

2012
Effects of immediate telephone follow-up with providers on sweat chloride test timing after cystic fibrosis newborn screening identifies a single mutation.
    The Journal of pediatrics, 2013, Volume: 162, Issue:3

    Topics: Chlorides; Cohort Studies; Cystic Fibrosis; Female; Health Communication; Humans; Infant; Infant, Ne

2013
Change in sweat chloride as a clinical end point in cystic fibrosis clinical trials: the ivacaftor experience.
    Chest, 2013, Volume: 143, Issue:1

    Topics: Aminophenols; Chlorides; Clinical Trials as Topic; Cystic Fibrosis; Cystic Fibrosis Transmembrane Co

2013
CFTR p.Arg117His associated with CBAVD and other CFTR-related disorders.
    Journal of medical genetics, 2013, Volume: 50, Issue:4

    Topics: Child; Child, Preschool; Cystic Fibrosis; Cystic Fibrosis Transmembrane Conductance Regulator; Femal

2013
Response to "Use of nasal potential differences and sweat chloride as outcome measures in multicenter clinical trials in subjects with cystic fibrosis".
    Pediatric pulmonology, 2002, Volume: 34, Issue:2

    Topics: Chloride Channels; Clinical Trials as Topic; Cystic Fibrosis; Humans; Membrane Potentials; Multicent

2002
Screening for cystic fibrosis in newborn infants: results of a pilot programme based on a two tier protocol (IRT/DNA/IRT) in the Italian population.
    Journal of medical screening, 2002, Volume: 9, Issue:2

    Topics: Cystic Fibrosis; Cystic Fibrosis Transmembrane Conductance Regulator; DNA Mutational Analysis; Genet

2002
Variant cystic fibrosis phenotypes in the absence of CFTR mutations.
    The New England journal of medicine, 2002, Aug-08, Volume: 347, Issue:6

    Topics: Adolescent; Adult; Chi-Square Distribution; Chlorides; Cystic Fibrosis; Cystic Fibrosis Transmembran

2002
[A food loving child with rhinitis].
    Duodecim; laaketieteellinen aikakauskirja, 2001, Volume: 117, Issue:18

    Topics: Appetite; Child, Preschool; Cystic Fibrosis; Diarrhea; Female; Humans; Rectal Prolapse; Rhinitis; Sw

2001
CFTR gene mutations in patients suffering from acute pancreatitis.
    Medical science monitor : international medical journal of experimental and clinical research, 2002, Volume: 8, Issue:9

    Topics: Adult; Aged; Alleles; Chlorine; Cystic Fibrosis; Cystic Fibrosis Transmembrane Conductance Regulator

2002
[Clinical and molecular genetic study of cystic fibrosis in the 5th Region of Chile].
    Revista medica de Chile, 2002, Volume: 130, Issue:8

    Topics: Adolescent; Adult; Child; Child, Preschool; Chile; Cystic Fibrosis; Cystic Fibrosis Transmembrane Co

2002
An indigenously developed method for sweat collection and estimation of chloride for diagnosis of cystic fibrosis.
    Indian pediatrics, 2002, Volume: 39, Issue:11

    Topics: Cystic Fibrosis; Iontophoresis; Observer Variation; Reproducibility of Results; Specimen Handling; S

2002
Modified method to measure nasal potential difference.
    Clinical chemistry and laboratory medicine, 2003, Volume: 41, Issue:1

    Topics: Adolescent; Adult; Amiloride; Biological Transport, Active; Case-Control Studies; Child; Chlorides;

2003
Molecular diagnosis of cystic fibrosis in Indian patients--a preliminary report.
    The Journal of the Association of Physicians of India, 2003, Volume: 51

    Topics: Adolescent; Adult; Child; Child, Preschool; Chlorides; Cystic Fibrosis; Cystic Fibrosis Transmembran

2003
Increased prevalence of CFTR mutations and variants and decreased chloride secretion in primary sclerosing cholangitis.
    Human genetics, 2003, Volume: 113, Issue:3

    Topics: Action Potentials; Adult; Aged; Case-Control Studies; Chloride Channels; Chlorides; Cholangitis, Scl

2003
Analysis of the costs of diagnosing cystic fibrosis with a newborn screening program.
    The Journal of pediatrics, 2003, Volume: 142, Issue:6

    Topics: Chlorides; Cost Savings; Cystic Fibrosis; Health Care Costs; Humans; Infant, Newborn; Monte Carlo Me

2003
An indigenously developed method for sweat collection.
    Indian pediatrics, 2003, Volume: 40, Issue:7

    Topics: Cystic Fibrosis; Humans; Iontophoresis; Sweat

2003
A girl with cystic fibrosis and failure to thrive.
    The Journal of pediatrics, 2003, Volume: 143, Issue:1

    Topics: Amebicides; Biopsy; Celiac Disease; Chlorides; Cystic Fibrosis; Diagnosis, Differential; Dientamoebi

2003
Mutations located in exon 24 of the CFTR gene are associated with a mild cystic fibrosis phenotype.
    Clinical genetics, 2003, Volume: 64, Issue:3

    Topics: Adolescent; Adult; Age of Onset; Amino Acid Sequence; Amino Acid Substitution; Chlorides; Codon, Ter

2003
CFTR genotypes in patients with normal or borderline sweat chloride levels.
    Human mutation, 2003, Volume: 22, Issue:4

    Topics: Adolescent; Adult; Child; Child, Preschool; Chlorides; Cystic Fibrosis; Cystic Fibrosis Transmembran

2003
Sweat test results in children with primary protein energy malnutrition.
    Journal of pediatric gastroenterology and nutrition, 2003, Volume: 37, Issue:3

    Topics: Case-Control Studies; Child, Preschool; Chlorides; Cystic Fibrosis; Diagnosis, Differential; Electri

2003
Electrolyte abnormalities of the sweat in fibrocystic disease of the pancreas.
    The American journal of the medical sciences, 1953, Volume: 225, Issue:1

    Topics: Cystic Fibrosis; Disease; Electrolytes; Pancreas; Pancreatic Diseases; Sweat; Sweating

1953
Abnormal electrolyte composition of sweat in cystic fibrosis of the pancreas.
    A.M.A. American journal of diseases of children, 1953, Volume: 86, Issue:5

    Topics: Cystic Fibrosis; Disease; Electrolytes; Humans; Pancreas; Pancreatic Diseases; Sweat

1953
Abnormal electrolyte composition of sweat in cystic fibrosis of the pancreas; clinical significance and relationship to the disease.
    Pediatrics, 1953, Volume: 12, Issue:5

    Topics: Cystic Fibrosis; Disease; Electrolytes; Humans; Pancreas; Pancreatic Diseases; Sweat

1953
ELECTROLYTE losses from sweat in fibrocystic disease.
    Nutrition reviews, 1956, Volume: 14, Issue:2

    Topics: Cystic Fibrosis; Disease; Electrolytes; Humans; Pancreas; Pancreatic Diseases; Sweat; Sweating

1956
Measurement of the electrical conductivity of sweat; its application to the study of cystic fibrosis of the pancreas.
    Clinical chemistry, 1957, Volume: 3, Issue:1

    Topics: Cystic Fibrosis; Electric Conductivity; Humans; Sweat

1957
The electrolyte content of the sweat in fibrocystic disease of the pancreas.
    Archives of disease in childhood, 1957, Volume: 32, Issue:162

    Topics: Cystic Fibrosis; Electrolytes; Humans; Sweat

1957
The sweat test in cystic fibrosis of the pancreas.
    A.M.A. journal of diseases of children, 1957, Volume: 94, Issue:1

    Topics: Cystic Fibrosis; Humans; Pancreas; Sweat

1957
[A simple method for detecting increased salt excretion in sweat].
    Maandschrift voor kindergeneeskunde, 1957, Volume: 25, Issue:4

    Topics: Cystic Fibrosis; Humans; Pancreas; Sodium Chloride; Sodium Chloride, Dietary; Sweat; Sweating

1957
Fingerprint sweat test in fibrocystic disease of pancreas; preliminary communication.
    British medical journal, 1957, Aug-03, Volume: 2, Issue:5039

    Topics: Communication; Cystic Fibrosis; Electrolytes; Female; Fibrocystic Breast Disease; Humans; Pancreas;

1957
The sweat test in the diagnosis of fibrocystic disease of the pancreas.
    Journal of clinical pathology, 1957, Volume: 10, Issue:3

    Topics: Cystic Fibrosis; Female; Fibrocystic Breast Disease; Humans; Pancreas; Sweat

1957
[Practical importance of analysis of electrolytes in sweat in children].
    Revista paulista de medicina, 1957, Volume: 51, Issue:2

    Topics: Anemia; Child; Cystic Fibrosis; Electrolytes; Humans; Infant; Nephrosis; Pancreas; Pneumonia; Sweat

1957
[Value of the sweat test in pancreatic fibrosis].
    Nederlands tijdschrift voor geneeskunde, 1957, Dec-14, Volume: 101, Issue:50

    Topics: Cystic Fibrosis; Humans; Pancreas; Sweat

1957
Sweat analysis in fibrocystic disease, chronic pulmonary disease and controls.
    Archives of disease in childhood, 1958, Volume: 33, Issue:167

    Topics: Child; Chronic Disease; Cystic Fibrosis; Humans; Infant; Lung Diseases; Sweat

1958
Sweat test for the diagnosis of fibrocystic disease of the pancreas; report of a fatality.
    Archives of disease in childhood, 1958, Volume: 33, Issue:168

    Topics: Cystic Fibrosis; Humans; Sweat

1958
A simple method of sweat collection with analysis of electrolytes in patients with fibrocystic disease of the pancreas, and their families.
    The Medical journal of Australia, 1958, Mar-29, Volume: 45, Issue:13

    Topics: Cystic Fibrosis; Electrolytes; Humans; Pancreas; Sweat

1958
The finger-print sweat test.
    South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde, 1958, Mar-22, Volume: 32, Issue:12

    Topics: Cystic Fibrosis; Dermatoglyphics; Humans; Sweat

1958
[Sweat test by intradermal injection of a synthetic parasympathomimetic: Alvin, M. Mauer & Clark D. West method].
    La semaine des hopitaux : organe fonde par l'Association d'enseignement medical des hopitaux de Paris, 1958, Mar-24, Volume: 34, Issue:14/3

    Topics: Cystic Fibrosis; Humans; Injections, Intradermal; Pancreas; Parasympathomimetics; Sweat; Sweating

1958
[Electrolyte content of sweat as a diagnostic sign in cystic fibrosis of the pancreas].
    Ceskoslovenska pediatrie, 1958, Jun-05, Volume: 13, Issue:5

    Topics: Cystic Fibrosis; Electrolytes; Humans; Pancreas; Physical Examination; Sweat

1958
Saliva, tears and duodenal contents in cystic fibrosis of the pancreas.
    Pediatrics, 1958, Volume: 22, Issue:3

    Topics: Cystic Fibrosis; Duodenum; Humans; Lacrimal Apparatus; Saliva; Sweat; Tears

1958
Performance of the sweat test under standardized conditions.
    Clinica chimica acta; international journal of clinical chemistry, 1958, Volume: 3, Issue:5

    Topics: Cystic Fibrosis; Humans; Pancreas; Reference Standards; Sweat

1958
Sweat tests for diagnosis of cystic fibrosis.
    Quarterly review of pediatrics, 1958, Volume: 13, Issue:4

    Topics: Cystic Fibrosis; Humans; Pancreas; Sweat

1958
[Diagnostic value of the sweat test in incomplete types of mucoviscidosis].
    La Presse medicale, 1958, Dec-17, Volume: 66, Issue:89

    Topics: Cystic Fibrosis; Humans; Pancreas; Sweat

1958
A test for concentration of electrolytes in sweat in cystic fibrosis of the pancreas utilizing pilocarpine by iontophoresis.
    Pediatrics, 1959, Volume: 23, Issue:3

    Topics: Chlorides; Cystic Fibrosis; Electrolytes; Humans; Iontophoresis; Pilocarpine; Sodium; Sodium, Dietar

1959
A patch test for chloride in sweat as a simple screening method for detecting cystic fibrosis of the pancreas; preliminary report.
    Pediatrics, 1959, Volume: 23, Issue:4

    Topics: Chlorides; Cystic Fibrosis; Humans; Patch Tests; Sweat

1959
A comparison of sweat chlorides and intestinal fat absorption in chronic obstructive pulmonary emphysema and fibrocystic disease of the pancreas.
    The New England journal of medicine, 1959, May-07, Volume: 260, Issue:19

    Topics: Chlorides; Cystic Fibrosis; Emphysema; Fats; Humans; Intestinal Absorption; Intestines; Pancreas; Pu

1959
Evaluation of the finger imprint method for sweat electrolyte estimation in fibrocystic disease of the pancreas.
    The Medical journal of Australia, 1959, Jun-06, Volume: 1, Issue:23

    Topics: Cystic Fibrosis; Electrolytes; Fingers; Humans; Pancreas; Regression Analysis; Sweat

1959
'Sweat test' results in normal persons of different ages compared with families with fibrocystic disease of the pancreas.
    Archives of disease in childhood, 1960, Volume: 35

    Topics: Cystic Fibrosis; Humans; Sweat

1960
[The sweat test in pancreatic cystic fibrosis].
    Nederlands tijdschrift voor geneeskunde, 1960, Aug-06, Volume: 104

    Topics: Cystic Fibrosis; Humans; Sweat

1960
Components of sweat. Cystic fibrosis of the pancreas compared with controls.
    American journal of diseases of children (1960), 1961, Volume: 101

    Topics: Cystic Fibrosis; Humans; Sweat

1961
[Electrolyte concentrations in the sweat of children with pancreatic cystic fibrosis, Addison's disease and hypophyseal dwarfism].
    Schweizerische medizinische Wochenschrift, 1961, May-13, Volume: 91

    Topics: Addison Disease; Adrenal Insufficiency; Child; Cystic Fibrosis; Dwarfism; Electrolytes; Humans; Hypo

1961
Thiocyanate secretion in sweat in cystic fibrosis.
    Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine (New York, N.Y.), 1961, Volume: 106

    Topics: Cystic Fibrosis; Humans; Sweat; Thiocyanates

1961
[The composition of sweat in patients with pancreatic fibrosis].
    Ugeskrift for laeger, 1960, Sep-09, Volume: 122

    Topics: Cystic Fibrosis; Humans; Sweat

1960
[On mucoviscidosis in adults and diabetes mellitus].
    Klinische Wochenschrift, 1961, Aug-15, Volume: 39

    Topics: Anions; Chlorides; Cystic Fibrosis; Diabetes Mellitus; Humans; Ions; Sodium; Sodium, Dietary; Sweat

1961
[Technic and interpretation of the sweat test in the adult].
    Pathologie et biologie, 1961, Volume: 9

    Topics: Adult; Cystic Fibrosis; Humans; Sweat

1961
[Determination of sweat electrolytes after pilocarpin iontophoresis].
    Monatsschrift fur Kinderheilkunde, 1961, Volume: 109

    Topics: Cystic Fibrosis; Electrolytes; Humans; Iontophoresis; Pilocarpine; Sweat

1961
[Mucoviscidosis-role of sweat examination].
    Ceskoslovenska pediatrie, 1960, Aug-05, Volume: 15

    Topics: Cystic Fibrosis; Humans; Sweat

1960
[Sweat production with the aid of iontophoresis in the diagnosis of hereditary mucoviscidosis in children].
    Klinische Wochenschrift, 1961, Jan-15, Volume: 39

    Topics: Child; Cystic Fibrosis; Humans; Iontophoresis; Sweat; Sweating

1961
The electrical conductivity of electrolytes found in the sweat of patients with fibrocystic disease of the pancreas.
    Archives of disease in childhood, 1959, Volume: 34

    Topics: Cystic Fibrosis; Electric Conductivity; Electrolytes; Humans; Sweat

1959
Sweat iodide excretion in patients with cystic fibrosis of the pancreas.
    Journal of applied physiology, 1960, Volume: 15

    Topics: Biological Transport; Cystic Fibrosis; Humans; Iodides; Sweat

1960
A study of the free amino acids in sweat from patients with cystic fibrosis.
    A.M.A. journal of diseases of children, 1960, Volume: 99

    Topics: Amino Acids; Antifibrinolytic Agents; Biochemical Phenomena; Cystic Fibrosis; Humans; Sweat

1960
Observations on (i) sweat sodium levels in relation to chronic respiratory disease in adults and (ii) the incidence of respiratory and other disease in parents and siblings of patients with fibrocystic disease of the pancreas.
    The Medical journal of Australia, 1962, Jun-23, Volume: 49(1)

    Topics: Adult; Chronic Disease; Cystic Fibrosis; Disease; Humans; Incidence; Pancreas; Parents; Respiration

1962
Sweat chloride concentration in children with allergy and with cystic fibrosis of the pancreas.
    Pediatrics, 1962, Volume: 29

    Topics: Child; Chlorides; Cystic Fibrosis; Humans; Hypersensitivity; Infant; Sweat

1962
Observations on skin resistance to electricity and sweat chloride content. A preliminary report.
    The Journal of pediatrics, 1962, Volume: 60

    Topics: Central Nervous System Diseases; Chlorides; Cystic Fibrosis; Electricity; Humans; Skin Physiological

1962
[The palm print test according to Knights' method for the routine investigation of pancreatic cystic fibrosis].
    Rivista di clinica pediatrica, 1961, Volume: 67

    Topics: Cystic Fibrosis; Hand; Humans; Sweat

1961
[Apropos of the attempted detection of incomplete forms of mucoviscidosis in adults. New contribution to the study of the sweat test].
    La Presse medicale, 1961, Nov-11, Volume: 69

    Topics: Cystic Fibrosis; Humans; Sweat; Sweat Glands

1961
[The respiratory forms of mucoviscidosis. Critical study of the sweat test].
    Pediatrie, 1961, Volume: 16

    Topics: Bronchopneumonia; Cystic Fibrosis; Humans; Sweat

1961
Sweat collection in cystic fibrosis. Report of a simplified method employing pilocarpine iontophoresis and cellulose sponge.
    The Ohio State medical journal, 1962, Volume: 58

    Topics: Animals; Cellulose; Cystic Fibrosis; Humans; Iontophoresis; Pilocarpine; Porifera; Sweat; Sweating

1962
Some practical simplifications of perspiration electrolyte analysis ("sweat test").
    Clinical chemistry, 1961, Volume: 7

    Topics: Cystic Fibrosis; Electrolytes; Sweat

1961
Pilocarpine iontophoresis as a method of obtaining sweat for electrolyte determinations; a preliminary report.
    Virginia medical monthly, 1962, Volume: 89

    Topics: Cystic Fibrosis; Electrolytes; Humans; Iontophoresis; Pilocarpine; Sweat

1962
Acetylcholine in sweat in fibrocystic disease of the pancreas.
    Nature, 1961, Oct-07, Volume: 192

    Topics: Acetylcholine; Cystic Fibrosis; Humans; Pancreas; Sweat

1961
[Considerations on the modified Shwachman test for diagnosis of mucoviscidosis].
    Minerva pediatrica, 1961, Sep-29, Volume: 13

    Topics: Cystic Fibrosis; Humans; Sweat

1961
The sweat test.
    Pediatrics, 1962, Volume: 30

    Topics: Cystic Fibrosis; Humans; Sweat

1962
[Sweat test. Physiological basis, methodology and clinical evaluation].
    Tidsskrift for den Norske laegeforening : tidsskrift for praktisk medicin, ny raekke, 1962, Mar-15, Volume: 82

    Topics: Cystic Fibrosis; Humans; Sweat

1962
[The importance of sweat electrolyte concentration in the differential diagnosis of chronic nonspecific lungs diseases in childhood].
    Neue osterreichische Zeitschrift fur Kinderheilkunde, 1961, Volume: 6

    Topics: Child; Chronic Disease; Cystic Fibrosis; Diagnosis, Differential; Electrolytes; Humans; Infant; Lung

1961
[A method for the determination of chlorides in the diagnosis of mucoviscidosis].
    Ceskoslovenska pediatrie, 1962, Volume: 17

    Topics: Chlorides; Cystic Fibrosis; Sweat

1962
[Significance of the Na-plus and Cl-minus concentration in the sweat for the diagnosis of mucoviscidosis in adults].
    Nederlands tijdschrift voor geneeskunde, 1962, Jun-30, Volume: 106

    Topics: Cystic Fibrosis; Humans; Sodium; Sweat

1962
Response of sweat electrolyte concentrations to 9 alpha--fluorohydrocortisone in patients with cystic fibrosis and their families.
    The Journal of pediatrics, 1963, Volume: 62

    Topics: Cystic Fibrosis; Electrolytes; Fludrocortisone; Humans; Sweat

1963
[Aldosterone blocks the sweat test in mucoviscidosis patients].
    Bollettino della Societa italiana di biologia sperimentale, 1962, Sep-15, Volume: 38

    Topics: Aldosterone; Cystic Fibrosis; Humans; Sweat

1962
[Determination of sweat electrolytes].
    Duodecim; laaketieteellinen aikakauskirja, 1963, Volume: 79

    Topics: Asthma; Chlorides; Cystic Fibrosis; Deficiency Diseases; Electrolytes; Humans; Lung Diseases; Sweat

1963
Electrical conductivity of sweat: a simple, home-assembled apparatus.
    Pediatrics, 1963, Volume: 32

    Topics: Cystic Fibrosis; Electric Conductivity; Humans; Sweat

1963
Studies of salt excretion in sweat. Relationships between rate, conductivity, and electrolyte composition of sweat from patients with cystic fibrosis and from control subjects.
    The Journal of pediatrics, 1963, Volume: 62

    Topics: Cystic Fibrosis; Electrolytes; Humans; Potassium; Sodium Chloride; Sweat; Sweating

1963
[Critical study of the sweat test for detection of mucoviscidosis heterozygotes].
    Schweizerische medizinische Wochenschrift, 1962, Nov-24, Volume: 92

    Topics: Cystic Fibrosis; Heterozygote; Humans; Sweat

1962
Electrical conductivity of sweat: a simple diagnostic test in children.
    Pediatrics, 1963, Volume: 32

    Topics: Child; Cystic Fibrosis; Diagnostic Tests, Routine; Electric Conductivity; Humans; Sweat

1963
[Electrolyte concentrations in the sweat of newborn infants].
    Neue osterreichische Zeitschrift fur Kinderheilkunde, 1961, Volume: 6

    Topics: Cystic Fibrosis; Electrolysis; Electrolytes; Humans; Infant; Infant, Newborn; Sweat

1961
The excretion of Na-22 in sweat.
    Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 1963, Volume: 4

    Topics: Biological Transport; Cystic Fibrosis; Lung Diseases; Sodium; Sweat

1963
[Mucoviscidosis and chronic broncho-pulmonary diseases. Results of the sweat test performed on 55 patients].
    Concours medical, 1962, Oct-20, Volume: 84

    Topics: Bronchial Diseases; Chronic Disease; Cystic Fibrosis; Humans; Lung Diseases; Sweat; Sweating

1962
Sweat chloride in patients with chronic bronchial disease and its relation to mucoviscidosis (cystic fibrosis).
    The American review of respiratory disease, 1963, Volume: 87

    Topics: Bronchial Diseases; Bronchitis; Chlorides; Chronic Disease; Cystic Fibrosis; Humans; Sweat

1963
[Mucoviscidosis of the adult. Clinico-biologic findings].
    Bollettino della Societa italiana di biologia sperimentale, 1962, Sep-15, Volume: 38

    Topics: Adult; Biological Products; Bronchiectasis; Bronchitis; Cystic Fibrosis; Diabetes Mellitus; Humans;

1962
[Sweat levels of K in mucoviscidosis of the adult].
    Bollettino della Societa italiana di biologia sperimentale, 1962, Sep-15, Volume: 38

    Topics: Adult; Bronchitis; Cystic Fibrosis; Diabetes Mellitus; Humans; Peptic Ulcer; Potassium; Sweat

1962
[ON METHODS OF SWEAT PRODUCTION FOR THE DIAGNOSIS OF MUCOVISCIDOSIS].
    Monatsschrift fur Kinderheilkunde, 1963, Volume: 111

    Topics: Baths; Child; Cystic Fibrosis; Humans; Iontophoresis; Pilocarpine; Sweat; Sweating

1963
THE MECHANISM OF ECCRINE SWEAT-GLAND FUNCTION IN NORMAL SUBJECTS AND IN PATIENTS WITH MUCOVISCOIDOSIS.
    Dermatologica, 1963, Volume: 127

    Topics: Cystic Fibrosis; Eccrine Glands; Electrolytes; Histocytochemistry; Humans; Physiology; Sweat; Sweat

1963
[ON THE ASSOCIATION OF A CHRONIC BRONCHOPNEUMOPATHY, PANCREATIC INSUFFICIENCY AND A NORMAL SWEAT TEST. INTERPRETATIVE CONSIDERATIONS].
    Minerva pediatrica, 1963, Jun-30, Volume: 15

    Topics: Bronchiectasis; Bronchitis; Bronchopneumonia; Child; Cystic Fibrosis; Diagnosis; Electrolytes; Exocr

1963
ELEVATED SWEAT SODIUM AND CHLORIDE IN ADULT WITHOUT CYSTIC FIBROSIS.
    Archives of internal medicine, 1963, Volume: 112

    Topics: Adolescent; Adult; Chlorides; Cystic Fibrosis; Diagnosis, Differential; Genetics, Medical; Heat Exha

1963
[MUCOVISCIDOSIS IN AN INTERNAL DISEASE CLINIC].
    Polskie Archiwum Medycyny Wewnetrznej, 1963, Volume: 33

    Topics: Cystic Fibrosis; Humans; Photometry; Sodium Chloride; Sweat

1963
SALT EXCRETION IN SWEAT IN CYSTIC FIBROSIS.
    JAMA, 1963, Dec-28, Volume: 186

    Topics: Biological Transport; Cystic Fibrosis; Diagnosis; Humans; Sodium Chloride; Sweat

1963
CYSTIC FIBROSIS OF THE PANCREAS. DIAGNOSIS BY APPLICATION OF A SODIUM ELECTRODE TO THE SKIN.
    The New England journal of medicine, 1963, Dec-19, Volume: 269

    Topics: Cystic Fibrosis; Electrodes; Electrodiagnosis; Humans; Skin; Sodium; Sodium, Dietary; Sweat; Sweatin

1963
STUDY OF THE GALVANIC SKIN RESPONSE IN CYSTIC FIBROSIS.
    Archives of dermatology, 1963, Volume: 88

    Topics: Adolescent; Child; Chlorides; Cystic Fibrosis; Galvanic Skin Response; Humans; Infant; Potassium; So

1963
SWEAT SODIUM CONTENT AND FLOW RATE IN CYSTIC FIBROSIS OF THE PANCREAS.
    Journal of applied physiology, 1963, Volume: 18

    Topics: Adolescent; Child; Cystic Fibrosis; Humans; Injections; Ions; Iontophoresis; Metabolism; Methacholin

1963
EVALUATION OF THE SWEAT CHLORIDE ASSAY IN ADULTS: USE OF PILOCARPINE IONTOPHORESIS.
    The American journal of the medical sciences, 1963, Volume: 246

    Topics: Adolescent; Adult; Aging; Child; Chlorides; Cystic Fibrosis; Humans; Infant; Iontophoresis; Lung Dis

1963
MUCOVISCIDOSIS AND CHRONIC LUNG DISEASE IN ADULTS.
    The American review of respiratory disease, 1963, Volume: 88

    Topics: Adult; Bronchiectasis; Bronchitis; Chlorides; Cystic Fibrosis; Genetics; Humans; Lung Diseases; Sodi

1963
[STUDY OF THE SWEAT TEST IN DIABETIC CHILDREN].
    Le Diabete, 1963, Volume: 11

    Topics: Adolescent; Child; Cystic Fibrosis; Diabetes Mellitus; Diabetes Mellitus, Type 1; Diagnosis; Humans;

1963
[THE PROBLEM OF MUCOVISCIDOSIS IN ADULTS BASED ON SWEAT ELECTROLYTE TESTS].
    Orvosi hetilap, 1963, Oct-13, Volume: 104

    Topics: Adult; Bronchitis; Colitis; Colitis, Ulcerative; Cystic Fibrosis; Diabetes Mellitus; Duodenal Ulcer;

1963
[MUCOVISCIDOSIS IN ADULTS, A RARE DISEASE].
    Schweizerische medizinische Wochenschrift, 1963, Oct-26, Volume: 93

    Topics: Adult; Anions; Chlorides; Cystic Fibrosis; Humans; Ions; Rare Diseases; Sodium; Sodium, Dietary; Swe

1963
[MUCOVISCIDOSIS].
    Concours medical, 1963, Dec-28, Volume: 85

    Topics: Adolescent; Anti-Bacterial Agents; Antibiotics, Antitubercular; Blood Protein Disorders; Bronchopneu

1963
THE EFFECT OF ACETAZOLAMIDE ON SWEAT ELECTROLYTES IN MUCOVISCIDOSIS.
    Metabolism: clinical and experimental, 1963, Volume: 12

    Topics: Acetazolamide; Carbonic Anhydrases; Child; Chlorides; Cystic Fibrosis; Electrolytes; Humans; Iontoph

1963
[A CASE OF PURE BRONCHOPULMONARY MUCOVISCIDOSIS IN AN 11-YEAR-OLD BOY].
    Minerva pediatrica, 1963, Oct-06, Volume: 15

    Topics: Bronchiectasis; Bronchography; Bronchopneumonia; Bronchospirometry; Cardiac Catheterization; Cystic

1963
[STATISTICAL STUDY OF RESULTS OF THE SWEAT TEST IN 595 ADULTS (200 CONTROLS, 190 BRONCHO-EMPHYSEMA PATIENTS, 160 DIABETICS, 45 SPONTANEOUS PNEUMOTHORAX PATIENTS)].
    La Presse medicale, 1963, Dec-07, Volume: 71

    Topics: Bronchitis; Cystic Fibrosis; Diabetes Mellitus; Emphysema; Pneumothorax; Pulmonary Emphysema; Sweat;

1963
[A RECENT CASE OF LYMPHOCYTO-PHTHISIS WITH HYPOGAMMAGLOBULINEMIA, HAVING PREDOMINANTLY RESPIRATORY MANIFESTATIONS].
    Pediatrie, 1963, Volume: 18

    Topics: Agammaglobulinemia; Cystic Fibrosis; Dermatomycoses; Diagnosis, Differential; Hematology; Humans; Ly

1963
ALBUMIN IN THE MECONIUM OF INFANTS WITH CYSTIC FIBROSIS: A PRELIMINARY REPORT.
    Pediatrics, 1964, Volume: 33

    Topics: Albumins; Chlorides; Cystic Fibrosis; Diagnosis; Humans; Immunoelectrophoresis; Infant; Infant, Newb

1964
[MUCOVISCIDOSIS AND CHRONIC LUNG DISEASES IN ADULTS].
    Polski tygodnik lekarski (Warsaw, Poland : 1960), 1963, Dec-02, Volume: 18

    Topics: Chlorides; Chronic Disease; Cystic Fibrosis; Humans; Lung Diseases; Sweat

1963
[DETERMINATION OF SODIUM AND CHLORIDE IN THE SWEAT OF ADULT CHRONIC BRONCHITICS].
    La Presse medicale, 1964, Mar-14, Volume: 72

    Topics: Adult; Bronchitis; Chlorides; Colorimetry; Cystic Fibrosis; Geriatrics; Humans; Ions; Photometry; So

1964
[CHRONIC BRONCHITIS AND MUCOVISCIDOSIS].
    Bulletins et memoires de la Societe medicale des hopitaux de Paris, 1964, Jan-10, Volume: 115

    Topics: Adolescent; Bronchitis; Bronchitis, Chronic; Cystic Fibrosis; Diagnosis; Geriatrics; Humans; Sweat

1964
[MUCOVISCIDOSIS, WITH SPECIAL REFERENCE TO 3 CLINICAL CASES].
    Medicina interna, 1964, Volume: 16

    Topics: Adolescent; Bronchitis; Cystic Fibrosis; Electrolytes; Humans; Lung Neoplasms; Pulmonary Atelectasis

1964
[EVALUATION OF THE SHWACHMAN-GAHM TEST IN VARIOUS CHILDHOOD DISEASES].
    Gyermekgyogyaszat : az Orvosegeszsegugyi Szakszervezet Gyermekorvos Szakcsoportjanak folyoirata = Pediatriia, 1964, Volume: 15

    Topics: Adolescent; Asthma; Biomedical Research; Child; Chlorides; Clinical Laboratory Techniques; Cystic Fi

1964
[IMMUNOELECTROPHORESIS OF PROTEINS IN SWEAT AND ON THE PROBLEM OF ITS USE IN THE LABORATORY DIAGNOSIS OF MUCOVISCIDOSIS].
    Acta Universitatis Carolinae. Medica, 1964, Volume: 10

    Topics: Antigens; Clinical Laboratory Techniques; Cystic Fibrosis; Humans; Immunoelectrophoresis; Pilocarpin

1964
ELECTROENCEPHALOGRAMS OF PATIENTS WITH CYSTIC FIBROSIS.
    American journal of diseases of children (1960), 1964, Volume: 108

    Topics: Adolescent; Black People; Blood Chemical Analysis; Blood Gas Analysis; Child; Chlorides; Cystic Fibr

1964
EFFECT OF EXPERIMENTAL SALT DEPLETION AND ALDOSTERONE LOAD ON SODIUM AND CHLORIDE CONCENTRATION IN THE SWEAT OF PATIENTS WITH CYSTIC FIBROSIS OF THE PANCREAS AND OF NORMAL CHILDREN.
    Archives of disease in childhood, 1964, Volume: 39

    Topics: Adolescent; Aldosterone; Biochemical Phenomena; Biochemistry; Body Weight; Child; Chlorides; Chlorth

1964
[SIGNIFICANCE AND LIMITS OF THE SWEAT TEST AS AN ORIENTATION TO THE DIAGNOSIS OF MUCOVISCIDOSIS. POSSIBILITY OF A SEMIQUANTITATIVE EVALUATION OF CHLORIDES IN SWEAT WITH KNIGHTS' TEST].
    La Pediatria, 1963, Dec-16, Volume: 71

    Topics: Biomedical Research; Child; Chlorides; Cystic Fibrosis; Diagnosis; Genetics, Medical; Humans; Infant

1963
[BRONCHOPULMONARY MUCOVISCIDOSIS IN THE CHILD].
    La Semana medica, 1964, Apr-06, Volume: 124

    Topics: Aerosols; Anti-Bacterial Agents; Antibiotics, Antitubercular; Bronchopneumonia; Child; Cystic Fibros

1964
SPECTROSCOPIC ANALYSIS OF TISSUES FROM PATIENTS WITH CYSTIC FIBROSIS AND CONTROLS.
    Nature, 1964, May-02, Volume: 202

    Topics: Aluminum; Blood; Boron; Cobalt; Copper; Cystic Fibrosis; Duodenum; Exudates and Transudates; Hair; H

1964
[MUCOVISCIDOSIS AND OTORHINOLARYNGOLOGICAL MANIFESTATIONS].
    L'Oto-rino-laringologia italiana, 1963, Volume: 32

    Topics: Child; Cystic Fibrosis; Diagnosis; Electrolytes; Humans; Nasal Mucosa; Nasal Polyps; Paranasal Sinus

1963
[A CASE OF PULMONARY MUCOVISCIDOSIS IN AN ADULT].
    Gruzlica (Warsaw, Poland : 1926), 1964, Volume: 32

    Topics: Adult; Cystic Fibrosis; Diagnosis, Differential; Humans; Lung Diseases; Sweat; Tuberculosis; Tubercu

1964
[MUCOVISCIDOSIS OF THE ADULT: A NOT TOO RARE DISEASE].
    Il Policlinico. Sezione pratica, 1964, Sep-21, Volume: 71

    Topics: Adult; Bronchitis; Cystic Fibrosis; Diagnosis; Duodenal Ulcer; Humans; Radiography, Thoracic; Rare D

1964
A NEW METHOD OF IONTOPHORESIS AND ANALYSIS OF SWEAT ELECTROLYTE.
    The American review of respiratory disease, 1964, Volume: 90

    Topics: Chemistry Techniques, Analytical; Cystic Fibrosis; Electrolytes; Genetics, Medical; Humans; Iontopho

1964
SWEAT CHLORIDE CONCENTRATION; A COMPARATIVE STUDY IN CHILDREN WITH BRONCHIAL ASTHMA AND WITH CYSTIC FIBROSIS.
    American journal of diseases of children (1960), 1965, Volume: 109

    Topics: Adolescent; Asthma; Biomedical Research; Black People; Chemistry Techniques, Analytical; Child; Chlo

1965
THE ELECTROLYTE ABNORMALITY IN CYSTIC FIBROSIS.
    Pediatric clinics of North America, 1964, Volume: 11

    Topics: Acidosis; Anti-Bacterial Agents; Bronchi; Bronchiectasis; Child; Chlorides; Cystic Fibrosis; Drug Th

1964
SWEAT CHLORIDE BY IONTOPHORESIS.
    Southern medical journal, 1964, Volume: 57

    Topics: Chlorides; Clinical Laboratory Techniques; Cystic Fibrosis; Humans; Infant; Iontophoresis; Pilocarpi

1964
CYSTIC FIBROSIS IN NEGRO CHILDREN: RESULTS OF A SEARCH.
    Clinical pediatrics, 1964, Volume: 3

    Topics: Adolescent; Black People; Child; Chlorides; Cystic Fibrosis; District of Columbia; Humans; Infant; I

1964
STUDIES IN CYSTIC FIBROSIS: ANALYSIS OF NAIL CLIPPINGS FOR SODIUM AND POTASSIUM.
    The New England journal of medicine, 1965, Mar-11, Volume: 272

    Topics: Cystic Fibrosis; Diagnosis; Genetics, Medical; Humans; Ions; Nails; Potassium; Sodium; Sodium, Dieta

1965
A STANDARD PROCEDURE FOR MEASURING CONDUCTIVITY OF SWEAT AS A DIAGNOSTIC TEST FOR CYSTIC FIBROSIS.
    The Journal of pediatrics, 1965, Volume: 66

    Topics: Adolescent; Child; Cystic Fibrosis; Diagnosis; Diagnostic Tests, Routine; Humans; Infant; Sweat

1965
CONTINUOUS RECORDING OF SWEATING BY RESISTANCE HYGROMETRY.
    Pediatrics, 1965, Volume: 35

    Topics: Arrhythmias, Cardiac; Biochemical Phenomena; Biochemistry; Child; Chlorides; Cystic Fibrosis; Electr

1965
[RESULTS OF MASS TESTS FOR MINIMAL OR RESIDUAL CASES OF MUCOVISCIDOSIS].
    Pediatria polska, 1964, Volume: 39

    Topics: Biometry; Child; Cystic Fibrosis; Humans; Infant; Mass Screening; Poland; Statistics as Topic; Sweat

1964
A NEW METHOD OF IONTOPHORESIS AND ANALYSIS OF SWEAT ELECTROLYTE: A SURVEY OF SEVERAL KINDRED WITH CYSTIC FIBROSIS.
    Southern medical journal, 1965, Volume: 58

    Topics: Child; Cystic Fibrosis; Data Collection; Electrolytes; Genetics, Medical; Geriatrics; Humans; Iontop

1965
SWEAT CHLORIDES IN SALT-DEPRIVED CYSTIC FIBROSIS HETEROZYGOTES.
    Canadian Medical Association journal, 1965, Apr-24, Volume: 92

    Topics: Aldosterone; Carrier State; Child; Chlorides; Cystic Fibrosis; Diagnosis; Diet, Sodium-Restricted; H

1965
[THE IMPRINT TEST IN SCREENING FOR MUCOVISCIDOSIS].
    Ceskoslovenska pediatrie, 1965, Volume: 20

    Topics: Chlorides; Cystic Fibrosis; Diagnosis, Differential; Humans; Sweat

1965
STUDIES OF SWEAT ELECTROLYTES IN JAPANESE CHILDREN.
    Acta paediatrica Japonica : Overseas edition, 1964, Volume: 26

    Topics: Adolescent; Asian People; Child; Cystic Fibrosis; Electrolytes; Humans; Infant; Infant, Newborn; Jap

1964
THE SILVER ELECTRODE METHOD FOR RAPID ANALYSIS OF SWEAT CHLORIDE.
    Pediatrics, 1965, Volume: 36

    Topics: Chlorides; Cystic Fibrosis; Diagnosis; Electrodes; Humans; Silver; Sweat

1965
[GENE CARRIERS OF MUCOVISICIDOSIS AND THE DETERMINATION OF SUDORAL CHLORIDE. (PRELIMINARY RESULTS)].
    Pathologie et biologie, 1965, Volume: 13

    Topics: Chlorides; Cystic Fibrosis; Genetics, Medical; Heterozygote; Humans; Infant; Sweat

1965
[SODIUM AND POTASSIUM DETERMINATION IN THE SWEAT OF CHILDREN WITH CHRONIC OR RECURRENT LUNG INFECTIONS].
    Ugeskrift for laeger, 1965, Mar-18, Volume: 127

    Topics: Child; Cystic Fibrosis; Humans; Infant; Infant, Newborn; Potassium; Respiratory Tract Infections; So

1965
[A CASE OF MUCOVISCIDOSIS IN AN ADULT TREATED AS PULMONARY TUBERCULOSIS].
    Gruzlica (Warsaw, Poland : 1926), 1965, Volume: 33

    Topics: Adult; Cystic Fibrosis; Diagnosis, Differential; Humans; Sweat; Tuberculosis; Tuberculosis, Pulmonar

1965
[SODIUM AND POTASSIUM CONTENT IN THE SWEAT OF PATIENTS WITH GASTRIC ULCER AND CHRONIC BRONCHITIS].
    Ugeskrift for laeger, 1965, Mar-18, Volume: 127

    Topics: Adolescent; Bronchitis; Bronchitis, Chronic; Child; Cystic Fibrosis; Geriatrics; Humans; Peptic Ulce

1965
[A simplified "sweat test"].
    Harefuah, 1959, Aug-16, Volume: 57

    Topics: Cystic Fibrosis; Humans; Sweat; Sweating

1959
Consideration of cystic fibrosis in adults, with a study of sweat electrolyte values.
    Journal of the American Medical Association, 1959, Sep-05, Volume: 171

    Topics: Adult; Cystic Fibrosis; Electrolytes; Humans; Sweat

1959
[Cystic fibrosis in adults. Study of electrolyte values of sweat].
    Medicina panamericana, 1960, Apr-15, Volume: 14

    Topics: Adult; Cystic Fibrosis; Electrolytes; Humans; Sweat

1960
[Shwachmann's test in mucoviscidosis and in other diseases].
    Ceskoslovenska pediatrie, 1960, Feb-05, Volume: 15

    Topics: Chlorides; Cystic Fibrosis; Humans; Sweat

1960
Fibrocystic disease and sweat.
    Lancet (London, England), 1961, May-13, Volume: 1, Issue:7185

    Topics: Cystic Fibrosis; Humans; Pancreas; Sweat

1961
[Experiences with the fingerprint test by Shwachman and Gahm in adults with chronic emphysema bronchitis and ulcer with reference to mucoviscidosis].
    Klinische Wochenschrift, 1962, Mar-15, Volume: 40

    Topics: Bronchitis; Bronchitis, Chronic; Cystic Fibrosis; Emphysema; Lung; Peptic Ulcer; Pulmonary Emphysema

1962
[Sweat electrolyte values in adults and their relation to mucoviscoidosis].
    Klinische Wochenschrift, 1961, Nov-15, Volume: 39

    Topics: Cystic Fibrosis; Electrolytes; Humans; Sweat

1961
[Diabetes and mucoviscidosis].
    Journees annuelles de diabetologie de l'Hotel-Dieu, 1962, Volume: 3

    Topics: Chlorides; Cystic Fibrosis; Diabetes Mellitus; Humans; Sweat

1962
Effect of age, sex, and cystic fibrosis on the sodium and potassium content of human sweat.
    Pediatrics, 1962, Volume: 30

    Topics: Aging; Cystic Fibrosis; Humans; Potassium; Sex; Sodium; Sodium, Dietary; Sweat

1962
[Role of the sweat test in diseases in children with special reference to mucoviscidosis].
    Pediatria polska, 1962, Volume: 37

    Topics: Child; Cystic Fibrosis; Humans; Sweat

1962
Effect of sodium intake upon sweat electrolyte concentrations in children.
    The Journal of pediatrics, 1962, Volume: 61

    Topics: Child; Cystic Fibrosis; Diet; Electrolytes; Humans; Nutrition Assessment; Nutritional Status; Sodium

1962
[Determination of excessive chlorine excretion by the skin in pancreatic fibrosis].
    Rontgen- und Laboratoriumspraxis, 1962, Volume: 15

    Topics: Body Fluids; Chlorine; Cystic Fibrosis; Humans; Pancreatic Diseases; Skin; Sweat

1962
[The sweat test with intradermal injection of pilocarpine nitrate].
    El Dia medico, 1961, Volume: 33(Special)

    Topics: Cystic Fibrosis; Humans; Injections, Intradermal; Pilocarpine; Sweat; Sweating

1961
Serum CA 19-9 levels as a diagnostic marker in cystic fibrosis patients with borderline sweat tests.
    Clinical and experimental medicine, 2003, Volume: 3, Issue:2

    Topics: Adolescent; Adult; CA-19-9 Antigen; Child; Cystic Fibrosis; Cystic Fibrosis Transmembrane Conductanc

2003
Validation of a disease-specific measure of health-related quality of life for children with cystic fibrosis.
    Journal of pediatric psychology, 2003, Volume: 28, Issue:8

    Topics: Adolescent; Child; Cystic Fibrosis; Depressive Disorder; Female; Humans; Male; Predictive Value of T

2003
Validation of a disease-specific measure of health-related quality of life for children with cystic fibrosis.
    Journal of pediatric psychology, 2003, Volume: 28, Issue:8

    Topics: Adolescent; Child; Cystic Fibrosis; Depressive Disorder; Female; Humans; Male; Predictive Value of T

2003
Validation of a disease-specific measure of health-related quality of life for children with cystic fibrosis.
    Journal of pediatric psychology, 2003, Volume: 28, Issue:8

    Topics: Adolescent; Child; Cystic Fibrosis; Depressive Disorder; Female; Humans; Male; Predictive Value of T

2003
Validation of a disease-specific measure of health-related quality of life for children with cystic fibrosis.
    Journal of pediatric psychology, 2003, Volume: 28, Issue:8

    Topics: Adolescent; Child; Cystic Fibrosis; Depressive Disorder; Female; Humans; Male; Predictive Value of T

2003
Validation of a disease-specific measure of health-related quality of life for children with cystic fibrosis.
    Journal of pediatric psychology, 2003, Volume: 28, Issue:8

    Topics: Adolescent; Child; Cystic Fibrosis; Depressive Disorder; Female; Humans; Male; Predictive Value of T

2003
Validation of a disease-specific measure of health-related quality of life for children with cystic fibrosis.
    Journal of pediatric psychology, 2003, Volume: 28, Issue:8

    Topics: Adolescent; Child; Cystic Fibrosis; Depressive Disorder; Female; Humans; Male; Predictive Value of T

2003
Validation of a disease-specific measure of health-related quality of life for children with cystic fibrosis.
    Journal of pediatric psychology, 2003, Volume: 28, Issue:8

    Topics: Adolescent; Child; Cystic Fibrosis; Depressive Disorder; Female; Humans; Male; Predictive Value of T

2003
Validation of a disease-specific measure of health-related quality of life for children with cystic fibrosis.
    Journal of pediatric psychology, 2003, Volume: 28, Issue:8

    Topics: Adolescent; Child; Cystic Fibrosis; Depressive Disorder; Female; Humans; Male; Predictive Value of T

2003
Validation of a disease-specific measure of health-related quality of life for children with cystic fibrosis.
    Journal of pediatric psychology, 2003, Volume: 28, Issue:8

    Topics: Adolescent; Child; Cystic Fibrosis; Depressive Disorder; Female; Humans; Male; Predictive Value of T

2003
Sweat test results in children with primary protein energy malnutrition.
    Journal of pediatric gastroenterology and nutrition, 2004, Volume: 38, Issue:4

    Topics: Chlorides; Cystic Fibrosis; Humans; Protein-Energy Malnutrition; Sweat

2004
Sweat test results in children with primary protein energy malnutrition.
    Journal of pediatric gastroenterology and nutrition, 2004, Volume: 38, Issue:4

    Topics: Chlorides; Cystic Fibrosis; Diagnosis, Differential; Humans; Prevalence; Protein-Energy Malnutrition

2004
An analysis of communication following newborn screening for cystic fibrosis.
    Health communication, 2004, Volume: 16, Issue:2

    Topics: Adult; Alleles; Communication; Cystic Fibrosis; Female; Genetic Counseling; Genetic Testing; Humans;

2004
Heat wave and acute pancreatitis: very unusual cystic fibrosis presentation.
    Pediatrics, 2004, Volume: 113, Issue:6

    Topics: Acute Disease; Child; Child, Preschool; Chlorides; Cystic Fibrosis; Diagnostic Errors; Exocrine Panc

2004
Mutations in CFTR gene and clinical correlation in Argentine patients with congenital bilateral absence of the vas deferens.
    Medicina, 2004, Volume: 64, Issue:3

    Topics: Adult; Argentina; Cystic Fibrosis; Cystic Fibrosis Transmembrane Conductance Regulator; Female; Gene

2004
Relation of sweat chloride concentration to severity of lung disease in cystic fibrosis.
    Pediatric pulmonology, 2004, Volume: 38, Issue:3

    Topics: Adolescent; Adult; Child; Chlorides; Cystic Fibrosis; Female; Humans; Male; Severity of Illness Inde

2004
Sweat testing in newborns positive to neonatal screening for cystic fibrosis.
    Archives of disease in childhood. Fetal and neonatal edition, 2004, Volume: 89, Issue:5

    Topics: Aging; Chlorides; Cystic Fibrosis; Female; Follow-Up Studies; Humans; Infant, Newborn; Male; Neonata

2004
Disease severity associated with cystic fibrosis mutations deltaF508 and S549R(T-->G).
    Eastern Mediterranean health journal = La revue de sante de la Mediterranee orientale = al-Majallah al-sihhiyah li-sharq al-mutawassit, 2001, Volume: 7, Issue:6

    Topics: Amino Acid Substitution; Arabs; Child; Child, Preschool; Chlorides; Cystic Fibrosis; Cystic Fibrosis

2001
CF or not CF? That is the question.
    Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society, 2002, Volume: 1, Issue:1

    Topics: Adolescent; Adult; Child; Child, Preschool; Cystic Fibrosis; Cystic Fibrosis Transmembrane Conductan

2002
Sweat conductivity and chloride titration for cystic fibrosis diagnosis in 3834 subjects.
    Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society, 2003, Volume: 2, Issue:1

    Topics: Adolescent; Adult; Child; Child, Preschool; Chlorides; Cystic Fibrosis; Electric Conductivity; Femal

2003
Diagnosis of cystic fibrosis in adults with diffuse bronchiectasis.
    Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society, 2004, Volume: 3, Issue:1

    Topics: Adolescent; Adult; Bronchiectasis; Chlorides; Cohort Studies; Cystic Fibrosis; Cystic Fibrosis Trans

2004
Sweat conductivity for the diagnosis of cystic fibrosis.
    Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society, 2004, Volume: 3, Issue:3

    Topics: Adolescent; Adult; Child; Child, Preschool; Cystic Fibrosis; Electric Conductivity; Humans; Infant;

2004
Clinical manifestations of cystic fibrosis among patients with diagnosis in adulthood.
    Chest, 2004, Volume: 126, Issue:4

    Topics: Adult; Cystic Fibrosis; DNA Mutational Analysis; Female; Forced Expiratory Volume; Humans; Male; Ret

2004
Clinical problem-solving. Unfashionably late.
    The New England journal of medicine, 2005, Jan-06, Volume: 352, Issue:1

    Topics: Adolescent; Biopsy; Burkholderia cepacia; Burkholderia Infections; Chest Pain; Chlorides; Cough; Cys

2005
Misdiagnosing cystic fibrosis in the era of gene analysis: case reports.
    Pediatric pulmonology, 2005, Volume: 39, Issue:4

    Topics: Amino Acid Substitution; Child; Cystic Fibrosis; Female; Humans; Infant, Newborn; Mutation; Penetran

2005
Testing diagnostic tests: why size matters.
    The Journal of pediatrics, 2005, Volume: 146, Issue:2

    Topics: Chlorides; Cystic Fibrosis; Diagnostic Tests, Routine; Humans; Reproducibility of Results; Sample Si

2005
Cystic fibrosis in Korean children:a case report identified by a quantitative pilocarpine iontophoresis sweat test and genetic analysis.
    Journal of Korean medical science, 2005, Volume: 20, Issue:1

    Topics: Blood Pressure; Bronchiectasis; Child; Cough; Cystic Fibrosis; Cystic Fibrosis Transmembrane Conduct

2005
Sweat-testing in preterm and full-term infants less than 6 weeks of age.
    Pediatric pulmonology, 2005, Volume: 40, Issue:1

    Topics: Black or African American; Body Weight; Chlorides; Cystic Fibrosis; Female; Gestational Age; Humans;

2005
Cystic fibrosis.
    The New England journal of medicine, 2005, May-12, Volume: 352, Issue:19

    Topics: Absorption; Body Fluids; Cystic Fibrosis; Cystic Fibrosis Transmembrane Conductance Regulator; Human

2005
Cystic fibrosis.
    The New England journal of medicine, 2005, May-12, Volume: 352, Issue:19

    Topics: Absorption; Body Fluids; Cystic Fibrosis; Cystic Fibrosis Transmembrane Conductance Regulator; Human

2005
Cystic fibrosis.
    The New England journal of medicine, 2005, May-12, Volume: 352, Issue:19

    Topics: Absorption; Body Fluids; Cystic Fibrosis; Cystic Fibrosis Transmembrane Conductance Regulator; Human

2005
Cystic fibrosis.
    The New England journal of medicine, 2005, May-12, Volume: 352, Issue:19

    Topics: Absorption; Body Fluids; Cystic Fibrosis; Cystic Fibrosis Transmembrane Conductance Regulator; Human

2005
Psychosocial risk associated with newborn screening for cystic fibrosis: parents' experience while awaiting the sweat-test appointment.
    Pediatrics, 2005, Volume: 115, Issue:6

    Topics: Adaptation, Psychological; Adult; Anxiety; Appointments and Schedules; Attitude to Health; Chlorides

2005
A CFTR mutation (D1152H) in a family with mild lung disease and normal sweat chlorides.
    Clinical genetics, 2005, Volume: 68, Issue:1

    Topics: Aged; Chlorides; Cystic Fibrosis; Cystic Fibrosis Transmembrane Conductance Regulator; Family; Femal

2005
Sweat collection for testing in Canadian Cystic Fibrosis Centers, is it optimal?
    Clinical biochemistry, 2005, Volume: 38, Issue:10

    Topics: Adult; Canada; Child; Clinical Chemistry Tests; Cystic Fibrosis; Diagnostic Services; Humans; Infant

2005
The sweat test: effect of elution time on chloride and sodium concentrations.
    Annals of clinical biochemistry, 2005, Volume: 42, Issue:Pt 5

    Topics: Chlorides; Cystic Fibrosis; Guidelines as Topic; Humans; Quality Control; Sodium; Sweat

2005
Sweat testing infants detected by cystic fibrosis newborn screening.
    The Journal of pediatrics, 2005, Volume: 147, Issue:3 Suppl

    Topics: Age Factors; Algorithms; Chlorides; Cystic Fibrosis; Decision Trees; DNA Mutational Analysis; Early

2005
Newborn screening for cystic fibrosis in Wisconsin: nine-year experience with routine trypsinogen/DNA testing.
    The Journal of pediatrics, 2005, Volume: 147, Issue:3 Suppl

    Topics: Age Factors; Chlorides; Cystic Fibrosis; Cystic Fibrosis Transmembrane Conductance Regulator; DNA Mu

2005
Diagnostic dilemmas resulting from the immunoreactive trypsinogen/DNA cystic fibrosis newborn screening algorithm.
    The Journal of pediatrics, 2005, Volume: 147, Issue:3 Suppl

    Topics: Algorithms; Chlorides; Clinical Protocols; Cystic Fibrosis; Cystic Fibrosis Transmembrane Conductanc

2005
Two-tiered immunoreactive trypsinogen-based newborn screening for cystic fibrosis in Colorado: screening efficacy and diagnostic outcomes.
    The Journal of pediatrics, 2005, Volume: 147, Issue:3 Suppl

    Topics: Chlorides; Colorado; Cystic Fibrosis; Cystic Fibrosis Transmembrane Conductance Regulator; DNA Mutat

2005
Mild cystic fibrosis revealed by persistent hyponatremia during the French 2003 heat wave, associated with the S1455X C-terminus CFTR mutation.
    Clinical genetics, 2005, Volume: 68, Issue:6

    Topics: Blood Chemical Analysis; Child; Chlorides; Codon, Nonsense; Cystic Fibrosis; Cystic Fibrosis Transme

2005
Sweat testing for cystic fibrosis: How good is your laboratory?
    Journal of paediatrics and child health, 2006, Volume: 42, Issue:4

    Topics: Australia; Clinical Chemistry Tests; Cystic Fibrosis; Humans; New Zealand; Surveys and Questionnaire

2006
Sweat testing for cystic fibrosis: A review of New Zealand laboratories.
    Journal of paediatrics and child health, 2006, Volume: 42, Issue:4

    Topics: Chemistry, Clinical; Chlorides; Clinical Chemistry Tests; Cystic Fibrosis; Humans; Infant; Infant, N

2006
Newborn screening for cystic fibrosis.
    Southern medical journal, 2006, Volume: 99, Issue:4

    Topics: Chlorides; Cystic Fibrosis; DNA Mutational Analysis; Genetic Testing; Humans; Infant, Newborn; Neona

2006
Cystic fibrosis in 65- and 67-year-old siblings. Clinical feature and nasal potential difference measurement in patients with genotypes F508del and 2789+5G-->A.
    Respiration; international review of thoracic diseases, 2006, Volume: 73, Issue:5

    Topics: Aged; Amiloride; Chlorides; Cystic Fibrosis; Cystic Fibrosis Transmembrane Conductance Regulator; Ge

2006
Diagnosing CF: sweat, blood and years.
    Thorax, 2006, Volume: 61, Issue:7

    Topics: Algorithms; Chlorides; Cystic Fibrosis; Cystic Fibrosis Transmembrane Conductance Regulator; Humans;

2006
Cystic fibrosis detection in high-risk Egyptian children and CFTR mutation analysis.
    Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society, 2007, Volume: 6, Issue:2

    Topics: Child, Preschool; Chlorides; Cystic Fibrosis; Cystic Fibrosis Transmembrane Conductance Regulator; D

2007
Mutations in the cystic fibrosis transmembrane regulator gene and in vivo transepithelial potentials.
    American journal of respiratory and critical care medicine, 2006, Oct-01, Volume: 174, Issue:7

    Topics: Alleles; Amiloride; Chlorides; Cystic Fibrosis; Cystic Fibrosis Transmembrane Conductance Regulator;

2006
Newborn screening for cystic fibrosis: parents' preferences regarding counseling at the time of infants' sweat test.
    Journal of genetic counseling, 2006, Volume: 15, Issue:4

    Topics: Adaptation, Psychological; Adolescent; Adult; Choice Behavior; Consumer Behavior; Cystic Fibrosis; C

2006
The CF-CIRC study: a French collaborative study to assess the accuracy of cystic fibrosis diagnosis in neonatal screening.
    BMC pediatrics, 2006, Oct-03, Volume: 6

    Topics: Amiloride; Catheterization; Child, Preschool; Chlorides; Cystic Fibrosis; Cystic Fibrosis Transmembr

2006
The evaluation of a novel conductometric device for the diagnosis of cystic fibrosis.
    Annals of clinical biochemistry, 2006, Volume: 43, Issue:Pt 5

    Topics: Adolescent; Adult; Case-Control Studies; Child; Child, Preschool; Chlorides; Cystic Fibrosis; Diagno

2006
Prospective analysis of cystic fibrosis transmembrane regulator mutations in adults with bronchiectasis or pulmonary nontuberculous mycobacterial infection.
    Chest, 2006, Volume: 130, Issue:4

    Topics: Adult; Aged; Aged, 80 and over; Body Mass Index; Bronchiectasis; Chloride Channels; Chlorides; Cysti

2006
Genetic and physiologic correlates of longitudinal immunoreactive trypsinogen decline in infants with cystic fibrosis identified through newborn screening.
    The Journal of pediatrics, 2006, Volume: 149, Issue:5

    Topics: Biomarkers; Body Height; Body Weight; Chlorides; Cystic Fibrosis; DNA Mutational Analysis; Fats; Fec

2006
Cystic fibrosis presenting with haematological abnormalities.
    Clinical and laboratory haematology, 2006, Volume: 28, Issue:6

    Topics: Anemia; Bone Marrow Examination; Chlorides; Cystic Fibrosis; Diagnosis, Differential; DNA Mutational

2006
Hyponatremic dehydration as a presentation of cystic fibrosis.
    Pediatric emergency care, 2006, Volume: 22, Issue:11

    Topics: Alkalosis; Chlorides; Cystic Fibrosis; Dehydration; Diagnostic Tests, Routine; Female; Humans; Hypon

2006
N1303K and IVS8-5T, clinical presentation within a family with atypical cystic fibrosis.
    Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society, 2007, Volume: 6, Issue:3

    Topics: Chlorides; Cystic Fibrosis; Cystic Fibrosis Transmembrane Conductance Regulator; DNA Fingerprinting;

2007
The sweat test for the diagnosis of cystic fibrosis--a personal experience of guideline production.
    Annals of clinical biochemistry, 2007, Volume: 44, Issue:Pt 1

    Topics: Cystic Fibrosis; Evidence-Based Medicine; Humans; Infant, Newborn; Neonatal Screening; Practice Guid

2007
Guidelines for implementation of cystic fibrosis newborn screening programs: Cystic Fibrosis Foundation workshop report.
    Pediatrics, 2007, Volume: 119, Issue:2

    Topics: Algorithms; Cystic Fibrosis; Humans; Infant, Newborn; Neonatal Screening; Outcome Assessment, Health

2007
Is early identification of asymptomatic infants with 'mild' CFTR genotypes clinically useful?
    Acta paediatrica (Oslo, Norway : 1992), 2007, Volume: 96, Issue:3

    Topics: Child, Preschool; Chlorides; Cystic Fibrosis; Cystic Fibrosis Transmembrane Conductance Regulator; F

2007
Analysis of CFTR gene mutations and cystic fibrosis incidence in the Ecuadorian population.
    Investigacion clinica, 2007, Volume: 48, Issue:1

    Topics: Adolescent; Adult; Child; Child, Preschool; Cystic Fibrosis; Cystic Fibrosis Transmembrane Conductan

2007
Nanoduct sweat testing for rapid diagnosis in newborns, infants and children with cystic fibrosis.
    European journal of pediatrics, 2008, Volume: 167, Issue:3

    Topics: Child; Child, Preschool; Chlorides; Clinical Chemistry Tests; Cystic Fibrosis; Female; Humans; Infan

2008
Sweat testing in CF.
    Thorax, 2007, Volume: 62, Issue:5

    Topics: Chlorides; Cystic Fibrosis; Humans; Sweat

2007
Sweat testing practice in Swiss hospitals.
    Swiss medical weekly, 2007, Apr-07, Volume: 137, Issue:13-14

    Topics: Adult; Child; Chlorides; Clinical Chemistry Tests; Cystic Fibrosis; Electrolytes; Humans; Osmolar Co

2007
Diagnostic sweat testing: the Cystic Fibrosis Foundation guidelines.
    The Journal of pediatrics, 2007, Volume: 151, Issue:1

    Topics: Cystic Fibrosis; Diagnostic Tests, Routine; Female; Guideline Adherence; Humans; Infant, Newborn; Ma

2007
[Genotype and phenotype of gastrointestinal symptoms analysis in children with cystic fibrosis].
    Polski merkuriusz lekarski : organ Polskiego Towarzystwa Lekarskiego, 2005, Volume: 18, Issue:104

    Topics: Adolescent; Adult; Child; Child, Preschool; Cystic Fibrosis; Cystic Fibrosis Transmembrane Conductan

2005
Acute intestinal obstruction as a presentation of cystic fibrosis in infancy.
    Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society, 2008, Volume: 7, Issue:4

    Topics: Cystic Fibrosis; Diseases in Twins; Female; Humans; Infant; Intestinal Obstruction; Sweat; Syndrome;

2008
Diagnosing cystic fibrosis--asthma and failure to thrive as indications for a sweat test.
    Journal of medicine, 2004, Volume: 35, Issue:1-6

    Topics: Adolescent; Asthma; Child; Child, Preschool; Cystic Fibrosis; Failure to Thrive; Female; Humans; Inf

2004
Diversity of the basic defect of homozygous CFTR mutation genotypes in humans.
    Journal of medical genetics, 2008, Volume: 45, Issue:1

    Topics: Adolescent; Adult; Child; Chlorides; Cystic Fibrosis; Cystic Fibrosis Transmembrane Conductance Regu

2008
The changing face of the exocrine pancreas in cystic fibrosis: the correlation between pancreatic status, pancreatitis and cystic fibrosis genotype.
    European journal of gastroenterology & hepatology, 2008, Volume: 20, Issue:3

    Topics: Acute Disease; Adolescent; Adult; Child; Child, Preschool; Chlorides; Cohort Studies; Cystic Fibrosi

2008
Cystic fibrosis transmembrane conductance regulator ion channel function testing in recurrent acute pancreatitis.
    Journal of clinical gastroenterology, 2008, Volume: 42, Issue:7

    Topics: Acute Disease; Adolescent; Adult; Child; Chloride Channels; Chlorides; Cystic Fibrosis; Cystic Fibro

2008
Total intra-individual variation in sweat sodium and chloride concentrations for the diagnosis of cystic fibrosis.
    Clinica chimica acta; international journal of clinical chemistry, 2008, Jul-17, Volume: 393, Issue:2

    Topics: Adult; Chlorides; Cystic Fibrosis; Female; Humans; Male; Middle Aged; Reproducibility of Results; So

2008
Audit of sweat testing: a first report from Italian Cystic Fibrosis Centres.
    Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society, 2008, Volume: 7, Issue:5

    Topics: Adolescent; Child; Child, Preschool; Cystic Fibrosis; Cystic Fibrosis Transmembrane Conductance Regu

2008
Sweat test in patients with glucose-6-phosphate-1-dehydrogenase deficiency.
    Archives of disease in childhood, 2008, Volume: 93, Issue:10

    Topics: Adult; Child; Child, Preschool; Chlorides; Cystic Fibrosis; Diagnosis, Differential; Electric Conduc

2008
Cystic fibrosis of the pancreas.
    Advances in cardiopulmonary diseases, 1966, Volume: 3

    Topics: Acetylcysteine; Anti-Bacterial Agents; Bronchi; Bronchial Diseases; Child; Cystic Fibrosis; Digestiv

1966
[Apropos of mucoviscidosis in the adult].
    Recenti progressi in medicina, 1966, Volume: 41, Issue:1

    Topics: Adult; Cystic Fibrosis; Electrolytes; Humans; Sweat

1966
The effects of exogenous aldosterone on sweat electrolytes. II. Patients with cystic fibrosis of the pancreas.
    The Journal of pediatrics, 1967, Volume: 70, Issue:3

    Topics: Adolescent; Adult; Aldosterone; Body Weight; Child; Child, Preschool; Cystic Fibrosis; Female; Human

1967
Iontophoretic sweat test for cystic fibrosis: technical details.
    Pediatrics, 1967, Volume: 39, Issue:3

    Topics: Cystic Fibrosis; Iontophoresis; Sweat

1967
Nasal mucosa in pancreatic cystic fibrosis.
    Archives of otolaryngology (Chicago, Ill. : 1960), 1967, Volume: 86, Issue:2

    Topics: Chlorides; Cilia; Culture Techniques; Cystic Fibrosis; Epithelium; Humans; Nasal Mucosa; Nasal Polyp

1967
[Sodium level in the sweat of patients with gastric and duodenal ulcer, and the value of sweat electrolyte determination in detecting of mucoviscidosis in adults].
    Polskie Archiwum Medycyny Wewnetrznej, 1967, Volume: 38, Issue:2

    Topics: Adolescent; Adult; Aged; Cystic Fibrosis; Female; Humans; Iontophoresis; Male; Middle Aged; Peptic U

1967
Some genetic considerations in cystic fibrosis. A study of nail and sweat sodium in two sibships.
    Acta paediatrica Scandinavica, 1967

    Topics: Adolescent; Adult; Child; Child, Preschool; Cystic Fibrosis; Europe; Humans; Infant; Nails; Potassiu

1967
Clinical findings and research in cystic fibrosis.
    Bibliotheca paediatrica, 1967, Volume: 86

    Topics: Chlorides; Cystic Fibrosis; Exocrine Glands; Lung Diseases; Mucus; Pancreas; Saliva; Sodium; Sweat

1967
Pilocarpine iontophoresis sweat testing results of seven years' experience.
    Bibliotheca paediatrica, 1967, Volume: 86

    Topics: Adolescent; Adult; Child; Child, Preschool; Cystic Fibrosis; Female; Humans; Infant; Infant, Newborn

1967
Systematic research of the taint of mucoviscidosis in chronic bronchitis in adults.
    Bibliotheca paediatrica, 1967, Volume: 86

    Topics: Adult; Aged; Bronchitis; Chlorides; Chronic Disease; Cystic Fibrosis; Female; Humans; Male; Middle A

1967
Crystal forms in sweat from patients with cystic fibrosis.
    Bibliotheca paediatrica, 1967, Volume: 86

    Topics: Crystallography; Cystic Fibrosis; Humans; Sweat

1967
The ionic composition of pilocarpine induced sweat in relation to gland output during aging and in cystic fibrosis.
    Bibliotheca paediatrica, 1967, Volume: 86

    Topics: Adolescent; Adult; Aging; Calcium; Child; Child, Preschool; Chlorides; Cystic Fibrosis; Female; Huma

1967
Excretion of different substances in the sweat of children with cystic fibrosis and controls.
    Bibliotheca paediatrica, 1967, Volume: 86

    Topics: Aldosterone; Calcium; Child; Chlorides; Creatinine; Cystic Fibrosis; Humans; Lactates; Male; Sodium;

1967
Sodium transport: inhibitory factor in sweat of patients with cystic fibrosis.
    Science (New York, N.Y.), 1967, Oct-06, Volume: 158, Issue:3797

    Topics: Absorption; Animals; Antimetabolites; Biological Transport, Active; Cystic Fibrosis; Humans; Parotid

1967
Sweat chloride assay for cystic fibrosis. Using pilocarpine iontophoresis stimulation, filter paper collection and cotlove chloridometer analysis.
    Minnesota medicine, 1967, Volume: 50, Issue:8

    Topics: Chlorides; Cystic Fibrosis; Humans; Pilocarpine; Sweat

1967
[Estimation of sweat bromide content following oral administration of bromide preparations].
    Pediatria polska, 1967, Volume: 42, Issue:6

    Topics: Bromides; Child, Preschool; Cystic Fibrosis; Humans; Methods; Sweat

1967
[Excretion of chlorides and bromides in children's sweat after oral administration of sodium bromide].
    Pediatria polska, 1967, Volume: 42, Issue:6

    Topics: Bromides; Child; Child, Preschool; Chlorides; Cystic Fibrosis; Humans; Infant; Respiratory Tract Inf

1967
[Cases of mucoviscidosis in the Regional Allergologic Outpatient Hospital for Children in Zabrze].
    Polski tygodnik lekarski (Warsaw, Poland : 1960), 1967, Oct-09, Volume: 22, Issue:41

    Topics: Asthma; Child; Cystic Fibrosis; Humans; Outpatient Clinics, Hospital; Poland; Sweat

1967
[Sweat composition changes in mucoviscidosis following pilocarpine and adrenalin iontophoresis].
    Vnitrni lekarstvi, 1967, Volume: 13, Issue:7

    Topics: Adolescent; Child; Child, Preschool; Cystic Fibrosis; Epinephrine; Female; Humans; Iontophoresis; Ma

1967
Obstructive azoospermia as a diagnostic criterion for the cystic fibrosis syndrome.
    Lancet (London, England), 1982, Jun-19, Volume: 1, Issue:8286

    Topics: Adolescent; Adult; Child; Chlorides; Cystic Fibrosis; Diagnosis, Differential; Humans; Lung Diseases

1982
Diagnosis of cystic fibrosis.
    Lancet (London, England), 1982, Nov-27, Volume: 2, Issue:8309

    Topics: Age Factors; Child, Preschool; Cystic Fibrosis; Diagnostic Errors; Humans; Infant; Infant, Newborn;

1982
Overdiagnosis of cystic fibrosis.
    Lancet (London, England), 1982, Nov-27, Volume: 2, Issue:8309

    Topics: Adolescent; Child; Child, Preschool; Cystic Fibrosis; Diagnostic Errors; Diagnostic Tests, Routine;

1982
Sweat tests for cystic fibrosis.
    Lancet (London, England), 1983, Jan-01, Volume: 1, Issue:8314-5

    Topics: Chlorides; Cystic Fibrosis; Humans; Sodium; Sweat

1983
Sweat tests for cystic fibrosis.
    Lancet (London, England), 1983, Jan-22, Volume: 1, Issue:8317

    Topics: Chlorides; Cystic Fibrosis; Diagnostic Errors; Humans; Sodium; Sweat

1983
Cystic fibrosis: a case report.
    Journal of the Medical Association of Thailand = Chotmaihet thangphaet, 1981, Volume: 64, Issue:12

    Topics: Anti-Bacterial Agents; Biopsy; Chronic Disease; Cystic Fibrosis; Electrolytes; Fatal Outcome; Humans

1981
Cystic fibrosis in Jordan: a pilot study.
    Annals of tropical paediatrics, 1984, Volume: 4, Issue:4

    Topics: Child, Preschool; Chlorides; Cystic Fibrosis; Female; Humans; Infant; Infant, Newborn; Intestinal Ob

1984
Diagnostic testing in cystic fibrosis.
    The Journal of the Arkansas Medical Society, 1983, Volume: 79, Issue:12

    Topics: Adolescent; Adult; Child; Chlorides; Cystic Fibrosis; Humans; Iontophoresis; Pilocarpine; Sweat

1983
Decreased Cl permeability as the basis for increased bioelectrical potentials in Cystic Fibrosis.
    Pediatric research, 1983, Volume: 17, Issue:8

    Topics: Adolescent; Adult; Cell Membrane Permeability; Chlorides; Cystic Fibrosis; Humans; Ion Channels; Mem

1983
Defective beta adrenergic response of cystic fibrosis sweat glands in vivo and in vitro.
    The Journal of clinical investigation, 1984, Volume: 73, Issue:6

    Topics: Atropine; Child; Cystic Fibrosis; Humans; Isoproterenol; Methacholine Chloride; Methacholine Compoun

1984
Influence of abnormal Cl- impermeability on sweating in cystic fibrosis.
    The American journal of physiology, 1984, Volume: 247, Issue:1 Pt 1

    Topics: Adolescent; Adult; Cell Membrane Permeability; Chlorides; Cystic Fibrosis; Female; Humans; Hydrogen-

1984
Exercise and heat stress in cystic fibrosis patients.
    Pediatric research, 1983, Volume: 17, Issue:4

    Topics: Adolescent; Adult; Aldosterone; Child; Cystic Fibrosis; Female; Hot Temperature; Humans; Male; Physi

1983
Cystic fibrosis mimicking Bartter's syndrome.
    Acta paediatrica Scandinavica, 1983, Volume: 72, Issue:5

    Topics: Aldosterone; Bartter Syndrome; Cystic Fibrosis; Diagnosis, Differential; Electrolytes; Female; Human

1983
Heat acclimation in cystic fibrosis.
    Journal of applied physiology: respiratory, environmental and exercise physiology, 1984, Volume: 57, Issue:2

    Topics: Acclimatization; Adult; Aldosterone; Body Temperature; Body Weight; Chlorides; Cystic Fibrosis; Fema

1984
Diagnosis of maternal cystic fibrosis during pregnancy.
    Obstetrics and gynecology, 1983, Volume: 61, Issue:3 Suppl

    Topics: Adolescent; Adult; Ampicillin; Chlorides; Cystic Fibrosis; Female; Humans; Maternal Mortality; Obste

1983
Sweat tests to diagnose cystic fibrosis in adults.
    British medical journal (Clinical research ed.), 1983, Apr-30, Volume: 286, Issue:6375

    Topics: Adolescent; Adult; Cystic Fibrosis; Female; Fludrocortisone; Humans; Male; Reference Values; Sodium;

1983
Sweat tests to diagnose cystic fibrosis in adults.
    British medical journal (Clinical research ed.), 1983, Jun-11, Volume: 286, Issue:6381

    Topics: Adult; Age Factors; Cystic Fibrosis; Humans; Sodium; Sweat

1983
Sweat tests to diagnose cystic fibrosis in adults.
    British medical journal (Clinical research ed.), 1983, Aug-13, Volume: 287, Issue:6390

    Topics: Adolescent; Adult; Cystic Fibrosis; Electrolytes; Humans; Sweat

1983
Prospective study of fatty acid supplementation over 3 years in patients with cystic fibrosis.
    Journal of pediatric gastroenterology and nutrition, 1983, Volume: 2, Issue:3

    Topics: Adolescent; Child; Child, Preschool; Cystic Fibrosis; Fat Emulsions, Intravenous; Female; Humans; In

1983
Electrophoretic patterns of proteins in cystic fibrosis sweat.
    The Journal of investigative dermatology, 1984, Volume: 83, Issue:3

    Topics: Child; Cystic Fibrosis; Electrophoresis, Polyacrylamide Gel; Female; Heterozygote; Humans; Male; Pro

1984
Evaluation of a paper-patch test for sweat chloride determination.
    Clinical pediatrics, 1984, Volume: 23, Issue:11

    Topics: Adolescent; Adult; Child; Child, Preschool; Chlorides; Cystic Fibrosis; Evaluation Studies as Topic;

1984
Improved sweat test method for the diagnosis of cystic fibrosis.
    Archives of disease in childhood, 1984, Volume: 59, Issue:10

    Topics: Adolescent; Adult; Child; Child, Preschool; Cystic Fibrosis; Humans; Infant; Infant, Newborn; Middle

1984
The role of the laboratory in the diagnosis of cystic fibrosis.
    Clinical biochemistry, 1984, Volume: 17, Issue:5

    Topics: Adolescent; Blood Proteins; Child; Child, Preschool; Cystic Fibrosis; Humans; Infant; Infant, Newbor

1984
Improved prognosis in CF patients with normal fat absorption.
    Journal of pediatric gastroenterology and nutrition, 1984, Volume: 3 Suppl 1

    Topics: Adolescent; Adult; Age Factors; Body Weight; Celiac Disease; Child; Child, Preschool; Cystic Fibrosi

1984
Apparent absence of cystic fibrosis sweat factor on ion-selective and transport properties of the perfused human sweat duct.
    Pediatric research, 1984, Volume: 18, Issue:12

    Topics: Adult; Biological Transport, Active; Calcium; Chlorides; Cystic Fibrosis; Electrolytes; Humans; Perf

1984
Diagnosis and treatment of cystic fibrosis in adults.
    Comprehensive therapy, 1984, Volume: 10, Issue:12

    Topics: Adrenal Cortex Hormones; Adult; Age Factors; Anti-Bacterial Agents; Cholelithiasis; Cystic Fibrosis;

1984
The use of sweat osmolality in the diagnosis of cystic fibrosis.
    Helvetica paediatrica acta, 1984, Volume: 39, Issue:4

    Topics: Adolescent; Adult; Child; Child, Preschool; Cystic Fibrosis; Humans; Infant; Osmolar Concentration;

1984
A puzzling triad: anorexia nervosa, high sweat electrolytes and indication to partial exocrine pancreatic insufficiency.
    Helvetica paediatrica acta, 1983, Volume: 38, Issue:2

    Topics: 4-Aminobenzoic Acid; Adolescent; Anorexia Nervosa; Cystic Fibrosis; Diagnosis, Differential; Electro

1983
Pancreatitis as initial presentation of cystic fibrosis in young adults. A report of two cases.
    Digestive diseases and sciences, 1983, Volume: 28, Issue:10

    Topics: Adult; Cholangiopancreatography, Endoscopic Retrograde; Cystic Fibrosis; Diagnosis, Differential; Hu

1983
Measurement of osmolality and sodium concentration in heated-cup sweat collections for the investigation of cystic fibrosis.
    Annals of clinical biochemistry, 1983, Volume: 20 (Pt 6)

    Topics: Adult; Child; Cystic Fibrosis; Female; Hot Temperature; Humans; Iontophoresis; Male; Osmolar Concent

1983
Case records of the Massachusetts General Hospital. Weekly clinicopathological exercises. Case 6-1984. A 20-year-old woman with cough, hemoptysis, and a pulmonary cavitation.
    The New England journal of medicine, 1984, Feb-09, Volume: 310, Issue:6

    Topics: Adult; Bronchi; Bronchitis; Chlorides; Cystic Fibrosis; Diagnosis, Differential; Female; Hemoptysis;

1984
Early diagnosis of cystic fibrosis by means of sweat microosmometry.
    The Journal of pediatrics, 1984, Volume: 104, Issue:5

    Topics: Adolescent; Adult; Child; Child, Preschool; Cystic Fibrosis; Evaluation Studies as Topic; Humans; In

1984
Higher bioelectric potentials due to decreased chloride absorption in the sweat glands of patients with cystic fibrosis.
    The New England journal of medicine, 1983, May-19, Volume: 308, Issue:20

    Topics: Absorption; Adolescent; Adult; Chlorides; Cystic Fibrosis; Electrophysiology; Humans; Permeability;

1983
Hypogammaglobulinemia and elevated sweat chloride values.
    The Journal of pediatrics, 1983, Volume: 102, Issue:1

    Topics: Adolescent; Agammaglobulinemia; Cystic Fibrosis; Humans; Male; Sodium; Sweat

1983
[Laboratory diagnosis possibilities for the early detection and confirmation of cystic fibrosis (mucoviscidosis). Overview and personal studies].
    Zeitschrift fur medizinische Laboratoriumsdiagnostik, 1983, Volume: 24, Issue:2

    Topics: Amniocentesis; Child; Child, Preschool; Cystic Fibrosis; Female; Germany, West; Humans; Infant; Infa

1983
Sweat chloride concentration in adults with pulmonary diseases.
    The American review of respiratory disease, 1983, Volume: 128, Issue:1

    Topics: Adolescent; Adult; Aged; Aging; Chlorides; Cystic Fibrosis; Female; Humans; Lung Diseases; Male; Mid

1983
Prognostic value of sweat-chloride levels in cystic fibrosis: a negative report.
    European journal of respiratory diseases, 1983, Volume: 64, Issue:6

    Topics: Chlorides; Cystic Fibrosis; Humans; Infant, Newborn; Prognosis; Sweat

1983
Treatment and prognosis of rectal prolapse in cystic fibrosis.
    Gastroenterology, 1982, Volume: 82, Issue:4

    Topics: Adolescent; Adult; Child; Child, Preschool; Cystic Fibrosis; Female; Humans; Infant; Male; Prognosis

1982
Hypogammaglobulinemia and antibody deficiency in patients with elevated sweat chloride concentrations.
    The Journal of pediatrics, 1982, Volume: 100, Issue:3

    Topics: Adolescent; Adult; Agammaglobulinemia; Chlorides; Cystic Fibrosis; Diagnosis, Differential; Female;

1982
[Simple method of sweat chloride determination (author's transl)].
    Monatsschrift Kinderheilkunde : Organ der Deutschen Gesellschaft fur Kinderheilkunde, 1982, Volume: 130, Issue:2

    Topics: Adolescent; Child; Child, Preschool; Chlorides; Cystic Fibrosis; Humans; Methods; Sweat

1982
Cystic fibrosis mistaken for gastroesophageal reflux.
    American journal of diseases of children (1960), 1982, Volume: 136, Issue:3

    Topics: Cystic Fibrosis; Diagnosis, Differential; Gastroesophageal Reflux; Humans; Infant; Sweat

1982
Case study: cystic fibrosis.
    The American journal of medical technology, 1982, Volume: 48, Issue:1

    Topics: Child; Cystic Fibrosis; Electrolytes; Female; Humans; Pseudomonas Infections; Respiratory Tract Infe

1982
Sweat sodium and chloride values.
    The Journal of pediatrics, 1982, Volume: 100, Issue:6

    Topics: Chlorides; Cystic Fibrosis; Humans; Sodium; Sweat

1982
Improved respiratory prognosis in patients with cystic fibrosis with normal fat absorption.
    The Journal of pediatrics, 1982, Volume: 100, Issue:6

    Topics: Adolescent; Adult; Child; Child, Preschool; Chlorides; Cystic Fibrosis; Dietary Fats; Female; Humans

1982
Commentary: the clinical forms of cystic fibrosis.
    The Journal of pediatrics, 1982, Volume: 100, Issue:6

    Topics: Cystic Fibrosis; Electrolytes; Humans; Sweat

1982
Suggestion of an abnormal anion exchange mechanism in sweat glands of cystic fibrosis patients.
    Pediatric research, 1982, Volume: 16, Issue:7

    Topics: Adult; Anions; Chlorides; Cystic Fibrosis; Humans; Hydrogen; Potassium; Sodium; Sweat; Sweat Glands

1982
Effect of temperature on response of the sweat chloride ion-selective electrode.
    Clinical chemistry, 1982, Volume: 28, Issue:12

    Topics: Body Temperature; Chlorides; Cystic Fibrosis; Electrodes; Humans; Quality Control; Sweat

1982
Cystic fibrosis presenting with chronic electrolyte depletion, metabolic alkalosis and hyperaldosteronism.
    Scottish medical journal, 1982, Volume: 27, Issue:4

    Topics: Alkalosis; Chlorides; Cystic Fibrosis; Exocrine Pancreatic Insufficiency; Humans; Hyperaldosteronism

1982
The sweat test: sodium and chloride values.
    The Journal of pediatrics, 1981, Volume: 98, Issue:4

    Topics: Child; Chlorides; Cystic Fibrosis; Humans; Potassium; Sodium; Sweat

1981
Case records of the Massachusetts General Hospital. Weekly clinicopathological exercises. Case 14-1981.
    The New England journal of medicine, 1981, Apr-02, Volume: 304, Issue:14

    Topics: Adult; Chlorides; Cystic Fibrosis; Humans; Lung Diseases; Male; Oligospermia; Sweat

1981
A 69-year-old man with chronic obstructive pulmonary disease, pancreatic insufficiency and elevated sweat electrolytes.
    Acta medica Scandinavica, 1981, Volume: 209, Issue:1-2

    Topics: Age Factors; Aged; Chlorides; Cystic Fibrosis; Diagnosis, Differential; Exocrine Pancreatic Insuffic

1981
[Rational diagnosis of mucoviscidosis by a modified method of sweat chloride determination].
    Kinderarztliche Praxis, 1981, Volume: 49, Issue:6

    Topics: Child, Preschool; Chlorides; Cystic Fibrosis; Humans; Infant; Infant, Newborn; Methods; Sweat

1981
[Sweat electrolyte analysis by pilocarpine iontophoresis].
    Ugeskrift for laeger, 1981, Aug-31, Volume: 143, Issue:36

    Topics: Adolescent; Adult; Child; Child, Preschool; Cystic Fibrosis; Female; Humans; Infant; Infant, Newborn

1981
False-positive sweat tests.
    The Journal of pediatrics, 1981, Volume: 99, Issue:6

    Topics: Chlorides; Cystic Fibrosis; False Positive Reactions; Humans; Sodium; Sweat

1981
An unusual case of XXY Klinefelter's syndrome associated with cystic fibrosis.
    Israel journal of medical sciences, 1981, Volume: 17, Issue:12

    Topics: Cystic Fibrosis; Follow-Up Studies; Humans; Infant; Klinefelter Syndrome; Male; Sweat

1981
[Neonatal screening program for cystic fibrosis of the pancreas].
    La Pediatria, 1981, Dec-31, Volume: 89, Issue:4

    Topics: Albumins; Chlorides; Cystic Fibrosis; Humans; Infant, Newborn; Italy; Mass Screening; Meconium; Sodi

1981
Incidence of meconium abnormalities in newborn infants with cystic fibrosis.
    American journal of diseases of children (1960), 1980, Volume: 134, Issue:1

    Topics: Child, Preschool; Cystic Fibrosis; Humans; Infant; Infant, Newborn; Intestinal Diseases; Intestinal

1980
[Organoleptic method in the diagnosis of mycoviscidosis in young infants].
    Pediatriia, 1980, Issue:2

    Topics: Cystic Fibrosis; Female; Forehead; Humans; Infant; Sweat; Taste

1980
Cystic fibrosis in South India.
    Tropical and geographical medicine, 1980, Volume: 32, Issue:1

    Topics: Cystic Fibrosis; Female; Humans; India; Infant; Male; Pedigree; Sodium; Sweat

1980
[The dilemma of borderline sweat tests].
    Harefuah, 1980, Feb-15, Volume: 98, Issue:4

    Topics: Cystic Fibrosis; Humans; Sweat

1980
The diagnosis of cystic fibrosis.
    The Practitioner, 1980, Volume: 224, Issue:1341

    Topics: Child; Cystic Fibrosis; Diagnostic Errors; Humans; Infant; Infant, Newborn; Pancreas; Radiography; S

1980
[Sweat test with the use of Tc-99m in the diagnosis of mucoviscidosis. Preliminary report].
    Pediatria polska, 1980, Volume: 55, Issue:9

    Topics: Child; Child, Preschool; Cystic Fibrosis; Humans; Infant; Isotope Labeling; Radioactivity; Sweat; Te

1980
Low sweat electrolytes in a patient with cystic fibrosis.
    The American journal of medicine, 1980, Volume: 69, Issue:4

    Topics: Adult; Chlorides; Cystic Fibrosis; Electrolytes; Exocrine Pancreatic Insufficiency; Female; Humans;

1980
Undiagnosed patients with cystic fibrosis.
    Journal of chronic diseases, 1980, Volume: 33, Issue:11-12

    Topics: Adolescent; Adult; Age Factors; Child; Child, Preschool; Cystic Fibrosis; Humans; Infant; Infant, Ne

1980
[Normal sweat electrolyte concentrations in patients with mucoviscidosis in infancy].
    Kinderarztliche Praxis, 1980, Volume: 48, Issue:7

    Topics: Age Factors; Chlorides; Cystic Fibrosis; Humans; Infant; Sweat

1980
Cooperative study comparing three methods of performing sweat tests to diagnose cystic fibrosis.
    Pediatrics, 1980, Volume: 66, Issue:5

    Topics: Child; Cystic Fibrosis; Electrodes; False Negative Reactions; False Positive Reactions; Humans; Iont

1980
Reappraisal of the chloride plate test as screening test for cystic fibrosis.
    Archives of disease in childhood, 1981, Volume: 56, Issue:2

    Topics: Agar; Child; Child, Preschool; Chlorides; Cystic Fibrosis; Humans; Infant; Methods; Sweat

1981
Screening for cystic fibrosis by a stool trypsin method.
    Archives of disease in childhood, 1981, Volume: 56, Issue:2

    Topics: Cystic Fibrosis; Feces; Humans; Infant, Newborn; Mass Screening; Sweat; Trypsin

1981
New approach to cystic fibrosis diagnosis by use of an improved sweat-induction/collection system and osmometry.
    Clinical chemistry, 1981, Volume: 27, Issue:3

    Topics: Chlorides; Cystic Fibrosis; Humans; Iontophoresis; Osmolar Concentration; Pilocarpine; Specimen Hand

1981
Correlation of sweat chloride concentration with classes of the cystic fibrosis transmembrane conductance regulator gene mutations.
    The Journal of pediatrics, 1995, Volume: 127, Issue:5

    Topics: Child; Child, Preschool; Chlorides; Cystic Fibrosis; Cystic Fibrosis Transmembrane Conductance Regul

1995
A cystic fibrosis mutation associated with mild lung disease.
    The New England journal of medicine, 1995, Dec-14, Volume: 333, Issue:24

    Topics: Chlorides; Cystic Fibrosis; Humans; Mutation; Sodium; Sweat

1995
Nasal epithelial ion transport and genetic analysis of infertile men with congenital bilateral absence of the vas deferens.
    Human molecular genetics, 1993, Volume: 2, Issue:10

    Topics: Biological Transport; Chloride Channels; Chlorides; Cystic Fibrosis; Cystic Fibrosis Transmembrane C

1993
Screening for CF mutations in adult cystic fibrosis patients with a directed and optimized SSCP strategy.
    Human mutation, 1994, Volume: 3, Issue:3

    Topics: Adolescent; Adult; Base Sequence; Chlorides; Cystic Fibrosis; Cystic Fibrosis Transmembrane Conducta

1994
A novel mutation in the cystic fibrosis gene in patients with pulmonary disease but normal sweat chloride concentrations.
    The New England journal of medicine, 1994, Oct-13, Volume: 331, Issue:15

    Topics: Adolescent; Adult; Base Sequence; Child; Child, Preschool; Chloride Channels; Chlorides; Chromosomes

1994
Normal sweat chloride values do not exclude the diagnosis of cystic fibrosis.
    American journal of respiratory and critical care medicine, 1995, Volume: 151, Issue:3 Pt 1

    Topics: Adult; Chlorides; Cystic Fibrosis; Cystic Fibrosis Transmembrane Conductance Regulator; Female; Hete

1995
Sweat sodium and chloride analysis using BM/Hitachi 911 ion-selective electrodes.
    British journal of biomedical science, 1995, Volume: 52, Issue:1

    Topics: Chlorides; Cystic Fibrosis; Humans; Ion-Selective Electrodes; Sodium; Sweat

1995
Delayed diagnosis of cystic fibrosis due to normal sweat electrolytes.
    Journal of the Royal Society of Medicine, 1995, Volume: 88, Issue:7

    Topics: Chlorides; Cystic Fibrosis; Electrolytes; False Negative Reactions; Follow-Up Studies; Humans; Infan

1995
Normal sweat chloride values do not exclude the diagnosis of cystic fibrosis.
    American journal of respiratory and critical care medicine, 1995, Volume: 152, Issue:5 Pt 1

    Topics: Chlorides; Cystic Fibrosis; Humans; Mutation; Sweat

1995
Application of DNA analysis in a population-screening program for neonatal diagnosis of cystic fibrosis (CF): comparison of screening protocols.
    American journal of human genetics, 1993, Volume: 52, Issue:3

    Topics: Analysis of Variance; Australia; Cohort Studies; Colorado; Cystic Fibrosis; Cystic Fibrosis Transmem

1993
Congenital bilateral absence of vas deferens in absence of cystic fibrosis.
    Lancet (London, England), 1995, Jan-21, Volume: 345, Issue:8943

    Topics: Abnormalities, Multiple; Adult; Chlorides; Cystic Fibrosis; Humans; Infertility, Male; Kidney; Male;

1995
Diagnostic criteria for cystic fibrosis in men with congenital absence of the vas deferens.
    Medicine, 1995, Volume: 74, Issue:1

    Topics: Adult; Chlorides; Cystic Fibrosis; Genetic Carrier Screening; Genotype; Humans; Infertility, Male; M

1995
Increased Na+/Mg2+ antiport in erythrocytes of patients with cystic fibrosis.
    European journal of clinical chemistry and clinical biochemistry : journal of the Forum of European Clinical Chemistry Societies, 1994, Volume: 32, Issue:11

    Topics: Adolescent; Adult; Antiporters; Child; Cystic Fibrosis; Erythrocytes; Female; Genotype; Humans; Magn

1994
Cystic fibrosis screening in neonates--measurement of immunoreactive trypsin and direct genotype analysis for delta F508 mutation.
    European journal of pediatrics, 1994, Volume: 153, Issue:8

    Topics: Cystic Fibrosis; DNA Mutational Analysis; Genetic Testing; Genotype; Humans; Infant, Newborn; Neonat

1994
Pseudohypoaldosteronism with increased sweat and saliva electrolyte values and frequent lower respiratory tract infections mimicking cystic fibrosis.
    The Journal of pediatrics, 1994, Volume: 125, Issue:5 Pt 1

    Topics: Aldosterone; Child; Cystic Fibrosis; Diagnosis, Differential; Diseases in Twins; Female; Humans; Inf

1994
Current status of sweat testing in North America. Results of the College of American Pathologists needs assessment survey.
    Archives of pathology & laboratory medicine, 1994, Volume: 118, Issue:9

    Topics: Chemistry, Clinical; Chlorides; Cystic Fibrosis; Data Collection; Humans; North America; Sodium; Swe

1994
Mild cystic fibrosis and normal or borderline sweat test in patients with the 3849 + 10 kb C-->T mutation.
    Lancet (London, England), 1993, Jul-03, Volume: 342, Issue:8862

    Topics: Age Factors; Child; Chlorides; Cystic Fibrosis; Female; Humans; Male; Phenotype; Point Mutation; Swe

1993
Sweat chloride and delta F508 mutation in chronic bronchitis or bronchiectasis.
    Lancet (London, England), 1993, Oct-16, Volume: 342, Issue:8877

    Topics: Adult; Aged; Bronchiectasis; Bronchitis; Chlorides; Chronic Disease; Cystic Fibrosis; Humans; Male;

1993
Screening for cystic fibrosis in dried blood spots of newborns.
    Molecular and cellular probes, 1993, Volume: 7, Issue:6

    Topics: Algorithms; Chlorides; Cystic Fibrosis; DNA Mutational Analysis; Electrophoresis, Polyacrylamide Gel

1993
Sweat osmolality in some of the congenital diseases.
    Indian journal of pathology & microbiology, 1993, Volume: 36, Issue:4

    Topics: Adolescent; Adult; Age Factors; Child; Cystic Fibrosis; Down Syndrome; Female; Humans; Intellectual

1993
Clinical evaluation of the macroduct sweat collection system and conductivity analyzer in the diagnosis of cystic fibrosis.
    The Journal of pediatrics, 1994, Volume: 124, Issue:2

    Topics: Adolescent; Adult; Aged; Case-Control Studies; Child; Child, Preschool; Chlorides; Cystic Fibrosis;

1994
Improved correlation of sweat chloride quantification by the CF Indicator System and the Gibson-Cooke Sweat Test.
    Clinical chemistry, 1993, Volume: 39, Issue:8

    Topics: Chlorides; Cystic Fibrosis; Humans; Sweat

1993
Clinical quiz. Sweat test indicates cystic fibrosis in a child with sweat sodium of 99 mmol/l and sweat chloride of 139 mmol/l.
    Pediatric nephrology (Berlin, Germany), 1993, Volume: 7, Issue:1

    Topics: Chlorides; Cystic Fibrosis; Diagnosis, Differential; Humans; Infant; Sodium; Sweat

1993
Clinical spectrum in homozygotes and compound heterozygotes inheriting cystic fibrosis mutation 3849 + 10kbC > T: significance for geneticists.
    American journal of medical genetics, 1995, Sep-25, Volume: 58, Issue:4

    Topics: Adolescent; Adult; Child; Child, Preschool; Chlorides; Cystic Fibrosis; Forced Expiratory Volume; Ge

1995
Sweat chloride concentrations in infants homozygous or heterozygous for F508 cystic fibrosis.
    Pediatrics, 1996, Volume: 97, Issue:4

    Topics: Age Factors; Alleles; Base Composition; Chlorides; Codon; Cystic Fibrosis; DNA; Follow-Up Studies; G

1996
The significance of sweat Cl/Na ratio in patients with borderline sweat test.
    Pediatric pulmonology, 1995, Volume: 20, Issue:6

    Topics: Child; Chlorides; Cystic Fibrosis; Cystic Fibrosis Transmembrane Conductance Regulator; Humans; Muta

1995
[The usefulness of the conduction sweat test in diagnosis of cystic fibrosis].
    Pediatria polska, 1995, Volume: 70, Issue:8

    Topics: Adolescent; Adult; Biomarkers; Child; Child, Preschool; Cystic Fibrosis; Electric Conductivity; Fema

1995
[A study evaluating the correlation between the phenotype and genotype among 65 cystic fibrosis patients].
    Pediatria polska, 1995, Volume: 70, Issue:8

    Topics: Adolescent; Child; Child, Preschool; Chlorides; Cystic Fibrosis; Exocrine Pancreatic Insufficiency;

1995
Pulmonary function and clinical observations in men with congenital bilateral absence of the vas deferens.
    Chest, 1996, Volume: 110, Issue:2

    Topics: Adult; Body Height; Body Weight; Cystic Fibrosis; Cystic Fibrosis Transmembrane Conductance Regulato

1996
Pancreatitis and an abnormal sweat test at presentation in a child with non-Hodgkin's lymphoma.
    Pancreas, 1996, Volume: 12, Issue:2

    Topics: Child; Chlorides; Cystic Fibrosis; Humans; Lymphoma, Non-Hodgkin; Male; Pancreatitis; Sweat

1996
[Increase of chlorine in sweat in the absence of cystic fibrosis].
    Archives de pediatrie : organe officiel de la Societe francaise de pediatrie, 1996, Volume: 3, Issue:4

    Topics: Child, Preschool; Chlorides; Cystic Fibrosis; Female; Humans; Male; Sweat

1996
Analysis of sweat chloride by reversed phase high-performance liquid chromatography.
    Annals of clinical biochemistry, 1995, Volume: 32 ( Pt 5)

    Topics: Chlorides; Chromatography, High Pressure Liquid; Cystic Fibrosis; Evaluation Studies as Topic; Human

1995
A baby with eczema and an abnormal sweat test.
    Lancet (London, England), 1996, Oct-05, Volume: 348, Issue:9032

    Topics: Cystic Fibrosis; Dermatitis, Atopic; Diagnostic Errors; False Positive Reactions; Humans; Infant; Ma

1996
Measurement of sweat sodium using a modified enzymatic assay.
    Annals of clinical biochemistry, 1996, Volume: 33 ( Pt 5)

    Topics: Child; Clinical Enzyme Tests; Cystic Fibrosis; Humans; Nitrophenols; Reagent Kits, Diagnostic; Sodiu

1996
Enzymatic determination of sodium and chloride in sweat.
    Clinical biochemistry, 1996, Volume: 29, Issue:1

    Topics: alpha-Amylases; beta-Galactosidase; Bridged Bicyclo Compounds, Heterocyclic; Chelating Agents; Chlor

1996
Eczema and an abnormal sweat test.
    Lancet (London, England), 1996, Dec-07, Volume: 348, Issue:9041

    Topics: Cystic Fibrosis; Eczema; False Positive Reactions; Humans; Infant; Sweat

1996
Sweat testing for the diagnosis of cystic fibrosis: practical considerations.
    The Journal of pediatrics, 1996, Volume: 129, Issue:6

    Topics: Arm; Chlorides; Cystic Fibrosis; Electric Conductivity; False Negative Reactions; False Positive Rea

1996
Cystic fibrosis presenting with hypokalemia and metabolic alkalosis in a previously healthy adolescent.
    Journal of the American Society of Nephrology : JASN, 1997, Volume: 8, Issue:2

    Topics: Acidosis; Adolescent; Cystic Fibrosis; Cystic Fibrosis Transmembrane Conductance Regulator; Genotype

1997
[Male infertility caused by bilateral agenesis of the vas deferens: a new clinical form of cystic fibrosis?].
    La Revue de medecine interne, 1997, Volume: 18, Issue:2

    Topics: Adult; Chlorine; Cystic Fibrosis; Cystic Fibrosis Transmembrane Conductance Regulator; Genotype; Het

1997
Identification of a splice site mutation (2789 +5 G > A) associated with small amounts of normal CFTR mRNA and mild cystic fibrosis.
    Human mutation, 1997, Volume: 9, Issue:4

    Topics: Adult; Chlorides; Cystic Fibrosis; Cystic Fibrosis Transmembrane Conductance Regulator; DNA Mutation

1997
Nasal potential difference in cystic fibrosis patients presenting borderline sweat test.
    The European respiratory journal, 1997, Volume: 10, Issue:5

    Topics: Adolescent; Adult; Child; Cystic Fibrosis; DNA; Female; Humans; Male; Membrane Potentials; Nasal Muc

1997
[A method of sampling material for the determination of chlorides in sweat].
    Klinicheskaia laboratornaia diagnostika, 1997, Issue:2

    Topics: Chlorides; Cystic Fibrosis; Electrophoresis, Paper; Forearm; Humans; Pilocarpine; Specimen Handling;

1997
A missense cystic fibrosis transmembrane conductance regulator mutation with variable phenotype.
    Pediatrics, 1997, Volume: 100, Issue:3

    Topics: Age of Onset; Child; Chlorides; Cystic Fibrosis; Cystic Fibrosis Transmembrane Conductance Regulator

1997
Urticaria associated with the pilocarpine iontophoresis sweat test.
    Pediatric pulmonology, 1997, Volume: 24, Issue:4

    Topics: Child; Chlorides; Cystic Fibrosis; Female; Histamine H1 Antagonists; Humans; Iontophoresis; Pilocarp

1997
Genotype-phenotype correlation in cystic fibrosis patients compound heterozygous for the A455E mutation.
    Human genetics, 1997, Volume: 101, Issue:2

    Topics: Adolescent; Adult; Canada; Child; Child, Preschool; Cystic Fibrosis; Cystic Fibrosis Transmembrane C

1997
Sweat sodium is not sweat chloride.
    Archives of disease in childhood, 1997, Volume: 77, Issue:5

    Topics: Adolescent; Adult; Child; Chlorides; Cystic Fibrosis; Humans; Sodium; Sweat

1997
[Cystic fibrosis in adults--clinical aspects].
    Pneumonologia i alergologia polska, 1997, Volume: 65, Issue:3-4

    Topics: Adolescent; Adult; Bronchiectasis; Chlorides; Cystic Fibrosis; DNA; Female; Humans; Male; Mutation;

1997
A mutation in the cystic fibrosis transmembrane conductance regulator gene associated with elevated sweat chloride concentrations in the absence of cystic fibrosis.
    Human molecular genetics, 1998, Volume: 7, Issue:4

    Topics: Child; Chlorides; Cystic Fibrosis; Cystic Fibrosis Transmembrane Conductance Regulator; Female; Huma

1998
P67L: a cystic fibrosis allele with mild effects found at high frequency in the Scottish population.
    Journal of medical genetics, 1998, Volume: 35, Issue:2

    Topics: Adolescent; Adult; Alleles; Child; Cystic Fibrosis; DNA; Exocrine Pancreatic Insufficiency; Female;

1998
Sweat electrolyte and cystic fibrosis mutation analysis allows early diagnosis in Brazilian children with clinical signs compatible with cystic fibrosis.
    American journal of medical genetics, 1998, Apr-01, Volume: 76, Issue:4

    Topics: Age Factors; Brazil; Child; Child, Preschool; Chlorides; Cystic Fibrosis; DNA Mutational Analysis; F

1998
Correlation of sweat chloride concentration with genotypes in cystic fibrosis patients in Saguenay Lac-Saint-Jean, Quebec, Canada.
    Clinical biochemistry, 1998, Volume: 31, Issue:1

    Topics: Chlorides; Cystic Fibrosis; Cystic Fibrosis Transmembrane Conductance Regulator; Genetic Testing; Ge

1998
Making the diagnosis of cystic fibrosis.
    The Journal of pediatrics, 1998, Volume: 132, Issue:4

    Topics: Consensus Development Conferences as Topic; Cystic Fibrosis; Cystic Fibrosis Transmembrane Conductan

1998
Uncertainty in the diagnosis of cystic fibrosis: possible role of in vivo nasal potential difference measurements.
    The Journal of pediatrics, 1998, Volume: 132, Issue:4

    Topics: Adolescent; Adult; Case-Control Studies; Child; Cystic Fibrosis; Cystic Fibrosis Transmembrane Condu

1998
Test for the concentration of electrolytes in cystic fibrosis of the pancreas utilizing pilocarpine by iontophoresis, by Lewis E. Gibson and Robert E. Cooke, Pediatrics; 1959;24:545-549.
    Pediatrics, 1998, Volume: 102, Issue:1 Pt 2

    Topics: Cystic Fibrosis; Electrolytes; History, 20th Century; Humans; Iontophoresis; Pilocarpine; Sweat

1998
Mutations of the cystic fibrosis gene in patients with chronic pancreatitis.
    The New England journal of medicine, 1998, Sep-03, Volume: 339, Issue:10

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Chlorides; Chronic Disease; Cystic Fibrosis; Cystic Fibr

1998
Relation between mutations of the cystic fibrosis gene and idiopathic pancreatitis.
    The New England journal of medicine, 1998, Sep-03, Volume: 339, Issue:10

    Topics: Adolescent; Adult; Aged; Child; Chlorides; Chronic Disease; Cystic Fibrosis; Cystic Fibrosis Transme

1998
Nasal potential difference in congenital bilateral absence of the vas deferens.
    American journal of respiratory and critical care medicine, 1998, Volume: 158, Issue:3

    Topics: Adrenergic beta-Agonists; Adult; Amiloride; Chlorides; Cystic Fibrosis; Cystic Fibrosis Transmembran

1998
Cystic fibrosis, Young's syndrome, and normal sweat chloride.
    Lancet (London, England), 1998, Jul-04, Volume: 352, Issue:9121

    Topics: Adult; Asthma; Chlorides; Cystic Fibrosis; Diagnosis, Differential; Humans; Male; Mutation; Oligospe

1998
Cystic fibrosis mutations in heterozygous newborns with hypertrypsinemia and low sweat chloride.
    American journal of human genetics, 1999, Volume: 64, Issue:1

    Topics: Chlorides; Cystic Fibrosis; Cystic Fibrosis Transmembrane Conductance Regulator; Heterozygote; Human

1999
Mutations of the cystic fibrosis gene and pancreatitis.
    The New England journal of medicine, 1999, Jan-21, Volume: 340, Issue:3

    Topics: Chlorides; Chronic Disease; Cystic Fibrosis; Cystic Fibrosis Transmembrane Conductance Regulator; Hu

1999
Pitfall in the use of genotype analysis as the sole diagnostic criterion for cystic fibrosis.
    Pediatrics, 1999, Volume: 103, Issue:4 Pt 1

    Topics: Chlorides; Cystic Fibrosis; Diagnostic Errors; Female; Genetic Testing; Genotype; Humans; Infant; Mu

1999
Sunshine, sweating, and main d'accoucheur.
    Lancet (London, England), 1999, May-01, Volume: 353, Issue:9163

    Topics: Adult; Cystic Fibrosis; Cystic Fibrosis Transmembrane Conductance Regulator; Electrolytes; Hand; Hum

1999
Cystic fibrosis: the twilight zone.
    Pediatric pulmonology, 1999, Volume: 28, Issue:3

    Topics: Adolescent; Child; Cystic Fibrosis; Cystic Fibrosis Transmembrane Conductance Regulator; Female; Hum

1999
Increased sweat chloride concentrations in adult patients with pancreatic insufficiency: cystic fibrosis phenotype or lack of specificity of sweat test?
    Scandinavian journal of gastroenterology, 1999, Volume: 34, Issue:12

    Topics: Adult; Chlorides; Cystic Fibrosis; Cystic Fibrosis Transmembrane Conductance Regulator; Exocrine Pan

1999
Evidence of mild respiratory disease in men with congenital absence of the vas deferens.
    Respiratory medicine, 1999, Volume: 93, Issue:12

    Topics: Adult; Chlorides; Cystic Fibrosis; Cystic Fibrosis Transmembrane Conductance Regulator; Genotype; Hu

1999
Triple A syndrome mimicking cystic fibrosis.
    Journal of pediatric endocrinology & metabolism : JPEM, 2000, Volume: 13, Issue:3

    Topics: Adrenal Glands; Child, Preschool; Chlorides; Cystic Fibrosis; Diagnosis, Differential; Esophageal Ac

2000
Cystic fibrosis diagnosed in adult patients.
    The New Zealand medical journal, 2000, Jan-28, Volume: 113, Issue:1102

    Topics: Adolescent; Adult; Aged; Cystic Fibrosis; Cystic Fibrosis Transmembrane Conductance Regulator; Follo

2000
Inconsistencies in sweat testing in UK laboratories.
    Archives of disease in childhood, 2000, Volume: 82, Issue:5

    Topics: Age Factors; Clinical Laboratory Techniques; Cystic Fibrosis; Humans; Infant; Infant, Newborn; Labor

2000
Indirect measurements of sweat electrolyte concentration in the laboratory diagnosis of cystic fibrosis.
    Archives of disease in childhood, 2000, Volume: 82, Issue:5

    Topics: Adolescent; Age Factors; Case-Control Studies; Child; Child, Preschool; Chlorides; Cystic Fibrosis;

2000
Micro-flowcell conductometric sweat analysis for cystic fibrosis diagnosis.
    Annals of clinical biochemistry, 2000, Volume: 37 ( Pt 3)

    Topics: Adult; Automation; Calibration; Conductometry; Cystic Fibrosis; Humans; Iontophoresis; Sweat; Temper

2000
Sweat testing following newborn screening for cystic fibrosis.
    Pediatric pulmonology, 2000, Volume: 29, Issue:6

    Topics: Chlorides; Cystic Fibrosis; Diagnosis, Differential; DNA Mutational Analysis; Female; Genetic Testin

2000
Protracted neonatal hypertrypsinogenaemia, normal sweat chloride, and cystic fibrosis.
    Archives of disease in childhood, 2000, Volume: 82, Issue:6

    Topics: Adolescent; Chlorides; Cystic Fibrosis; Humans; Male; Neonatal Screening; Sputum; Sweat; Trypsinogen

2000
[A normal sweat test does not exclude the diagnosis of cystic fibrosis].
    Archives de pediatrie : organe officiel de la Societe francaise de pediatrie, 2000, Volume: 7, Issue:6

    Topics: Cystic Fibrosis; False Negative Reactions; Humans; Predictive Value of Tests; Sweat

2000
Newborn screening for cystic fibrosis in Victoria: 10 years' experience (1989-1998).
    The Medical journal of Australia, 2000, Jun-19, Volume: 172, Issue:12

    Topics: Chlorides; Cystic Fibrosis; Humans; Neonatal Screening; Retrospective Studies; Sweat; Trypsinogen; V

2000
Time to think again: cystic fibrosis is not an "all or none" disease.
    Pediatric pulmonology, 2000, Volume: 30, Issue:2

    Topics: Cystic Fibrosis; Diagnosis, Differential; DNA Mutational Analysis; Female; Humans; Infant; Male; Phe

2000
Clinical features associated with a delayed diagnosis of cystic fibrosis.
    Respiration; international review of thoracic diseases, 2000, Volume: 67, Issue:4

    Topics: Adolescent; Adult; Burkholderia cepacia; Chlorides; Cystic Fibrosis; Cystic Fibrosis Transmembrane C

2000
Reliability of sweat-testing by the Macroduct collection method combined with conductivity analysis in comparison with the classic Gibson and Cooke technique.
    Acta paediatrica (Oslo, Norway : 1992), 2000, Volume: 89, Issue:8

    Topics: Adolescent; Adult; Child; Child, Preschool; Cystic Fibrosis; Electrolytes; Humans; Infant; Infant, N

2000
Serum lipase levels as a diagnostic marker in cystic fibrosis patients with normal or borderline sweat tests.
    Pediatric pulmonology, 2000, Volume: 30, Issue:4

    Topics: Adult; Child; Chlorides; Cystic Fibrosis; Cystic Fibrosis Transmembrane Conductance Regulator; Exocr

2000
Mutation in the gene responsible for cystic fibrosis and predisposition to chronic rhinosinusitis in the general population.
    JAMA, 2000, Oct-11, Volume: 284, Issue:14

    Topics: Adult; Aged; Case-Control Studies; Chronic Disease; Cystic Fibrosis; Cystic Fibrosis Transmembrane C

2000
Lung disease associated with the IVS8 5T allele of the CFTR gene.
    American journal of respiratory and critical care medicine, 2000, Volume: 162, Issue:5

    Topics: Age of Onset; Alleles; Cystic Fibrosis; Cystic Fibrosis Transmembrane Conductance Regulator; Epithel

2000
Recommendations for quality improvement in genetic testing for cystic fibrosis. European Concerted Action on Cystic Fibrosis.
    European journal of human genetics : EJHG, 2000, Volume: 8 Suppl 2

    Topics: Accreditation; Adolescent; Adult; Child; Cystic Fibrosis; Cystic Fibrosis Transmembrane Conductance

2000
Sweat analysis proficiency testing for cystic fibrosis.
    Pediatric pulmonology, 2000, Volume: 30, Issue:6

    Topics: Chlorides; Clinical Laboratory Techniques; Cystic Fibrosis; Health Care Surveys; Humans; Infant; Inf

2000
A simplified cyclic adenosine monophosphate-mediated sweat rate test for quantitative measure of cystic fibrosis transmembrane regulator (CFTR) function.
    The Journal of pediatrics, 2000, Volume: 137, Issue:6

    Topics: Adolescent; Adrenergic beta-Agonists; Adult; Aminophylline; Atropine; Child; Cyclic AMP; Cystic Fibr

2000
Genotype analysis and phenotypic manifestations of children with intermediate sweat chloride test results.
    Chest, 2000, Volume: 118, Issue:6

    Topics: Adolescent; Child; Child, Preschool; Chlorides; Cystic Fibrosis; Cystic Fibrosis Transmembrane Condu

2000
Point-of-need diagnosis of cystic fibrosis using a potentiometric ion-selective electrode array.
    The Analyst, 2000, Volume: 125, Issue:12

    Topics: Chlorine; Cluster Analysis; Cystic Fibrosis; Humans; Point-of-Care Systems; Potassium; Potentiometry

2000
Cystic fibrosis and Down's syndrome: not always a poor prognosis.
    Pediatric pulmonology, 2001, Volume: 31, Issue:4

    Topics: Bronchiolitis; Child; Cystic Fibrosis; Diagnosis, Differential; Down Syndrome; Female; Humans; Mosai

2001
Analysis of the entire coding region of the cystic fibrosis transmembrane regulator gene in neonatal hypertrypsinaemia with normal sweat test.
    Journal of medical genetics, 2001, Volume: 38, Issue:3

    Topics: Alleles; Cystic Fibrosis; Cystic Fibrosis Transmembrane Conductance Regulator; DNA; DNA Mutational A

2001
Genetic counseling and neonatal screening for cystic fibrosis: an assessment of the communication process.
    Pediatrics, 2001, Volume: 107, Issue:4

    Topics: Adult; Attitude to Health; Child, Preschool; Chlorides; Communication; Cystic Fibrosis; Electrolytes

2001
Sweat Chloride and conductivity 1.
    Archives of disease in childhood, 2001, Volume: 84, Issue:5

    Topics: Chlorides; Cystic Fibrosis; Electric Conductivity; Humans; Sensitivity and Specificity; Sweat

2001
Sweat chloride and conductivity 2.
    Archives of disease in childhood, 2001, Volume: 84, Issue:5

    Topics: Chlorides; Clinical Trials as Topic; Cystic Fibrosis; Electric Conductivity; Humans; Sensitivity and

2001
Cystic fibrosis: the 'bicarbonate before chloride' hypothesis.
    Current biology : CB, 2001, Jun-26, Volume: 11, Issue:12

    Topics: Bicarbonates; Biological Transport; Chlorides; Cystic Fibrosis; Cystic Fibrosis Transmembrane Conduc

2001
Sweat chloride: quantitative patch for collection and measurement.
    Clinical laboratory science : journal of the American Society for Medical Technology, 2001,Summer, Volume: 14, Issue:3

    Topics: Adolescent; Adult; Aged; Child; Child, Preschool; Chlorides; Cystic Fibrosis; Humans; Infant; Iontop

2001
[Cystic fibrosis and normal sweat chloride values: a case-report].
    Revue des maladies respiratoires, 2001, Volume: 18, Issue:4 Pt 1

    Topics: Adolescent; Chlorides; Cystic Fibrosis; Cystic Fibrosis Transmembrane Conductance Regulator; Female;

2001
Assessment of sweat-testing practices for the diagnosis of cystic fibrosis.
    Archives of pathology & laboratory medicine, 2001, Volume: 125, Issue:11

    Topics: Chemistry, Clinical; Chlorides; Cystic Fibrosis; Humans; Laboratories; Quality Control; Surveys and

2001
Cystic fibrosis gene mutations and pancreatitis risk: relation to epithelial ion transport and trypsin inhibitor gene mutations.
    Gastroenterology, 2001, Volume: 121, Issue:6

    Topics: Adolescent; Adult; Alleles; alpha-Amylases; Child; Chlorides; Cystic Fibrosis; Epithelium; Female; G

2001
Cystic fibrosis diagnosis: new dilemmas for an old disorder.
    Pediatric pulmonology, 2002, Volume: 33, Issue:2

    Topics: Codon, Nonsense; Cystic Fibrosis; Cystic Fibrosis Transmembrane Conductance Regulator; Diagnosis, Di

2002
Use of nasal potential difference and sweat chloride as outcome measures in multicenter clinical trials in subjects with cystic fibrosis.
    Pediatric pulmonology, 2002, Volume: 33, Issue:2

    Topics: Adolescent; Adult; Analysis of Variance; Chlorides; Clinical Trials, Phase I as Topic; Cystic Fibros

2002
Cystic fibrosis: keeping it in the family.
    Pediatric pulmonology, 2002, Volume: 33, Issue:2

    Topics: Adult; Chlorides; Cystic Fibrosis; Cystic Fibrosis Transmembrane Conductance Regulator; Female; Fert

2002
Biological variation in sweat sodium chloride conductivity.
    Annals of clinical biochemistry, 2002, Volume: 39, Issue:Pt 1

    Topics: Adolescent; Adult; Case-Control Studies; Child; Child, Preschool; Cystic Fibrosis; Electric Conducti

2002
Mutations of the cystic fibrosis gene and intermediate sweat chloride levels in children.
    American journal of respiratory and critical care medicine, 2002, Mar-15, Volume: 165, Issue:6

    Topics: Adolescent; Belgium; Child; Child, Preschool; Chlorides; Cystic Fibrosis; Cystic Fibrosis Transmembr

2002
Mercurimetric determination of chloride in sweat.
    Clinica chimica acta; international journal of clinical chemistry, 2002, May-07, Volume: 319, Issue:1

    Topics: Chlorides; Cystic Fibrosis; Humans; Linear Models; Mercury; Sensitivity and Specificity; Sweat; Titr

2002
Negative sweat test in hypertrypsinaemic infants with cystic fibrosis carrying rare CFTR mutations.
    European journal of pediatrics, 2002, Volume: 161, Issue:4

    Topics: Child; Child, Preschool; Chlorides; Cystic Fibrosis; Cystic Fibrosis Transmembrane Conductance Regul

2002
Positive sweat test following meningococcal septicaemia.
    Acta paediatrica (Oslo, Norway : 1992), 2002, Volume: 91, Issue:3

    Topics: Bacteremia; Child, Preschool; Cystic Fibrosis; Diagnosis, Differential; Diagnostic Tests, Routine; E

2002
pH of sweat of patients with cystic fibrosis.
    Klinische Wochenschrift, 1976, Mar-15, Volume: 54, Issue:6

    Topics: Bicarbonates; Cystic Fibrosis; Humans; Hydrogen-Ion Concentration; Sweat; Sweating

1976
[Pathogenesis and early diagnosis of mucoviscidosis in children (literature survey)].
    Voprosy okhrany materinstva i detstva, 1976, Volume: 21, Issue:8

    Topics: Adrenal Cortex Hormones; Albumins; Bronchi; Calcium; Calcium Metabolism Disorders; Child; Child, Pre

1976
Sweat testing for cystic fibrosis: errors associated with the in-situ sweat test using chloride ion selective electrodes.
    Clinica chimica acta; international journal of clinical chemistry, 1977, Oct-15, Volume: 80, Issue:2

    Topics: Chlorides; Cystic Fibrosis; Electrodes; Humans; Hydrogen-Ion Concentration; Methods; Skin Absorption

1977
Ultramicro-electrophoresis of protein in sweat from patients with cystic fibrosis of the pancreas and controls.
    European journal of pediatrics, 1978, May-22, Volume: 128, Issue:1

    Topics: Adolescent; Binding Sites; Cell Membrane; Child; Child, Preschool; Cystic Fibrosis; Electrophoresis;

1978
Serum alpha - fetoprotein levels in patients with cystic fibrosis and their parents and siblings.
    British medical journal, 1975, Mar-29, Volume: 1, Issue:5960

    Topics: alpha-Fetoproteins; Bronchiectasis; Celiac Disease; Chlorides; Cystic Fibrosis; Fetal Proteins; Gene

1975
[Sweat test for diagnosis of mucoviscidosis].
    Laboratornoe delo, 1975, Issue:6

    Topics: Child; Chlorine; Cystic Fibrosis; Humans; Iontophoresis; Silver Nitrate; Sodium; Sweat

1975
Letter: Screening for cystic fibrosis.
    Lancet (London, England), 1976, Apr-03, Volume: 1, Issue:7962

    Topics: Albumins; Cystic Fibrosis; False Positive Reactions; Humans; Infant, Newborn; Infant, Newborn, Disea

1976
Cystic fibrosis: normal volumes of red cells. Model experiments on the pathomechanism of the disease.
    European journal of pediatrics, 1976, Jul-12, Volume: 122, Issue:4

    Topics: Cystic Fibrosis; Erythrocytes; Gramicidin; Humans; Ion Exchange; Permeability; Potassium; Sodium; Sw

1976
Cystic-fibrosis heterozygosity in childhood bronchial asthma.
    Lancet (London, England), 1977, Jan-22, Volume: 1, Issue:8004

    Topics: Asthma; Bromides; Child; Chlorides; Cystic Fibrosis; Heterozygote; Humans; Sodium; Sweat

1977
[Comparative evaluation of various tests in the diagnosis of mucoviscidosis in children].
    Laboratornoe delo, 1977, Issue:12

    Topics: Adolescent; Child; Child, Preschool; Chlorides; Cystic Fibrosis; Humans; Infant; Methods; Potassium;

1977
Does that child really have cystic fibrosis?
    Lancet (London, England), 1978, Aug-19, Volume: 2, Issue:8086

    Topics: Amylases; Bicarbonates; Child; Child, Preschool; Chlorides; Cholecystokinin; Cystic Fibrosis; Evalua

1978
Cystic-fibrosis variants--or variations?
    Lancet (London, England), 1978, Nov-11, Volume: 2, Issue:8098

    Topics: Bronchitis; Chlorides; Chronic Disease; Cystic Fibrosis; Diagnosis, Differential; Humans; Pancreas;

1978
Sweat tests in cystic fibrosis.
    Lancet (London, England), 1978, Nov-11, Volume: 2, Issue:8098

    Topics: Child; Chlorides; Cystic Fibrosis; Eczema; False Positive Reactions; Humans; Sodium; Sweat

1978
'Rusters'. The corrosive action of palmar sweat: I. Sodium chloride in sweat.
    Acta dermato-venereologica, 1979, Volume: 59, Issue:2

    Topics: Administration, Topical; Adolescent; Adult; Aluminum; Chlorides; Corrosion; Cystic Fibrosis; Dermato

1979
Prostaglandins and cystic fibrosis.
    Monographs in paediatrics, 1979, Volume: 10

    Topics: Adult; Child; Cyclic AMP; Cystic Fibrosis; Humans; Platelet Aggregation; Prostaglandins E; Sweat

1979
[A new type of sweat test and its use in children].
    Problemy medycyny wieku rozwojowego, 1979, Volume: 8

    Topics: Adolescent; Age Factors; Child; Child, Preschool; Chlorides; Cystic Fibrosis; Electrodes; Humans; In

1979
Improvement on the safety of sweat-test equipment.
    Medical & biological engineering & computing, 1978, Volume: 16, Issue:5

    Topics: Accident Prevention; Burns, Electric; Cystic Fibrosis; Humans; Iontophoresis; Safety; Sweat

1978
Diagnosing cystic fibrosis in adults.
    The New England journal of medicine, 1979, May-17, Volume: 300, Issue:20

    Topics: Adult; Age Factors; Cystic Fibrosis; Electrolytes; Humans; Sweat

1979
Sweat tests.
    JAMA, 1979, May-25, Volume: 241, Issue:21

    Topics: Cystic Fibrosis; Humans; Sweat

1979
[Chlorine determination method in the screening of mucoviscidosis].
    Orvosi hetilap, 1979, Jul-15, Volume: 120, Issue:28

    Topics: Adolescent; Child; Child, Preschool; Chlorine; Cystic Fibrosis; Humans; Infant; Skin; Sweat

1979
Reliability of sweat test in cystic fibrosis.
    The Journal of pediatrics, 1979, Volume: 95, Issue:4

    Topics: Chlorides; Cystic Fibrosis; False Positive Reactions; Humans; Sodium; Sweat

1979
The sweat test for cystic fibrosis.
    JAMA, 1979, Nov-02, Volume: 242, Issue:18

    Topics: Cystic Fibrosis; Humans; Sweat

1979
Metabolic alkalosis in infants with cystic fibrosis.
    Pediatrics, 1979, Volume: 64, Issue:3

    Topics: Alkalosis; Carbon Dioxide; Chlorides; Cystic Fibrosis; Electrolytes; Female; Humans; Infant; Male; S

1979
[Improvement of the sweat test in diagnosis of mucoviscidosis].
    Zeitschrift fur medizinische Laboratoriumsdiagnostik, 1979, Volume: 20, Issue:2

    Topics: Child; Cystic Fibrosis; Humans; Mass Screening; Pilocarpine; Secretory Rate; Sweat

1979
[Problems in the early diagnosis of mucoviscidosis (cystic fibrosis].
    Zeitschrift fur arztliche Fortbildung, 1979, Nov-15, Volume: 73, Issue:22

    Topics: Adolescent; Albumins; Bronchitis; Child; Child, Preschool; Cystic Fibrosis; Female; Genes, Recessive

1979
Limitations of diagnostic value of the sweat test.
    Archives of disease in childhood, 1977, Volume: 52, Issue:11

    Topics: Adolescent; Asthma; Child; Child, Preschool; Cystic Fibrosis; Diagnosis, Differential; Humans; Sodiu

1977
Bronchiectasis and mucoviscidosis.
    Journal of the Indian Medical Association, 1977, Dec-16, Volume: 69, Issue:12

    Topics: Adolescent; Adult; Aged; Bronchiectasis; Chlorides; Cystic Fibrosis; Humans; Male; Middle Aged; Swea

1977
Meconium screening for cystic fibrosis.
    Pediatric annals, 1978, Volume: 7, Issue:1

    Topics: Albumins; Cystic Fibrosis; False Negative Reactions; Humans; Infant, Newborn; Mass Screening; Meconi

1978
[A simple test for the screening of mucoviscidosis (cystic fibrosis)].
    Orvosi hetilap, 1978, Jan-29, Volume: 119, Issue:5

    Topics: Child; Child, Preschool; Chlorides; Cystic Fibrosis; Female; Humans; Hungary; Male; Mass Screening;

1978
Edema as the presenting symptom of cystic fibrosis: difficulties in diagnosis.
    American journal of diseases of children (1960), 1978, Volume: 132, Issue:3

    Topics: Chlorides; Cystic Fibrosis; Edema; Female; Humans; Hypoproteinemia; Infant; Male; Sweat

1978
[Simultaneous occurrence of mucoviscidosis and bronchial asthma and its significance from the viewpoint of therapy and care].
    Orvosi hetilap, 1978, Mar-12, Volume: 119, Issue:11

    Topics: Asthma; Child; Child, Preschool; Cystic Fibrosis; Female; Humans; Male; Sweat

1978
Limitations of the sweat test.
    Archives of disease in childhood, 1978, Volume: 53, Issue:4

    Topics: Child; Chlorides; Cystic Fibrosis; Humans; Pancreas; Sodium; Sweat

1978
Intermediate-range sweat chloride concentration and Pseudomonas bronchitis. A cystic fibrosis variant with preservation of exocrine pancreatic function.
    JAMA, 1978, Jun-23, Volume: 239, Issue:25

    Topics: Adolescent; Bronchitis; Child; Child, Preschool; Chlorides; Cystic Fibrosis; Diagnosis, Differential

1978
[Family studies in mucoviscidosis with special emphasis on the elucidation of the heterozygote gene carrier state and heredity].
    Kinderarztliche Praxis, 1978, Volume: 46, Issue:3

    Topics: Bromides; Chlorides; Cystic Fibrosis; Female; Heterozygote; Humans; Male; Pedigree; Sodium; Sweat

1978
A modified ion-selective electrode method for measurement of chloride in sweat.
    American journal of clinical pathology, 1978, Volume: 69, Issue:6

    Topics: Adolescent; Adult; Child; Child, Preschool; Chlorides; Cystic Fibrosis; Electrodes; Humans; Infant;

1978
The significance of the sweat test in chronic pancreatitis.
    The Tohoku journal of experimental medicine, 1978, Volume: 125, Issue:1

    Topics: Adolescent; Adult; Age Factors; Aged; Child; Chronic Disease; Cystic Fibrosis; Eating; Female; Human

1978
Sweat testing for cystic fibrosis. Diagnostic screening with a combination chloride ion-selective electrode.
    Archives of disease in childhood, 1978, Volume: 53, Issue:6

    Topics: Age Factors; Chlorides; Cystic Fibrosis; Electrodes; Female; Humans; Infant, Newborn; Infant, Newbor

1978
False negative sweat tests with apparently adequate sweat collections.
    Australian paediatric journal, 1978, Volume: 14, Issue:2

    Topics: Child; Chlorides; Cystic Fibrosis; False Negative Reactions; Humans; Sodium; Sweat

1978
Cystic fibrosis. Problems encountered with sweat testing.
    JAMA, 1978, Oct-27, Volume: 240, Issue:18

    Topics: Chlorides; Cystic Fibrosis; False Negative Reactions; False Positive Reactions; Humans; Iontophoresi

1978
Measurement of chloride in sweat with the chloride-selective electrode.
    Clinical chemistry, 1978, Volume: 24, Issue:11

    Topics: Chlorides; Cystic Fibrosis; Electrodes; Humans; Infant, Newborn; Methods; Pilocarpine; Sweat

1978
Sweat testing for cystic fibrosis.
    Archives of disease in childhood, 1978, Volume: 53, Issue:11

    Topics: Chlorides; Cystic Fibrosis; False Negative Reactions; Humans; Infant, Newborn; Mass Screening; Sweat

1978
Quality of sweat test performance in the diagnosis of cystic fibrosis.
    Clinical chemistry, 1979, Volume: 25, Issue:1

    Topics: Adolescent; Adult; Child; Child, Preschool; Cystic Fibrosis; Humans; Infant; Pilocarpine; Sweat; Swe

1979
Atypical cystic fibrosis of the pancreas with normal levels of sweat chloride and minimal pancreatic lesions.
    The Journal of pediatrics, 1979, Volume: 94, Issue:2

    Topics: Child; Chlorides; Cystic Fibrosis; Humans; Infant; Male; Pancreas; Sweat

1979
False positive sweat test, malnutrition, and the Mauriac syndrome.
    The Journal of pediatrics, 1979, Volume: 94, Issue:2

    Topics: Child; Chlorides; Cystic Fibrosis; Diabetes Mellitus, Type 1; Dwarfism; False Positive Reactions; Fe

1979
Cystic fibrosis in adolescents and adults.
    The Quarterly journal of medicine, 1976, Volume: 45, Issue:179

    Topics: Adolescent; Adult; Aspergillus; Cystic Fibrosis; Female; Gastrointestinal Diseases; Growth; Humans;

1976
Test strip meconium screening for cystic fibrosis.
    American journal of diseases of children (1960), 1977, Volume: 131, Issue:1

    Topics: Albumins; Cystic Fibrosis; False Negative Reactions; False Positive Reactions; Female; Humans; Indic

1977
[Sweat bromide test in infants with dystrepsia].
    Pediatria polska, 1977, Volume: 52, Issue:2

    Topics: Age Factors; Bromides; Cystic Fibrosis; Heterozygote; Homozygote; Humans; Infant; Sweat

1977
Dietary essential fatty acids in cystic fibrosis.
    Pediatrics, 1977, Volume: 59, Issue:3

    Topics: Adolescent; Child; Child, Preschool; Cystic Fibrosis; Dietary Fats; Fatty Acids; Fatty Acids, Essent

1977
Renin-like (angiotensinogenase) activity in sweat of patients with cystic fibrosis and controls.
    Klinische Wochenschrift, 1977, Mar-15, Volume: 55, Issue:6

    Topics: Adolescent; Adult; Child; Child, Preschool; Cystic Fibrosis; Humans; Renin; Sweat; Sweat Glands

1977
Cystic fibrosis: a new outlook. 70 patients above 25 years of age.
    Medicine, 1977, Volume: 56, Issue:2

    Topics: Adult; Anti-Bacterial Agents; Child; Clubfoot; Cystic Fibrosis; Educational Status; Family Character

1977
Case records of the Massachusetts General Hospital. Weekly clinicopathological exercises. Case 26-1977.
    The New England journal of medicine, 1977, Jun-30, Volume: 296, Issue:26

    Topics: Age Factors; Cystic Fibrosis; Diagnosis, Differential; Epididymis; Humans; Intestines; Liver; Lung;

1977
[Sweat-electrolyte studies under intravenous load with sodium chloride in patients with mucoviscidosis and chronic bronchitis].
    Padiatrie und Grenzgebiete, 1977, Volume: 16, Issue:2

    Topics: Adult; Bronchitis; Child; Chronic Disease; Cystic Fibrosis; Humans; Injections, Intravenous; Middle

1977
[The results of bromide tests in patients with cystic fibrosis, in their parents and control subjects].
    Ceskoslovenska pediatrie, 1977, Volume: 32, Issue:3

    Topics: Adolescent; Adult; Bromides; Child, Preschool; Cystic Fibrosis; Heterozygote; Humans; Parents; Sweat

1977
Sweat testing for cystic fibrosis: characteristics of a combination chloride ion-selective electrode.
    Clinica chimica acta; international journal of clinical chemistry, 1977, May-16, Volume: 77, Issue:1

    Topics: Chemistry, Clinical; Chlorides; Cystic Fibrosis; Drug Stability; Electrodes; Humans; Methods; Sweat;

1977
Mother and daughter with cystic fibrosis.
    The Journal of pediatrics, 1977, Volume: 91, Issue:2

    Topics: Adult; Chlorides; Cystic Fibrosis; Female; Follow-Up Studies; Humans; Infant; Infant, Newborn; Pregn

1977
[Neonatal screening for cystic fibrosis with the BM test on meconium. Preliminary results].
    Minerva pediatrica, 1977, Mar-31, Volume: 29, Issue:11

    Topics: Cystic Fibrosis; Humans; Infant, Newborn; Infant, Newborn, Diseases; Meconium; Sweat

1977
Cystic fibrosis screening by sweat analysis: a critical review of techniques.
    The Medical journal of Australia, 1977, Jun-18, Volume: 1, Issue:25

    Topics: Child; Child, Preschool; Cystic Fibrosis; Electric Conductivity; Humans; Infant; Infant, Newborn; Os

1977
Collecting sweat in patients with cystic fibrosis.
    South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde, 1977, Aug-27, Volume: 52, Issue:10

    Topics: Child; Cystic Fibrosis; Humans; Specimen Handling; Sweat

1977
[Current use of the sweat test (author's transl)].
    Padiatrie und Padologie, 1977, Volume: 12, Issue:4

    Topics: Cystic Fibrosis; Humans; Infant, Newborn; Iontophoresis; Methods; Pilocarpine; Sweat

1977
[Usefulness of the bromide sweat test in early diagnosis of mucoviscidosis].
    Pediatria polska, 1977, Volume: 52, Issue:9

    Topics: Age Factors; Bromides; Cystic Fibrosis; Humans; Infant; Infant, Newborn; Sweat

1977
ALPHA-Amylase activity in sweat and serum of patients with cystic fibrosis of the pancreas.
    European journal of pediatrics, 1976, Jul-12, Volume: 122, Issue:4

    Topics: Adolescent; Amylases; Child; Child, Preschool; Cystic Fibrosis; Humans; Sweat

1976
[Diagnosis of cystic fibrosis].
    Lakartidningen, 1976, Mar-03, Volume: 73, Issue:10

    Topics: Albumins; Chlorides; Cystic Fibrosis; Humans; Infant, Newborn; Infant, Newborn, Diseases; Meconium;

1976
The use of electrolyte measurements in the detection of cystic fibrosis.
    Clinica chimica acta; international journal of clinical chemistry, 1976, Jun-15, Volume: 69, Issue:3

    Topics: Adolescent; Adult; Child; Child, Preschool; Chlorides; Cystic Fibrosis; Female; Heterozygote; Humans

1976
[Sweat conductometry in cellulose acetate foil--a simplified method for diagnosis of cystic fibrosis].
    Kinderarztliche Praxis, 1976, Volume: 44, Issue:5

    Topics: Conductometry; Cystic Fibrosis; Humans; Sweat

1976
Electrolyte values of sweat obtained by local and whole body collection methods in cystic fibrosis patients.
    The Journal of pediatrics, 1976, Volume: 89, Issue:3

    Topics: Adult; Chlorides; Cystic Fibrosis; Humans; Male; Sodium; Sweat

1976
Letter: Intralipid and cystic fibrosis.
    Pediatrics, 1976, Volume: 58, Issue:3

    Topics: Cystic Fibrosis; Electrolytes; Humans; Infant Food; Infant, Newborn; Sweat

1976
Laboratory confirmation of the diagnosis of cystic fibrosis.
    Clinical chemistry, 1976, Volume: 22, Issue:11

    Topics: Adolescent; Adult; Child; Child, Preschool; Chlorides; Clinical Laboratory Techniques; Cystic Fibros

1976
[Concentration values of sodium, potassium and chlorine electrolytes and lactic acid concentrations in the sweat of healthy children, in children with chronic infections of the respiratory tract (perinasal sinusitis, recurrent bronchitis, sinal-and-bronch
    Problemy medycyny wieku rozwojowego, 1975, Volume: 4

    Topics: Age Factors; Bronchitis; Child; Chlorine; Chronic Disease; Cystic Fibrosis; Humans; Lactates; Potass

1975
[Determination of lastic acid concentration in the blood, sweat and faeces of children with mucoviscidosis and in healthy children (author's transl)].
    Problemy medycyny wieku rozwojowego, 1975, Volume: 4

    Topics: Child; Cystic Fibrosis; Feces; Humans; Lactates; Photometry; Sweat

1975
[BM-test Meconium. A new screening method for cystic fibrosis].
    Ugeskrift for laeger, 1975, Feb-03, Volume: 137, Issue:6

    Topics: Albumins; Cystic Fibrosis; Electrolytes; Humans; Infant, Newborn; Mass Screening; Meconium; Sodium;

1975
Insulin iontophoresis in cystic fibrosis.
    Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine (New York, N.Y.), 1975, Volume: 149, Issue:3

    Topics: Chlorides; Cystic Fibrosis; Heterozygote; Humans; Insulin; Iontophoresis; Pilocarpine; Sweat

1975
Negative sweat tests and cystic fibrosis.
    Archives of disease in childhood, 1975, Volume: 50, Issue:6

    Topics: Amylases; Bicarbonates; Child; Child, Preschool; Chronic Disease; Cystic Fibrosis; Female; Humans; L

1975
The source of Na+ and Cl- activities on the skin surface. Experiences with electrode measurements in children.
    The Journal of laboratory and clinical medicine, 1975, Volume: 86, Issue:3

    Topics: Adolescent; Adult; Child; Child, Preschool; Chlorides; Cystic Fibrosis; Electrodes; Humans; Infant;

1975
Cystic fibrosis: present status and future prospects in detection of patients and carriers.
    Canadian Medical Association journal, 1975, Sep-20, Volume: 113, Issue:6

    Topics: Biological Assay; Blood Proteins; Carrier State; Cystic Fibrosis; Female; Heterozygote; Homozygote;

1975
[Appendicitis and mucoviscidosis].
    Medecine & chirurgie digestives, 1975, Volume: 4, Issue:1

    Topics: Adolescent; Appendicitis; Appendix; Cystic Fibrosis; Humans; Sweat

1975
Unusual clinical course in a child with cystic fibrosis treated with fat emulsion.
    Archives of disease in childhood, 1975, Volume: 50, Issue:1

    Topics: Cystic Fibrosis; Emulsions; Female; Glycine max; Humans; Ileostomy; Infant; Infant, Newborn; Infusio

1975
Polyamines in cystic fibrosis.
    Pediatric research, 1975, Volume: 9, Issue:9

    Topics: Bile; Cystic Fibrosis; Duodenum; Humans; Intestinal Secretions; Polyamines; Saliva; Spermidine; Sper

1975
[Determination of sweat chloride with an ion-selective electrode].
    Lakartidningen, 1976, Mar-03, Volume: 73, Issue:10

    Topics: Adolescent; Child; Child, Preschool; Chlorides; Cystic Fibrosis; Electrodes; Humans; Infant; Infant,

1976
A therapeutic trial of fatty acid supplementation in cystic fibrosis.
    Pediatrics, 1976, Volume: 57, Issue:4

    Topics: Body Weight; Chymotrypsin; Cystic Fibrosis; Fatty Acids; Feces; Humans; Infant; Linoleic Acids; Sodi

1976
[Cystic fibrosis screening using a simplified night sweat test--results of a pilot study].
    Kinderarztliche Praxis, 1976, Volume: 44, Issue:4

    Topics: Child; Child, Preschool; Cystic Fibrosis; Humans; Mass Screening; Sweat; Time Factors

1976
Cystic fibrosis screening in the newborn.
    Archives of disease in childhood, 1976, Volume: 51, Issue:4

    Topics: Chymotrypsin; Clinical Enzyme Tests; Cystic Fibrosis; Feces; Humans; Infant, Newborn; Sweat; Trypsin

1976
The kallikrein-kinin system of sweat in normal and cystic fibrosis subjects.
    Agents and actions. Supplements, 1992, Volume: 38 ( Pt 3)

    Topics: Child; Cystic Fibrosis; Female; Humans; Isoproterenol; Kallikreins; Male; Pilocarpine; Prekallikrein

1992
Cystic fibrosis in a 70 year old woman.
    Thorax, 1992, Volume: 47, Issue:3

    Topics: Aged; Bronchiectasis; Celiac Disease; Cystic Fibrosis; Family; Female; Genotype; Humans; Respiratory

1992
Lithium treatment of a bipolar patient with cystic fibrosis.
    The American journal of psychiatry, 1992, Volume: 149, Issue:4

    Topics: Adult; Bipolar Disorder; Chlorides; Cystic Fibrosis; Female; Humans; Lithium Carbonate; Sweat

1992
Variation of sweat sodium and chloride with age in cystic fibrosis and normal populations: further investigations in equivocal cases.
    Annals of clinical biochemistry, 1992, Volume: 29 ( Pt 2)

    Topics: Adolescent; Adult; Age Factors; Child; Chlorides; Cystic Fibrosis; DNA; Female; Humans; Male; Osmola

1992
[Determination of nasal transepithelial potential difference (DDPTE) in cystic fibrosis. Analysis of a simplified measurement technique].
    Archives francaises de pediatrie, 1991, Volume: 48, Issue:9

    Topics: Child; Child, Preschool; Cystic Fibrosis; Epithelium; Humans; Infant; Ion Channels; Membrane Potenti

1991
[Comparison of the classical Gibson-Cooke methods and the chloride-sensitive electrode in sweat testing for diagnosis of cystic fibrosis].
    Padiatrie und Padologie, 1991, Volume: 26, Issue:4

    Topics: Adolescent; Child; Child, Preschool; Chlorides; Cystic Fibrosis; Electrodes; Female; Humans; Infant;

1991
A simple and disposable sweat collector.
    European journal of applied physiology and occupational physiology, 1991, Volume: 63, Issue:3-4

    Topics: Adolescent; Adult; Child; Cystic Fibrosis; Electrolytes; Exercise Test; Humans; Lactates; Male; Spec

1991
Efficacy of statewide neonatal screening for cystic fibrosis by assay of trypsinogen concentrations.
    The New England journal of medicine, 1991, Sep-12, Volume: 325, Issue:11

    Topics: Clinical Protocols; Cystic Fibrosis; False Negative Reactions; False Positive Reactions; Humans; Inc

1991
Cystic fibrosis gene mutation in two sisters with mild disease and normal sweat electrolyte levels.
    The New England journal of medicine, 1991, Dec-05, Volume: 325, Issue:23

    Topics: Base Sequence; Cystic Fibrosis; DNA; Electrolytes; Exons; Female; Humans; Middle Aged; Molecular Seq

1991
Benign missense variations in the cystic fibrosis gene.
    American journal of human genetics, 1990, Volume: 47, Issue:4

    Topics: Adult; Alleles; Base Sequence; Chlorides; Chromosome Deletion; Cystic Fibrosis; DNA Mutational Analy

1990
Sweat sodium or chloride?
    Clinical chemistry, 1991, Volume: 37, Issue:1

    Topics: Adolescent; Child; Child, Preschool; Chlorides; Cystic Fibrosis; Humans; Infant; Infant, Newborn; So

1991
Colonic transepithelial potential difference in infants with cystic fibrosis.
    The Journal of pediatrics, 1991, Volume: 118, Issue:3

    Topics: Amiloride; Chlorides; Cystic Fibrosis; Humans; Infant; Infant, Newborn; Intestinal Absorption; Intes

1991
Correlation of phenotypic and genetic heterogeneity in cystic fibrosis: variability in sweat electrolyte levels contributes to heterogeneity and is increased with the XV-2c/KM19 B haplotype.
    American journal of medical genetics, 1991, May-01, Volume: 39, Issue:2

    Topics: Child; Cystic Fibrosis; DNA; Electrolytes; Genetic Markers; Haplotypes; HLA-DR Antigens; Humans; Phe

1991
Sweat chloride concentration in cystic fibrosis patients varies with KM.19 genotype but not with the presence of the common F508 deletion.
    American journal of medical genetics, 1991, May-01, Volume: 39, Issue:2

    Topics: Adolescent; Adult; Child; Child, Preschool; Chlorides; Chromosome Deletion; Cystic Fibrosis; Female;

1991
Lung perfusion scintigrams in children with intermittently increased sweat electrolytes.
    Acta Universitatis Carolinae. Medica, 1990, Volume: 36, Issue:1-4

    Topics: Child; Cystic Fibrosis; Electrolytes; Humans; Lung; Radionuclide Imaging; Sweat

1990
The effect of nicardipine, a calcium channel blocker, on the sweat test in adult patients with cystic fibrosis.
    Acta Universitatis Carolinae. Medica, 1990, Volume: 36, Issue:1-4

    Topics: Adult; Cystic Fibrosis; Humans; Nicardipine; Sodium; Sweat

1990
Study of the forms of sweat crystallisation in cystic fibrosis patients.
    Acta Universitatis Carolinae. Medica, 1990, Volume: 36, Issue:1-4

    Topics: Crystallization; Cystic Fibrosis; Diagnostic Errors; Humans; Sweat

1990
Na+, K+, H+, Cl-, and Ca2+ concentrations in cystic fibrosis eccrine sweat in vivo and in vitro.
    The Journal of laboratory and clinical medicine, 1990, Volume: 115, Issue:4

    Topics: Adolescent; Adult; Calcium; Chlorides; Cystic Fibrosis; Hot Temperature; Humans; Hydrogen-Ion Concen

1990
[The form of crystallization of perspiration in pancreatic cystic fibrosis].
    Anales espanoles de pediatria, 1990, Volume: 32, Issue:6

    Topics: Crystallization; Cystic Fibrosis; Electrolytes; Humans; Iontophoresis; Pilocarpine; Sweat

1990
The relation between genotype and phenotype in cystic fibrosis--analysis of the most common mutation (delta F508).
    The New England journal of medicine, 1990, Nov-29, Volume: 323, Issue:22

    Topics: Adolescent; Adult; Alleles; Child; Child, Preschool; Chlorides; Chromosomes, Human, Pair 7; Cystic F

1990
[Reference values of Na(+) and Cl(-) concentrations in adult sweat].
    Zeitschrift fur Erkrankungen der Atmungsorgane, 1990, Volume: 175, Issue:2

    Topics: Adult; Bronchiectasis; Bronchitis; Child, Preschool; Chlorides; Cystic Fibrosis; Female; Humans; Inf

1990
Assay of a urinary CF-lectin factor as a second diagnostic test for cystic fibrosis.
    The American journal of the medical sciences, 1990, Volume: 299, Issue:2

    Topics: Adolescent; Adult; Chlorides; Chromatography, Gel; Chromatography, Ion Exchange; Cystic Fibrosis; Fe

1990
DNA analysis of cystic fibrosis genotypes in relatives with equivocal sweat test results.
    Clinical and investigative medicine. Medecine clinique et experimentale, 1990, Volume: 13, Issue:1

    Topics: Chromosomes, Human, Pair 7; Cystic Fibrosis; DNA; Electrolytes; Family Health; Female; Genetic Marke

1990
The sweat crystallization test in the diagnosis of cystic fibrosis.
    Journal of pediatric gastroenterology and nutrition, 1990, Volume: 10, Issue:3

    Topics: Crystallization; Cystic Fibrosis; Diagnostic Errors; Humans; Sweat

1990
Depressive illness and abnormal sweat electrolytes. A case report.
    South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde, 1990, Jan-20, Volume: 77, Issue:2

    Topics: Adolescent; Chlorides; Cystic Fibrosis; Depression; Diagnosis, Differential; False Positive Reaction

1990
The sweat test for cystic fibrosis.
    North Carolina medical journal, 1990, Volume: 51, Issue:6

    Topics: Cystic Fibrosis; False Negative Reactions; False Positive Reactions; Humans; Sweat

1990
Sweat sodium and chloride concentrations--essential criteria for the diagnosis of cystic fibrosis in adults.
    Annals of clinical biochemistry, 1990, Volume: 27 ( Pt 4)

    Topics: Adolescent; Adult; Chlorides; Cystic Fibrosis; Female; Humans; Male; Predictive Value of Tests; Repr

1990
Quantification of chloride in sweat with the Cystic Fibrosis Indicator System.
    Clinical chemistry, 1990, Volume: 36, Issue:1

    Topics: Chlorides; Cystic Fibrosis; Diagnosis, Computer-Assisted; Humans; Patch Tests; Skin Tests; Sweat

1990
Pathophysiology of cystic fibrosis with emphasis on salivary gland involvement.
    Journal of dental research, 1987, Volume: 66 Spec No

    Topics: Animals; Chlorides; Cystic Fibrosis; Exocrine Glands; Humans; Ion Channels; Mucus; Saliva; Salivary

1987
Prenatal diagnosis of cystic fibrosis by using linked DNA markers in 138 pregnancies at 1-in-4 risk.
    American journal of medical genetics, 1989, Volume: 33, Issue:2

    Topics: Cystic Fibrosis; Evaluation Studies as Topic; Female; Genetic Linkage; Genetic Markers; Humans; Pedi

1989
Results of second trimester prenatal diagnosis of cystic fibrosis in risk families.
    Czechoslovak medicine, 1989, Volume: 12, Issue:2

    Topics: Adult; Amniotic Fluid; Chlorides; Clinical Enzyme Tests; Cystic Fibrosis; Female; gamma-Glutamyltran

1989
[Are there mucoviscidosis specific humoral factors? 1: Properties, prevalence, preparation, formation].
    Zeitschrift fur Erkrankungen der Atmungsorgane, 1985, Volume: 164, Issue:1

    Topics: alpha-Macroglobulins; Blood Proteins; Calgranulin A; Ciliary Motility Disorders; Complement C3; Comp

1985
[Diagnosis of mucoviscidosis by examination of sweat: value of conductometry].
    Kinderarztliche Praxis, 1989, Volume: 57, Issue:10

    Topics: Adolescent; Child; Child, Preschool; Cystic Fibrosis; Flame Ionization; Galvanic Skin Response; Huma

1989
Fractional measurements of sweat osmolality in patients with cystic fibrosis.
    Archives of disease in childhood, 1989, Volume: 64, Issue:12

    Topics: Adolescent; Child; Child, Preschool; Cystic Fibrosis; Female; Humans; Iontophoresis; Male; Osmolar C

1989
Elevated sweat potassium, hyperaldosteronism and pseudo-Bartter's syndrome: a spectrum of disorders associated with cystic fibrosis.
    Journal of the Royal Society of Medicine, 1989, Volume: 82 Suppl 16

    Topics: Bartter Syndrome; Child, Preschool; Chlorides; Cystic Fibrosis; Female; Humans; Hyperaldosteronism;

1989
"Typical" cystic fibrosis in an elderly woman.
    The American journal of medicine, 1989, Volume: 86, Issue:6 Pt 1

    Topics: Aged; Chlorides; Chronic Disease; Cystic Fibrosis; Female; Humans; Lung; Radiography; Sweat

1989
Interpretation of sweat sodium results--the effect of patient age.
    Annals of clinical biochemistry, 1989, Volume: 26 ( Pt 1)

    Topics: Age Factors; Child; Child, Preschool; Cystic Fibrosis; False Negative Reactions; Humans; Infant; Inf

1989
Neonatal screening for cystic fibrosis.
    Lancet (London, England), 1986, Feb-08, Volume: 1, Issue:8476

    Topics: Age Factors; Child; Child, Preschool; Cystic Fibrosis; Female; Growth; Humans; Infant; Infant, Newbo

1986
Reduced morbidity in cystic fibrosis.
    Lancet (London, England), 1986, Feb-22, Volume: 1, Issue:8478

    Topics: Australia; Cystic Fibrosis; Humans; Infant, Newborn; Length of Stay; Sweat

1986
Neonatal screening for cystic fibrosis.
    Lancet (London, England), 1986, Mar-15, Volume: 1, Issue:8481

    Topics: Child, Preschool; Cystic Fibrosis; Humans; Infant; Infant, Newborn; Sweat

1986
Neonatal screening for cystic fibrosis.
    Lancet (London, England), 1986, Apr-05, Volume: 1, Issue:8484

    Topics: Adolescent; Adult; Child; Child, Preschool; Cystic Fibrosis; Humans; Infant; Infant, Newborn; Nether

1986
Diagnosis of cystic fibrosis in premature infants.
    Lancet (London, England), 1987, Jan-03, Volume: 1, Issue:8523

    Topics: Adult; Child; Cystic Fibrosis; Electrolytes; Humans; Infant, Newborn; Infant, Premature, Diseases; S

1987
Use of DNA markers linked to cystic fibrosis gene to resolve equivocal sweat test results.
    Lancet (London, England), 1987, Jul-18, Volume: 2, Issue:8551

    Topics: Child; Cystic Fibrosis; DNA; Genetic Markers; Humans; Infant; Male; Polymorphism, Restriction Fragme

1987
Diagnosis of cystic fibrosis.
    Lancet (London, England), 1987, Aug-29, Volume: 2, Issue:8557

    Topics: Chlorides; Cystic Fibrosis; Humans; Sodium; Sweat

1987
Diagnosis of cystic fibrosis.
    Lancet (London, England), 1987, Nov-14, Volume: 2, Issue:8568

    Topics: Cystic Fibrosis; Humans; Infant; Infant, Newborn; Sweat

1987
Variable reduction in beta-adrenergic sweat secretion in cystic fibrosis heterozygotes.
    The Journal of laboratory and clinical medicine, 1988, Volume: 111, Issue:5

    Topics: Acclimatization; Adrenergic beta-Agonists; Adult; Cystic Fibrosis; Dose-Response Relationship, Drug;

1988
DNA typing of a cystic fibrosis family with borderline sweat tests.
    Acta paediatrica Scandinavica, 1988, Volume: 77, Issue:3

    Topics: Child; Child, Preschool; Cystic Fibrosis; DNA; Female; Humans; Male; Polymorphism, Genetic; Polymorp

1988
Sweat tests and flucloxacillin.
    Archives of disease in childhood, 1989, Volume: 64, Issue:2

    Topics: Cloxacillin; Cystic Fibrosis; Floxacillin; Humans; Infant; Male; Sweat

1989
Abnormally high sweat osmolality in children with Down's syndrome.
    Journal of mental deficiency research, 1985, Volume: 29 ( Pt 3)

    Topics: Child, Preschool; Cystic Fibrosis; Down Syndrome; Humans; Iontophoresis; Osmolar Concentration; Swea

1985
Sweat osmolality in Down's syndrome and cystic fibrosis in an Indian population.
    British medical journal (Clinical research ed.), 1987, Jan-17, Volume: 294, Issue:6565

    Topics: Adolescent; Adult; Age Factors; Child; Cystic Fibrosis; Down Syndrome; Electrolytes; Female; Humans;

1987
Diagnosis of cystic fibrosis.
    Australian paediatric journal, 1988, Volume: 24, Issue:3

    Topics: Child, Preschool; Chlorides; Cystic Fibrosis; Genetic Techniques; Humans; Infant; Infant, Newborn; M

1988
Abnormal sweat electrolytes in symptomatic human immunodeficiency virus infection in a child.
    British medical journal (Clinical research ed.), 1987, Dec-05, Volume: 295, Issue:6611

    Topics: Acquired Immunodeficiency Syndrome; Child, Preschool; Cystic Fibrosis; Diagnosis, Differential; Fema

1987
An evaluation of screening for cystic fibrosis.
    Progress in clinical and biological research, 1987, Volume: 254

    Topics: Attitude of Health Personnel; Cost-Benefit Analysis; Cystic Fibrosis; False Negative Reactions; Fals

1987
Diagnosis of cystic fibrosis.
    British medical journal (Clinical research ed.), 1988, Jan-30, Volume: 296, Issue:6618

    Topics: Cystic Fibrosis; Female; Humans; Sodium Chloride; Sweat

1988
Borderline sweat test: criteria for cystic fibrosis diagnosis.
    Scandinavian journal of gastroenterology. Supplement, 1988, Volume: 143

    Topics: Adult; Child; Cystic Fibrosis; Diet, Sodium-Restricted; False Negative Reactions; False Positive Rea

1988
Cystic fibrosis: chromosome 7 DNA genotyping. An aide in resolving ambiguous diagnoses in siblings of known patients.
    Clinical pediatrics, 1988, Volume: 27, Issue:12

    Topics: Adolescent; Child; Child, Preschool; Chlorides; Chromosomes, Human, Pair 7; Cystic Fibrosis; Female;

1988
Screening for cystic fibrosis: a four year regional experience.
    Archives of disease in childhood, 1988, Volume: 63, Issue:12

    Topics: Age Factors; Child; Child, Preschool; Chlorides; Cystic Fibrosis; False Negative Reactions; False Po

1988
The sweat chloride concentration and prolactin activity in cystic fibrosis.
    Scandinavian journal of gastroenterology. Supplement, 1988, Volume: 143

    Topics: Animals; Chlorides; Cystic Fibrosis; Humans; Mice; Mice, Nude; Prolactin; Skin Transplantation; Swea

1988
Automated Ektachem method for measuring sodium in sweat.
    Clinical chemistry, 1988, Volume: 34, Issue:2

    Topics: Autoanalysis; Cystic Fibrosis; Reference Values; Sodium; Sweat

1988
Biochemical changes and endocrine responses in cystic fibrosis in relation to a marathon race.
    International journal of sports medicine, 1988, Volume: 9 Suppl 1

    Topics: Adolescent; Adult; Chlorides; Cystic Fibrosis; Hormones; Humans; Male; Physical Exertion; Running; S

1988
[Decentralized screening for mucoviscidosis with a chloride-sensitive electrode].
    Kinderarztliche Praxis, 1988, Volume: 56, Issue:1

    Topics: Child; Child, Preschool; Chlorides; Cystic Fibrosis; Electrodes; Female; Germany, East; Humans; Infa

1988
Incidence and implications of false-negative sweat test reports in patients with cystic fibrosis.
    Pediatric pulmonology, 1988, Volume: 4, Issue:3

    Topics: Cystic Fibrosis; False Negative Reactions; Humans; Retrospective Studies; Sweat; Time Factors

1988
Sweat test in children with cystic fibrosis.
    Acta paediatrica Scandinavica, 1988, Volume: 77, Issue:3

    Topics: Cystic Fibrosis; False Negative Reactions; Female; Humans; Infant; Infant, Newborn; Sodium; Sweat

1988
[Sweat chloride concentration and pancreatic function tests in patients with diffuse panbronchiolitis].
    Nihon Kyobu Shikkan Gakkai zasshi, 1988, Volume: 26, Issue:2

    Topics: Adult; Aged; Bronchiolitis; Chlorides; Cystic Fibrosis; Diagnosis, Differential; Female; Humans; Mal

1988
Sweat tests and flucloxacillin.
    Archives of disease in childhood, 1988, Volume: 63, Issue:7

    Topics: Adolescent; Child; Child, Preschool; Chlorides; Cloxacillin; Cystic Fibrosis; Floxacillin; Humans; I

1988
Sweat testing by capillary collection and osmometry: suitability of the Wescor Macroduct System for screening suspected cystic fibrosis patients.
    Australian paediatric journal, 1988, Volume: 24, Issue:3

    Topics: Adolescent; Capillary Permeability; Child; Child, Preschool; Cystic Fibrosis; Electrodes; Equipment

1988
Cystic fibrosis--clinical viewpoint--a disease that doesn't make sense.
    Progress in clinical and biological research, 1987, Volume: 254

    Topics: Chlorides; Cystic Fibrosis; Exocrine Pancreatic Insufficiency; Humans; Infant, Newborn; Intestinal O

1987
The sweat test.
    Archives of disease in childhood, 1987, Volume: 62, Issue:3

    Topics: Cystic Fibrosis; Humans; Sodium Chloride; Sweat

1987
Sweat sodium levels in adults with nasal polyps.
    Annals of allergy, 1987, Volume: 58, Issue:5

    Topics: Adult; Cystic Fibrosis; Female; Humans; Immunotherapy; Male; Nasal Polyps; Skin Tests; Sodium; Sweat

1987
[Sweat collection and osmometry in the diagnosis of cystic fibrosis: a new method].
    Padiatrie und Padologie, 1987, Volume: 22, Issue:2

    Topics: Cystic Fibrosis; Electrolytes; Humans; Infant; Osmolar Concentration; Specimen Handling; Sweat

1987
Chloride measurement by microelectrode in cystic fibrosis and normal sweat.
    Mineral and electrolyte metabolism, 1987, Volume: 13, Issue:3

    Topics: Chlorides; Chromatography, High Pressure Liquid; Cystic Fibrosis; False Negative Reactions; False Po

1987
[Diagnosis of cystic fibrosis].
    Ceskoslovenska pediatrie, 1987, Volume: 42, Issue:7

    Topics: Child; Cystic Fibrosis; Humans; Methods; Sweat

1987
[A simple and economical method of screening diagnosis of cystic fibrosis].
    Pediatriia, 1987, Issue:6

    Topics: Child; Child, Preschool; Chlorides; Cystic Fibrosis; Humans; Infant; Mass Screening; Sweat

1987
Cystic fibrosis: report of a Chinese case with suggestive family history.
    Taiwan yi xue hui za zhi. Journal of the Formosan Medical Association, 1987, Volume: 86, Issue:8

    Topics: Asian People; Child; Cystic Fibrosis; Humans; Male; Pedigree; Radiography; Sweat; Taiwan

1987
Sweat sulfate concentrations are decreased in cystic fibrosis.
    Clinica chimica acta; international journal of clinical chemistry, 1986, Mar-28, Volume: 155, Issue:3

    Topics: Adolescent; Adult; Biological Transport; Child; Chlorides; Chromatography, Ion Exchange; Cystic Fibr

1986
[Incidence of cystic fibrosis in children with diseases of the respiratory system].
    Pediatria polska, 1986, Volume: 61, Issue:1

    Topics: Child; Child, Preschool; Cystic Fibrosis; Diagnosis, Differential; False Positive Reactions; Humans;

1986
Malnutrition: a cause of elevated sweat chloride concentration.
    Acta paediatrica Scandinavica, 1986, Volume: 75, Issue:4

    Topics: Adolescent; Child; Child, Preschool; Chlorides; Cystic Fibrosis; Deficiency Diseases; Female; Humans

1986
Sweat sodium related to amount of sweat after sweat test in children with and without cystic fibrosis.
    Acta paediatrica Scandinavica, 1986, Volume: 75, Issue:4

    Topics: Adolescent; Child; Child, Preschool; Cystic Fibrosis; Humans; Infant; Infant, Newborn; Sodium; Sweat

1986
Munchausen syndrome by proxy simulating cystic fibrosis.
    Pediatrics, 1986, Volume: 78, Issue:4

    Topics: Body Weight; Child Abuse; Child, Preschool; Chlorides; Cystic Fibrosis; Diagnosis, Differential; Fat

1986
Interpretation of sweat sodium and chloride concentrations.
    Annals of clinical biochemistry, 1986, Volume: 23 ( Pt 1)

    Topics: Chlorides; Cystic Fibrosis; Humans; Sodium; Sweat

1986
The sweat test.
    Archives of disease in childhood, 1986, Volume: 61, Issue:11

    Topics: Chlorides; Cystic Fibrosis; Diagnostic Errors; Humans; Sodium; Specimen Handling; Sweat

1986
Lactate and bicarbonate uptake in the sweat duct of cystic fibrosis and normal subjects.
    Pediatric research, 1987, Volume: 21, Issue:1

    Topics: Bicarbonates; Chlorides; Cystic Fibrosis; Humans; Hydrogen-Ion Concentration; Lactates; Lactic Acid;

1987
Misdiagnosis of cystic fibrosis. Need for continuing follow-up and reevaluation.
    Clinical pediatrics, 1987, Volume: 26, Issue:2

    Topics: Asthma; Child; Child, Preschool; Cystic Fibrosis; Diagnosis, Differential; Electrolytes; False Posit

1987
Abnormal sweat electrolytes in a case of celiac disease and a case of psychosocial failure to thrive. Review of other reported causes.
    Clinical pediatrics, 1987, Volume: 26, Issue:2

    Topics: Celiac Disease; Cystic Fibrosis; Diagnosis, Differential; Electrolytes; Failure to Thrive; False Pos

1987
[Results of the sweat test, carried out by 2 methods, for the diagnosis of cystic fibrosis].
    Anales espanoles de pediatria, 1987, Volume: 26, Issue:1

    Topics: Adolescent; Child; Child, Preschool; Chlorides; Cystic Fibrosis; Electric Conductivity; Humans; Infa

1987
[Determination of electrolytes in sweat in the diagnosis of cystic fibrosis. A 23-year experience].
    Revista medica de Chile, 1985, Volume: 113, Issue:8

    Topics: Chlorine; Cystic Fibrosis; Electrolytes; Humans; Iontophoresis; Potassium; Sodium; Sweat

1985
Increased sweat chloride levels associated with prostaglandin E1 infusion.
    The Journal of pediatrics, 1985, Volume: 106, Issue:6

    Topics: Abnormalities, Multiple; Alprostadil; Chlorides; Cystic Fibrosis; Humans; Infant, Newborn; Long-Term

1985
Diagnosis of cystic fibrosis during adolescence.
    Journal of adolescent health care : official publication of the Society for Adolescent Medicine, 1986, Volume: 7, Issue:1

    Topics: Adolescent; Adult; Body Height; Body Weight; Child; Chlorides; Cystic Fibrosis; Female; Forced Expir

1986
[Cystic fibrosis].
    Duodecim; laaketieteellinen aikakauskirja, 1986, Volume: 102, Issue:1

    Topics: Child, Preschool; Cystic Fibrosis; Finland; Humans; Infant; Infant, Newborn; Sweat

1986
Advances in cystic fibrosis.
    Comprehensive therapy, 1986, Volume: 12, Issue:2

    Topics: Cystic Fibrosis; Humans; Pilocarpine; Sodium Chloride; Sweat

1986
Increased nasal potential difference and amiloride sensitivity in neonates with cystic fibrosis.
    The Journal of pediatrics, 1986, Volume: 108, Issue:4

    Topics: Adult; Amiloride; Biological Transport; Child; Chlorides; Cystic Fibrosis; Electron Transport; Human

1986
Plasma and urinary catecholamines in patients with cystic fibrosis.
    Pediatric research, 1985, Volume: 19, Issue:1

    Topics: Adolescent; Adult; Blood Pressure; Catecholamines; Ceruloplasmin; Child; Copper; Cystic Fibrosis; El

1985
Screening for cystic fibrosis.
    The Journal of pediatrics, 1985, Volume: 106, Issue:3

    Topics: Child; Cystic Fibrosis; Evaluation Studies as Topic; Humans; Infant; Reagent Kits, Diagnostic; Sweat

1985
Detection of cystic fibrosis heterozygotes using a modified loading with bromide.
    Human genetics, 1985, Volume: 69, Issue:3

    Topics: Administration, Oral; Adolescent; Adult; Bromides; Child; Child, Preschool; Chlorides; Cystic Fibros

1985
Coulometric titration of sweat collected with the Webster Collection System.
    Respiration; international review of thoracic diseases, 1985, Volume: 47, Issue:3

    Topics: Chlorides; Cystic Fibrosis; Female; Follow-Up Studies; Humans; Male; Specimen Handling; Sweat

1985
Is the sweat test infallible in cystic fibrosis?
    Acta paediatrica Scandinavica, 1985, Volume: 74, Issue:3

    Topics: Cystic Fibrosis; Female; Humans; Infant; Male; Sodium; Sweat

1985
A study of sweat sodium and chloride; criteria for the diagnosis of cystic fibrosis.
    Annals of clinical biochemistry, 1985, Volume: 22 ( Pt 2)

    Topics: Adolescent; Child; Child, Preschool; Chlorides; Cystic Fibrosis; Diagnostic Errors; Humans; Infant;

1985
Liquid-chromatographic determination of chloride in sweat from cystic fibrosis patients and normal persons.
    Clinical chemistry, 1985, Volume: 31, Issue:7

    Topics: Child, Preschool; Chlorides; Chromatography, Ion Exchange; Cystic Fibrosis; Female; Humans; Infant;

1985
Environmental deprivation and transient elevation of sweat electrolytes.
    The Journal of pediatrics, 1985, Volume: 107, Issue:2

    Topics: Child, Preschool; Cystic Fibrosis; Electrolytes; Failure to Thrive; Humans; Male; Psychosocial Depri

1985
[Mucoviscidosis in the adult].
    Revista clinica espanola, 1985, Volume: 176, Issue:8

    Topics: Adolescent; Chlorine; Cystic Fibrosis; Humans; Male; Pneumonia; Sweat

1985
Anion-exchange chromatography to determine the concentration of chloride in sweat for diagnosis of cystic fibrosis.
    Clinical chemistry, 1985, Volume: 31, Issue:10

    Topics: Adult; Child; Child, Preschool; Chlorides; Chromatography, Ion Exchange; Cystic Fibrosis; Female; Hu

1985
Recurrent respiratory disease, azoospermia, and nasal polyposis. A syndrome that mimics cystic fibrosis and immotile cilia syndrome.
    Archives of internal medicine, 1985, Volume: 145, Issue:12

    Topics: Adult; Chronic Disease; Ciliary Motility Disorders; Cystic Fibrosis; Diagnosis, Differential; Humans

1985
Thermal sweat lactate in cystic fibrosis and in normal children.
    European journal of applied physiology and occupational physiology, 1985, Volume: 54, Issue:5

    Topics: Child; Child, Preschool; Chlorides; Cystic Fibrosis; Energy Metabolism; Hot Temperature; Humans; Inf

1985
Mucoid Pseudomonas aeruginosa in patients with chronic illnesses.
    Lancet (London, England), 1971, Jan-30, Volume: 1, Issue:7692

    Topics: Adolescent; Adult; Bacteriuria; Bronchiectasis; Calcium; Child; Child, Preschool; Chronic Disease; C

1971
Screening for cystic fibrosis.
    Lancet (London, England), 1973, Dec-22, Volume: 2, Issue:7843

    Topics: Anti-Bacterial Agents; Child Health Services; Costs and Cost Analysis; Cystic Fibrosis; England; Fem

1973
Letter: Skin wrinkling in cystic fibrosis.
    Lancet (London, England), 1974, Oct-12, Volume: 2, Issue:7885

    Topics: Cystic Fibrosis; Hand; Humans; Hydrogen-Ion Concentration; Immersion; Keratins; Protein Binding; Ski

1974
Plasma proteins in meconium from normal infants and from babies with cystic fibrosis.
    Archives of disease in childhood, 1974, Volume: 49, Issue:11

    Topics: Antigens; Beta-Globulins; Blood Proteins; Chymotrypsin; Cystic Fibrosis; gamma-Globulins; Humans; Im

1974
Mechanism of water and electrolyte secretion by the eccrine sweat gland.
    Lancet (London, England), 1966, Jun-04, Volume: 1, Issue:7449

    Topics: Chemical Phenomena; Chemistry; Chlorides; Cystic Fibrosis; Humans; Lactates; Potassium; Sodium; Swea

1966
Elevated sweat chlorides and hypothyroidism.
    The Journal of pediatrics, 1968, Volume: 73, Issue:2

    Topics: Chlorides; Cystic Fibrosis; Diagnosis, Differential; Electrolytes; Humans; Hypothyroidism; Infant; M

1968
Effect of cystic-fibrosis sweat on sodium reabsorption by the normao sweat-gland.
    Lancet (London, England), 1970, May-09, Volume: 1, Issue:7654

    Topics: Cystic Fibrosis; Humans; Potassium; Sodium; Sweat; Sweat Glands

1970
Down's syndrome and cystic fibrosis.
    Pediatrics, 1969, Volume: 43, Issue:5

    Topics: Bone Marrow Diseases; Chlorides; Cystic Fibrosis; Down Syndrome; Humans; Infant; Pancreatic Diseases

1969
[Current views on the etiopathogenesis of mucoviscidosis and on the characterization of the defect].
    Recenti progressi in medicina, 1971, Volume: 50, Issue:3

    Topics: Calcium; Cystic Fibrosis; Electrolytes; Glucosyltransferases; Glycoproteins; Glycosaminoglycans; Hum

1971
[Mucoviscidosis in adults].
    La semaine des hopitaux : organe fonde par l'Association d'enseignement medical des hopitaux de Paris, 1968, Apr-14, Volume: 44, Issue:18

    Topics: Acetylcysteine; Adult; Bronchitis; Cystic Fibrosis; Duodenal Ulcer; Humans; Male; Middle Aged; Oxyte

1968
Diminished excretion of bicarbonate from the single sweat gland of patients with cystic fibrosis of the pancreas.
    European journal of clinical investigation, 1974, Volume: 4, Issue:4

    Topics: Adult; Bicarbonates; Biological Transport; Body Water; Cell Membrane Permeability; Child; Child, Pre

1974
Proceedings: Experience with an ion-specific electrode to measure sweat chloride.
    Archives of disease in childhood, 1974, Volume: 49, Issue:10

    Topics: Child; Chlorides; Cystic Fibrosis; Electrodes; Humans; Infant, Newborn; Sweat

1974
Screening for cystic fibrosis with chloride electrode. An investigation of sweat chloride with chloride electrode orion 417 in normal persons and in patients with cystic fibrosis.
    Danish medical bulletin, 1974, Volume: 21, Issue:6

    Topics: Adolescent; Adult; Child; Child, Preschool; Chlorides; Cystic Fibrosis; Electric Stimulation; Female

1974
[Mucoviscidosis and nasal polyposis in children].
    Medicinski pregled, 1974, Volume: 27, Issue:3-4

    Topics: Child; Chlorine; Cystic Fibrosis; Humans; Nasal Polyps; Nose Neoplasms; Sweat

1974
[Nightsweat collection for simple diagnosis of mucoviscidosis (author's transl)].
    Padiatrie und Padologie, 1974, Volume: 9, Issue:1

    Topics: Child; Chlorides; Cystic Fibrosis; Humans; Iontophoresis; Methods; Pilocarpine; Specimen Handling; S

1974
Cystic fibrosis and coeliac disease: coexistence in two children.
    Archives of disease in childhood, 1973, Volume: 48, Issue:9

    Topics: Biopsy; Body Height; Body Weight; Celiac Disease; Child; Child, Preschool; Chlorides; Cystic Fibrosi

1973
Cystic fibrosis in a patient with Kartagener syndrome.
    American journal of diseases of children (1960), 1974, Volume: 127, Issue:5

    Topics: Chlorides; Cystic Fibrosis; Humans; Infant; Kartagener Syndrome; Lung; Male; Radiography; Situs Inve

1974
Cystic fibrosis--survival could depend on you.
    Clinical pediatrics, 1972, Volume: 11, Issue:12

    Topics: Adolescent; Adult; Child; Child, Preschool; Chlorides; Cystic Fibrosis; Diet Therapy; Feces; Humans;

1972
Viscosity of exocrine secretions in cystic fibrosis: sweat, duodenal fluid and submaxillary saliva.
    Biorheology, 1972, Volume: 9, Issue:1

    Topics: Cystic Fibrosis; Duodenum; Humans; Intestinal Secretions; Saliva; Submandibular Gland; Surface Prope

1972
[Pathogenesis of mucoviscidosis].
    Zeitschrift fur Allgemeinmedizin, 1972, Aug-31, Volume: 48, Issue:24

    Topics: Cystic Fibrosis; Heart; Humans; Liver; Lung; Metabolism, Inborn Errors; Pancreas; Sweat; Water-Elect

1972
Sweat bromide test--a diagnostic tool for mucoviscidosis. A micromethod of bromide determination.
    Zeitschrift fur Kinderheilkunde, 1972, Volume: 113, Issue:4

    Topics: Adolescent; Adult; Bromides; Child; Child, Preschool; Cystic Fibrosis; Humans; Infant; Methods; Micr

1972
Cystic fibrosis: an improved diagnostic method utilizing constant current iontophoresis.
    Revista brasileira de biologia, 1972, Volume: 32, Issue:2

    Topics: Chlorides; Cystic Fibrosis; Humans; Iontophoresis; Methods; Pilocarpine; Sodium; Sweat

1972
[Risk of error in the determination of sweat chlorine with the Orion iontophoresis apparatus].
    La Nouvelle presse medicale, 1973, Feb-10, Volume: 2, Issue:6

    Topics: Child, Preschool; Chlorides; Cystic Fibrosis; Electrodes; False Positive Reactions; Female; Humans;

1973
[Laboratory studies of children with asthma and mucoviscidosis].
    Polski tygodnik lekarski (Warsaw, Poland : 1960), 1973, Jan-29, Volume: 28, Issue:5

    Topics: Asthma; Child; Chlorides; Cystic Fibrosis; Diagnosis, Differential; Humans; Sweat

1973
Cystic fibrosis and the role of the physical therapist in its management.
    Physical therapy, 1973, Volume: 53, Issue:4

    Topics: Aerosols; Breathing Exercises; Chlorides; Cystic Fibrosis; Drainage; Exercise Therapy; Family; Healt

1973
Cystic fibrosis (mucoviscidosis).
    American family physician, 1973, Volume: 7, Issue:3

    Topics: Cystic Fibrosis; Female; Humans; Infant, Newborn; Infant, Newborn, Diseases; Intestinal Obstruction;

1973
Effects of vasopressin on sweat rate and composition in patients with diabetes insipidus and normal controls.
    The Journal of investigative dermatology, 1973, Volume: 60, Issue:4

    Topics: Adolescent; Adult; Child; Chlorides; Cystic Fibrosis; Diabetes Insipidus; Female; Humans; Iontophore

1973
Metabolic alkalosis and salt depletion in cystic fibrosis.
    The Journal of pediatrics, 1973, Volume: 82, Issue:3

    Topics: Alkalosis; Cystic Fibrosis; Humans; Hyponatremia; Infant; Male; Potassium; Sodium; Sweat

1973
Sweat tests in the newborn period.
    Archives of disease in childhood, 1973, Volume: 48, Issue:4

    Topics: Age Factors; Bethanechol Compounds; Chlorides; Cystic Fibrosis; Female; Humans; Infant; Infant, Newb

1973
Newborn screening for cystic fibrosis with the chloride electrode and neutron activation analysis.
    Helvetica paediatrica acta, 1973, Volume: 28, Issue:2

    Topics: Activation Analysis; Chlorides; Cystic Fibrosis; Electrodes; Female; Humans; Male; Mass Screening; M

1973
Direct measurement of chloride in sweat with an ion-selective electrode.
    Clinical chemistry, 1973, Volume: 19, Issue:7

    Topics: Adolescent; Bicarbonates; Child; Child, Preschool; Chlorides; Cystic Fibrosis; Diagnosis, Differenti

1973
Calcium and magnesium concentration in sweat of normal children and patients with cystic fibrosis.
    Pediatrics, 1973, Volume: 52, Issue:3

    Topics: Adolescent; Calcium; Child; Child, Preschool; Cystic Fibrosis; Humans; Infant; Magnesium; Sweat

1973
[Screening of cystic fibrosis by means of a simplified night sweat test].
    Kinderarztliche Praxis, 1973, Volume: 41, Issue:4

    Topics: Child; Cystic Fibrosis; Humans; Methods; Sweat; Sweating

1973
Cystic fibrosis and coeliac disease. Report of two cases.
    Archives of disease in childhood, 1973, Volume: 48, Issue:9

    Topics: Biopsy; Body Height; Body Weight; Celiac Disease; Cystic Fibrosis; Diet Therapy; Disaccharides; Duod

1973
[Sweat secretion tests in diabetic children].
    Pediatria polska, 1973, Volume: 48, Issue:4

    Topics: Adolescent; Bromides; Child; Child, Preschool; Chlorides; Cystic Fibrosis; Diabetes Mellitus, Type 1

1973
Possible genetic links between cystic fibrosis of the pancreas and aspirin sensitive asthma.
    Annals of allergy, 1973, Volume: 31, Issue:7

    Topics: Amino Acids; Animals; Aspirin; Asthma; Binding Sites; Cystic Fibrosis; Drug Hypersensitivity; Hetero

1973
The decline of the sweat test. Comments on pitfalls and reliability.
    Clinical pediatrics, 1973, Volume: 12, Issue:7

    Topics: Cystic Fibrosis; Humans; Iontophoresis; Methods; Sodium Chloride; Sweat; Sweating

1973
Survey of electrolytes of unstimulated sweat from the hand in normal and diseased adults.
    The American review of respiratory disease, 1973, Volume: 108, Issue:3

    Topics: Adolescent; Adult; Age Factors; Child; Child, Preschool; Chlorides; Cystic Fibrosis; Female; Hand; H

1973
Studies on ciliary dyskinesia factor in cystic fibrosis. 3. Skin fibroblasts and cultured amniotic fluid cells.
    Pediatric research, 1973, Volume: 7, Issue:12

    Topics: Amniotic Fluid; Biological Assay; Blood; Cell Division; Cells, Cultured; Cilia; Culture Media; Cysti

1973
Letter: Screening for cystic fibrosis by specific ion electrode.
    Clinical chemistry, 1973, Volume: 19, Issue:11

    Topics: Chlorides; Cystic Fibrosis; Evaluation Studies as Topic; Humans; Mass Screening; Methods; Pilocarpin

1973
[Follow-up studies in 10 cases of mucoviscidosis diagnosed in children].
    Wiadomosci lekarskie (Warsaw, Poland : 1960), 1973, Dec-01, Volume: 26, Issue:23

    Topics: Adolescent; Age Factors; Child; Child, Preschool; Cystic Fibrosis; Diagnosis, Differential; Diet, So

1973
Cystic fibrosis with edema and falsely negative sweat test.
    The Journal of pediatrics, 1973, Volume: 83, Issue:1

    Topics: Chlorides; Cystic Fibrosis; Edema; False Negative Reactions; Humans; Hypoproteinemia; Infant, Newbor

1973
[Necessity and possibilities of mass screening in mucoviscidosis].
    Kinderarztliche Praxis, 1973, Volume: 41, Issue:9

    Topics: Adolescent; Age Factors; Bronchitis; Child; Child, Preschool; Chlorides; Chronic Disease; Cystic Fib

1973
[Experiences in the standardisation of sweat analysis].
    Padiatrie und Grenzgebiete, 1973, Volume: 12, Issue:3

    Topics: Child, Preschool; Cystic Fibrosis; Humans; Infant; Infant, Newborn; Methods; Sweat

1973
[Sweat calcium concentration in children with cystic fibrosis of the pancreas and in normal children].
    Helvetica paediatrica acta, 1973, Volume: 28, Issue:6

    Topics: Calcium; Child; Child, Preschool; Cystic Fibrosis; Humans; Sweat

1973
[Sodium content in the sweat and ungual laminae in healthy children and in those with mucoviscoidosis, as well as in relatives of the patients].
    Voprosy okhrany materinstva i detstva, 1973, Volume: 18, Issue:10

    Topics: Adult; Child; Child, Preschool; Chlorine; Chronic Disease; Cystic Fibrosis; Female; Foot; Hand; Huma

1973
[Diabetes mellitus and mucoviscidosis].
    Kinderarztliche Praxis, 1973, Volume: 41, Issue:12

    Topics: Adolescent; Child; Child, Preschool; Chlorides; Cystic Fibrosis; Diabetes Complications; Glucose Tol

1973
[Perspiration test for chronic recidive bronchitis in children (author's transl)].
    Padiatrie und Padologie, 1973, Volume: 8, Issue:1

    Topics: Adolescent; Bronchitis; Child; Chronic Disease; Cystic Fibrosis; Female; Histamine; Humans; Infant,

1973
Microperfusion study of the sweat gland abnormality in cystic fibrosis.
    Texas reports on biology and medicine, 1973,Winter, Volume: 31, Issue:4

    Topics: Adult; Animals; Carbon Radioisotopes; Cattle; Chlorides; Cystic Fibrosis; Female; Humans; In Vitro T

1973
Sweat electrolytes as a clinical and genetic test in mucoviscidosis. Study of variability and genetic conditioning.
    Acta geneticae medicae et gemellologiae, 1973, Volume: 22

    Topics: Adolescent; Adult; Age Factors; Child; Child, Preschool; Chlorides; Cystic Fibrosis; Environment; Fe

1973
Letter: Effect of antibiotics on sweat chloride levels in cystic fibrosis.
    The Journal of pediatrics, 1974, Volume: 84, Issue:2

    Topics: Chlorides; Cloxacillin; Cystic Fibrosis; Humans; Infant; Sweat

1974
[Electrolyte transport in sweat glands of cystic fibrosis].
    Die Medizinische Welt, 1974, Feb-15, Volume: 25, Issue:7

    Topics: Adolescent; Adult; Biological Transport; Child; Child, Preschool; Cystic Fibrosis; Electrolytes; Hum

1974
Letter: Rates and calcium concentrations of sweat in relation to cystic fibrosis.
    Pediatrics, 1974, Volume: 53, Issue:4

    Topics: Calcium; Cystic Fibrosis; Humans; Secretory Rate; Sweat

1974
Letter: Cystic fibrosis with edema and falsely negative sweat test.
    The Journal of pediatrics, 1974, Volume: 84, Issue:6

    Topics: Chlorides; Cystic Fibrosis; Edema; False Negative Reactions; Female; Humans; Infant; Sodium; Sweat

1974
[Bromide sweat test in diagnosis of mycoviscidosis. A micromethod for the determination of bromide].
    Pediatria polska, 1974, Volume: 49, Issue:4

    Topics: Adolescent; Adult; Bromides; Child; Child, Preschool; Cystic Fibrosis; Heterozygote; Humans; Infant;

1974
[Impression tests in the diagnosis of mucoviscidosis].
    Pediatriia, 1974, Volume: 3

    Topics: Agar; Child; Chlorine; Cystic Fibrosis; Humans; Iontophoresis; Methods; Sweat

1974
[Test with desoxycorticosterone acetate in the diagnosis of mucoviscidosis in children].
    Pediatriia, 1974, Volume: 3

    Topics: Adolescent; Adult; Child; Child, Preschool; Cystic Fibrosis; Desoxycorticosterone; Diet, Sodium-Rest

1974
A methodological study of the diagnosis of cystic fibrosis by instrumental neutron activation analysis of sodium in nail clippings.
    Acta paediatrica Scandinavica, 1974, Volume: 63, Issue:3

    Topics: Activation Analysis; Child, Preschool; Cystic Fibrosis; Humans; Methods; Nails; Sodium; Sweat; Time

1974
[Bromide test using ion-selective membrane electrodes in the demonstration of heterozygotes among patients with mucoviscidosis].
    Orvosi hetilap, 1974, Aug-18, Volume: 115, Issue:33

    Topics: Bromides; Cystic Fibrosis; Heterozygote; Homozygote; Humans; Ions; Sweat

1974
[Determination of the bromidine index in mucoviscidosis using an ionselective membrane-electrode].
    Acta paediatrica Academiae Scientiarum Hungaricae, 1974, Volume: 15, Issue:1

    Topics: Bromides; Cell Membrane Permeability; Chlorides; Cystic Fibrosis; Electrodes; Filtration; Heterozygo

1974
Chronic suppurative lung disease in sisters mimicking cystic fibrosis.
    Archives of disease in childhood, 1974, Volume: 49, Issue:7

    Topics: Autopsy; Child; Chronic Disease; Cystic Fibrosis; Diagnosis, Differential; Female; Humans; Lung; Lun

1974
[Determination of DNase activity in the sweat and the urine. Micro disc-electrophoretic assay in health and mucoviscidosis disease (author's transl)].
    Archiv fur dermatologische Forschung, 1974, Jul-01, Volume: 250, Issue:1

    Topics: Adolescent; Calcium; Child; Child, Preschool; Cystic Fibrosis; Densitometry; Deoxyribonucleases; Ele

1974
Cystic fibrosis cases found by re-examination of histology of pancreas and postmortem protocol in Japanese children and sweat test on the siblings.
    Acta paediatrica Japonica : Overseas edition, 1965, Volume: 7, Issue:13

    Topics: Adolescent; Child; Child, Preschool; Cystic Fibrosis; Female; Humans; In Vitro Techniques; Infant; I

1965
Sweat proteins in cystic fibrosis.
    Bibliotheca paediatrica, 1967, Volume: 86

    Topics: Cystic Fibrosis; Humans; Immunodiffusion; Immunoelectrophoresis; Proteins; Sweat

1967
Micro-isoelectric focusing of proteins in pilocarpine-induced sweat.
    Clinica chimica acta; international journal of clinical chemistry, 1971, Volume: 31, Issue:2

    Topics: Adult; Animals; Child; Child, Preschool; Cystic Fibrosis; Glycoproteins; Horses; Humans; Immune Sera

1971
[Personal experience and general considerations concerning the determination of sweat electrolyte levels by means of pilocarpine iontophoresis].
    Minerva pediatrica, 1972, Mar-17, Volume: 24, Issue:9

    Topics: Child; Child, Preschool; Cystic Fibrosis; Electrolytes; Female; Humans; Infant; Iontophoresis; Male;

1972
[Diagnosis of mucoviscidosis. Gibson's and Cook's apparatus without batteries for sweat collection using pilocarpine iontophoresis].
    Das Deutsche Gesundheitswesen, 1972, Feb-10, Volume: 27, Issue:6

    Topics: Cystic Fibrosis; Humans; Iontophoresis; Pilocarpine; Sodium Chloride; Sweat

1972
Anomalous sweat chloride levels in cystic fibrosis during antibiotic therapy.
    Archives of disease in childhood, 1972, Volume: 47, Issue:251

    Topics: Child, Preschool; Chlorides; Cloxacillin; Cystic Fibrosis; Electrodes; Female; Humans; Infant, Newbo

1972
[Mucoviscidosis in childhood. Optimal sweat production and analysis].
    Das Deutsche Gesundheitswesen, 1972, Feb-17, Volume: 27, Issue:7

    Topics: Adolescent; Child; Child, Preschool; Cystic Fibrosis; Female; Humans; Infant; Infant, Newborn; Ionto

1972
The diagnosis of cystic fibrosis in the practice of allergy.
    Journal of the Medical Association of Georgia, 1972, Volume: 61, Issue:5

    Topics: Child; Cystic Fibrosis; Diagnosis, Differential; Humans; Hypersensitivity; Male; Sweat

1972
Reliability of sweat tests in diagnosis of cystic fibrosis.
    The Journal of pediatrics, 1972, Volume: 81, Issue:1

    Topics: Chlorides; Cystic Fibrosis; Diseases in Twins; False Negative Reactions; False Positive Reactions; H

1972
[Development of chloride losses by sweating in children].
    Ceskoslovenska pediatrie, 1972, Volume: 27, Issue:6

    Topics: Adult; Child; Child, Preschool; Chlorides; Cystic Fibrosis; Female; Humans; Male; Sweat; Sweating; W

1972
Mucus, calcium, sweat, water, and permeability in cystic fibrosis.
    Pediatrics, 1972, Volume: 50, Issue:2

    Topics: Animals; Calcium; Cell Membrane Permeability; Cystic Fibrosis; Humans; Mucus; Rats; Sweat; Water-Ele

1972
[Results concerning the state of children with mucoviscidosis treated in a specialized center. (4 years of experience at the Heliomarin Centre in roscoff)].
    Annales de pediatrie, 1972, Volume: 19, Issue:2

    Topics: Breathing Exercises; Celiac Disease; Child; Child, Preschool; Cystic Fibrosis; Female; France; Hospi

1972
Elevated sweat chlorides in a child with malnutrition.
    Clinical pediatrics, 1971, Volume: 10, Issue:5

    Topics: Child, Preschool; Chlorides; Cystic Fibrosis; Diagnosis, Differential; Follow-Up Studies; Humans; In

1971
[Liver changes in mucoviscidosis heterozygotes].
    Pediatria polska, 1971, Volume: 46, Issue:5

    Topics: Biopsy; Bronchitis; Bronchography; Child; Chronic Disease; Connective Tissue; Cystic Fibrosis; Diagn

1971
Some observations on sweat test by Pilocarpine Iontophoresis.
    Indian pediatrics, 1971, Volume: 8, Issue:7

    Topics: Child; Child, Preschool; Cystic Fibrosis; Diagnosis, Differential; Humans; Infant; Iontophoresis; Nu

1971
Effect of mineralocorticoids on sweat sodium in cystic fibrosis.
    The Journal of pediatrics, 1971, Volume: 79, Issue:6

    Topics: Cystic Fibrosis; Humans; Mineralocorticoids; Sodium; Sweat

1971
Metabolic alkalosis in cystic fibrosis.
    The Journal of pediatrics, 1971, Volume: 79, Issue:6

    Topics: Alkalosis; Bicarbonates; Birth Weight; Cystic Fibrosis; Diet Therapy; Diseases in Twins; Female; Hum

1971
[Sweat analysis following pilocarpine iontophoresis. Normal values of chloride in sweat, saliva and tears in relation to the child's age].
    Kinderarztliche Praxis, 1971, Volume: 39, Issue:4

    Topics: Adult; Age Factors; Child; Cystic Fibrosis; Diagnosis, Differential; Humans; Iontophoresis; Methods;

1971
[Sweating in the newborn infant. Studies on the pilocarpine stimulated single sweat gland].
    Helvetica paediatrica acta, 1971, Volume: 26, Issue:5

    Topics: Cystic Fibrosis; Female; Humans; Infant, Newborn; Male; Pilocarpine; Potassium; Sodium; Sweat; Sweat

1971
[Screening for mucoviscidosis (cystic fibrosis-CF). Systematic review and results].
    Monatsschrift fur Kinderheilkunde, 1971, Volume: 119, Issue:12

    Topics: Child, Preschool; Cystic Fibrosis; Electrodes; Electrodiagnosis; Electrolytes; False Negative Reacti

1971
Sweat tests in cystic fibrosis: a comparison of the thermal test with pilocarpine stimulation at two dose levels.
    Clinical biochemistry, 1971, Volume: 4, Issue:1

    Topics: Adolescent; Adult; Aged; Child; Child, Preschool; Chlorides; Cystic Fibrosis; Evaluation Studies as

1971
[Electrolytic disorders in patients with mucoviscidosis].
    Srpski arhiv za celokupno lekarstvo, 1968, Volume: 96, Issue:1

    Topics: Adolescent; Child; Child, Preschool; Chlorides; Cystic Fibrosis; Electrolytes; Humans; Infant; Infan

1968
Meconium ileus and fibrocystic disease of the pancreas in Japan.
    The Bulletin of Tokyo Medical and Dental University, 1966, Volume: 13, Issue:1

    Topics: Child, Preschool; Chlorides; Cystic Fibrosis; Female; Humans; In Vitro Techniques; Infant; Infant, N

1966
An analysis of 46 autopsy cases of Japanese children, showing fibrocystic changes of the pancreas and one case of fibrocystic disease of the pancreas.
    The Bulletin of Tokyo Medical and Dental University, 1967, Volume: 14, Issue:4

    Topics: Age Factors; Birth Weight; Chlorides; Cystic Fibrosis; Female; Humans; Infant; Infant, Newborn; Kidn

1967
Fibrocystic disease of the pancreas (mucoviscidosis) in New Zealand.
    The New Zealand medical journal, 1968, Volume: 68, Issue:435

    Topics: Child, Preschool; Cystic Fibrosis; Electrolytes; Health Surveys; Humans; Infant; Infant, Newborn; Ne

1968
Sweat electrolyte concentrations in Puerto Rican children.
    Boletin de la Asociacion Medica de Puerto Rico, 1969, Volume: 61, Issue:1

    Topics: Child; Child, Preschool; Cystic Fibrosis; Electrolytes; Female; Humans; Infant; Infant, Newborn; Mal

1969
[Determination of electrolytes in sweat. Generalities].
    Revista da Associacao Medica Brasileira, 1965, Volume: 11, Issue:5

    Topics: Chlorides; Cystic Fibrosis; Humans; Iontophoresis; Methods; Sodium; Sweat

1965
[Dependency on age and diagnostic evidence of sweat electrolytes].
    Das Deutsche Gesundheitswesen, 1967, Mar-02, Volume: 22, Issue:9

    Topics: Adolescent; Age Factors; Child; Child, Preschool; Cystic Fibrosis; Diabetes Mellitus; Humans; Infant

1967
[The sweat test].
    Maandschrift voor kindergeneeskunde, 1969, Volume: 37, Issue:4

    Topics: Cystic Fibrosis; Humans; Iontophoresis; Pilocarpine; Sweat

1969
[Diagnostic difficulties in mucoviscidosis].
    Polski tygodnik lekarski (Warsaw, Poland : 1960), 1969, Sep-23, Volume: 24, Issue:38

    Topics: Child; Child, Preschool; Chlorides; Cystic Fibrosis; Diagnosis, Differential; Humans; Lung Diseases;

1969
[Clinical findings in adult mucoviscidosis].
    Zeitschrift fur die gesamte innere Medizin und ihre Grenzgebiete, 1969, Aug-01, Volume: 24, Issue:15

    Topics: Adolescent; Chlorine; Cystic Fibrosis; Humans; Male; Radiography, Thoracic; Skull; Sodium; Sweat

1969
Cystic fibrosis of pancreas in adults. A report of 4 cases.
    The Indian journal of chest diseases, 1969, Volume: 11, Issue:3

    Topics: Adolescent; Adult; Child; Chlorides; Cystic Fibrosis; Female; Humans; Iontophoresis; Male; Pilocarpi

1969
[Measurement of sweat resistance in mucoviscodosis using a simple capillary probe].
    Monatsschrift fur Kinderheilkunde, 1969, Volume: 117, Issue:11

    Topics: Cystic Fibrosis; Electric Conductivity; Electrolytes; Humans; Infant, Newborn; Methods; Sodium Chlor

1969
[Hair sodium, potassium and chloride content in normal conditions and in mucoviscidosis].
    Minerva pediatrica, 1970, Jan-21, Volume: 22, Issue:3

    Topics: Adolescent; Adult; Age Factors; Child; Child, Preschool; Chlorides; Cystic Fibrosis; Hair; Humans; I

1970
Detection of heterozygocity for mucoviscidosis by the sweat bromide test.
    Polish medical journal, 1970, Volume: 9, Issue:1

    Topics: Bromides; Chlorides; Cystic Fibrosis; Eugenics; Gastrointestinal Diseases; Heterozygote; Respiratory

1970
[Amylasemia, heterogeneity of serum amylase and activity of the sweat amylolytic enzyme in members of families afflicted with mucoviscidosis].
    Ceskoslovenska pediatrie, 1970, Volume: 25, Issue:2

    Topics: Adolescent; Adult; Amylases; Child; Child, Preschool; Cystic Fibrosis; Female; Humans; Isoenzymes; M

1970
Studies in cystic fibrosis. Report of 130 patients diagnosed under 3 months of age over a 20-year period.
    Pediatrics, 1970, Volume: 46, Issue:3

    Topics: Anemia; Body Weight; Chloramphenicol; Chlortetracycline; Cough; Cystic Fibrosis; Diabetes Mellitus,

1970
[Problem of mucoviscidosis in children with diseases of the respiratory organs and diagnostic value of several tests].
    Voprosy okhrany materinstva i detstva, 1970, Volume: 15, Issue:7

    Topics: Child; Child, Preschool; Clinical Enzyme Tests; Cystic Fibrosis; Electrolytes; Humans; Infant; Respi

1970
[Factors in interpretation of sweat test in children. Determination of electrolytes using the neutron activation technic].
    Pediatrie, 1970, Volume: 25, Issue:8

    Topics: Activation Analysis; Adolescent; Child; Child, Preschool; Chlorine; Cystic Fibrosis; Female; Humans;

1970
[Bronchiectasis in mucoviscidosis (cystic fibrosis)].
    Pneumonologie. Pneumonology, 1970, Volume: 143, Issue:2

    Topics: Bronchiectasis; Cystic Fibrosis; Humans; Infant, Newborn; Prognosis; Respiratory Therapy; Sweat

1970
[The significance of the sweat test in adults].
    Acta paediatrica Belgica, 1970, Volume: 24, Issue:5

    Topics: Adolescent; Adult; Age Factors; Aged; Child; Child, Preschool; Chlorine; Cystic Fibrosis; Humans; In

1970
[The sweat test: a simple method of specimen collection with a rubber cap].
    Minerva pediatrica, 1970, May-19, Volume: 22, Issue:20

    Topics: Cystic Fibrosis; Electrolytes; Humans; Infant; Infant, Newborn; Specimen Handling; Sweat

1970
[Aldosterone effect on the sodium chloride and potassium excretion in the sweat of cystic fibrosis patients and healthy persons].
    Klinische Wochenschrift, 1970, Aug-15, Volume: 48, Issue:16

    Topics: Adolescent; Aldosterone; Biological Transport; Child; Cystic Fibrosis; Female; Humans; Male; Photome

1970
Neutron activation analysis technique for nail sodium concentration in cystic fibrosis patients.
    Pediatrics, 1971, Volume: 47, Issue:1

    Topics: Activation Analysis; Adult; Age Factors; Child; Cystic Fibrosis; Female; Humans; Infant, Newborn; Ma

1971
Distribution of pulmonary blood flow in children with cystic fibrosis.
    Acta paediatrica Scandinavica, 1971, Volume: 60, Issue:2

    Topics: Adult; Body Height; Body Weight; Carbon Dioxide; Child; Child, Preschool; Chlorides; Cystic Fibrosis

1971
[Value of the systematic sweat test in chronic bronchitis for detection of mucoviscidosis with delayed manifestation].
    Le Poumon et le coeur, 1971, Volume: 27, Issue:1

    Topics: Activation Analysis; Bronchitis; Chlorides; Chronic Disease; Cystic Fibrosis; Humans; Radioisotopes;

1971
[Significance of the Shvakhman-Gam test and determination of sweat electrolyte levels in the diagnosis of mucoviscidosis in children with bronchial asthma].
    Voprosy okhrany materinstva i detstva, 1971, Volume: 16, Issue:2

    Topics: Adolescent; Asthma; Child; Child, Preschool; Chlorides; Cystic Fibrosis; Humans; Infant; Sodium; Swe

1971
[Modification of a test for recognition of heterozygotic genecarriers of mucoviscidosis].
    Das Deutsche Gesundheitswesen, 1971, Apr-15, Volume: 26, Issue:16

    Topics: Child; Child, Preschool; Chromosome Aberrations; Chromosome Disorders; Cystic Fibrosis; Genes; Heter

1971
Effect of exogenous mineralocorticoids on sweat sodium in cystic fibrosis.
    The Journal of pediatrics, 1971, Volume: 78, Issue:6

    Topics: Child; Child, Preschool; Cystic Fibrosis; Female; Humans; Hydrocortisone; Male; Sodium; Sweat

1971
[Sweat electrolytes in a selected group of children with suspected muscoviscidosis].
    Wiadomosci lekarskie (Warsaw, Poland : 1960), 1971, May-01, Volume: 24, Issue:9

    Topics: Body Weight; Child; Child, Preschool; Chlorine; Cystic Fibrosis; Humans; Infant; Sweat

1971
[Salt loss as the initial symptom in mucoviscidosis].
    Lakartidningen, 1971, Apr-21, Volume: 68, Issue:17

    Topics: Adrenal Gland Diseases; Cystic Fibrosis; Diagnosis, Differential; Humans; Infant; Male; Pancreatic D

1971
The sweat chloride content in various diseases.
    Polish medical science and history bulletin, 1967, Volume: 10, Issue:4

    Topics: Adolescent; Child; Child, Preschool; Chlorides; Cystic Fibrosis; Humans; Infant; Sweat

1967
Determination of bromide in the sweat after oral administration of bromide preparations.
    Polish medical journal, 1967, Volume: 6, Issue:6

    Topics: Bromides; Child, Preschool; Cystic Fibrosis; Humans; Infant; Infant, Newborn; Sweat

1967
Chloride and bromide excretion in the sweat of children after oral administration of sodium bromide.
    Polish medical journal, 1967, Volume: 6, Issue:6

    Topics: Bromides; Child; Child, Preschool; Chlorides; Cystic Fibrosis; Diagnosis, Differential; Dyspepsia; H

1967
[Value of a simple method for collecting perspiration].
    Revue medicale de Liege, 1967, May-01, Volume: 22, Issue:9

    Topics: Adolescent; Child; Child, Preschool; Chlorides; Cystic Fibrosis; Electrodes; Humans; Infant; Iontoph

1967
[Functions of sweat glands].
    Praxis, 1967, Oct-19, Volume: 56, Issue:42

    Topics: Cystic Fibrosis; Humans; Sweat; Sweat Glands

1967
Biochemical studies of sweat secretion in cystic fibrosis.
    Proceedings of the Royal Society of Medicine, 1968, Volume: 61, Issue:3

    Topics: Calcium; Child; Cystic Fibrosis; Humans; Iontophoresis; Potassium; Sodium; Sweat; Sweat Glands; Swea

1968
Sodium-potassium measurement interferences in various biological fluids.
    Clinica chimica acta; international journal of clinical chemistry, 1968, Volume: 20, Issue:1

    Topics: Body Fluids; Cystic Fibrosis; Intestinal Secretions; Methods; Mucus; Photometry; Potassium; Saliva;

1968
Sweat chloride analysis by chloride ion-specific electrode method using heat stimulation.
    American journal of clinical pathology, 1968, Volume: 49, Issue:6

    Topics: Chemistry, Clinical; Chlorides; Cystic Fibrosis; Electrodiagnosis; Hot Temperature; Humans; Iontopho

1968
Presumptive tests for cystic fibrosis based on serum protein in meconium.
    Pediatrics, 1968, Volume: 41, Issue:5

    Topics: Agglutination Tests; Blood Proteins; Cystic Fibrosis; Electrolytes; Humans; Infant, Newborn; Infant,

1968
[Studies directed to mucoviscidosis in the etiology of respiratory diseases and in systemic diseases of the connective tissue].
    Reumatologia, 1968, Volume: 6, Issue:2

    Topics: Arthritis, Rheumatoid; Child; Chlorides; Cystic Fibrosis; Humans; Iontophoresis; Respiratory Tract D

1968
Meconium ileus equivalent.
    Journal of the Irish Medical Association, 1968, Volume: 61, Issue:372

    Topics: Child; Cystic Fibrosis; Fecal Impaction; Female; Humans; Sodium; Sweat

1968
Cases of cystic fibrosis of the pancreas in the District Allergological Outpatient Department for Children in Zabrze.
    Polish medical journal, 1968, Volume: 7, Issue:3

    Topics: Asthma; Child; Chlorides; Cystic Fibrosis; Humans; Outpatient Clinics, Hospital; Sweat

1968
[Contribution to comparative studies of mucoviscidosis and bronchial asthma in children].
    Pediatria polska, 1968, Volume: 43, Issue:4

    Topics: Adolescent; Asthma; Child; Child, Preschool; Cystic Fibrosis; Electrolytes; Humans; Sweat

1968
The effect of adrenergic stimulation upon sweating in normal children and cystic fibrosis patients.
    Pediatrics, 1968, Volume: 42, Issue:3

    Topics: Adolescent; Adult; Atropine; Child; Child, Preschool; Cystic Fibrosis; Epinephrine; Humans; Iontopho

1968
[Study of the sweating function in 2 cases of adult mucoviscidosis].
    Schweizerische medizinische Wochenschrift, 1968, Sep-07, Volume: 98, Issue:36

    Topics: Absorption; Adult; Age Factors; Aldosterone; Bronchitis; Cystic Fibrosis; Female; Humans; Male; Pedi

1968
Protein in meconium from meconium ileus.
    Archives of disease in childhood, 1968, Volume: 43, Issue:228

    Topics: Albumins; Child; Child, Preschool; Cystic Fibrosis; Electrophoresis; Humans; Infant; Infant, Newborn

1968
Cystic fibrosis and pregnancy.
    JAMA, 1968, Jan-15, Volume: 203, Issue:3

    Topics: Adult; Cystic Fibrosis; Diagnosis, Differential; Female; Humans; Infant, Newborn; Iontophoresis; Pil

1968
Some hazards of the sweat test.
    Archives of disease in childhood, 1968, Volume: 43, Issue:232

    Topics: Blister; Burns, Chemical; Burns, Electric; Child; Cystic Fibrosis; Electrodiagnosis; Humans; Hydroch

1968
[Diagnosis and differential diagnosis of mucoviscidosis (short report)].
    Monatsschrift fur Kinderheilkunde, 1968, Volume: 116, Issue:6

    Topics: Child; Cystic Fibrosis; Diagnosis, Differential; Duodenum; Electrolytes; Humans; Pancreas; Sweat

1968
[False pathologic findings in sweat test].
    Monatsschrift fur Kinderheilkunde, 1968, Volume: 116, Issue:6

    Topics: Adolescent; Child; Child, Preschool; Cystic Fibrosis; Diagnosis, Differential; Electrolytes; Humans;

1968
Sweat composition in relation to rate of sweating in patients with cystic fibrosis of the pancreas.
    Pediatric research, 1968, Volume: 2, Issue:6

    Topics: Calcium; Chlorides; Creatinine; Cystic Fibrosis; Glucose; Humans; Hydrogen-Ion Concentration; Lactat

1968
[Study of the mucoviscidosis factor and familiar factors in chronic bronchitis of the miners].
    Folia medica. Folia medica (Naples, Italy), 1968, Volume: 51, Issue:3

    Topics: Adult; Aged; Bronchitis; Chronic Disease; Cystic Fibrosis; Environment; Humans; Male; Middle Aged; M

1968
[Behavior of extracellular fluid volume and volume of the chlorine metabolic pool in mucoviscidosis].
    Minerva pediatrica, 1968, Mar-24, Volume: 20, Issue:12

    Topics: Chlorine; Cystic Fibrosis; Electrolytes; Endocrine Glands; Extracellular Space; Humans; Infant; Swea

1968
Sweat electrolytes in mature and premature neonates after normal and pathological gestations and births.
    Polish medical science and history bulletin, 1968, Volume: 11, Issue:1

    Topics: Calcium; Cystic Fibrosis; Female; Humans; Infant, Newborn; Infant, Premature; Iontophoresis; Pilocar

1968
The values of polarographically active proteinaceous substances in the sweat of children.
    Acta Universitatis Carolinae. Medica, 1968, Volume: 14, Issue:6

    Topics: Adolescent; Age Factors; Child; Child, Preschool; Cystic Fibrosis; Humans; Infant; Polarography; Pro

1968
General discussion. Sweat--"First sample phenomenon".
    Ciba Foundation study group, 1968, Volume: 32

    Topics: Adult; Aldosterone; Animals; Binding Sites; Biological Transport; Calcium; Cats; Cell Membrane Perme

1968
Studies in cystic fibrosis: determination of sweat electrolytes in situ with direct reading electrodes.
    Pediatrics, 1969, Volume: 43, Issue:5

    Topics: Child; Child, Preschool; Chlorides; Cystic Fibrosis; Electrodes; Hot Temperature; Humans; Infant; In

1969
Cystic fibrosis of the pancreas. Diagnosis by sodium electrode sweat tests.
    California medicine, 1969, Volume: 110, Issue:5

    Topics: Adult; Child, Preschool; Cystic Fibrosis; Humans; Sodium; Sweat

1969
Investigation of the child with asthma.
    The Medical journal of Australia, 1969, Mar-01, Volume: 1, Issue:9

    Topics: Allergens; Asthma; Blood Gas Analysis; Body Height; Body Weight; Child; Child, Preschool; Cystic Fib

1969
Cystic fibrosis of the pancreas.
    The British journal of clinical practice, 1969, Volume: 23, Issue:5

    Topics: Child; Cystic Fibrosis; Humans; Saliva; Sweat

1969
[Results of studies for mucoviscidosis in school children in Cieszyn].
    Polski tygodnik lekarski (Warsaw, Poland : 1960), 1969, Volume: 24, Issue:14

    Topics: Adolescent; Child; Cystic Fibrosis; Humans; Mass Screening; Poland; School Health Services; Sodium C

1969
[On the problem of mucoviscidosis in adults].
    Bratislavske lekarske listy, 1969, Volume: 51, Issue:5

    Topics: Adult; Age Factors; Aged; Bronchitis; Chlorides; Cystic Fibrosis; Diagnosis, Differential; Female; H

1969
Micropuncture studies of the sweat formation in cystic fibrosis patients.
    The Journal of clinical investigation, 1969, Volume: 48, Issue:8

    Topics: Adolescent; Adult; Child; Chlorides; Cystic Fibrosis; Female; Humans; Male; Methods; Osmolar Concent

1969
[On the diagnosis of mucoviscidosis (cystic fibrosis)].
    Deutsche medizinische Wochenschrift (1946), 1969, Aug-22, Volume: 94, Issue:34

    Topics: Child; Child, Preschool; Chlorides; Cystic Fibrosis; Humans; Indicators and Reagents; Infant; Iontop

1969
Excretion of 4-14C-cortisol and 1,2-3H-D-aldosterone in human thermal sweat.
    The Journal of clinical endocrinology and metabolism, 1969, Volume: 29, Issue:8

    Topics: Adult; Aldosterone; Carbon Isotopes; Chromatography, Paper; Cortisone; Cystic Fibrosis; Humans; Hydr

1969
An infant with both cystic fibrosis and coeliac disease.
    Archives of disease in childhood, 1969, Volume: 44, Issue:236

    Topics: Biopsy; Celiac Disease; Cystic Fibrosis; Diet Therapy; Duodenum; Glutens; Humans; Infant; Intestinal

1969
[Detection of mucoviscidosis heterozygotes by the bromide sweat test].
    Polski tygodnik lekarski (Warsaw, Poland : 1960), 1969, May-26, Volume: 24, Issue:21

    Topics: Adult; Bromides; Child; Cystic Fibrosis; Heterozygote; Homozygote; Humans; Sweat

1969
A new screening test for cystic fibrosis.
    Pediatrics, 1965, Volume: 36, Issue:5

    Topics: Adolescent; Child; Child, Preschool; Chlorides; Cystic Fibrosis; Humans; Infant; Mass Screening; Sod

1965
Accuracy of the sweat test: advantage of a micromethod.
    Archives of disease in childhood, 1965, Volume: 40, Issue:214

    Topics: Cystic Fibrosis; Humans; In Vitro Techniques; Iontophoresis; Pilocarpine; Sweat

1965
Absence of detrimental effect of the carrier state for the cystic fibrosis gene.
    The American review of respiratory disease, 1965, Volume: 92, Issue:5

    Topics: Adult; Carrier State; Chlorides; Communicable Diseases; Cystic Fibrosis; Ethnology; Female; Humans;

1965
[Pancreatic cystic fibrosis. Its diagnosis by means of the determination of the electric conductivity of the sweat. Our experience in 216 determinations].
    Prensa medica argentina, 1965, Sep-24, Volume: 52, Issue:35

    Topics: Adolescent; Chemical Phenomena; Chemistry, Physical; Child; Child, Preschool; Cystic Fibrosis; Elect

1965
[Contribution to the study of mucoviscidosis in the adult].
    Bollettino della Societa italiana di biologia sperimentale, 1964, Nov-15, Volume: 40, Issue:21

    Topics: Adult; Cystic Fibrosis; Desoxycorticosterone; Electrolytes; Humans; Male; Sweat

1964
[Influence of aldosterone on the concentration of sodium and chloride in sweat in mucoviscidosis and in the normal subject].
    Helvetica medica acta, 1963, Volume: 30, Issue:4

    Topics: Adolescent; Aldosterone; Child; Chlorides; Cystic Fibrosis; Diet, Sodium-Restricted; Electrolytes; H

1963
The electrolyte composition of normal adult sweat.
    The American review of respiratory disease, 1966, Volume: 93, Issue:1

    Topics: Adolescent; Adult; Aged; Child; Child, Preschool; Chlorides; Cystic Fibrosis; Humans; In Vitro Techn

1966
Cystic fibrosis of the pancreas: a study of sweat electrolyte levels in thirty-six families using pilocarpine iontophoresis.
    Southern medical journal, 1966, Volume: 59, Issue:2

    Topics: Adult; Child; Cystic Fibrosis; Electrolytes; Humans; Iontophoresis; Pilocarpine; Sweat

1966
Quantitative estimation of sweat chloride in cases of recurrent bronchitis in children.
    The Journal of the Association of Physicians of India, 1966, Volume: 14, Issue:1

    Topics: Adult; Aged; Bronchitis; Child; Child, Preschool; Chlorides; Cystic Fibrosis; Humans; Middle Aged; S

1966
Characteristics of cystic fibrosis in adults: a report of seven patients.
    Diseases of the chest, 1966, Volume: 49, Issue:2

    Topics: Adolescent; Adult; Chlorides; Cystic Fibrosis; Diagnosis, Differential; Female; Follow-Up Studies; H

1966
Diagnosis of heterozygosity for cystic fibrosis by discriminatory analysis of sweat chloride distribution.
    The Journal of pediatrics, 1966, Volume: 69, Issue:5

    Topics: Adolescent; Adult; Child; Child, Preschool; Chlorides; Cystic Fibrosis; Female; Humans; Male; Statis

1966
The sweat test in cystic fibrosis. A comparison of overnight sweat collection versus the pilocarpine iontophoresis method.
    The Journal of pediatrics, 1966, Volume: 69, Issue:2

    Topics: Adolescent; Adult; Child; Child, Preschool; Cystic Fibrosis; Electrolytes; Humans; Infant; Infant, N

1966
Cystic fibrosis sweat test for newborns.
    JAMA, 1966, Oct-03, Volume: 198, Issue:1

    Topics: Cystic Fibrosis; Humans; Infant, Newborn; Mass Screening; Sweat

1966
The influx and outflux of sodium in the sweat-gland.
    Dermatologica, 1966, Volume: 132, Issue:2

    Topics: Cystic Fibrosis; Humans; Secretory Rate; Sodium; Sweat; Sweat Glands; Urea

1966
The surgical treatment of bronchiectasis and the possibility of mucoviscidosis.
    Annales chirurgiae et gynaecologiae Fenniae, 1966, Volume: 55, Issue:3

    Topics: Adolescent; Adult; Bronchiectasis; Chlorides; Cystic Fibrosis; Humans; Middle Aged; Sweat

1966
[Total osmolarity and principal osmoactive constituents of sweat in subjects with mucoviscidosis and their families].
    Bollettino della Societa italiana di biologia sperimentale, 1966, Oct-31, Volume: 42, Issue:20

    Topics: Adult; Child, Preschool; Chlorides; Cystic Fibrosis; Humans; Infant; Lactates; Middle Aged; Potassiu

1966
[Total osmolarity of sweat in normal subjects of the 1st, 2nd and 3rd pediatric ages].
    Bollettino della Societa italiana di biologia sperimentale, 1966, Jun-30, Volume: 42, Issue:12

    Topics: Chemical Phenomena; Chemistry, Physical; Child, Preschool; Chlorides; Cystic Fibrosis; Humans; Infan

1966
[Mercurimetric determination of chlorides in sweat].
    Ceskoslovenska pediatrie, 1966, Volume: 21, Issue:11

    Topics: Child; Child, Preschool; Chlorides; Cystic Fibrosis; Diagnosis, Differential; Female; Humans; Infant

1966